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1.1 GENERAL INTRODUCTION 
1.1.1 THE VALUE OF ECHOCARDIOGRAPHY   
	  
One	   of	   the	   technical	   revolutions	   that	   changed	   the	   face	   and	   practice	   of	   pediatric	  
cardiology	  was	  the	  development	  of	  noninvasive	  imaging	  techniques.	  Until	  fifty	  years	  
ago,	   clinical	   skills	  were	   at	   the	   core	   of	   the	   profession.	   It	  was	   the	   stethoscope,	   the	  
ECG	  and	  the	  chest	  X-­‐ray	  that	  guided	  the	  clinician	  to	  reach	  to	  a	  diagnosis	  and	  form	  a	  
treatment	   plan.	   Imaging	   techniques	   to	   enable	   the	   assessment	   of	   detailed	   cardiac	  
anatomy	  and	  the	  quantification	  of	  myocardial	  function	  were	  not	  available.	  	  
	  
In	   the	   1970s	   two-­‐dimensional	   (2D)	   echocardiography	  was	   developed,	  which	   is	   an	  
attractive	  imaging	  modality	  for	  several	  reasons.1,2	  Images	  are	  displayed	  in	  real	  time	  
allowing	   prompt	   diagnosis,	   it	   is	   easily	   available,	   bed-­‐side,	   noninvasive,	   relatively	  
inexpensive	   to	   perform	   and	   it	   does	   not	   involve	   ionizing	   radiation.	   During	   the	   last	  
two	   decades,	   echocardiography	   has	   become	   the	   primary	   imaging	   tool	   in	   the	  
assessment	   of	   both	   pediatric	   and	   adult	   heart	   disease.	   As	   technology	   has	   evolved,	  
the	   focus	   of	   new	   developments	   in	   echocardiographic	   imaging	   has	   shifted	   from	  
dynamic	   characterization	   of	   cardiac	   anatomy	   to	   the	   assessment	   of	   myocardial	  
performance.	   It	   has	   become	   clear	   that	   the	   clinical	   outcome	   of	   children	   with	  
different	   forms	   of	   congenital	   and	   acquired	   heart	   disease	   is	   greatly	   dependent	   on	  
myocardial	   systolic	   and	   diastolic	   functioning.	   Global	   cardiac	   performance	   is	  
determined	   by	   a	   complex	   interaction	   between	   intrinsic	   myocardial	   contractility,	  
preload,	   afterload,	   and	   heart	   rate.	   The	   ultimate	   goal	   is	   to	   describe	   intrinsic	  
myocardial	  contractility.	  However,	  due	  to	  the	  fact	  that	  loading	  conditions	  influences	  
most	   of	   the	   conventional	   echocardiographic	   parameters,	   heart	   rate	   and	   cardiac	  
geometry,	  the	  assessment	  of	  true	  myocardial	  contractility	  has	  turned	  out	  to	  become	  
one	  of	  the	  important	  challenges	  in	  the	  field.	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1.1.2 CONVENTIONAL ECHOCARDIOGRAPHIC INDICES USED TO 
INDICATE SYSTOLIC FUNCTION 
	  
Traditionally,	   dimensional	   changes	   (i.e.,	   fractional	   shortening)	   or	   volumetric	  
changes	  	  (i.e.,	  ejection	  fraction)	  during	  the	  ejection	  phase	  of	  the	  cardiac	  cycle	  have	  
been	   used	   to	   assess	   systolic	   ventricular	   function.	   These	   techniques	   are	   especially	  
load-­‐sensitive	  and	  provide	  no	   information	  about	   regional	  myocardial	   contraction.3	  
Importantly,	   they	   are	   not	   always	   applicable	   to	   pediatric	   hearts	   with	   complex	  
congenital	  malformations.	  The	   reason	   for	   this	   is	   that	  geometrical	  assumptions	  are	  
made	   in	   the	   calculation	   of	   volumetric	   changes,	   which	   overlook	   the	   complex	  
anatomical	  and	  related	  functional	  characteristics	  of	  congenital	  heart	  disease.4	  New	  
developments	  in	  echocardiography,	  as	  well	  as	  other	  forms	  of	  cardiac	  imaging,	  have	  
tried	  to	  address	  these	  shortcomings	  in	  recent	  years.	  	  
	  
1.2 STRAIN IMAGING     
1.2.1 STRAIN  
	  
Strain	  and	  strain-­‐rate	   imaging	  techniques	  have	  emerged	  as	  quantitative	  modalities	  
to	   accurately	   estimate	   regional	   as	   well	   as	   global	   myocardial	   function.	   Strain	   is	   a	  
dimensionless	  parameter	   representing	  deformation	   (‘contraction	  or	   stretching’)	  of	  
an	  object	  relative	  to	  its	  original	  shape.	  In	  cardiac	  muscle	  physiology,	  strain	  is	  directly	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“Lagrangian”	  strain	  and	  strain-­‐rate	  are	  defined	  by	  the	  following	  formulas:	  
	  
	  
Figure 1 - Lagrangian formulas, which are used to calculate strain and strain-rate 
Where	   L	   is	   the	   instantaneous	   length,	   L0	   is	   the	   initial	   length,	   and	   Δt	   is	   the	   time	  
interval	   between	   initial	   and	   deformed	   conditions	   (Figure	   1).	   Strain,	   symbolically	  
denoted	  as	  epsilon	   (ε),	   is	  expressed	  as	   the	  percentage	   (or	   fractional)	   change	   from	  
the	  original	  dimension,	  whilst	  strain-­‐rate	  is	  expressed	  as	  [s-­‐1].	  From	  these	  formulas,	  
it	   is	  evident	   that	  positive	   strain	   is	   lengthening,	   thickening	  or	   ‘stretching’.	  Negative	  
strain	   is	   shortening,	   thinning	   or	   compression	   in	   relation	   to	   the	   original	   length.	  
Strain-­‐rate	  is	  negative	  during	  compression	  and	  positive	  during	  stretching.	  
	  
Strain	   is	   often	   mistaken	   for	   motion,	   a	   parameter	   that	   is	   obtained	   using	   Tissue	  
Doppler	   Imaging	   (TDI).6,7	   However,	   a	  moving	   subject	   is	   not	   necessary	   undergoing	  
deformation	  as	  long	  as	  every	  part	  of	  the	  object	  moves	  with	  the	  same	  velocity.	  The	  
object	  may	  then	  be	  said	  to	  have	  pure	  “translational”	  velocity,	  but	  the	  shape	  remains	  
unchanged.	  Over	  time,	  the	  object	  will	  change	  position	  (displacement).	  On	  the	  other	  
hand,	   if	   different	   parts	   of	   the	   object	   have	   different	   velocities,	   the	   object	   has	   to	  
change	  shape	  and	  deformation	  occurs	  (Figure	  2).	  Strain	  rate	  is	  measured	  using	  TDI-­‐
based	  strain-­‐rate	  imaging.8	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Figure 2 - Relation between displacement-velocity based (blue) indices and 
deformation-based (green) parameters 
The	   superiority	   of	   strain-­‐based	   (deformation-­‐based)	   parameters	   for	   assessing	  
cardiac	  function	  compared	  to	  velocity-­‐displacement-­‐based	  parameters	  is	  explained	  
by	  the	  strain-­‐algorithm.	  	  
Unlike	  velocity-­‐based	  parameters,	  strain	  calculations	  are	  not	  affected	  by	  movement	  
due	  to	  global	  cardiac	  motion	  within	  the	  chest	  (cardiac	  translation)	  nor	  by	  the	  effect	  
(pulling	  or	  tethering)	  of	  surrounding	  segments	  on	  the	  region	  of	  interest.	  Completely	  
passive	  segments	  can	  show	  motion	  relative	  to	  the	  transducer	  due	  to	  tethering,	  but	  
without	   active	   deformation,	   making	   velocity	   and	   displacement	   unreliable	   for	   the	  
characterization	  of	  myocardial	   function	  of	   such	  regions.5	  Strain	  parameters	  on	   the	  
other	   hand,	   are	   referred	   to	   as	   motion-­‐deformation	   between	   two	   points	   in	   the	  
myocardial	   wall,	   which	   is	   unrelated	   to	   the	   motion	   towards	   the	   transducer.	   This	  
characteristic	  of	   strain	  discriminates	  passive	  movement	   from	  true	  contraction	   in	  a	  
myocardial	  region	  under	  investigation.5,9,10,11	  
A	   second	   important	   advantage	   of	   strain	   is	   that	   it	   is	   geometry-­‐independent	   and	  
hereby	  may	  be	  valuable	  for	  the	  quantification	  of	  ventricular	  function	   in	  cases	  with	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variable	  abnormal	  ventricular	  morphology	  (e.g.,	  in	  case	  of	  complex	  congenital	  heart	  
disease	  or	  pathological	  right	  ventricular	  function).12	  	  
	  
Third,	  deformation	  techniques	  are	  able	  to	  quantify	  regional	  myocardial	   function	   in	  
addition	  to	  global	  ventricular	  function.	  Strain	  imaging	  makes	  it	  possible	  to	  quantify	  
regional	  myocardial	  performance	  in	  different	  segments	  of	  the	  (ventricular)	  wall	  and	  
to	  identify	  regional	  dysfunction.5,9,10,11	  In	  congenital	  heart	  disease	  it	  is	  still	  uncertain	  
how	   regional	   myocardial	   dysfunction	   affects	   global	   (dys-­‐)function.	   The	   role	   of	  
regional	   functional	   differences	   during	   the	   progression	   of	   myocardial	   dysfunction	  
needs	  to	  be	  explored.	  Strain	   imaging	  could	  be	  helpful	   in	  answering	   (part	  of)	   these	  
questions.	  	  
	  
Importantly,	   strain	   imaging	   techniques	   appear	   to	   be	   able	   to	   detect	   sub-­‐clinical	  
myocardial	  dysfunction	  at	  an	  earlier	  stage	  when	  compared	  to	  conventional	  imaging	  
modalities	  and	  applications.13,14,15,16,17	  
1.2.2 HOW CAN STRAIN BE MEASURED?   
	  
Tagged	  magnetic	  resonance	  imaging	  (tagged	  MRI)	  of	  the	  heart	  is	  currently	  used	  as	  
the	   gold	   standard	   to	   evaluate	   myocardial	   strain	   and	   strain-­‐rate.	   It	   is	   a	   sensitive,	  
accurate	  and	   load-­‐independent	   technique.	  However,	   several	   characteristics	  of	   this	  
technique	  preclude	  its	  use	  in	  daily	  clinical	  practice.	  It	  is	  characterized	  by	  a	  time	  and	  
labor-­‐consuming	  nature,	   its	   frame	   rate	   cannot	   be	   as	   high	   as	   in	   echocardiography,	  
which	   is	  of	   importance	   in	   children,	   it	   is	  not	  always	  easily	  accessible	  and	  obviously	  
not	   bed-­‐side.	   Furthermore,	   it	   is	   an	   expensive	   method,	   and	   in	   case	   of	   (young)	  
children	  often	  indicates	  a	  need	  for	  sedation	  and	  anesthesia.	  	  
	  
A	   second	   modality	   to	   measure	   strain	   is	   Tissue	   Doppler	   Imaging.18	   Doppler	  
echocardiography	   relies	   on	   quantification	   of	   the	   shift	   in	   frequency	   of	   ultrasound	  
signals	   reflected	   by	   moving	   objects.	   Using	   this	   principle,	   conventional	   Doppler	  
Chapter	  1	  	  |	  19	  
techniques	  assess	  the	  velocity	  of	  blood	  flow	  by	  measuring	  relatively	  high	  frequency,	  
low-­‐amplitude	  signals	  from	  small,	  fast-­‐moving	  blood	  cells.	  In	  TDI,	  the	  same	  Doppler	  
principles	   are	   used	   to	   quantify	   selectively	   the	   higher-­‐amplitude,	   low	   frequency	  
signals	   of	   myocardial	   tissue	   motion.	   The	   quantification	   of	   strain	   rate	   and	   strain	  
derived	  from	  TDI	  has	  been	  extensively	  validated.	  Tissue	  Doppler-­‐derived	  strain	  has	  
been	  utilized	  over	  the	  last	  decade	  in	  a	  great	  number	  of	  clinical	  situations,	  mainly	  in	  
adults,	   including	   the	   assessment	   of	   ischemia,	   evaluation	   of	   dyssynchronous	  
myocardial	   contraction	   and	   the	   assessment	   of	   function	   in	   relation	   to	   valve	  
abnormalities.	  However,	   TDI	   has	   several	   limitations.	   The	   first	   and	  most	   important	  
limitation	  is	  angle-­‐dependency.	  The	  tissue	  velocities	  as	  measured	  with	  TDI	  are,	  like	  
all	   Doppler-­‐derived	   measurements,	   dependent	   on	   the	   angle	   of	   insonation.	   TDI	   is	  
only	  able	  to	  reliably	  estimate	  strain	  when	  the	  angle	  between	  the	  ultrasound	  beam	  
and	   the	   tissue	   motion	   is	   small.	   Strain	   in	   the	   perpendicular	   plane	   cannot	   be	  
determined	   at	   all	   using	   this	   technique.	   Although	   a	   correction	   for	   the	   angle	   of	  
insonation	  can	  be	  applied	  if	  the	  tissue	  under	  investigation	  is	  not	  moving	  perfectly	  in	  
line	   with	   the	   ultrasound	   beam,	   the	   measurement	   obtained	   will	   be	   subject	   to	  
inaccuracy.	   Secondly,	   TDI	   is	   inherently	   one-­‐dimensional.	   As	   a	   consequence,	   strain	  
can	  only	  be	  assessed	  in	  one	  direction	  of	  contraction.18,19	  
	  
A	   third,	   relatively	   new	   technique,	   is	   known	   as	   two-­‐dimensional	   strain	  
echocardiography	  or	   ‘two-­‐dimensional	  speckle	  tracking	  echocardiography’	   (2DSTE).	  
This	   technique	   uses	   sequentional,	   two-­‐dimensional	   B-­‐Mode	   (grayscale)	   images	   to	  
quantify	   strain	   and	   strain-­‐rate.10,11	   It	   was	   developed	   in	   an	   attempt	   to	   (partly)	  
overcome	   the	   previously	  mentioned	   shortcomings	   of	   TDI	   (and	   to	   a	   lesser	   extend	  
tagged	  MRI).	  	  
1.2.3 TWO-DIMENSIONAL STRAIN ECHOCARDIOGRAPHY 
	  
Two-­‐dimensional	   strain	   echocardiography	   analyzes	   motion	   by	   tracking	   speckles	  
(acoustic	   “markers”	   related	   to	   the	   backscattering	   of	   ultrasound	   by	   myocardial	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tissue)	  in	  the	  2D	  ultrasonic	  image.	  These	  markers	  are	  a	  kind	  of	  spatial	  “noise”	  that	  is	  
homogeneously	  distributed	  throughout	  the	  image	  of	  the	  myocardium.	  In	  2D	  speckle	  
tracking,	  first	  the	  echo	  amplitude	  features	  of	  the	  speckle	  pattern	  are	  used	  to	  follow	  
the	   movement	   of	   small,	   partially	   overlapping,	   “windows”	   accurately	   over	  
consecutive	   frames.	  To	  achieve	   this,	  a	   local	   search	  algorithm,	  aimed	   to	  detect	   the	  
position	  of	  the	  image	  window	  with	  the	  most	  similar	  speckle	  pattern	  from	  one	  frame	  
to	   another,	   is	   used.	   This	   procedure	   is	   repeated	   for	   each	   window	   overlaying	   the	  
image.	  The	  appearance	  of	  the	  speckle	  pattern	  within	  a	  window	  may	  be	  considered	  
to	  be	  relatively	  stable	  between	  two	  subsequent	  image	  frames,	  whereas	  a	  change	  in	  
its	  position	  is	  assumed	  to	  be	  the	  result	  of	  tissue	  motion	  and	  deformation.	  When	  the	  
frame	  rate	  is	  known,	  the	  assessment	  of	  this	  change	  in	  position	  of	  a	  window,	  i.e.,	  its	  
displacement,	   allows	   determination	   of	   the	   deformation	   and	   its	   rate	   of	   change.	  
Finally,	   two-­‐dimensional	   strain	   and	   strain-­‐rate	   values	   are	   then	   obtained	   from	   the	  
differential	  displacement	  between	  pairs	  of	  windows	  within	  the	  myocardium.	  In-­‐vitro	  
and	   in-­‐vivo	   validations	   of	   2DSTE	   have	   been	   undertaken	   previously	   (primarily	   in	  
adults).20,21,22	   It	  may	   be	   remarked	   that	   a	   level	   of	   sophistication	   has	   been	   reached	  
where	   2DSTE	   can	   be	   considered	   ready	   for	   more	   widespread	   investigations	   of	   its	  
clinical	  utility.	  
1.2.4 ADVANTAGES OF 2DSTE OVER TDI 
	  
One	  important	  advantage	  of	  2DSTE	  is	  its	  independence	  on	  the	  angle	  of	  insonation,	  
in	  contrast	   to	  TDI	  where	   it	   is	  necessary	   for	   the	  main	  motion	  vector	   to	  be	   (almost)	  
parallel	  to	  the	  ultrasonic	  beam.	  	  
	  
The	   speckle	   pattern	   can	   be	   tracked	   in	   multiple	   directions,	   which	   allows	  
quantification	  of	  myocardial	  deformation	  in	  all	  three	  main	  directions	  of	  strain.	  	  
	  
These	   directions	   of	   deformation	   in	   the	  myocardium	   consist	   of:	   longitudinal	   (from	  
base	   to	   apex),	   radial	   or	   transmural	   (perpendicular	   to	   the	   epicardium	   and	   to	   the	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longitudinal	   axis)	   and	   circumferential	   strain	   (perpendicular	   to	   both	   radial	   and	  
longitudinal	  axis)	  (Figure	  3	  to	  5).22,23	  
	  
Figure 3 - Myocardial strain in all three principal directions. L: longitudinal; C: 
circumferential; R: radial 
	  
Figure 4 - Schematic cross sectional images of myocardial strain in all three principal 
directions 
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Figure 5 - On the left side: Longitudinal plane of the heart from apical 4-chamber view; 
the image below shows the different segments of the septal and lateral wall of the left 
ventricle that are indicated (BS: basal septum; MS: mid septum; AS: apical septum; BL: 
basal lateral wall; ML: mid lateral wall; AL: apical lateral wall). On the right side: Short-
axis view (transversal plane) of the heart; the image below shows the different 
segments of the left ventricular wall that are indicated (antsep: anterior septal wall; ant: 
anterior wall; lat: lateral wall; post: posterior wall; inf: inferior wall; sep: septal wall). 
	  
Importantly,	  2DSTE	  has	  been	  shown	  to	  be	  more	  accurate	  than	  strain	  obtained	  from	  
TDI.	   When	   TDI-­‐,	   2DSTE-­‐,	   and	   tagged	   MRI-­‐derived	   strain	   measurements	   were	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compared,	   strain	  data	  obtained	  with	   TDI	  were	   less	   comparable	   to	   those	  obtained	  
with	  tagged	  MRI	  than	  2DSTE-­‐derived	  data.24,25,26,27,28,29	  
	  
Furthermore,	  TDI	  has	  been	  reported	  to	  have	  higher	  interobserver	  and	  intraobserver	  
variabilities	  compared	  with	  strain	  data	  assessed	  by	  2DSTE.30,31,32,33,34	  	  
	  
Given	   the	   high	   reproducibility,	   relatively	   geometry-­‐	   and	   angle-­‐independency,	   and	  
automated	   tracking	   system	   (which	   facilitates	   easy	   acquisition	   of	   accurate	  
measurements),	   2DSTE	   has	   the	   potential	   to	   become	   a	   widespread	   strain	   imaging	  
technique	  with	  many	  clinical	  implications.	  	  
1.2.5 (CURRENT) LIMITATIONS OF 2DSTE 
	  
• As	   with	   TDI,	   the	   ejection	   phase	   indices	   of	   deformation	   are	   known	   to	   be	  
influenced	  by	  afterload	  and	  preload.	  This	  means	  that	  these	  indices	  do	  not	  
directly	   reflect	   pure	   myocardial	   intrinsic	   contractility.	   However,	   although	  
influenced	   by	   loading	   conditions,	   strain	   and	   especially	   strain-­‐rate	   indices	  
are	  likely	  less	  load-­‐dependent	  than	  tissue	  velocities.35,36,37	  	  
• The	   relatively	   low	   inherent	   quality	   of	   the	   2D	   echocardiographic	   images	  
(spatial	   resolution	   and	   speckle	   noise	   phenomenon)	   remains	   a	   limiting	  
factor,	  which	  is	  true	  for	  all	  ultrasound-­‐based	  imaging	  modalities.	  In	  young,	  
healthy	  subjects,	  approximately	  7%	  of	  all	  LV	  segments	  cannot	  be	  analyzed	  
due	  to	  poor	  image	  quality.	  	  
• Tracking	   algorithms	   use	   spatial	   and	   temporal	   smoothing	   and	   a	   priori	  
knowledge	  of	  “normal”	  LV	  function,	  which	  may	  affect	  the	  strain	  estimates	  
and	   thus	   erroneously	   indicate	   regional	   dysfunction	   or	   affect	   neighboring	  
segmental	  strain	  values.	  This	   is	   illustrated	  by	  the	  fact	  that	   in	  multi	  vendor	  
comparison	   studies,	   different	   strain	   values	   were	   obtained.	   The	   different	  
implementation	   of	   smoothing	   is	   considered	   to	   be	   one	   of	   the	   reasons	   for	  
differences	  between	  vendors.34	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• Measurements	   in	   the	   radial	   direction	   were	   shown	   to	   correlate	   less	   well	  
with	   the	   reference	   tool	   of	   ultrasonomicrometry.	   This	   is	   due	   to	   the	  
relatively	  limited	  thickness	  of	  the	  LV	  wall.	  A	  second	  contributing	  factor	  is	  a	  
greater	   proportion	   of	   movement	   being	   perpendicular	   to	   the	   ultrasound	  
beam	   which	   is	   associated	   with	   greater	   variance.34,38,39	   Consequently,	  
different	   manufacturers	   have	   developed	   different	   implementations	   for	  
deriving	   the	   radial	   strain,	   resulting	   in	   different	   radial	   strain	   values	   in	   the	  
same	  individuals.34	  	  
• The	  method	  is	  dependent	  on	  frame	  rate.	  Too	  low	  frame	  rate	  will	  result	   in	  
too	  great	  changes	  from	  frame	  to	  frame,	  resulting	  in	  poor	  tracking.	  This	  may	  
also	   limit	   the	   use	   in	   high	   heart	   rates,	   as	   the	   motion	   and	   thus	   frame-­‐to-­‐
frame	   change	   increases	   relative	   to	   the	   frame	   rate.	   Furthermore,	   too	   low	  
frame	  rates	  may	  lead	  to	  undersampling,	  erroneously	  reducing	  peak	  values	  
of	  strain	   indices.	  This	   is	  most	   important	   for	  measuring	  peak	  values	  during	  
diastole	   and	   isovolumic	   phases,	   not	   so	   much	   for	   systolic	   strain-­‐rate.	  
Systolic	  strain	  is	  associated	  with	  the	  least	  frame	  rate	  sensitivity	  of	  all.11,40,41	  
On	   the	   other	   hand,	   higher	   frame	   rates	   are	   obtained	   by	   reduced	   lateral	  
spatial	   resolution	   (i.e.,	   reducing	   the	   acoustic	   line	   density),	   and	   thus	  
resulting	   in	   poorer	   tracking	   (at	   least	   in	   the	   transverse	   direction).	   In	  
addition,	   too	   high	   frame	   rates	  may	   result	   in	   erroneous	   cumulative	   strain	  
estimates.	  For	  each	  strain	  estimation,	  an	  error	   is	  present.	  When	  very	  high	  
frame	   rates	   are	   applied,	   many	   strain	   estimates	   per	   cardiac	   cycle	   are	  
determined,	  which	  may	   result	   in	   a	   large	   error	  when	   cumulating	   all	   these	  
estimates	   for	   calculating	   the	   strain	   curve.	   At	   present,	   the	   optimal	   frame	  
rate	  for	  speckle	  tracking	  seems	  to	  be	  60-­‐90	  FPS.11,40	  	  
• Finally,	   another	   limitation	   of	   any	   two-­‐dimensional	   technique	   is	   that	   of	  
‘through	   plane	   motion’.	   Rotation	   and	   motion	   of	   the	   heart	   in	   the	   chest	  
cavity	   cause	   out-­‐of-­‐plane	  motion.	   However,	   these	  movements	   cause	   the	  
disappearance	  of	   the	   speckles	   over	   a	  multiple	   frames,	   rather	   than	  within	  
two	  consecutive	  frames.	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Figure 6 - Radial strain at the level of the papillary muscle in a healthy individual. The 
peak values of strain and strain-rate are similar for all six myocardial regions and the 
time to achieve this peak is uniform and synchronous. Radial strain is positive in 
systole as the LV thickens and so increases in the radial dimension. 
	  
1.3 OUTLINE OF THIS THESIS 
	  
This	  thesis	  concentrates	  on	  the	  application	  of	  2DSTE	  in	  children.	  	  
	  
The	   ultimate	   goal	   of	   two-­‐dimensional	   strain	   echocardiography	   is	   to	   provide	  
accurate,	  objective	  and	  quantitative	  indices	  of	  myocardial	  performance	  that	  are	  also	  
applicable	   to	   ventricles	  with	  different	  morphology	   (e.g.,	   right	   ventricle,	   congenital	  
heart	   disease).	   Previous	   research	   using	   2DSTE	   to	   evaluate	   ventricular	   myocardial	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function	  has	  focused	  on	  adults	  (with	  or	  without	  cardiac	  disease).	  The	  establishment	  
of	  reference	  values	  in	  a	  healthy	  pediatric	  cohort	  is	  a	  mandatory	  prerequisite	  for	  its	  
use	  in	  evaluating	  (pathologic)	  changes	  in	  ventricular	  function	  in	  children.	  Data	  in	  this	  
area	   are	   scarce	   and	   include	   only	   peak	   systolic	   strain	   in	   one	   or	   two	   directions,	  
without	  exact	  information	  on	  the	  timing	  of	  peak	  systolic	  strain.42,43	  
	  
SECTION	  ONE	  	  
	  
In	   the	   first	   section	  of	   this	   thesis	  we	  present	   reference	  values	   for	   two-­‐dimensional	  
strain	  echocardiography.	  	  
Chapter	  2	  describes	  left	  ventricular	  myocardial	  strain	  in	  all	  three	  principal	  directions	  
(longitudinal,	   circumferential	   and	   radial)	   assessed	   by	   means	   of	   2DSTE	   in	   a	   large,	  
healthy	  pediatric	  and	  young	  adult	  cohort.	  	  
Chapter	   3	   describes	   the	   timing	   of	   systolic	   deformation	   throughout	   the	   left	  
ventricular	  wall	  and	  its	  extent	  of	  synchronicity	  between	  ventricular	  wall	  segments	  in	  




In	   this	   part	   of	   the	   thesis	   we	   applied	   the	   2DSTE	   modality	   to	   evaluate	   LV	   systolic	  
function	  in	  children	  with	  various	  congenital	  and	  acquired	  heart	  diseases.	  	  
	  
Chapter	   4	   evaluates	   two-­‐dimensional	   strain	   echocardiographic	   findings	   in	  
asymptomatic	   children	   diagnosed	   with	   various	   degrees	   of	   isolated	   congenital	  
valvular	  aortic	  stenosis.	  None	  of	  the	  patients	  had	  a	  history	  of	  prior	   intervention	  to	  
relieve	  pressure	  overload	  of	  the	  left	  ventricle.	  
In	   Chapter	   5	   we	   investigate	   the	   recovery	   of	   left	   ventricular	   myocardial	   systolic	  
performance	   using	   (conventional	   and)	   two-­‐dimensional	   strain	   echocardiography	  
prior	   to	  and	  after	  balloon	  valvuloplasty	   in	  children	  with	   severe	  congenital	   valvular	  
aortic	  stenosis.	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In	   Chapter	   6	   we	   describe	   left	   ventricular	   myocardial	   performance	   assessed	   by	  
means	   of	   physical	   examination,	   electrocardiography,	   conventional	  
echocardiography	  and	  2DSTE	  in	  a	  group	  of	  children	  with	  established	  mitochondrial	  
disease.	  	  
In	  Chapter	  7	  we	  evaluate	   cardiac	   anatomy	  and	   left	   ventricular	  myocardial	   systolic	  
function	   in	   children	   previously	   diagnosed	   with	   Prader-­‐Willi	   syndrome.	   Cardiac	  
evaluation	   consisted	   of	   physical	   examination,	   electrocardiography,	   conventional	  
echocardiography	  and	  2DSTE.	  	  
In	  Chapter	  8	  we	  describe	   signs	  of	   early-­‐onset	   anthracycline	   induced	   cardiotoxicity	  
assessed	  with	  two-­‐dimensional	  strain	  echocardiography	  and	  biochemical	  assays.	  	  
	  
SECTION	  THREE	   	  
	  
The	  most	  important	  findings	  are	  summarized	  in	  Chapter	  9	  and	  Chapter	  10.	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2.1 ABSTRACT  
	  
Background:	  Two-­‐dimensional	  strain	  echocardiography	  or	  speckle	  tracking	  	  (2DSTE)	  
appears	   to	   hold	   significant	   promise	   as	   a	   tool	   to	   improve	   the	   assessment	   of	  
ventricular	  myocardial	  function.	  	  
	  
Aim:	  We	  aimed	  to	  estimate	  left	  ventricular	  myocardial	  systolic	  function	  with	  2DSTE	  
in	   a	   large	   cohort	   consisting	   of	   healthy	   children	   and	   young	   adults	   to	   establish	  
reference	  strain	  values.	  	  
	  
Methods:	   Transthoracic	   echocardiograms	   were	   acquired	   in	   195	   healthy	   subjects	  
(139	  children	  and	  56	  young	  adults)	  and	  were	  retrospectively	  analyzed.	  Longitudinal,	  
circumferential	  and	  radial	  peak	  systolic	  strain	  values	  were	  determined	  by	  means	  of	  
speckle	   tracking.	  Nonlinear	   regression	  analysis	  was	  performed	  to	  assess	   the	  effect	  
of	  aging	  on	  these	  2DSTE	  parameters.	  	  
	  
Results:	  There	  was	  a	  strong,	  statistically	  significant	  second-­‐order	  polynomial	  relation	  
(P<0.001)	   between	   global	   peak	   systolic	   strain	   parameters	   and	   age.	   Global	   peak	  
systolic	  strain	  values	  were	  lowest	  in	  the	  youngest	  and	  oldest	  age	  groups.	  	  
	  
Conclusion:	  This	   is	  the	  first	  report	  to	  establish	  age-­‐dependent	  reference	  values	  per	  
cardiac	   segment	   for	  myocardial	   strain	   in	  all	   three	  directions	  assessed	  using	  2DSTE	  
imaging	   in	   a	   large	   pediatric	   and	   young	   adult	   cohort.	  We	   emphasize	   the	   need	   for	  




Despite	   impressive	  developments	   in	  echocardiographic	   technology	  during	  the	  past	  
fifty	  years,	  there	  are	  still	   important	  challenges,	  which	  new	  techniques	  try	  to	  meet.	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One	  important,	  yet	  partially	  unresolved,	  challenge	  that	  remains	  is	  the	  quantification	  
of	  ventricular	  myocardial	   function	   in	  children	  with	  congenital	  heart	  disease	   (CHD).	  
Traditional	   methods,	   such	   as	   the	   one-­‐dimensional	   M-­‐mode	   technique	   (e.g.,	  
fractional	   shortening)	   and	   two-­‐dimensional	   imaging	   (e.g.,	   ejection	   fraction),	   are	  
used	  to	  evaluate	   left	  ventricular	  function.	  However,	  these	  methods	  are	  not	  always	  
applicable	  to	  pediatric	  hearts	  with	  complex	  congenital	  malformations.	  The	  cardinal	  
reason	   for	   this	   is	   that	   they	  are	  based	  on	  geometric	  assumptions	  and	  overlook	   the	  
complex	   characteristics	   of	   CHD.1	   Moreover,	   those	   current	   indices	   provide	   no	  
information	  about	  regional	  alterations	  in	  ventricular	  myocardial	  contraction.2	  These	  
disadvantages	   complicate	   the	   assessment	   of	   systolic	   and	   diastolic	   function	   in	  
children	  with	   CHD	   and	  underscore	   the	   need	   for	   better	   quantitative	   techniques	   to	  
assess	  ventricular	  function	  in	  this	  subset	  of	  patients.	  	  
	  
New	   applications,	   such	   as	   strain	   imaging,	   have	   been	   developed	   to	   address	   the	  
previously	   mentioned	   shortcomings.	   Myocardial	   strain	   is	   a	   dimensionless	  
assessment	  of	  regional	  ventricular	  deformation	  (i.e.,	  a	  percentage	  of	  deformation),	  
whereas	  myocardial	  strain	  rate,	  which	  is	  a	  time	  derivate	  of	  strain,	  indicates	  the	  rate	  
of	  deformation	  of	  a	  defined	  myocardial	  segment.	  Multiple	  studies	  have	  proven	  the	  
accuracy	  and	  reliability	  of	  strain	  imaging	  techniques	  in	  the	  assessment	  of	  (regional)	  
ventricular	  myocardial	  function.3,4	  Moreover,	  these	  techniques	  appear	  to	  be	  able	  to	  
detect	   sub-­‐clinical	   myocardial	   dysfunction	   at	   an	   earlier	   stage	   compared	   with	  
conventional	  imaging	  modalities.5,6,7	  Several	  diagnostic	  imaging	  modalities	  to	  assess	  
myocardial	  strain	  and	  strain	  rate	  have	  been	  developed	   in	  recent	  years.	   In	  addition	  
to	   tagged	   magnetic	   resonance	   imaging	   (tagged	   MRI)	   and	   tissue	   Doppler	   imaging	  
(TDI),	   a	   third	  method	   to	   determine	  myocardial	   strain	  was	   introduced	   some	   years	  
ago.	  This	  relatively	  novel	  technique	  is	  based	  on	  two-­‐dimensional	  echocardiographic	  
images,	   hence	   the	   name:	   two-­‐dimensional	   strain	   echocardiography	   (2DSTE).	   It	  
determines	   myocardial	   deformation	   by	   means	   of	   frame-­‐by-­‐frame	   tracking	   and	  
motion	   analysis	   of	   speckles	   within	   B-­‐mode	   images	   using	   optical	   flow	   algorithms.	  
Validation	   studies	   with	   tagged	   MRI	   and	   sonomicrometry	   in	   the	   adult	   population	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have	   provided	   evidence	   that	   2DSTE	   is	   a	   reliable	  method	   to	   determine	   ventricular	  
myocardial	   function.3,4	  Despite	   its	   limitations,	   such	  as	   sensitivity	   to	   signal	  noise,	   it	  
has	  the	  advantages	  over	  TDI-­‐based	  strain	  imaging	  that	  the	  strain	  estimates	  are	  not	  
angle-­‐dependent	   and	   that	   strain	   is	   obtained	   in	   two	   dimensions.4,8,9,10,11	  
Intraobserver	  and	   interobserver	  reliability	  scores	  have	  been	  established	  previously	  
and	   are	   high	   for	   almost	   all	   parameters.12	   Because	   this	   novel	   technique	   could	   be	  
easily	   accessible	   and	   applicable,	   and	   moreover	   is	   not	   based	   on	   geometric	  
assumptions,	   it	  may	   serve	   as	   an	   important	   tool	   in	   the	   evaluation	   of	   regional	   and	  
global	  ventricular	  function	  in	  pediatric	  subjects	  with	  or	  without	  CHD.	  	  
	  
The	   establishment	   of	   normal	   values	   in	   a	   healthy	   pediatric	   cohort	   is	   a	  mandatory	  
prerequisite	   for	   its	   use	   in	   evaluating	   (pathologic)	   changes	   in	   ventricular	   function.	  
Data	   in	   this	   area	   are	   scarce	   and	   include	   only	   peak	   systolic	   strain	   in	   one	   or	   two	  
directions.13,14	  For	   these	  reasons,	  we	  aimed	  to	  evaluate	   left	  ventricular	  myocardial	  
strain	   in	   all	   three	   directions	   (longitudinal,	   circumferential	   and	   radial)	   assessed	   by	  
means	   of	   2DSTE	   in	   a	   large,	   healthy	   pediatric	   and	   young	   adult	   cohort	   to	   establish	  
2DSTE	  reference	  values	  and	  to	  determine	  the	  influence	  of	  age	  and	  growth	  on	  these	  
values.	  	  
	  
2.3 MATERIAL and METHODS 
2.3.1 STUDY POPULATION 
	  
Subjects	   who	   were	   routinely	   referred	   for	   echocardiographic	   evaluation	   of	   an	  
asymptomatic,	   innocent	   heart	   murmur	   between	   May	   1,	   2005	   and	   November	   1,	  
2009,	  were	  retrospectively	  analyzed	  for	  their	  eligibility	  for	  inclusion	  in	  the	  study.	  All	  
consecutive	  healthy	  subjects,	  aged	  from	  birth	  to	  40	  years,	  were	  identified	  from	  our	  
echocardiographic	  database	  from	  the	  outpatient	  clinic	  at	  both	  the	  Children’s	  Heart	  
Centre	   and	   the	   Adult	   Heart	   Centre,	   Nijmegen,	   the	   Netherlands.	   Subjects	   with	  
structural	   (congenital)	   heart	   disease	   or	   abnormal	   cardiac	   rhythms	  were	   excluded.	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Other	   exclusion	   criteria	   consisted	   of	   hypertension,	   chronic	   illness,	   recent	   acute	  
illness	   or	   poor	   echocardiographic	   image	   quality.	   Demographic	   characteristics,	  
including	   age	   and	   gender	  were	   collected	   at	   the	   time	   the	   echocardiographic	   study	  
was	  performed.	   Informed	  consent	  was	  obtained	   from	  each	  participant.	   This	   study	  
was	  approved	  by	  the	  local	  medical	  ethics	  committee.	  	  
2.3.2 2DSTE DATA ACQUISITION 
	  
A	   complete	   physical	   examination	   was	   performed,	   including	   weight,	   height	   and	  
blood	   pressure	   measurements.	   Subsequently,	   all	   subjects	   underwent	   a	   detailed	  
transthoracic	  echocardiographic	  examination	  in	  the	  left	  lateral	  position	  according	  to	  
the	   recommendations	   of	   the	   American	   Society	   of	   Echocardiography.15	   Every	  
examination	  was	  performed	  at	  rest,	  without	  using	  sedation.	  Images	  were	  obtained	  
with	  a	  3.0-­‐MHz	  (S3)	  or	  a	  5.0-­‐MHz	  (S5)	  phased-­‐array	  transducer	  using	  a	  commercially	  
available	   system,	   the	   Vivid	   7	   echocardiographic	   scanner	   (GE,	   Vingmed	  Ultrasound	  
AS,	  Horten,	  Norway).	  The	  choice	  of	  an	  S3	  or	  a	  S5	  transducer	  depended	  on	  the	  age	  
and	  weight	  of	  the	  subject.	  Two-­‐dimensional	  multi-­‐frame	  B-­‐mode	  (grayscale)	  images	  
were	  obtained	  in	  the	  apical	  four-­‐chamber	  (4C),	  and	  parasternal	  midcavity	  short-­‐axis	  
view	   (at	   the	   level	  of	   the	  papillary	  muscle:	  SaxPM)	  and	  parasternal	  basal	   short-­‐axis	  
view	  (at	  the	  level	  of	  the	  mitral	  valve:	  SaxMV).	  	  
	  
A	  sector	  scan	  angle	  of	  30	  to	  60	  degrees	  was	  chosen	  and	  frame	  rates	  of	  60	  to	  90	  Hz	  
were	   used,	   since	   these	   rates	   are	   considered	   to	   be	   optimal	   for	   2D	   speckle	  
tracking.4,11,16	   Data	   were	   stored	   at	   the	   same	   frame	   rate	   as	   the	   acquisition	   frame	  
rate.	  Preferably	  images	  from	  five	  cardiac	  cycles	  triggered	  by	  the	  R	  wave	  of	  the	  QRS	  
complex	   were	   digitally	   saved	   in	   cineloop	   format.	   Offline	   speckle	   tracking	   analysis	  
was	  performed	  using	  software	  for	  echocardiographic	  quantification	  (EchoPAC	  6.1.0;	  
GE	   Vingmed	   Ultrasound	   AS,	   Horten,	   Norway).	   The	   timing	   of	   aortic	   valve	   closure	  
(AVC)	   and	   mitral	   valve	   opening	   (MVO)	   with	   respect	   to	   peak	   systolic	   strain	   were	  
manually	   obtained,	   using	   single	   gated	   pulsed-­‐wave	   (PW-­‐)Doppler	   or	   continuous-­‐
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wave	   (CW-­‐)	   Doppler	   images	   of	   the	   left	   ventricular	   outflow	   tract.	   For	   these	  
measurements,	  special	  care	  was	  taken	  to	  keep	  the	  heart	  rate	  in	  the	  same	  range	  as	  
during	   the	   2D	   grayscale	   imaging	   used	   for	   2D	   strain	   calculations.	   Endomyocardial	  
borders	  of	  the	  left	  ventricle	  were	  manually	  traced	  within	  the	  end-­‐systolic	  frame.	  The	  
second,	  epicardial	   tracing	  was	  automatically	  generated	  by	  the	  computer	  algorithm	  
and,	  when	  necessary,	  manually	   adjusted	   to	   cover	   the	  whole	  myocardial	  wall.	   The	  
tracking	  algorithm	  then	   followed	  the	  myocardial	   speckles	  during	   the	  cardiac	  cycle.	  
Tracking	   was	   accepted	   only	   if	   both	   visual	   inspection	   as	   well	   as	   the	   EchoPAC	  
software	   indicated	   adequate	   tracking.	   This	   means	   that	   tracking	   of	   any	   given	  
segment	  was	  accepted	  only	  when	   it	  was	   indicated	  with	  a	  green	  box.	  The	  software	  
automatically	   divided	   the	   cross-­‐sectional	   image	   into	   six	   segments,	   which	   were	  
named	  and	  identified	  according	  to	  the	  statement	  of	  the	  Cardiac	  Imaging	  Committee	  
of	   the	  Council	   on	  Clinical	  Cardiology	  of	   the	  American	  Heart	  Association.17	   The	   left	  
ventricular	  segments	  to	  be	  analyzed	  were	  the	  apical,	  middle	  and	  basal	  segments	  of	  
the	   septal	   (ApSept,	   MidSept,	   BasSept,	   respectively)	   and	   the	   lateral	   wall	   (ApLat,	  
MidLat,	  BasLat,	  respectively)	  of	  the	  4C	  view,	  as	  well	  as	  the	  anteroseptal	   (AntSept),	  
anterior	  (Ant),	  lateral	  (Lat),	  posterior	  (Post),	  inferior	  (Inf)	  and	  septal	  (Sept)	  segments	  
of	   the	  basal	  and	  midcavity	  short-­‐axis	  views.	  Strain	  curves	  of	   the	  three	  consecutive	  
cardiac	  cycles	  and	  values	  of	  the	  manual	  timing	  were	  imported	  into	  a	  custom-­‐made	  
software	   package	   for	   further	   analysis.	   The	  Q-­‐Q	   interval	  was	   determined	   from	   the	  
electrocardiographic	   signal	   to	   obtain	   cardiac	   cycle	   length.	   It	   is	   known	   that	   the	  
duration	  of	  the	  systolic	  phase	  of	  the	  cardiac	  cycle	  in	  rest	  does	  not	  change	  with	  small	  
changes	   in	  heart	   rate,	   in	   contrast	   to	   the	  diastolic	  phase.18	   Therefore,	   the	  diastolic	  
phase	  of	   the	  three	  cardiac	  cycles	  was	  automatically	  extended	  and	  adjusted	  by	  the	  
software	   package	   to	   the	   longest	   of	   the	   three	   cardiac	   cycles.	   This	   intervention	  
prevents	   a	   shift	   of	   the	   peak	   systolic	   strain	  while	   averaging	   the	   three	   consecutive	  
cardiac	  cycles.	  Cardiac	  cycles	  with	  lengths	  more	  than	  ten	  percent	  different	  from	  the	  
mean	  length	  of	  the	  three	  cardiac	  cycles	  were	  excluded	  from	  averaging	  and	  thus	  for	  
further	   analysis.	   Myocardial	   longitudinal,	   radial	   and	   circumferential	   strain	   values	  
were	   obtained.	   To	   determine	   global	   strain,	   the	   strain	   values	   of	   the	   six	   segments	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were	  averaged	   for	   the	   four-­‐chamber	   as	  well	   as	   the	   short-­‐axis	   views.	   Strain	   values	  
are	  dimensionless	  and	  are	  expressed	  as	  percentages.	  Negative	  strain	  values	  reflect	  
shortening/thinning,	  while	  positive	   strain	  values	   reflect	   lengthening/thickening.	  All	  
offline	  measurements	  with	  EchoPAC	  were	  performed	  by	  a	  single	  observer	  (K.A.M.).	  
Interobserver	  and	  intraobserver	  variability	  was	  determined	  by	  measurement	  of	  left	  
ventricular	  myocardial	  strain	  in	  40	  randomly	  selected	  subjects	  (5	  in	  each	  age	  group).	  
To	   assess	   intraobserver	   variability,	   the	   same	   observer	   (K.A.M.)	  measured	   the	   left	  
ventricular	   segments	   again	  with	   an	   interval	   greater	   than	  2	  months	   to	   avoid	   recall	  
bias.	  To	  assess	  interobserver	  variability,	  strain	  measurements	  were	  performed	  by	  a	  
second	  observer	  (M.B.)	  who	  was	  blinded	  to	  the	  results	  of	  the	  first	  observer	  (K.A.M.).	  
Figure	  7	  and	  8	  show	  an	  illustration	  of	  2D	  strain	  imaging.	  
	  
	  
Figure 7 - Short-axis imaging at the level of the papillary muscle with segmentation 
used for two-dimensional strain echocardiography. Ant: anterior wall; Antsep: anterior 
septal wall; Inf: inferior wall; Lat: lateral wall; LV: left ventricle; Post: posterior wall; RV: 
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Figure 8 – Radial and circumferential strain and strain rate curves of the septal wall at 
the level of the papillary muscle; ECG: electrocardiogram; ES: end-sysole; Sax-PM: 
short-axis view at the level of the papillary muscle.  
2.3.3 CONVENTIONAL ECHOCARDIOGRAPHIC PARAMETERS 
	  
Quantification	   of	   cardiac	   chamber	   size,	   ventricular	  mass	   and	   systolic	   and	  diastolic	  
left	   ventricular	   function	  were	  measured	   in	  accordance	  with	   the	   recommendations	  
for	   chamber	   quantification	   by	   the	   American	   Society	   of	   Echocardiography.15	   Left	  
ventricular	  systolic	  function	  was	  indicated	  using	  fractional	  shortening	  (FS),	  ejection	  
fraction	   (EF),	   left	   ventricular	   myocardial	   performance	   index,	   or	   Tei	   index,	   end-­‐
systolic	   wall	   stress	   (ESWS)	   and	   rate-­‐corrected	   velocity	   of	   circumferential	   fiber	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shortening	   (VCFc).	   Ejection	   fraction	   (EF)	   was	   calculated	   using	   the	   modified	  
Simpson’s	  rule.	  The	  PWD-­‐derived	  myocardial	  performance	  index	  was	  calculated	  by	  
adding	   the	   iso-­‐volumetric	   contraction	   time	   (ICT)	   and	   the	   iso-­‐volumetric	   relaxation	  
time	  (IVRT),	  and	  dividing	  the	  sum	  by	  the	  ejection	  time	  (ET).19	  Left	  ventricular	  end-­‐
systolic	  wall	   stress	   (ESWS)	  was	   calculated	   using	   the	  modified	   formula	   of	   Rowland	  
and	   Gutgesell.20	   VCFc	   was	   calculated	   using	   the	   formula	   obtained	   from	   Colan	   and	  
colleagues.21	   Left	   ventricular	   mass	   (LVM)	   was	   calculated	   with	   the	   formula	   for	  
estimation	   of	   LVM	   according	   to	   Devereux	   and	   Reichek	   and	   was	   subsequently	  
indexed	  to	  body	  surface	  area	  (BSA).22	  
2.3.4 STATISTICAL ANALYSIS 
	  
Patients	  were	  divided	  in	  eight	  different	  age	  groups	  for	  further	  analysis	  (see	  Table	  1).	  
All	   demographic,	   conventional	   echocardiographic	   and	   2D	   strain	   values	   are	  
expressed	  as	  mean	  ±	  standard	  deviation	  (SD).	  The	  relations	  between	  age	  and	  global	  
strain	   parameters	   were	   reported	   using	   scatterplots,	   one-­‐way	   analysis	   of	   variance	  
(ANOVA),	   and	   second-­‐order	   polynomial	   regression	   analysis.	   Multiple	   linear	  
regression	   analysis	   was	   performed	   to	   determine	   the	   additional	   effect	   of	  
anthropometrics	   (including	   heart	   rate,	   weight	   and	   height)	   and	   conventional	  
echocardiographic	  parameters	  on	  the	  myocardial	  global	  strain	  variables.	  	  
	  
Intraobserver	  and	   interobserver	  agreement	  was	  calculated	  using	  the	  Bland-­‐Altman	  
approach,	   including	   the	   calculation	   of	   mean	   bias	   (average	   difference	   between	  
measurements),	   the	   statistical	   significance	  of	   the	  mean	  bias	  on	  paired	   t	   tests	   (the	  
null	  hypothesis	  was	  zero	  bias),	  and	  the	   lower	  and	  upper	   limits	  of	  agreement	   (95%	  
limits	   of	   agreement	   of	   mean	   bias).	   In	   addition,	   the	   coefficient	   of	   variation	   was	  
determined	  (i.e.,	  the	  standard	  deviation	  of	  the	  difference	  of	  paired	  samples	  divided	  
by	  the	  average	  of	   the	  paired	  samples).	  P-­‐values	   less	   than	  0.05	  were	  considered	  to	  
indicate	   significance.	   Statistical	   analyses	   were	   performed	   using	   the	   Statistical	  
Package	  for	  Social	  Sciences	  for	  Windows,	  version	  16.0	  (SPSS	  Inc,	  Chicago,	  IL).	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2.4 RESULTS 
2.4.1 DEMOGRAPHIC AND ANTHROPOMETRIC PARAMETERS 
	  
A	  total	  of	  226	  subjects	  were	  evaluated	  for	  inclusion	  in	  the	  study.	  Of	  those	  subjects,	  
31	   (13.7%)	   were	   subsequently	   excluded	   in	   light	   of	   incomplete	   echocardiographic	  
data	  or	  suboptimal	  imaging	  quality.	  In	  total	  195	  healthy	  subjects	  (139	  children	  and	  
56	   young	   adults)	   were	   enrolled	   in	   the	   study.	   Subject	   characteristics	   and	  
anthropometric	  parameters	  are	  described	  in	  Table	  1.	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Table 1 - Demographic and anthropometric characteristics (mean ± standard deviation) 
of study subjects (n=195) categorized by age group  
BSA: body surface area; BMI: body mass index; DiaBP: diastolic blood pressure;  
HR: heart rate; SysBP: systolic blood pressure. 
	   	  






Table 2 - Conventional echocardiographic parameters (mean ± standard deviation) of 
study subject (n=195) categorized by age group 
EF biplane: ejection fraction measured by modified Simpson’s method; ESWS: end-systolic 
wall stress; FS: fractional shortening; LVET: left ventricular ejection time; LVETc: LVET 
corrected for heart rate; LV mass/BSA: left ventricular mass corrected for body surface area; 
VCFc: heart rate corrected velocity of circumferential fiber shortening. 
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2.4.2 CONVENTIONAL ECHOCARDIOGRAPHIC PARAMETERS 
	  
Conventional	  echocardiographic	  parameters	  of	  the	  study	  subjects	  are	  presented	  in	  
Table	   2.	   All	   standard	   echocardiographic	   findings	  were	  within	   previously	   described	  
reference	  values.	  	  
2.4.3 MYOCARDIAL STRAIN PARAMETERS 
Myocardial	   strain	   parameters	   are	   presented	   in	   Figures	   9	   –	   11	   and	   Tables	   3	   -­‐	   5.	  
Tracking	  was	  feasible	  in	  91%	  of	  all	  segments	  of	  the	  four	  chamber	  view,	  in	  96%	  of	  all	  
segments	  in	  the	  short-­‐axis	  view	  at	  the	  level	  of	  the	  papillary	  muscle	  and	  in	  91%	  of	  all	  
segments	   in	   the	   short-­‐axis	   view	   at	   the	   level	   of	   the	   mitral	   valve. 
Figure 9 - Global peak systolic longitudinal strain (Global SL) (%) versus age (years) 
among study subjects (scatter plot). Lines indicate regression line (mean) in the middle 
and 95% individual prediction interval. 
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Figure 10 - Midventricular peak systolic circumferentil strain (Global SCP) (%) versus 
age (years) among study subjects (scatter plot). Lines indicate regression line (mean) in 



















R Sq Quadratic =0,319
Page 1
Chapter	  2	  	  |	  47	  
	  
Figure 11 - Midventricular peak systolic radial strain (Global SRP)(%) versus age (years) 
among study subjects (scatter plot). Lines indicate regression line (mean) in the middle 
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Table 3 - Longitudinal peak systolic strain (mean ± standard deviation) of study 
subjects (n=195) categorized by age group  
Strain values are presented in percentages; SL: longitudinal peak systolic strain;  
P5: 5th percentile; P95: 95th percentile; * P < .05 when compared with age groups denoted by 
superscript numerals determined by means of one-way analysis of variance with Bonferroni 
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Table 5 - Circumferential peak systolic strain (mean ± standard deviation)  
of study subjects (n=195) categorized by age group  
Age	  group	  	   0	  years	  	  (1)	   1-­‐4	  years	  (2)	   5-­‐9	  years	  (3)	   10-­‐14	  years	  (4)	  
Ant.Sept.	  PM	   -­‐25.2	  ±	  5.7	   -­‐26.8	  ±	  3.6	   -­‐26.3	  ±	  2.3	   -­‐26.1	  ±	  3.0	  
Ant.	  PM	   -­‐18.2	  ±	  1.6	   -­‐21.3	  ±	  4.1	   -­‐24.4	  ±	  2.2	   -­‐24.1	  ±	  2.0	  
Lat.	  PM	   -­‐13.8	  ±	  2.3	   -­‐18.1	  ±	  2.0	   -­‐20.5	  ±	  1.5	   -­‐21.0	  ±	  1.7	  
Post.	  PM	   -­‐10.7	  ±	  4.0	   -­‐16.0	  ±	  1.9	   -­‐19.4	  ±	  1.1	   -­‐20.0	  ±	  1.4	  
Inf.	  PM	   -­‐17.0	  ±	  6.5	   -­‐20.4	  ±	  2.0	   -­‐22.7	  ±	  2.0	   -­‐22.8	  ±	  1.7	  
Sept.	  PM	   -­‐26.5	  ±	  6.0	   -­‐25.3	  ±	  3.6	   -­‐27.2	  ±	  2.6	   -­‐26.9	  ±	  2.8	  
Global	  S-­‐CP	   -­‐18.6	  ±	  3.3	  *2,3,4,5,6,7,8	   -­‐21.3	  ±	  2.0	  *1,3,4,5	   -­‐23.4	  ±	  1.7	  *1,2,7,8	   -­‐23.5	  ±	  1.8	  *1,2,7,8	  
P5	  Global	  S-­‐CP	   -­‐12.0	   -­‐17.3	   -­‐20.0	   -­‐19.9	  
P95	  Global	  S-­‐CP	   -­‐25.2	   -­‐25.3	   -­‐26.8	   -­‐27.1	  
Ant.Sept.	  MV	   -­‐25.1	  ±	  3.8	   -­‐27.1	  ±	  3.9	   -­‐25.3	  ±	  3.8	   -­‐24.3	  ±	  3.3	  
Ant.	  MV	   -­‐16.5	  ±	  4.2	   -­‐20.3	  ±	  4.4	   -­‐21.1	  ±	  2.1	   -­‐21.8	  ±	  2.0	  
Lat.	  MV	   -­‐11.5	  ±	  3.6	   -­‐15.4	  ±	  3.6	   -­‐17.4	  ±	  2.9	   -­‐19.2	  ±	  1.5	  
Post.	  MV	   -­‐11.4	  ±	  4.0	   -­‐12.4	  ±	  2.7	   -­‐15.3	  ±	  2.9	   -­‐18.2	  ±	  1.2	  
Inf.	  MV	   -­‐16.0	  ±	  7.6	   -­‐17.8	  ±	  3.4	   -­‐20.1	  ±	  2.1	   -­‐20.7	  ±	  1.8	  
Sept.	  MV	   -­‐24.5	  ±	  5.2	   -­‐24.9	  ±	  4.7	   -­‐26.4	  ±	  3.4	   -­‐24.7	  ±	  2.3	  
Global	  S-­‐CM	   -­‐17.5	  ±	  2.5	  *2,3,4,5,6,7,8	   -­‐19.7	  ±	  2.0	  *1,4,5	   -­‐20.9	  ±	  2.0	  *1	   -­‐21.5	  ±	  1.7	  *1,2	  
P5	  Global	  S-­‐CM	   -­‐12.5	   -­‐15.7	   -­‐16.9	   -­‐18.1	  
P95	  Global	  S-­‐CM	   -­‐22.5	   -­‐23.7	   -­‐24.9	   -­‐24.9	  
Age	  group	  	   15-­‐19	  years	  (5)	   20-­‐24	  years	  (6)	   25-­‐29	  years	  (7)	   30-­‐40	  years	  (8)	  
Ant.Sept.	  PM	   -­‐27.5	  ±	  2.8	   -­‐25.2	  ±	  2.1	   -­‐24.7	  ±	  2.5	   -­‐24.1	  ±	  2.0	  
Ant.	  PM	   -­‐22.9	  ±	  2.0	   -­‐22.5	  ±	  1.7	   -­‐20.9	  ±	  2.6	   -­‐20.4	  ±	  2.3	  
Lat.	  PM	   -­‐21.1	  ±	  2.2	   -­‐19.7	  ±	  1.5	   -­‐18.6	  ±	  2.1	   -­‐17.8	  ±	  2.0	  
Post.	  PM	   -­‐19.2	  ±	  2.5	   -­‐18.0	  ±	  1.6	   -­‐18.0	  ±	  2.1	   -­‐17.3	  ±	  2.4	  
Inf.	  PM	   -­‐22.4	  ±	  2.1	   -­‐20.9	  ±	  1.9	   -­‐19.6	  ±	  1.5	   -­‐20.7	  ±	  2.8	  
Sept.	  PM	   -­‐28.6	  ±	  2.5	   -­‐24.8	  ±	  2.8	   -­‐24.6	  ±	  3.2	   -­‐23.5	  ±	  2.7	  
Global	  S-­‐CP	   -­‐23.6	  ±	  2.0	  *1,2,7,8	   -­‐21.8	  ±	  1.5	  *1	   -­‐21.1	  ±	  1.9	  *1,3,4,5	   -­‐20.6	  ±	  2.2	  *1,3,4,5	  
P5	  Global	  S-­‐CP	   -­‐19.6	   -­‐18.8	   -­‐17.3	   -­‐16.2	  
P95	  Global	  S-­‐CP	   -­‐27.6	   -­‐24.8	   -­‐24.9	   -­‐25.0	  
Ant.Sept.	  MV	   -­‐24.0	  ±	  2.5	   -­‐24.8	  ±	  2.6	   -­‐25.1	  ±	  4.1	   23.2	  ±	  2.3	  
Ant.	  MV	   -­‐22.4	  ±	  1.9	   -­‐20.8	  ±	  2.0	   -­‐20.6	  ±	  1.5	   -­‐19.7	  ±	  1.6	  
Lat.	  MV	   -­‐19.3	  ±	  2.4	   -­‐18.2	  ±	  1.4	   -­‐18.8	  ±	  1.2	   -­‐18.3	  ±	  1.1	  
Post.	  MV	   -­‐17.7	  ±	  2.0	   -­‐18.2	  ±	  2.1	   -­‐16.9	  ±	  2.0	   -­‐16.2	  ±	  1.2	  
Inf.	  MV	   -­‐21.9	  ±	  2.7	   -­‐20.3	  ±	  1.8	   -­‐20.1	  ±	  1.6	   -­‐20.2	  ±	  2.2	  
Sept.	  MV	   -­‐26.0	  ±	  2.5	   -­‐24.0	  ±	  2.2	   -­‐24.3	  ±	  3.4	   -­‐23.4	  ±	  3.9	  
Global	  S-­‐CM	   -­‐21.9	  ±	  2.1	  *1,2	   -­‐21.1	  ±	  1.3	  *1	   -­‐21.0	  ±	  1.6	  *1	   -­‐20.2	  ±	  1.4	  *1	  
P5	  Global	  S-­‐CM	   -­‐17.7	   -­‐18.5	   -­‐17.8	   -­‐17.4	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Caption Table 4:  
Strain values are presented in percentages; Global S-RM: global radial peak systolic strain at 
the level of the mitral valve; Global S-RP: global radial peak systolic strain at the level of the 
papillary muscle; MV: at the level of the mitral valve; PM: at the level of the papillary muscle; 
P5: 5th percentile; P95: 95th percentile; * P < .05 when compared with age groups denoted by 
superscript numerals determined by means of one-way analysis of variance with Bonferroni 
correction for multiple comparisons. 
 
Caption Table 5:  
Strain values are presented in percentages; Global S-CM: global circumferential peak systolic 
strain at the level of the mitral valve; Global S-CP: global circumferential peak systolic strain at 
the level of the papillary muscle; MV: at the level of the mitral valve; PM: at the level of the 
papillary muscle; P5: 5th percentile; P95: 95th percentile; * P < .05 when compared with age 
groups denoted by superscript numerals determined by means of one-way analysis of 
variance with Bonferroni correction for multiple comparisons. 
	  
The	   most	   striking	   observation	   was	   a	   quadratic	   relationship	   (P<0.001)	   between	  
global	  peak	  systolic	  parameters	  and	  age.	  This	  means	  that	  global	  peak	  systolic	  strain	  
values	  were	  lowest	  in	  the	  youngest	  and	  oldest	  age	  groups.	  In	  contrast	  to	  teens,	  who	  
showed	   the	  highest	   global	   peak	   systolic	   values.	   There	  were	   statistically	   significant	  
differences	   (P<0.05)	   between	   most	   of	   the	   age	   groups	   for	   all	   global	   peak	   systolic	  
parameters	   as	   assessed	   by	   means	   of	   the	   one-­‐way	   analysis	   of	   variance	   with	  
Bonferroni	   correction	   for	   multiple	   comparisons	   (Tables	   3	   -­‐	   5).	   A	   second-­‐order	  
polynomial	   regression	   analysis	   revealed	   that	   age	   (together	   with	   its	   square)	  
accounted	  for	  37%	  of	  variation	  in	  global	  longitudinal	  peak	  systolic	  strain	  (R2=0.368;	  
P<0.05).	   Age	   (and	   its	   square)	   accounted	   for	   22%	   and	   29%	   of	   variation	   in	   global	  
circumferential	   peak	   systolic	   strain	   at	   the	   level	   of	   the	   papillary	  muscle	   (R2=0.222;	  
P<0.05)	  and	  mitral	  valve	  (R2=0.293;	  P<0.05)	  respectively.	  In	  the	  radial	  direction,	  age	  
(together	  with	   its	   square)	  accounted	   for	  12%	  and	  14%	  of	  variation	   in	  global	   radial	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peak	  systolic	  strain	  at	  the	  level	  of	  the	  papillary	  muscle	  (R2=0.117;	  P<0.05)	  and	  mitral	  
valve	  (R2=0.142;	  P<0.05)	  respectively.	  	  
	  
Multiple	   linear	   regression	   analyses	   among	   the	   anthropometric	   and	   standard	  
echocardiographic	  parameters	  were	  performed	   to	  determine	   the	  additional	   effect	  
of	   these	   parameters	   on	   the	  myocardial	   global	   strain	   variables	   (Table	   6).	   Of	   these	  
parameters,	  only	  VCFc	  and	  LVETc	  appear	   to	  be	  significantly	  associated	  with	  global	  
strain	   values	   after	   adjustment	   for	   age.	   VCFc	   was	   associated	   with	   global	  
circumferential	   strain	   (P<0.05).	   A	   1-­‐unit	   (i.e.,	   circ/sec)	   increase	   of	   VCFc	  
corresponded	  to	  a	  1.5%	  decrease	  in	  global	  circumferential	  peak	  systolic	  strain	  at	  the	  
level	   of	   the	   papillary	   muscle	   (95%	   CI:	   0.3%	   -­‐	   2.8%)	   and	   1.7%	   decrease	   in	   global	  
circumferential	   peak	   systolic	   strain	  at	   the	   level	  of	   the	  mitral	   valve	   (95%	  CI	  0.5%	  –	  
2.9%).	  LVETc	  was	  associated	  with	  both	  global	  circumferential	  and	  global	  longitudinal	  
peak	   systolic	   strain	   (P<0.05).	  A	   1-­‐millisecond	   increase	  of	   LVETc	   corresponded	   to	   a	  
0.015%	   decrease	   in	   global	   longitudinal	   peak	   systolic	   strain	   (95%	   CI:	   0.006%	   –	  
0.023%).	  	  
	  
As	  with	  global	  peak	  systolic	  circumferential	  strain,	  a	  1-­‐millisecond	  increase	  in	  LVETc	  
corresponded	   to	  a	  0.05%	  decrease	   in	  global	  peak	   systolic	   circumferential	   strain	  at	  
the	  level	  of	  the	  papillary	  muscle	  (95%	  CI:	  0.034%	  -­‐0.067%)	  and	  a	  0.024%	  decrease	  at	  
the	   level	   of	   the	   mitral	   valve	   (95%	   CI:	   0.009%	   –	   0.039%).	   No	   gender-­‐based	  
differences	   were	   present.	   Figure	   12	   and	   13	   illustrate	   peak	   systolic	   strain	   in	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  GlobalSL	   GlobalSCP	   GlobalSCM	   GlobalSRP	   GlobalSRM	  
Age//Age2	   0.37	  e	   0.22	  e	   0.29	  e	   0.12	  e	   0.14	  e	  
Age//Age2	  //	  LVETc	   0.41	  b	   0.25	  b	   0.34	  c	   0.12	   0.14	  
Age//Age2	  //	  VCFc	   0.37	   0.24	  b	   0.31	  b	   0.12	   0.14	  
Age//Age2	  //	  Tei	  index	   0.37	   0.23	   0.29	   0.12	   0.14	  
Age//Age2	  //	  FS	   0.38	   0.22	   0.29	   0.12	   0.14	  
Age//Age2	  //	  EF	  biplane	   0.37	   0.22	   0.29	   0.13	   0.14	  
Age//Age2	  //	  ESWS	   0.38	   0.23	   0.29	   0.12	   0.14	  
Age//Age2	  //	  LVIDs	   0.37	   0.22	   0.29	   0.12	   0.14	  
Age//Age2	  //	  LVIDd	   0.37	   0.22	   0.30	   0.12	   0.14	  
Age//Age2	  //	  LVEDV	   0.38	   0.23	   0.29	   0.12	   0.15	  
Age//Age2	  //	  HR	   0.37	   0.22	   0.30	   0.12	   0.14	  
Age//Age2	  //	  weight	   0.38	   0.22	   0.29	   0.12	   0.15	  
Age//Age2	  //	  height	   0.38	   0.22	   0.29	   0.12	   0.14	  
Age//Age2	  //	  BMI	   0.37	   0.22	   0.29	   0.12	   0.14	  
Age//Age2	  //	  BSA	   0.37	   0.22	   0.30	   0.12	   0.15	  
Final	  Model	  g	   0.41	  b	   0.28	  d	   0.37	  d	   0.12	  d	   0.14	  d	  
Predictors	  used	  in	  
Final	  Model	  f	  
Age//Age2	  	  	  
(P<0.0001)	  
LVETc	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(P=0.001)	  
Age//Age2	  	  	  
(P<0.0001)	  
LVETc	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(P<0.001)	  
VCFc	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(P=0.025)	  
Age//Age2	  	  	  
(P<0.0001)	  
LVETc	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(P<0.001)	  
VCFc	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(P=0.031)	  
Age//Age2	  	  	  
(P<0.0001)	  
Age//Age2	  	  	  
(P<0.0001)	  
	  
54	  |	  Chapter	  2	  
Caption Table 6:  
Predictors: LVETc: LV ejection time corrected for heart rate; VCFc: heart-rate corrected 
velocity of circumferential fiber shortening; FS: fractional shortening; EF biplane: ejection 
fraction measured by modified Simpson’s method; ESWS: end-systolic wall stress; LVIDs: LV 
internal diameter during systole; LVIDd: LV internal diameter during diastole; LVEDV: LV end 
diastolic volume; HR: heart rate; BMI: body mass index; BSA: body surface area.  
 
Outcome variables: GlobalSL: Global peak systolic longitudinal strain; Global SCP: Global 
peak systolic circumferential strain at the level of the papillary muscle (midcavity); Global 
SCM: Global peak systolic circumferential strain at the level of the mitral valve (basal); Global 
SRP: Global peak systolic radial strain at the level of the papillary muscle (midcavity); Global 
SRM: Global peak systolic radial strain at the level of the mitral valve (basal). 
 
Each R2 is based on the linear model that uses all subjects with known values for all predictors 
used in that particular model.  
a: P<0.05; b: P<0.01; c: P<0.001; d: P<0.0001; e: P< 0.0001 
a, b, c, d: P-value based on partial F-test comparing model with indicated predictors to model 
using only age and age2 as predictors. 
e: P-value based on global F-test for linear model using age and age2 as predictors. 
f: P-values based on partial F-test comparing the Final Model to the model based on all 
variables in Final Model minus the variable of concern.  
g: The Final Model uses as predictors age and age2 and the variables that contribute 
significantly over age and age2, as shown in the upper part of the table, and remained 




























































































































Figure 12 - Global peak systolic longitudinal strain versus various morphometric variables among 
study objects 






















































































































Figure 13 - Global peak systolic longitudinal strain versus various morphometric variables among study 
objects 
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Caption Figure 12: 
Scatterplots with locally weighted line smoothers (loess regression lines) to indicate curved 
linear relationships.  
GlobalSL: Global longitudinal peak systolic strain (%); LV_mass: left ventricular mass (g); 
LV_mass_BSA: left ventricular mass corrected for body surface area (g/m2);  
LVEDV: left ventricular end diastolic volume (ml); LVESV: left ventricular end systolic volume 
(ml). 
 
Caption Figure 13: 
Scatterplots with locally weighted line smoothers (loess regression lines) to indicate curved 
linear relationships. 
GlobalSL: Global longitudinal peak systolic strain (%); height (m); BSA: body surface area 
(m2); HR: heart rate (bpm); EF_biplane: left ventricular ejection fraction (%).   
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The	   intraobserver	  and	   interobserver	  variability	  results	  are	  shown	  in	  Table	  7.	  There	  
were	  no	  important	  differences	  in	  variability	  scores	  between	  the	  various	  age	  groups	  
or	  various	  segments.	  	  
	  
Table 7 - Intraobserver and interobserver variability of global peak systolic strain 
Variable	   Bias	   LLA	   ULA	   CV	  
INTRAOBSERVER	  
Global	  S-­‐L	   0.03	   -­‐2.89	   2.95	   7.15	  
Global	  S-­‐CP	   -­‐0.39	   -­‐3.51	   2.74	   7.22	  
Global	  S-­‐CM	   -­‐0.02	   -­‐3.19	   3.14	   7.89	  
Global	  S-­‐RP	   -­‐0.32	   -­‐10.01	   9.36	   8.91	  
Global-­‐S-­‐RM	   -­‐0.23	   -­‐9.19	   8.73	   8.52	  
INTEROBSERVER	  
Global	  S-­‐L	   -­‐0.04	   -­‐3.35	   3.27	   8.12	  
Global	  S-­‐CP	   0.46	   -­‐3.61	   4.54	   9.44	  
Global	  S-­‐CM	   -­‐0.09	   -­‐4.52	   4.34	   11.04	  
Global	  S-­‐RP	   -­‐0.39	   -­‐14.78	   14.01	   13.22	  
Global-­‐S-­‐RM	   0.28	   -­‐13.21	   13.78	   12.83	  
	  
Global S-L: global peak systolic longitudinal strain; Global-S-CP: global peak systolic 
circumferential strain at the level of the papillary muscle; Global-S-CM: global peak systolic 
circumferential strain at the level of the mitral valve; Global-S-RP: global peak systolic radial 
strain at the level of the papillary muscle;  
Global-S-RM: global peak systolic radial strain at the level of the mitral valve;  
Bias: mean difference between paired measurements;  
LLA: 95% lower limit of agreement;  
ULA: 95% upper limit of agreement;  
CV: coefficient of variation. 
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2.5 DISCUSSION 
	  
Reference	  values	  for	  2D	  strain	  echocardiography	  measurements	  in	  the	  pediatric	  and	  
young	  adult	  population	  are	  scarce.	  Two	  previously	  published	  reports	  have	  focused	  
on	   this	   subject.	   Lorch	   et	   al.	   investigated	   2D	   strain	   echocardiography	   in	   a	   large	  
healthy	   pediatric	   population.14	   Their	   study	   provided	   reference	   values	   for	   2D	  
longitudinal	   strain	   outcomes,	   however	   circumferential	   and	   radial	   strain	  
measurements	  were	   not	   included.	   Bussadori	  et	   al.	   described	   reference	   values	   for	  
circumferential	   and	   longitudinal	   strain	   and	   strain	   rate	   measurements	   in	   a	   small	  
pediatric	   (n=15)	   and	   adult	   (n=30)	   population.13	  Data	  on	   circumferential	   and	   radial	  
2D	  strain	  measurements	  in	  a	  large	  healthy	  pediatric	  and	  young	  adult	  population,	  to	  
establish	  their	  reference	  values	  and	  investigate	  the	  influence	  of	  age	  on	  them,	  were	  
still	  lacking.	  	  
	  
In	  the	  present	  study,	  we	  collected	  2D	  strain	  echocardiography	  data	  in	  different	  left	  
ventricular	   wall	   segments	   and	   in	   all	   three	   directions,	   longitudinal,	   radial	   and	  
circumferential,	   in	   a	   large	   healthy	   cohort	   consisting	   of	   children	   and	   young	   adults.	  
Our	  findings	  are	  in	  disagreement	  with	  the	  previous	  study	  performed	  by	  Lorch	  et	  al.	  
that	   showed	   a	   relative	   invariability	   of	   longitudinal	   peak	   systolic	   strain	  with	   age.14	  
Regression	   analysis	   performed	   on	   our	   data	   showed	   a	   statistically	   significant	  
relationship	   between	   age	   and	   global	   peak	   systolic	   strain	   values	   in	   all	   directions.	  
Subjects	  at	  both	  ends	  of	  the	  age	  spectrum	  displayed	  the	  lowest	  peak	  systolic	  strain	  
values	   in	   contrast	   to	   teenagers,	   whose	   strain	   values	   are	   significantly	   higher.	   In	  
several	  previous	  studies,	  the	  growth	  and	  function	  of	  the	  human	  heart	  was	  analyzed	  
by	  means	  of	  echocardiography	  and	  ergometry,	  which	  gave	  evidence	  for	  an	  increase	  
in	  cardiac	  contractility	  during	  puberty.23,24	  Increased	  cardiac	  contractility	  is	  probably	  
one	   of	   the	  most	   important	   factors	   that	   enables	   a	   substantial	   increase	   in	   physical	  
working	   capacity	   during	   puberty.25	   The	   systolic	   thickness	   of	   ventricular	   walls	  
increases	   disproportionally	   when	   related	   to	   the	   rise	   in	   afterload	   during	   pubertal	  
development.	  With	  this	  observation,	  it	  seems	  that	  cardiac	  systolic	  function	  prepares	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a	  reserve,	  probably	  for	  future	  increase	  in	  myocardial	  energy	  expenditure	  due	  to	  an	  
increase	  in	  functional	  working	  capacity.	  The	  same	  relationship	  between	  age	  on	  one	  
hand	   and	   left	   ventricular	  mass	   (LVM)	   on	   the	   other	   has	   been	   reported	   in	   healthy,	  
normotensive	  humans.	  A	  study	  performed	  by	  Cain	  et	  al.	  identified	  age	  as	  the	  major	  
determinant	   of	   LVM	   in	   healthy	   subjects.26	   LVM	   strongly	   increased	   when	   children	  
reached	  pubertal	  age	  and	  subsequently	  declined	  during	  adult	   life	   to	  a	   level	   that	   is	  
approximately	   80%	   of	   early	   adulthood	   despite	   increasing	   blood	   pressure	   and	  
exercise	   activity	   with	   increasing	   age	   in	   their	   study	   population.	   The	   underlying	  
biological	  trigger	  that	  causes	  the	  sudden	  surge	  in	  cardiac	  contractility	  and	  LVM	  has	  
not	  been	  identified.	  A	  possible	  explanation	  could	  be	  a	  physiological	  response	  as	  an	  
adaptation	  process	  to	  an	  increased	  oxygen	  demand	  due	  to	  an	  increasing	  body	  mass	  
and	   functional	  working	   tasks.	  Other	   factors,	   such	  as	  genetic	  and	  hormonal	   factors	  
should	   also	   be	   considered.	   There	   is	   evidence	   that	   hormones,	   such	   as	   growth	  
hormone	  and	  sex	  hormones	  whose	  concentrations	  surge	  during	  puberty,	   influence	  
cardiac	   growth	   and	   systolic	   function.	   The	   heart	   possesses	   specific	   myocardial	  
receptors	   for	   growth	  hormone	   (GH)	   and	   its	   anabolic	  mediator,	   insulin-­‐like	   growth	  
factor-­‐1	   (IGF-­‐1).	   Both	   GH	   and	   IGF-­‐1	   have	   been	   reported	   able	   to	   exert	   an	   acute	  
positive	   inotropic	   effect.27	   The	   administration	   of	   recombinant	   IGF-­‐1	   to	   healthy	  
human	  subjects	  has	  been	  reported	  to	  increase	  cardiac	  performance,	  as	  assessed	  by	  
impedance	   cardiography	   or	   echocardiography.28	   IGF-­‐1	   increases	   intracellular	  
calcium	   content	   and	   enhances	   the	   calcium	   sensitivity	   of	   myofilaments	   in	  
cardiomyocytes.29,30	   Another	   contributing	   factor	   to	   increasing	   contractility	   during	  
puberty	  could	  be	  cardioregulatory	  actions	  of	  sex	  hormones.	  Androgen	  exposure	  for	  
example	   has	   been	   shown	   to	   directly	   stimulate	   the	   contractility	   of	   isolated	   rat	  
ventricular	   myocytes	   and	   thus	   may	   play	   a	   role	   in	   regulating	   cardiac	  
performance.31,32	   Similar	   to	   testosterone,	   estrogen	   has	   been	   shown	   to	   improve	  
cardiac	  performance	  and	  hemodynamic	  function.33,34,35	  	  
	  
A	   remarkable	   result	   of	   our	   study	  was	   the	   observation	   of	   low	   global	   peak	   systolic	  
strain	  values	  in	  infants.	  Previous	  reports	  have	  not	  reached	  consensus	  on	  the	  cardiac	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contractile	   state	   in	   this	   age	   group	   compared	   with	   older	   children.	   Some	   have	  
concluded	  that	  newborn	  infants	  have	  a	  higher	  basal	  contractile	  state	  that	  cannot	  be	  
accounted	  for	  completely	  by	  a	  lower	  afterload.36,37,38	  Pena	  et	  al.,	  for	  instance,	  found	  
higher	   peak	   systolic	   radial	   and	   longitudinal	   strain	   assessed	   by	   means	   of	   TDI	   in	  
healthy	  neonates	  during	  their	  first	  day	  of	  life	  compared	  with	  a	  second	  measurement	  
at	   the	   age	   of	   one	   month.39	   Others	   have	   reported	   lower	   TDI	   velocities	   in	   infants	  
compared	  with	   older	   children,	  which	   is	   in	   accordance	  with	   the	   results	   of	   invasive	  
animal	  studies.40	  These	  studies	  describe	  a	  lower	  myocardial	  contractile	  state	  in	  the	  
newborn	  age	  group.41	  Besides	   lower	  global	   systolic	   strain	   results,	  we	  also	   found	  a	  
greater	   range	   of	   variation	   in	   the	   youngest	   age	   group	   in	   comparison	   with	   older	  
subjects.	   This	   variation	   could	   be	   explained	   by	   a	   previously	   reported	   greater	  
sensitivity	   of	   myocardial	   performance	   to	   changes	   in	   afterload.38	   Indeed,	   several	  
important	  hemodynamic	  changes	  occur	  during	  early	  neonatal	  life.	  Preload	  increases	  
due	  to	  the	  closure	  of	  the	  ductus	  arteriosus,	  with	  subsequent	  increase	  of	  pulmonary	  
blood	  flow.	  A	  postnatal	  increment	  in	  afterload	  is	  related	  to	  the	  removal	  of	  the	  low-­‐
resistance	   placental	   circulation	   and	   increased	   systemic	   arterial	   blood	   pressure.	  
When	  taking	  these	  alterations	  in	  loading	  conditions	  into	  account,	  it	  seems	  likely	  that	  
they	   exert	   at	   least	   some	   influence	   on	   myocardial	   deformation.	   Therefore,	   it	   is	  
important	  to	  note	  that	  our	  study	  population	  did	  not	  include	  infants	  below	  the	  age	  of	  
1	  month.	  Besides	  hemodynamic	  and	  other	  biological	  factors,	  it	  is	  possible	  that	  (part)	  
of	   the	   large	   variations	   in	   myocardial	   strain	   in	   neonates	   reflect	   a	   technical	  
shortcoming	   of	   2DSTE	   analysis.	   Thin	   left	   ventricular	   walls	   of	   infants	   with	   small	  
absolute	  deformation	  distances	  could	  be	  more	  susceptible	  to	  error.	  	  
	  
After	   adjustment	   for	   age,	   of	   the	   anthropometric	   and	   conventional	  
echocardiographic	  parameters	  tested	  in	  this	  study	  only	  VCFc	  and	  LVETc	  appeared	  to	  
be	  significantly	  associated	  with	  global	  strain	  values.	  Unlike	  the	  study	  by	  Lorch	  et	  al.,	  
we	   did	   not	   find	   a	   strong	   relation	   between	   cardiac	   size	   (e.g.,	   left	   ventricular	   end	  
diastolic	   volume)	   and	   peak	   systolic	   strain	   parameters.14	   Although	   our	   findings	   did	  
not	  indicate	  one	  specific	  anthropometric	  or	  hemodynamic	  variable	  that	  explains	  the	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observed	  differences	  in	  myocardial	  deformation	  between	  the	  various	  age	  groups,	  it	  
is	   likely	   that	   each	   individual	   morphometric	   variable	   (and	   their	   alterations	   during	  
growth	  and	  development)	  contributes	  to	  the	  overall	  changes	  in	  peak	  systolic	  strain	  
which	  we	  have	  observed.	  	  
Our	   results	   indicate	   a	   significant	   gradient	   of	   deformation	   from	   base	   to	   apex	   for	  
longitudinal	  strain	   in	  the	   left	  ventricular	  septum	  and	   lateral	   free	  walls.	   In	  addition,	  
circumferential	  and	  radial	  strain	  increased	  from	  base	  to	  midventricle	  as	  well.	  These	  
findings	  are	  in	  agreement	  with	  those	  of	  Bussadori	  et	  al.13	  However,	  considering	  that	  
in	  this	  latter	  study	  a	  different	  2D	  strain	  method	  was	  used	  that	  analyzed	  only	  the	  left	  
side	   of	   the	   septum	   for	   longitudinal	   strain	   and	   only	   the	   subendocardial	   layer	   for	  
circumferential	   strain,	   it	   is	   interesting	   to	  observe	   that	   in	  our	  study	  population	   this	  
base	  to	  apex	  gradient	  was	  significant	  even	  using	  speckle	  tracking	  that	  uses	  kernels	  
distributed	   throughout	   the	  whole	   thickness	  of	   the	  myocardial	  wall	  and	  septum.	   In	  
previous	  studies,	  different	  imaging	  techniques	  have	  given	  variable	  results	  regarding	  
the	  uniformity	  of	   left	  ventricular	  strain	   from	  base	  to	  apex.	  Tagged	  MRI	  and	  2DSTE	  
studies	   reported	   higher	   strain	   in	   the	   apex,	   in	   contrast	   to	   tissue	   velocity	   imaging	  
reports	   which	   did	   not	   show	   significant	   variation	   from	   base	   to	   apex.42,43,44,45	   The	  
latter	  could	  be	  a	  reflection	  of	  the	   implications	  of	  the	  angle	  of	   insonation	  on	  apical	  
measurements	  when	  using	  TDI.	   In	  addition	  to	  technical	   factors	  contributing	  to	  the	  
base-­‐to-­‐apex	   gradient	   of	   deformation,	   we	   consider	   that	   it	   is	   possible	   that	   there	  
exists	   a	  physiological	   substrate	   in	  which	   the	  base-­‐to-­‐apex	  gradient	   is	   the	   result	  of	  
the	   torsional	   mechanism	   of	   the	   left	   ventricular	   system	   and	   the	   direction	   of	  
contraction	   of	   the	   descending	   fibers	   in	   the	   internal	   loop	   of	   helical	   ventricular	  
myocardial	  band.	  	  
	  
2.6 STUDY LIMITATIONS 
	  
This	   study	   is	   limited	   by	   its	   retrospective	   nature.	   Our	   study	   population	   did	   not	  
include	   infants	   below	   the	   age	   of	   one	   month.	   Furthermore,	   the	   dependence	   of	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2DSTE	  on	  frame-­‐by-­‐frame	  tracking	  of	  the	  myocardial	  pattern	  makes	  it	  dependent	  on	  
image	   factors	   including	   reverberation	   artifacts	   and	   attenuation.	   Indeed,	   technical	  
proficiency	   remains	   important	   in	   image	   processing.	   Also,	   we	   did	   not	   investigate	  
radial	  and	  circumferential	  strain	  at	  the	  apical	  level	  of	  the	  left	  ventricle.	  Comparison	  
with	  an	  independent	  external	  technique,	  such	  as	  tagged	  MRI,	  was	  not	  performed	  in	  
the	  current	  study,	  primarily	  because	  the	  validation	  of	  speckle-­‐tracking	  software	  has	  
already	   been	   compared	   with	   MRI	   previously.46,47	   Overall,	   the	   variability	   of	   radial	  
peak	   systolic	   strain	   measurement	   was	   higher	   when	   compared	   to	   circumferential	  
and	   longitudinal	   measurement,	   which	   is	   in	   accordance	   with	   another	   study.48	  
However,	   the	   reproducibility	   of	   peak	   systolic	   strain	   measurements	   in	   all	   three	  
directions	  of	  deformation	  (expressed	  by	  intraobserver	  and	  interobserver	  variability	  
scores)	  was	   somewhat	   higher	   compared	  with	   this	   previous	   study.	   In	   addition,	  we	  
used	  custom-­‐made	  software,	  which	  is	  not	  commercially	  available.	  The	  custom-­‐made	  
software	  was	  specially	  developed	  to	  improve	  the	  reliability	  of	  timing	  of	  peak	  systolic	  
strain	   measurements	   while	   averaging	   strain	   curves,	   as	   well	   as	   to	   include	   peak	  
systolic	   strain	   measurements,	   which	   occur	   (shortly)	   before	   aortic	   valve	   closure.	  
Although	  the	  custom-­‐made	  software	  is	  not	  commercially	  available,	  this	  method	  can	  
be	   implemented	   in	   generally	   available	   software	   such	   as	  Matlab	   (The	  MathWorks	  
Inc.,	  Natick,	  MA;	  see	  appendix	  for	  instructions).	  	  	  
	  
2.7 CONCLUSION  
	  
With	   this	   study,	   we	   present	   age-­‐specific	   reference	   values	   for	   2D	   strain	  
echocardiography	   parameters,	   which	   are	   essential	   for	   its	   use	   in	   evaluating	  
(pathologic)	  changes	  in	  ventricular	  myocardial	  function.	  This	  study	  shows	  that	  age	  is	  
an	   important	   determinant	   of	   peak	   systolic	   strain	   values	   in	   healthy	   subjects	   and	  
therefore	   emphasizes	   the	   need	   for	   age-­‐specific	   reference	   values	   for	   adequate	  
interpretation	  of	  2DSTE	  measurements.	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2.8 APPENDIX 
	  
Three	   consecutive	   cardiac	   cycles	   were	   analyzed.	   Results	   from	   all	   views	   and	  
segments	  were	  separately	  digitally	  stored	  into	  text	  files	  on	  the	  local	  Hard	  	  
Drive	  of	  the	  GE	  workstation	  (with	  disabled	  drift	  compensation).	  	  
The	  data	  files	  then	  were	  exported	  from	  the	  system	  and	  stored	  on	  the	  network	  for	  
further	  analysis	  in	  a	  custom-­‐made	  software	  package	  	  
“CardiacCurveAnalysisTool”	  (CCAT)	  using	  Matlab	  version	  7.4.0.287	  (r2007a).	  	  	  
	  
CUSTOM-­‐MADE	  SOFTWARE	  -­‐	  STEP	  BY	  STEP	  
	  
-­‐ automatic	  load	  of	  the	  three	  consecutive	  cardiac	  cycles	  results	  
-­‐ up	  sampling	  (cubic	  spline)	  to	  2000	  samples	  per	  cardiac	  cycle	  (in	  order	  to	  be	  
able	  to	  select	  precise	  time	  stamps	  for	  the	  QQ-­‐definition)	  
-­‐ interactive	  QQ-­‐onset	  defining	  (on	  the	  three	  consecutive	  cardiac	  cycles)	  
-­‐ curve	  length	  check	  (If	  length	  difference	  is	  >10%	  then	  delete	  longest	  cycle)	  
-­‐ deletion	  of	  data	  before	  and	  after	  the	  selected	  QQ	  timestamps	  
-­‐ padding	  zeros	  (NaN’s)	  at	  the	  end	  of	  the	  diastolic	  phase	  for	  the	  shortest	  	  	  
cycles	  (to	  generate	  equal	  data	  lengths)	  
-­‐ drift	  compensation	  (using	  Matlab	  detrend	  linear	  function)	  
-­‐ curve	  averaging	  (using	  Matlab	  mean	  function)	  
-­‐ maximum	  detection	  
-­‐ estimation	  of	  averaged	  peak	  values	  per	  segment	  	  
	  
*	  The	  custom-­‐made	  software	  used	  in	  this	  study	  was	  specially	  developed	  to	  improve	  
the	   timing	   of	   systolic	   deformation	   (rate)	   while	   averaging	   multiple	   cardiac	   cycles.	  
This	   method	   does	   not	   affect	   the	   (average)	   maximum	   systolic	   strain	   (rate)	  
measurements	   when	   compared	   to	   commercially	   available	   EchoPAC	   software	   to	  
determine	  the	  average	  peak	  systolic	  strain	  (rate)	  values	  (per	  cardiac	  segment).	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Chapter 3 
Synchronicity of systolic deformation in healthy 
pediatric and young adult subjects assessed with 
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3.1 ABSTRACT  
	  
Background:	   Two-­‐dimensional	   speckle	   tracking	   echocardiography	   (2DSTE)	   offers	  
valuable	  information	  in	  the	  echocardiographic	  assessment	  of	  ventricular	  myocardial	  
function.	   It	  enables	  the	  quantification	  and	  timing	  of	  systolic	  ventricular	  myocardial	  
deformation.	   In	  addition,	  2DSTE	  can	  be	  used	  to	   identify	  mechanical	  dyssynchrony,	  
which	   is	   an	   important	   parameter	   in	   predicting	   the	   response	   to	   cardiac	  
resynchronization	  therapy	  for	  heart	  failure.	  Detailed	  knowledge	  of	  normal	  timing	  of	  
systolic	  deformation	  and	  its	  degree	  of	  synchronicity	  in	  children	  is	  lacking.	  	  
	  
Aim:	  We	  aimed	  to	  establish	  the	  normal	  timing	  of	  left	  ventricular	  myocardial	  systolic	  
deformation	  using	  2DSTE	  in	  a	  large	  cohort	  of	  healthy	  children	  and	  young	  adults.	  
	  
Methods:	   Transthoracic	   echocardiograms	   were	   acquired	   in	   195	   healthy	   subjects	  
(139	   children	   and	   56	   young	   adult	   <	   40	   years	   of	   age)	   and	   were	   retrospectively	  
analyzed.	   Time	   to	   peak	   systolic	   longitudinal,	   circumferential	   and	   radial	   strain	  was	  
determined	  by	  means	  of	  speckle	  tracking.	  
	  
Results:	   Strong,	   statistically	   significant	   relations	   between	   age	   as	   well	   as	   various	  
anthropometric	   variables	   (e.g.,	   heart	   rate)	   and	   timing	   of	   systolic	   deformation	  
(P<0.0001)	  were	  present.	   The	  degree	  of	   synchronous	  deformation	  decreased	  with	  
age.	  
	  
Conclusion:	   This	   is	   the	   first	   report	   that	   establishes	   reference	   values	   per	   cardiac	  
segment	   for	   time	   to	   peak	   systolic	   myocardial	   strain	   values	   in	   all	   three	   directions	  
assessed	  with	  2DSTE	  in	  a	  large	  pediatric	  and	  young	  adult	  cohort.	  We	  emphasize	  the	  
need	  for	  using	  age-­‐specific	  reference	  values	  as	  well	  as	  heart	  rate	  correction	  for	  the	  
adequate	  interpretation	  of	  2DSTE	  measurements.	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3.2 BACKGROUND 
	  
Coordinated	   contraction	   of	   the	   left	   ventricular	   myocardium	   is	   a	   mandatory	  
prerequisite	   for	   an	   efficient	   contractile	   function.	   In	   heart	   failure	   patients,	   this	  
contractile	   function	   is	   depressed	   due	   to	   various	   cellular	   and	   extracellular	  
biochemical	  abnormalities	  that	  often	  lead	  to	  asynchronous	  ventricular	  contraction.	  
Electromechanical	   dyssynchrony,	   in	   turn,	   causes	   a	   sequence	   of	   events	   that	   may	  
result	   in	   pathological	   ventricular	   remodeling	   and	   contributes	   independently	   to	  
further	   impairment	   in	   global	   systolic	   function.1	   Cardiac	   resynchronization	   therapy	  
(CRT)	   is	   an	   emerging	   option	   for	   treating	   dyssynchrony-­‐associated	   heart	   failure	   in	  
patients	  with	  pediatric	  or	  congenital	  heart	  disease.	  CRT	  has	  proven	  to	  be	  beneficial	  
for	  both	  the	  acute	  manipulation	  of	  cardiac	  output	  after	  surgery	  of	  congenital	  heart	  
defects,	  and	  for	  the	  management	  of	  chronic	  systemic	  ventricular	  failure.2,3,4,5,6,7,8,9,10	  
	  
An	  important	  issue	  in	  CRT	  that	  remains	  is	  the	  selection	  of	  patients.	  Current	  selection	  
criteria	   (for	   adults)	   consist	   of:	   (1)	   symptomatic	   heart	   failure,	   indicated	   by	   left	  
ventricular	  ejection	  fraction	  ≤	  35%	  and	  New	  York	  Heart	  Association	  (NYHA)	  class	  II-­‐
IV	   (2)	   QRS	   duration	   ≥	   120	   (150)	   msec.11,12,13,14	   Results	   from	   the	   MIRACLE	   trial	  
showed	   that	   approximately	   30%	   of	   the	   adult	   patients	   did	   not	   experience	   any	  
significant	   clinical	   response	   to	   CRT	   when	   current	   selection	   criteria	   were	   used.	   In	  
pediatric	  and	  congenital	  heart	  disease,	  the	  non-­‐response	  rate	  is	  20%.2,9,13	  In	  fact,	  the	  
rate	   of	   echocardiographic	   response	   in	   adults	   is	   even	   lower	   than	   clinical	  
improvement.15	   Previous	   studies	   have	   indicated	   that	   electrocardiographic	   indices,	  
such	  as	  QRS	  duration,	  are	  poor	  predictors	  of	  hemodynamic	  improvement	  achieved	  
by	   CRT.16,17,18,19	   These	   parameters	   have	   been	   shown	   to	   underestimate	  
intraventricular	   dyssynchrony	   in	   a	   significant	   number	   of	   patients,	   whereas	  
mechanical	   asynchrony	   is	   absent	   in	   nearly	   30%	   of	   patients	   with	   prolonged	   QRS	  
duration.20,21	   Besides	   their	   inaccuracy	   in	   predicting	   hemodynamic	   and	   clinical	  
response	   to	   CRT,	   the	   current	   adult	   criteria	   cannot	   be	   easily	   translated	   to	   the	  
pediatric	   population.22	   However,	   given	   the	   variety	   of	   anatomic	   and	   functional	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substrates	   subjected	   to	   CRT	   in	   the	   pediatric	   age	   group,	   evaluation	   of	  mechanical	  
dyssynchrony	  has	  become	  a	  substantial	  part	  of	  the	  decision	  process	  despite	  the	  fact	  
that	  reference	  values	  are	  lacking.	  
	  
At	   present,	   several	   (additional)	   visualization	   methods	   of	   assessing	   dyssynchrony	  
have	   been	   proposed,	   varying	   from	   conventional	   echocardiographic	   techniques	   to	  
more	   recently	   developed	   applications	   such	   as	   two-­‐dimensional	   strain	  
echocardiography	   or	   speckle	   tracking	   (2DSTE).	   This	   latter	   echocardiographic	  
technique	  determines	  the	  extent	  and	  timing	  of	  myocardial	  deformation	  by	  means	  of	  
frame-­‐by-­‐frame	  tracking	  and	  motion	  analysis	  of	  speckles	  within	  the	  B-­‐mode	  images	  
using	   correlation	  or	  optical	   flow	   search	  algorithms.	  Validation	   studies	  with	   tagged	  
MRI	  and	  sonomicrometry	   in	  the	  adult	  population	  have	  provided	  the	  evidence	  that	  
2DSTE	   is	   a	   reliable	  method	   to	   determine	   ventricular	  myocardial	   function.23,24	   The	  
fact	  that	  the	  estimation	  of	  the	  timing	  and	  extent	  of	  deformation	  using	  2DSTE	  is	  less	  
affected	   by	   passive	   translational	   motion	   of	   the	   heart	   or	   tethering	   effects	   of	  
neighboring	   myocardial	   segments	   than	   velocity-­‐motion	   based	   techniques,	   makes	  
strain	  an	  attractive	  modality	  to	  assess	  regional	  myocardial	  dyssynchrony.25	  Previous	  
studies	  have	   indicated	   that	   speckle	   tracking	  provides	  promising	  echocardiographic	  
parameters	   to	   predict	   beneficial	   effects	   of	   CRT	   in	   adult	   patients	   with	   heart	  
failure.26,27	  
	  
In	   healthy	   adult	   individuals,	   the	   timing	   of	   myocardial	   deformation	   as	   well	   as	   the	  
extent	   of	   asynchronous	   contraction	   between	   various	   ventricular	   segments	   appear	  
to	   be	   related	   to	   age.28,29,30	   Therefore,	   the	   application	   of	   2DSTE	   indices	   for	   the	  
assessment	   of	   ventricular	   dyssynchrony	   is	   dependent	   on	   establishing	   reference	  
ranges	   across	   a	  wide	   range	   of	   age	   groups	   in	   a	   large	   group	   of	   healthy	   individuals.	  
However,	   data	   regarding	   the	   normal	   timing	   of	   deformation	   and	   the	   extent	   of	  
synchrony	   of	   contraction	   between	   ventricular	   segments	   in	   healthy	   children	   is	  
lacking.	  Mapping	   of	   normal	   contraction	   times	   in	   the	   healthy	   pediatric	   heart	   may	  
give	  valuable	  insight	  into	  normal	  contraction	  patterns	  and	  may	  serve	  as	  a	  reference	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for	   interpreting	   data	   of	   patients	   considered	   for	   CRT	   and	   patients	   with	   ischemia-­‐
induced	   myocardial	   damage.	   Therefore,	   the	   primary	   aim	   of	   this	   study	   was	   to	  
establish	   reference	  values	   for	   the	  normal	   timing	  of	   left	   ventricular	  deformation	   in	  
pediatric	   and	   young	   adult	   age	   groups	   as	   assessed	   with	   2DSTE.	   In	   addition,	   we	  
examined	   the	   relation	   between	   timing	   of	   myocardial	   deformation	   and	   multiple	  
anthropometric	  as	  well	  as	  echocardiographic	  variables.	  	  
	  
3.3 MATERIAL and METHODS 
3.3.1 STUDY POPULATION 
	  
Subjects	   that	   were	   routinely	   referred	   for	   echocardiographic	   evaluation	   of	   an	  
asymptomatic,	   innocent	   heart	   murmur	   and	   screening	   purposes	   between	   May	   1,	  
2005	  and	  November	  1,	   2009,	  were	   retrospectively	   analyzed	   for	   their	   eligibility	   for	  
inclusion	  in	  the	  study.	  All	  consecutive	  healthy	  subjects,	  aged	  from	  birth	  to	  40	  years,	  
were	   identified	   from	  our	  echocardiographic	  database	   from	  the	  outpatient	  clinic	  at	  
both	   the	   Children’s	   Heart	   Centre	   and	   the	   Adult	   Heart	   Centre,	   Nijmegen,	   the	  
Netherlands.	   This	   study	   was	   approved	   by	   the	   local	   Medical	   Ethics	   Committee.	  
Demographic	   characteristics,	   including	   age	   and	   gender	  were	   collected	   at	   the	   time	  
the	  echocardiographic	  study	  was	  performed.	  A	  complete	  physical	  examination	  was	  
performed,	   including	  weight,	   height	   and	   blood	   pressure	  measurements.	   For	   each	  
subject	   a	   12-­‐lead	   electrocardiogram	   was	   recorded	   and	   subsequently	   evaluated	  
using	  age-­‐appropriate	  reference	  values.31,32,33	  Subjects	  were	  included	  only	  if	  clinical	  
examination,	   transthoracic	   echocardiogram,	   and	   electrocardiogram	   (ECG)	   showed	  
no	  evidence	  of	  preexisting	  cardiac	  disease	  or	  other	  significant	  coexisting	  illness.	  On	  
the	   12-­‐lead	   ECG,	   an	   abnormal	   cardiac	   rhythm,	   prolonged	   QRS	   duration,	   bundle	  
branch	  block,	  pathological	  Q	  waves,	  ventricular	  hypertrophy,	  or	  changes	  consistent	  
with	   myocardial	   ischemia	   resulted	   in	   exclusion	   as	   did	   evidence	   of	   (congenital)	  
structural	   heart	   disease,	   significant	   valvular	   abnormality,	   impaired	   systolic	   or	  
diastolic	   left	   ventricular	   function,	   or	   left	   ventricular	   hypertrophy	   on	   the	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transthoracic	   echocardiogram.	   Other	   exclusion	   criteria	   consisted	   of	   hypertension,	  
chronic	  illness,	  recent	  acute	  illness	  as	  well	  as	  poor	  echocardiographic	  image	  quality.	  
3.3.2 CONVENTIONAL ECHOCARDIOGRAPHIC PARAMETERS 
	  
All	   subjects	   underwent	   a	   detailed	   transthoracic	   echocardiographic	   examination	   in	  
the	  left	  lateral	  position	  according	  to	  the	  recommendations	  of	  the	  American	  Society	  
of	   Echocardiography.34	   Every	   examination	   was	   performed	   at	   rest,	   without	   using	  
sedation.	  Images	  were	  obtained	  with	  a	  3.0-­‐MHz	  (S3)	  or	  a	  5.0-­‐MHz	  (S5)	  phased-­‐array	  
transducer	   using	   a	   commercially	   available	   system,	   the	   Vivid	   7	   echocardiographic	  
scanner	  (GE,	  Vingmed	  Ultrasound	  AS,	  Horten,	  Norway).	  The	  choice	  of	  an	  S3	  or	  a	  S5	  
transducer	   depended	   on	   the	   age	   and	   weight	   of	   the	   subject.	   Quantification	   of	  
cardiac	   chamber	   size,	   ventricular	   mass	   and	   systolic	   and	   diastolic	   left	   ventricular	  
function	   were	   measured	   in	   accordance	   with	   the	   recommendations	   for	   chamber	  
quantification	   by	   the	   American	   Society	   of	   Echocardiography.34	   Left	   ventricular	  
systolic	   function	  was	  determined	  using	   fractional	   shortening	   (FS),	  ejection	   fraction	  
(EF),	   left	   ventricular	   myocardial	   performance	   (Tei-­‐)	   index,	   end-­‐systolic	   wall	   stress	  
(ESWS),	   and	   rate-­‐corrected	   velocity	   of	   circumferential	   fiber	   shortening	   (VCFc).	  
Ejection	   fraction	   (EF)	   was	   calculated	   using	   the	   modified	   Simpson’s	   rule.34,35	   The	  
pulsed-­‐wave	   Doppler-­‐derived	   myocardial	   performance	   index	   was	   calculated	   by	  
adding	   the	   iso-­‐volumetric	   contraction	   time	   (ICT)	   and	   the	   iso-­‐volumetric	   relaxation	  
time	  (IVRT),	  and	  dividing	  the	  sum	  by	  the	  ejection	  time	  (ET).36	  Left	  ventricular	  end-­‐
systolic	  wall	   stress	   (ESWS)	  was	   calculated	   using	   the	  modified	   formula	   of	   Rowland	  
and	   Gutgesell.37	   VCFc	   was	   calculated	   using	   the	   formula	   obtained	   from	   Colan	   and	  
colleagues.38	   Left	   ventricular	   mass	   (LVM)	   was	   calculated	   using	   the	   formula	   for	  
estimation	   of	   LVM	   according	   to	   Devereux	   and	   Reichek	   and	   was	   subsequently	  
indexed	  to	  body	  surface	  area	  (BSA).39	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3.3.3 2DSTE DATA ACQUISITION 
	  
Two-­‐dimensional	   multi-­‐frame	   B-­‐mode	   (grayscale)	   images	   were	   obtained	   in	   the	  
apical	  four-­‐chamber	  (4C),	  and	  parasternal	  midcavity	  short-­‐axis	  view	  (at	  the	  level	  of	  
the	  papillary	  muscle:	  SaxPM)	  and	  parasternal	  basal	   short-­‐axis	  view	   (at	   the	   level	  of	  
the	  mitral	  valve:	  SaxMV).	  A	  sector	  scan	  angle	  of	  30	  to	  60	  degrees	  was	  chosen	  and	  
frame	  rates	  of	  60	  to	  90	  Hz	  were	  used,	  since	  these	  rates	  are	  considered	  to	  be	  optimal	  
for	   2D	   speckle	   tracking.24,40,41	   Data	   were	   stored	   at	   the	   same	   frame	   rate	   as	   the	  
acquisition	  frame	  rate.	  Preferably	  images	  from	  five	  cardiac	  cycles	  triggered	  by	  the	  R	  
wave	  of	   the	  QRS	   complex	  were	   digitally	   saved	   in	   cineloop	   format.	  Offline	   speckle	  
tracking	   analysis	   was	   performed	   using	   software	   for	   echocardiographic	  
quantification	   (EchoPAC	   6.1.0;	   GE	   Vingmed	   Ultrasound	   AS,	   Horten,	   Norway).	   The	  
timing	  of	  aortic	  valve	  closure	  (AVC)	  and	  mitral	  valve	  opening	  (MVO)	  with	  respect	  to	  
peak	   systolic	   strain	   were	   manually	   obtained,	   using	   single	   gated	   pulsed-­‐wave	  
Doppler	   or	   continuous-­‐wave	   Doppler	   images	   of	   the	   left	   ventricular	   outflow	   tract.	  
For	  these	  measurements,	  special	  care	  was	  taken	  to	  keep	  the	  heart	  rate	  in	  the	  same	  
range	   as	   during	   the	   2D	   grayscale	   imaging	   used	   for	   2D	   strain	   calculations.	  
Endomyocardial	  borders	  of	  the	  left	  ventricle	  were	  manually	  traced	  within	  the	  end-­‐
systolic	   frame.	   The	   second,	   epicardial	   tracing	  was	   automatically	   generated	   by	   the	  
EchoPAC	   software	   and,	   when	   necessary,	   manually	   adjusted	   to	   cover	   the	   whole	  
myocardial	   wall.	   The	   tracking	   algorithm	   then	   followed	   the	   myocardial	   speckles	  
during	  the	  cardiac	  cycle.	  Tracking	  was	  accepted	  only	  if	  both	  visual	  inspection	  as	  well	  
as	   the	  EchoPAC	  software	   indicated	  adequate	   tracking.	  This	  means	   that	   tracking	  of	  
any	  given	  segment	  was	  accepted	  only	  when	  it	  was	  indicated	  with	  a	  green	  box.	  The	  
software	  automatically	   divided	   the	   cross-­‐sectional	   image	   into	   six	   segments,	  which	  
were	   named	   and	   identified	   according	   to	   the	   statement	   of	   the	   Cardiac	   Imaging	  
Committee	   of	   the	   Council	   on	   Clinical	   Cardiology	   of	   the	   American	   Heart	  
Association.42	  The	  left	  ventricular	  segments	  to	  be	  analyzed	  were	  the	  apical,	  middle	  
and	  basal	  segments	  of	  the	  septal	   (ApSept,	  MidSept,	  BasSept,	  respectively)	  and	  the	  
lateral	   wall	   (ApLat,	   MidLat,	   BasLat,	   respectively)	   of	   the	   4C	   view,	   as	   well	   as	   the	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anteroseptal	   (AntSept),	   anterior	   (Ant),	   lateral	   (Lat),	   posterior	   (Post),	   inferior	   (Inf)	  
and	   septal	   (Sept)	   segments	   of	   the	   basal	   and	   midcavity	   short-­‐axis	   views.	   Speckle	  
tracking	  was	  performed	  for	  all	  (three)	  consecutive	  cycles	  separately.	  Strain	  curves	  of	  
the	  three	  consecutive	  cardiac	  cycles	  and	  values	  of	  the	  manual	  timing	  were	  imported	  
into	  a	  custom-­‐made	  software	  package	  for	  further	  analysis	  (see	  Appendix).	  The	  Q-­‐Q	  
interval	  was	  determined	  from	  the	  electrocardiographic	  signal	  to	  obtain	  cardiac	  cycle	  
length.	  It	  is	  known	  that	  the	  duration	  of	  the	  systolic	  phase	  of	  the	  cardiac	  cycle	  in	  rest	  
does	   not	   change	   with	   small	   changes	   in	   heart	   rate,	   in	   contrast	   to	   the	   diastolic	  
phase.43	  Therefore,	  the	  diastolic	  phase	  of	  the	  three	  cardiac	  cycles	  was	  automatically	  
extended	  and	  adjusted	  by	  the	  software	  package	  to	  the	  longest	  of	  the	  three	  cardiac	  
cycles.	  This	  intervention	  prevents	  a	  shift	  of	  the	  peak	  systolic	  strain	  while	  averaging	  
the	   individually	   measured	   three	   consecutive	   cardiac	   cycles.	   Cardiac	   cycles	   with	  
lengths	  more	  than	  ten	  percent	  different	  from	  the	  mean	  length	  of	  the	  three	  cardiac	  
cycles	   were	   excluded	   from	   averaging	   and	   thus	   for	   further	   analysis.	   Timing	   of	  
myocardial	   longitudinal,	   radial	   and	   circumferential	   peak	   systolic	   strain	   was	  
obtained.	  For	  a	  parameter	  x	  we	  determined	  t(xi)	  as	  the	  time	  interval	  measured	  from	  
the	   beginning	   of	   the	   QRS	   complex	   of	   the	   surface	   electrocardiogram	   to	   the	   peak	  
value	   of	   the	   parameter	   x	   in	   the	   myocardial	   segment	   i	   within	   the	   analyzed	   heart	  
cycle	  period:	  	  	  
	  
t(xi)	  =	  ∆t	  [	  peak	  (xi)	  	  -­‐	  	  QRSECG	  ].	  
	  
To	   determine	   global	   time	   to	   peak	   systolic	   strain,	   the	   time	   to	   peak	   systolic	   strain	  
values	  of	  the	  six	  segments	  were	  averaged	  for	  the	  4C	  as	  well	  as	  the	  short-­‐axis	  views.	  
To	   measure	   the	   extent	   of	   synchronicity	   of	   regional	   deformation,	   a	   method	  
previously	  described	  by	  Yu	  et	  al.	  was	  used,	  which	  calculates	  the	  standard	  deviation	  
of	   the	   time	   to	   peak	   systolic	   strain	   measurements.21	   An	   increased	   index	   would	  
indicate	   increased	   regional	   heterogeneity	   with	   respect	   to	   time	   to	   peak	   systolic	  
strain.	   In	   addition,	   the	   difference	   in	   time	   to	   peak	   systolic	   longitudinal	   strain	  
between	  the	  lateral	  wall	  and	  septum	  was	  calculated.	  Correction	  for	  the	  influence	  of	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variation	   in	   heart	   rate	   on	   time	   to	   peak	   systolic	   strain	   values	   was	   achieved	   by	  
dividing	   time	   to	   peak	   systolic	   strain	  measurements	   by	   the	   square	   root	   of	   the	   R-­‐R	  
interval	   in	   these	   subjects	   (i.e.,	   Bazett’s	   formula).44,45,46,47	   All	   offline	  measurements	  
with	   EchoPAC	   were	   performed	   by	   a	   single	   observer	   (K.A.M.).	   Interobserver	   and	  
intraobserver	   variability	   scores	   have	   been	   described	   previously	   by	   our	   research	  
group.48	  Time	   to	  peak	  systolic	   strain	   is	  expressed	  as	  milliseconds.	  Figure	  14	  shows	  
an	  illustration	  of	  strain	  curves.	  	  
	  




ECG: Electrocardiogram; ES: end-systole; SAX-PM: short-axis view at the level of the 
papillary muscle. 
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3.3.4 STATISTICAL ANALYSIS 
	  
All	   demographic,	   conventional	   echocardiographic	   and	  2DSTE	   values	   are	   expressed	  
as	  mean	  ±	  standard	  deviation	  (SD).	  The	  relation	  between	  different	  anthropometric	  
and	   echocardiographic	   parameters	   on	   one	   hand,	   and	   time	   to	   (global)	   strain	  
parameters	   on	   the	   other	   was	   reported	   using	   scatter	   plots,	   one-­‐way	   analysis	   of	  
variance	   (ANOVA)	   with	   Bonferroni	   correction	   for	   multiple	   comparison	   and	   linear	  
regression	   analyses.	   P-­‐values	   less	   than	   0.05	   were	   considered	   to	   indicate	  
significance.	   Statistical	   analyses	   were	   performed	   using	   the	   Statistical	   Package	   for	  
Social	  Sciences	  for	  Windows,	  version	  16.0	  (SPSS	  Inc,	  Chicago,	  IL).	  
	  
3.4 RESULTS 
3.4.1 DEMOGRAPHIC AND ANTHROPOMETRIC PARAMETERS 
	  
A	  total	  of	  226	  subjects	  were	  evaluated	  for	  inclusion	  in	  the	  study.	  Of	  those	  subjects,	  
31	   (13.7%)	   were	   subsequently	   excluded	   in	   light	   of	   incomplete	   echocardiographic	  
data	  or	  suboptimal	  imaging	  quality.	  In	  total	  195	  healthy	  subjects	  (139	  children	  and	  
56	   young	   adults)	   were	   enrolled	   in	   the	   study.	   Subject	   characteristics	   and	  
anthropometric	   parameters	   are	   described	   in	   Table	   8.	   None	   of	   the	   subjects	   used	  
medication	  for	  cardiovascular	  illness.	  
3.4.2 CONVENTIONAL ECHOCARDIOGRAPHIC PARAMETERS 
	  
Conventional	  echocardiographic	  parameters	  of	  the	  study	  subjects	  are	  presented	  in	  
Table	   9.	   All	   standard	   echocardiographic	   findings	  were	  within	   previously	   described	  
reference	  values	  for	  age.	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Table 8 - Demographic and anthropometric characteristics (mean ± standard deviation) 
of study subjects (n=195) categorized by age group 
	  	   0	  years	  	   1-­‐4	  years	   5-­‐9	  years	   10-­‐14	  years	  
Age	  group	  No	   1	   2	   3	   4	  
Number	   24	   34	   36	   29	  
Male	   13	  (54%)	   19	  (56%)	   25	  (69%)	   16	  (55%)	  
Age	  (y)	   0.3	  ±	  0.3	   2.9	  ±	  1.0	   7.2	  ±	  1.2	   12.8	  ±	  1.6	  
Height	  (m)	   0.62	  ±	  0.11	  	   0.95	  ±	  0.10	   1.26	  ±	  0.09	   1.59	  ±	  0.13	  
Weight	  (kg)	   6.3	  ±	  2.6	   14.6	  ±	  3.4	   24.7	  ±	  4.4	   46.3	  ±	  12.0	  
BSA	  (m2)	   0.32	  ±	  0.10	   0.62	  ±	  0.10	   0.93	  ±	  0.12	   1.43	  ±	  0.23	  
BMI	  (kg/m2)	   15.9	  ±	  2.2	   15.9	  ±	  1.4	   15.4	  ±	  1.3	   17.9	  ±	  2.1	  
HR	  (bpm)	   118	  ±	  12	   101	  ±	  14	   84	  ±	  13	   77	  ±	  14	  
SysBP	  (mmHg)	   82	  ±	  8	   98	  ±	  10	   104	  ±	  8	   110	  ±	  10	  
DiaBP	  (mmHg)	   56	  ±	  6	   62	  ±	  10	   70	  ±	  8	   72	  ±	  8	  
	  	   15-­‐19	  years	   20-­‐24	  years	   25-­‐29	  years	   30-­‐40	  years	  
Age	  group	  No	   5	   6	   7	   8	  
Number	   21	   25	   13	   13	  
Male	   9	  (43%)	   16	  (64%)	   8	  (62%)	   6	  (46%)	  
Age	  (y)	   17.0	  ±	  1.3	   21.7	  ±	  1.2	   27.3	  ±	  1.3	   35.6	  ±	  2.6	  
Height	  (m)	   1.76	  ±	  0.09	   1.78	  ±	  0.10	   1.82	  ±	  0.08	   1.77	  ±	  0.10	  
Weight	  (kg)	   66.4	  ±	  12.0	   70.3	  ±	  11.9	   76.5	  ±	  11.9	   77.8	  ±	  11.0	  
BSA	  (m2)	   1.81	  ±	  0.20	   1.86	  ±	  0.20	   1.96	  ±	  0.19	   1.95	  ±	  0.18	  
BMI	  (kg/m2)	   21.2	  ±	  2.3	   22.1	  ±	  2.0	   23.1	  ±	  2.2	   24.9	  ±	  2.9	  
HR	  (bpm)	   65	  ±	  9	   63	  ±	  11	   60	  ±	  14	   65	  ±	  8	  
SysBP	  (mmHg)	   116	  ±	  11	   118	  ±	  12	   121	  ±	  11	   123	  ±	  12	  
DiaBP	  (mmHg)	   75	  ±	  9	   75	  ±	  8	   77	  ±	  8	   78	  ±	  9	  
	  
BSA: body surface area; BMI: body mass index; DiaBP: diastolic blood pressure; HR: heart 
rate; SysBP: systolic blood pressure. 
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Table 9 - Conventional echocardiographic parameters (mean ± standard deviation) of 
study subjects (n=195) categorized by age group 
	  	   0	  years	  	   1-­‐4	  years	   5-­‐9	  years	   10-­‐14	  years	  
Age	  group	  No	   1	  (n	  =	  24)	   2	  (n	  =	  34)	  	   3	  (n=	  36)	   4	  (n=	  29)	  
LVET	  (sec)	   0.19	  ±	  0.01	   0.23	  ±	  0.01	   0.26	  ±	  0.01	   0.28	  ±	  0.01	  
LVETc	  (sec)	   0.28	  ±	  0.02	   0.30	  ±	  0.02	   0.30	  ±	  0.02	   0.32	  ±	  0.03	  
QRS	  duration	  (sec)	   0.055	  ±	  0.02	   0.057	  ±	  0.02	   0.061	  ±	  0.04	   0.062	  ±	  0.03	  
QTc	  (sec)	   0.411	  ±	  0.02	   0.399	  ±	  0.02	   0.404	  ±	  0.02	   0.407	  ±	  0.02	  
VCFc	  	  (circ/sec)	   1.32	  ±	  0.22	   1.28	  ±	  0.20	   1.25	  ±	  0.19	   1.19	  ±	  0.19	  
Tei	  index	  	   	  0.37	  ±	  0.01	   0.37	  ±	  0.01	   0.38	  ±	  0.01	   0.38	  ±	  0.03	  
FS	   0.37	  ±	  0.05	   0.38	  ±	  0.05	   0.37	  ±	  0.04	   0.37	  ±	  0.04	  
EF	  biplane	   0.73	  ±	  0.07	   0.71	  ±	  0.06	   0.67	  ±	  0.05	   0.70	  ±	  0.06	  
ESWS	  (g/cm2)	   30.7	  ±	  11.0	   42.8	  ±	  13.9	   43.6	  ±	  10.7	   45.3	  ±	  11.6	  
LV	  mass/BSA	  (g/m2)	   36.2	  ±	  12.1	   48.5	  ±	  11.6	   57.2	  ±	  12.3	   59.9	  ±	  14.2	  
	  	   15-­‐19	  years	   20-­‐24	  years	   25-­‐29	  years	   30-­‐40	  years	  
Age	  group	  No	   5	  (n	  =	  21)	   6	  (n=	  25)	   7	  (n=	  13)	   8	  (n=	  13)	  
LVET	  (sec)	   0.29	  ±	  0.01	   0.29	  ±	  0.01	   0.29	  ±	  0.01	   0.30	  ±	  0.01	  
LVETc	  (sec)	   0.30	  ±	  0.02	   0.29	  ±	  0.03	   0.29	  ±	  0.03	   0.31	  ±	  0.03	  
QRS	  duration	  (sec)	   0.073	  ±	  0.02	   0.078	  ±	  0.04	   0.082	  ±	  0.04	   0.081	  ±	  0.05	  
QTc	  (sec)	   0.415	  ±	  0.02	   0.418	  ±	  0.02	   0.421	  ±	  0.02	   0.416	  ±	  0.02	  
VCFc	  	  (circ/sec)	   1.31	  ±	  0.20	   1.21	  ±	  0.43	   1.20	  ±	  0.43	   1.20	  ±	  0.41	  
Tei	  index	  	   0.40	  ±	  0.03	   0.39	  ±	  0.03	   0.38	  ±	  0.01	   0.38	  ±	  0.02	  
FS	   0.39	  ±	  0.06	   0.39	  ±	  0.07	   0.37	  ±	  0.05	   0.40	  ±	  0.04	  
EF	  biplane	   0.67	  ±	  0.07	   0.74	  ±	  0.04	   0.77	  ±	  0.04	   0.75	  ±	  0.05	  
ESWS	  (g/cm2)	   44.4	  ±	  13.4	   40.0	  ±	  10.4	   45.7	  ±	  16.2	   41.8	  ±	  10.1	  
LV	  mass/BSA	  (g/m2)	   71.8	  ±	  16.0	   78.6	  ±	  18.0	   77.3	  ±	  19.1	   75.4	  ±	  17.2	  
	  
EF biplane: ejection fraction measured by modified Simpson’s method; ESWS: end-systolic 
wall stress; FS: fractional shortening; LVET: left ventricular ejection time; LVETc: LVET 
corrected for heart rate; LV mass/BSA: left ventricular mass corrected for body surface area; 
QTc: QT interval corrected for heart rate; VCFc: heart rate corrected velocity of circumferential 
fiber shortening. 
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3.4.3 MYOCARDIAL STRAIN PARAMETERS 
	  
Tracking	  was	  feasible	  in	  91%	  of	  all	  segments	  of	  the	  four-­‐chamber	  view,	  in	  96%	  of	  all	  
segments	  in	  the	  short-­‐axis	  view	  at	  the	  level	  of	  the	  papillary	  muscle	  and	  in	  91%	  of	  all	  
segments	  in	  the	  short-­‐axis	  view	  at	  the	  level	  of	  the	  mitral	  valve.	  Left	  ventricular	  time	  
to	   peak	   systolic	   strain	   parameters	   corrected	   for	   heart	   rate	   using	   Bazett’s	   formula	  
are	   presented	   in	   Tables	   10-­‐12.	   Even	   after	   correction	   for	   heart	   rate,	   statistically	  
significant	   differences	   in	   the	   timing	  of	   peak	   systolic	   deformation	  between	   various	  
age	  groups	  (Tables	  10-­‐12)	  were	  present,	  as	  assessed	  by	  one-­‐way	  analysis	  of	  variance	  
with	  Bonferroni	   correction	   for	  multiple	   comparisons.	   The	   time	   to	   reach	  maximum	  
strain	   during	   systole	   increased	   until	   the	   age	   of	   ten	   years	   in	   all	   three	   principal	  
directions	   of	   contraction.	   After	   this	   age,	   2DSTE	   measurements	   remained	   fairly	  
stable.	  In	  the	  longitudinal	  plane,	  time	  to	  peak	  systolic	  strain	  was	  shorter	  at	  the	  apex	  
compared	  with	  the	  base	  of	  the	  ventricle	  (Table	  10).	  This	  pattern	  was	  also	  shown	  in	  
the	  circumferential	   and	   radial	  plane,	  where	   time	   to	   reach	  peak	   systolic	   strain	  was	  
shorter	  midventricular	  compared	  with	  the	  base	  of	  the	  ventricle.	  In	  addition,	  time	  to	  
reach	   peak	   systolic	   strain	   in	   all	   three	   directions	   of	   contraction	  was	   shorter	   in	   the	  
septum	  compared	  with	  the	  lateral	  free	  wall	  (Tables	  10-­‐12).	  	  	  
No	   significant	   sex-­‐related	   differences	   in	   time	   to	   peak	   systolic	   strain	   were	   found.	  
Figures	  15-­‐18	  show	  the	  degree	  of	  synchronous	  deformation	  among	  left	  ventricular	  
myocardial	  segments	   in	   longitudinal,	  circumferential	  and	  radial	  direction	  according	  
to	   age.	   Even	   after	   correction	   for	   heart	   rate,	   the	   degree	   of	   synchrony	   decreased	  
significantly	   with	   age	   (Table	   13	   and	   Figures	   15-­‐18).	   Our	   data	   indicate	   that	   the	  
degree	  of	  synchrony	  decreases	  with	  age	  and	  body	  growth	  (indices)	  (Table	  14).	  There	  
were	  no	  statistically	  significant	  correlations	  between	  synchronicity	  parameters	  and	  
FS	   or	   LVEF.	   QRS	   duration,	   QT	   interval	   corrected	   for	   heart	   rate	   (QTc)	   and	   blood	  
pressure	  did	  not	  correlate	  with	  the	  strain	  parameters	  under	  investigation	  (Table	  14).	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Table 10 - Time to peak systolic longitudinal strain corrected for heart rate (mean ± 
standard deviation) of study subjects (n=195) categorized by age group 
	  	   0	  years	  	   1-­‐4	  years	   5-­‐9	  years	   10-­‐14	  years	  
No.	  age	  group	   1	   2	   3	   4	  
N	  =	  	   24	   34	   36	   29	  
Bas.	  Sept.	   362	  ±	  20	   394	  ±	  22	   424	  ±	  25	   425	  ±	  28	  
Mid.	  Sept.	   334	  ±	  18	   360	  ±	  21	   390	  ±	  24	   392	  ±	  26	  
Apic.	  Sept.	   313	  ±	  16	   342	  ±	  17	   368	  ±	  18	   368	  ±	  20	  
Apic.	  Lat.	   329	  ±	  16	   358	  ±	  17	   382	  ±	  17	   380	  ±	  20	  
Mid.	  Lat.	   352	  ±	  17	   384	  ±	  19	   400	  ±	  21	   413	  ±	  22	  
Bas.	  Lat.	   372	  ±	  19	   401	  ±	  21	   435	  ±	  23	   439	  ±	  24	  
Global	  T2P	  SL	   341	  ±	  18	  *3,4,5,6,7,8	   373	  ±	  19	  *8	   400	  ±	  20	  *1	   402	  ±	  23	  *1	  
P5	  Global	  T2P	  SL	   305	   335	   361	   356	  
P95	  Global	  T2P	  SL	   377	   411	   439	   448	  
	  	   15-­‐19	  years	   20-­‐24	  years	   25-­‐29	  years	   30-­‐40	  years	  
No.	  age	  group	   5	   6	   7	   8	  
N	  =	  	   21	   25	   13	   13	  
Bas.	  Sept.	   433	  ±	  26	   422	  ±	  29	   443	  ±	  25	   453	  ±	  33	  
Mid.	  Sept.	   400	  ±	  25	   388	  ±	  24	   397	  ±	  26	   422	  ±	  28	  
Apic.	  Sept.	   370	  ±	  19	   362	  ±	  21	   380	  ±	  24	   362	  ±	  27	  
Apic.	  Lat.	   392	  ±	  20	   374	  ±	  23	   392	  ±	  26	   385	  ±	  30	  
Mid.	  Lat.	   417	  ±	  24	   395	  ±	  25	   422	  ±	  28	   440	  ±	  30	  
Bas.	  Lat.	   445	  ±	  25	   448	  ±	  29	   454	  ±	  23	   468	  ±	  32	  
Global	  T2P	  SL	   410	  ±	  23	  *1	   398	  ±	  24	  *1	   415	  ±	  25	  *1	   422	  ±	  31	  *1,2	  
P5	  Global	  T2P	  SL	   364	   350	   365	   360	  
P95	  Global	  T2P	  SL	   456	   446	   465	   484	  
	  
Time values are presented in milliseconds (ms); SL: longitudinal peak systolic strain; T2P: 
time to peak systolic strain; correction for heart rate was calculated by dividing the time to 
peak systolic strain by √R-R interval for each individual; * P < .05 when compared with age 
groups denoted by superscript numerals, determined by means of one-way analysis of 
variance with Bonferroni correction for multiple comparisons. 
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Table 11 - Time to peak systolic radial strain corrected for heart rate (mean ± standard 
deviation) of study subjects (n=195) categorized by age group 
	  	   0	  years	  	   1-­‐4	  years	   5-­‐9	  years	   10-­‐14	  years	  
No.	  age	  group	   1	   2	   3	   4	  
N	  =	  	   24	   34	   36	   29	  
Ant.Sept.	  PM	   332	  ±	  16	   372	  ±	  20	   381	  ±	  23	   380	  ±	  24	  
Ant.	  PM	   343	  ±	  15	   381	  ±	  22	   404	  ±	  24	   387	  ±	  23	  
Lat.	  PM	   379	  ±	  20	   412	  ±	  23	   431	  ±	  25	   430	  ±	  27	  
Post.	  PM	   381	  ±	  19	   414	  ±	  22	   434	  ±	  24	   437	  ±	  23	  
Inf.	  PM	   353	  ±	  18	   390	  ±	  20	   416	  ±	  25	   413	  ±	  23	  
Sept.	  PM	   325	  ±	  16	   340	  ±	  21	   355	  ±	  22	   361	  ±	  24	  
Global	  T2P	  S-­‐RP	   352	  ±	  18	  *2,3,4,5,6,7,8	   384	  ±	  22*1,7,8	   404	  ±	  24*1	   401	  ±	  25	  *1	  
P5	  Global	  T2P	  S-­‐RP	   316	   340	   356	   351	  
P95	  Global	  T2P	  S-­‐RP	   388	   428	   452	   451	  
Ant.Sept.	  MV	   372	  ±	  24	   401	  ±	  23	   420	  ±	  21	   418	  ±	  25	  
Ant.	  MV	   392	  ±	  25	   409	  ±	  26	   431	  ±	  22	   426	  ±	  26	  
Lat.	  MV	   419	  ±	  31	   449	  ±	  28	   479	  ±	  25	   473	  ±	  29	  
Post.	  MV	   429	  ±	  30	   457	  ±	  28	   488	  ±	  30	   493	  ±	  30	  
Inf.	  MV	   417	  ±	  22	   447	  ±	  22	   455	  ±	  32	   464	  ±	  30	  
Sept.	  MV	   370	  ±	  21	   399	  ±	  20	   410	  ±	  22	   414	  ±	  25	  
Global	  T2P	  S-­‐RM	   400	  ±	  22	  *6,7,8	   427	  ±	  24	  	   447	  ±	  27	  	   448	  ±	  28	  	  
P5	  Global	  T2P	  S-­‐RM	   356	   379	   393	   392	  
P95	  Global	  T2P	  S-­‐RM	   444	   475	   501	   504	  
	  	   15-­‐19	  years	   20-­‐24	  years	   25-­‐29	  years	   30-­‐40	  years	  
No.	  age	  group	   5	   6	   7	   8	  
N	  =	  	   21	   25	   13	   13	  
Ant.Sept.	  PM	   370	  ±	  21	   391	  ±	  25	   386	  ±	  27	   395	  ±	  29	  
Ant.	  PM	   389	  ±	  25	   408	  ±	  26	   406	  ±	  31	   416	  ±	  29	  
Lat.	  PM	   425	  ±	  27	   448	  ±	  29	   443	  ±	  30	   458	  ±	  33	  
Post.	  PM	   433	  ±	  26	   458	  ±	  27	   461	  ±	  29	   458	  ±	  32	  
Inf.	  PM	   414	  ±	  24	   424	  ±	  25	   431	  ±	  29	   442	  ±	  31	  
Sept.	  PM	   360	  ±	  23	   372	  ±	  24	   370	  ±	  27	   369	  ±	  28	  
Global	  T2P	  S-­‐RP	   399	  ±	  25	  *1	   417	  ±	  26*1	   416	  ±	  29*1,2	   423	  ±	  30	  *1,2	  
P5	  Global	  T2P	  S-­‐RP	   349	   366	   358	   363	  
P95	  Global	  T2P	  S-­‐RP	   449	   470	   474	   483	  
Ant.Sept.	  MV	   412	  ±	  25	   428	  ±	  26	   427	  ±	  29	   418	  ±	  30	  
Ant.	  MV	   423	  ±	  27	   430	  ±	  30	   439	  ±	  30	   484	  ±	  31	  
Lat.	  MV	   460	  ±	  31	   486	  ±	  33	   483	  ±	  30	   492	  ±	  36	  
Post.	  MV	   488	  ±	  33	   494	  ±	  35	   495	  ±	  35	   499	  ±	  38	  
Inf.	  MV	   474	  ±	  31	   482	  ±	  33	   483	  ±	  33	   492	  ±	  34	  
Sept.	  MV	   402	  ±	  22	   410	  ±	  28	   406	  ±	  30	   400	  ±	  38	  
Global	  T2P	  S-­‐RM	   443	  ±	  30	  	   456	  ±	  33	  *1	   457	  ±	  33	  *1	   464	  ±	  36	  *1	  
P5	  Global	  T2P	  S-­‐RM	   383	   390	   391	   392	  
P95	  Global	  T2P	  S-­‐RM	   503	   522	   523	   536	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Table 12 - Time to peak systolic circumferential strain corrected for heart rate (mean ± 
standard deviation) of study subjects (n=195) categorized by age group  
	  	   0	  years	  	   1-­‐4	  years	   5-­‐9	  years	   10-­‐14	  years	  
No.	  	  age	  group	   1	   2	   3	   4	  
N	  =	   24	   34	   36	   29	  
Ant.Sept.	  PM	   317	  ±	  17	   376	  ±	  20	   384	  ±	  24	   379	  ±	  26	  
Ant.	  PM	   332	  ±	  20	   386	  ±	  22	   389	  ±	  25	   387	  ±	  27	  
Lat.	  PM	   368	  ±	  23	   419	  ±	  26	   439	  ±	  28	   426	  ±	  29	  
Post.	  PM	   367	  ±	  24	   440	  ±	  27	   441	  ±	  28	   446	  ±	  28	  
Inf.	  PM	   337	  ±	  18	   407	  ±	  23	   411	  ±	  25	   421	  ±	  27	  
Sept.	  PM	   316	  ±	  17	   367	  ±	  21	   366	  ±	  24	   367	  ±	  27	  
Global	  T2P	  S-­‐CP	   339	  ±	  18	  *2,3,4,5,6,7,8	   399	  ±	  23	  *1	   405	  ±	  25	  *1	   404	  ±	  27	  *	  1	  
P5	  Global	  T2P	  S-­‐CP	   303	   353	   355	   350	  
P95	  Global	  T2P	  S-­‐CP	   375	   445	   455	   458	  
Ant.Sept.	  MV	   338	  ±	  16	   361	  ±	  22	   377	  ±	  25	   381	  ±	  29	  
Ant.	  MV	   351	  ±	  20	   375	  ±	  24	   391	  ±	  26	   400	  ±	  30	  
Lat.	  MV	   385	  ±	  25	   415	  ±	  27	   436	  ±	  25	   442	  ±	  35	  
Post.	  MV	   402	  ±	  26	   423	  ±	  27	   442	  ±	  31	   449	  ±	  34	  
Inf.	  MV	   364	  ±	  20	   400	  ±	  26	   428	  ±	  30	   443	  ±	  34	  
Sept.	  MV	   332	  ±	  20	   353	  ±	  23	   375	  ±	  26	   372	  ±	  29	  
Global	  T2P	  S-­‐CM	   362	  ±	  22	  *3,4,5,6,7,8	   388	  ±	  25	  *8	   408	  ±	  27*1	   415	  ±	  30*1	  
P5	  Global	  T2P	  S-­‐CM	   318	   338	   354	   355	  
P95	  Global	  T2P	  S-­‐CM	   406	   438	   462	   417	  
	  	   15-­‐19	  years	   20-­‐24	  years	   25-­‐29	  years	   30-­‐40	  years	  
No.	  	  age	  group	   5	   6	   7	   8	  
N	  =	   21	   25	   13	   13	  
Ant.Sept.	  PM	   366	  ±	  28	   365	  ±	  30	   384	  ±	  31	   384	  ±	  35	  
Ant.	  PM	   373	  ±	  28	   368	  ±	  33	   395	  ±	  29	   395	  ±	  39	  
Lat.	  PM	   420	  ±	  26	   425	  ±	  34	   451	  ±	  34	   455	  ±	  42	  
Post.	  PM	   428	  ±	  31	   439	  ±	  34	   469	  ±	  36	   463	  ±	  42	  
Inf.	  PM	   422	  ±	  29	   409	  ±	  32	   429	  ±	  35	   440	  ±	  34	  
Sept.	  PM	   362	  ±	  27	   362	  ±	  30	   381	  ±	  28	   370	  ±	  36	  
Global	  T2P	  S-­‐CP	   395	  ±	  28	  *	  1	   395	  ±	  30	  *1	   419	  ±	  31	  *	  1	   418	  ±	  35	  *1	  
P5	  Global	  T2P	  S-­‐CP	   339	   335	   357	   348	  
P95	  Global	  T2P	  S-­‐CP	   451	   455	   481	   488	  
Ant.Sept.	  MV	   377	  ±	  25	   367	  ±	  30	   388	  ±	  31	   388	  ±	  31	  
Ant.	  MV	   390	  ±	  27	   379	  ±	  33	   396	  ±	  33	   404	  ±	  34	  
Lat.	  MV	   440	  ±	  30	   437	  ±	  32	   456	  ±	  31	   457	  ±	  30	  
Post.	  MV	   447	  ±	  34	   446	  ±	  40	   476	  ±	  34	   466	  ±	  31	  
Inf.	  MV	   438	  ±	  35	   433	  ±	  35	   451	  ±	  37	   473	  ±	  37	  
Sept.	  MV	   365	  ±	  24	   365	  ±	  31	   381	  ±	  32	   378	  ±	  31	  
Global	  T2P	  S-­‐CM	   409	  ±	  32*1	   405	  ±	  34*1	   425	  ±	  36*1,2	   428	  ±	  38*1,2	  
P5	  Global	  T2P	  S-­‐CM	   345	   337	   353	   352	  
P95	  Global	  T2P	  S-­‐CM	   473	   473	   497	   504	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Caption Table 11: 
Time values are presented in milliseconds (ms); MV: at the level of the mitral valve; PM: at the 
level of the papillary muscle; S-RM: radial peak systolic strain at the level of the mitral valve; 
S-RP: radial peak systolic strain at the level of the papillary muscle; T2P: time to peak systolic 
strain; correction for heart rate was calculated by dividing the time to peak systolic strain by 
√R-R interval for each individual * P < .05 when compared with age groups denoted by 
superscript numerals, determined by means of one-way analysis of variance with Bonferroni 
correction for multiple comparisons. 
	  
Caption Table 12: 
Time values are presented in milliseconds (ms); MV: at the level of the mitral valve; PM: at the 
level of the papillary muscle; S-CM: circumferential peak systolic strain at the level of the mitral 
valve; S-CP: circumferential peak systolic strain at the level of the papillary muscle; T2P: time 
to peak systolic strain; correction for heart rate was calculated by dividing the time to peak 
systolic strain by √R-R interval for each individual; * P < .05 when compared with age groups 
denoted by superscript numerals, determined by means of one-way analysis of variance with 
Bonferroni correction for multiple comparisons. 
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Table 13 - Coefficient of determination R2 
Rate	  uncorrected	  outcome	  variable	   Age	   Heart	  Rate	   √	  R-­‐R	  
Diff.	  Sep-­‐Lat	  S-­‐L	   0.61	  *	   0.21	  *	   0.33	  *	  
SD	  T2P	  S-­‐L	   0.58	  *	   0.19	  *	   0.34	  *	  
SD	  T2P	  S-­‐RP	   0.63	  *	   0.20	  *	   0.32	  *	  
SD	  T2P	  S-­‐RM	   0.61	  *	   0.22	  *	   0.33	  *	  
SD	  T2P	  S-­‐CP	   0.47	  *	   0.18	  *	   0.29	  *	  
SD	  T2P	  S-­‐CM	   0.60	  *	   0.17	  *	   0.29	  *	  
	  
Each R2 is based on the linear model that uses all subjects with known values for the predictor 
used in that particular model. T2P: time to peak; Diff.Sep-Lat: difference in T2P between 
septum and lateral wall; SD T2P: synchrony index (standard deviation); S: peak systolic global 
strain; L: longitudinal; R: radial; C: circumferential; P: at the level of the papillary muscle; M: at 
the level of the mitral valve; * P<0.001. 
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Table 14 - Coefficient of determination R2 
	  	  	  	  	  










Corrected	  for	  heart	  
rate	  
Diff.	  Sep-­‐Lat	  S-­‐L	  /	  √R-­‐R	   0.43d	   0.28d	   0.26d	   0.15d	   0.18d	   0.20d	   0.01	   0.12d	   0.02	   0.01	  
SD	  T2P	  S-­‐L	  /	  √R-­‐R	   0.40d	   0.30d	   0.21d	   0.12d	   0.24d	   0.27d	   0.04b	   0.13d	   0.04b	   0.07c	  
SD	  T2P	  S-­‐RP	  /	  √R-­‐R	   0.49d	   0,36d	   0.26d	   0.14d	   0.23d	   0.23d	   0.01	   0.15d	   0.01	   0.01	  
SD	  T2P	  S-­‐RM	  /	  √R-­‐R	   0.42d	   0.22d	   0.13d	   0.14d	   0.20d	   0.13d	   0.01	   0.14d	   0.02	   0.02	  
SD	  T2P	  S-­‐CP	  /	  √R-­‐R	   0.33d	   0.23d	   0.13d	   0.08d	   0.17d	   0.14d	   0.01	   0.17d	   0.03a	   0.03a	  
SD	  T2P	  S-­‐CM	  /	  √R-­‐R	   0.42d	   0.34d	   0.29d	   0.24d	   0.34d	   0.32d	   0.01	   0.15d	   0.04b	   0.05b	  
	  
Each R2 is based on the linear model that uses all subjects with known values for the predictor 
used in that particular model. 
a: P<0.05; b: P<0.01; c: P<0.001; d: P<0.0001; BSA: body surface area; BMI: body mass 
index; LV mass/BSA: left ventricular mass corrected for body surface area; LVIDs: left 
ventricular internal diameter at end systole; LVEDV: left ventricular end diastolic volume; 
ESWS: end-systolic wall stress; QTc: QT duration corrected for heart rate using Bazett’s 
method; Syst. BP: systolic blood pressure; T2P: time to peak; Diff. Sep-Lat: difference in T2P 
between septum and lateral wall; SD T2P: synchrony index (standard deviation); S: peak 
systolic global strain; L: longitudinal; R: radial; C: circumferential; P: at the level of the papillary 
muscle; M: at the level of the mitral valve; all outcome variables are corrected for heart rate by 
dividing the timing measurements by the square root of the R-R interval of that particular 
subject.  
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Figure 15 – Difference in time to peak systolic longitudinal strain between lateral wall 
and septum corrected for heart rate with Bazett’s formula 
	  
	  
Age in years; DiffT2PSepLatCorrected: difference in time to peak systolic longitudinal strain 
between lateral wall and septum in milliseconds corrected for heart rate by Bazett’s formula; 
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Figure 16 – Synchronicity index: standard deviation of time to peak systolic 
longitudinal strain corrected for heart rate with Bazett’s formula according to age 
	  
	  
Age in years; deviationT2PS_L Corrected: standard deviation of time to peak systolic 
longitudinal strain in milliseconds corrected for heart rate by Bazett’s formula; lines indicate 
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Figure 17 – Synchronicity index: standard deviation of time to midventricular peak 




Age in years; deviationT2PSCP Corrected: standard deviation of time to peak systolic 
circumferential strain at the level of the papillary muscle in milliseconds corrected for heart rate 
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Figure 18 – Synchronicity index: standard deviation of time to midventricular peak 
systolic radial strain corrected for heart rate with Bazett’s formula according to age 
	  
Age in years; deviationT2PSRP Corrected: standard deviation of time to peak systolic radial 
strain at the level of the papillary muscle in milliseconds corrected for heart rate by Bazett’s 





Electromechanical	   dyssynchrony,	   with	   early	   and	   late	   contracting	   ventricular	  
myocardial	   segments,	   results	   in	   inefficient	   ventricular	   performance.	   Late	  
contracting	  segments	  are	  stretched	  by	  the	  early	  contracting	  regions	  and	  perform	  a	  
higher	   local	  myocardial	   workload.	   This	   workload	   is	   to	   some	   part	   wasted	   because	  
late	   contraction	   appears	   after	   semilunar	   valve	   closure	   and	   at	   the	   end	   of	   the	  
ventricular	  ejection	  phase.9,49	  The	  uneven	  distribution	  of	  work	  load	  leads	  to	  changes	  
in	  both	  regional	  blood	  flow	  and	  metabolism	  in	  addition	  to	  pathologic	  remodeling.50	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Oosterhout	  et	  al.	  showed	  development	  of	  asymmetric	  myocardial	  hypertrophy	  due	  
to	   electromechanical	   dyssynchrony	   with	   decrease	   in	   regional	   wall	   thickness	   and	  
volume	  at	  the	  early	  contracting	  sites	  and	  increase	  in	  the	  areas	  of	  late	  contraction.51	  	  
Together,	   these	   series	   of	   events	   lead	   to	   reduced	   overall	   cardiac	   efficiency	   and	  
increases	  myocardial	   energy	   demands,	  which	   eventually	   result	   in	   (progression	   of)	  
heart	   failure.52	   Furthermore,	   dyssynergistic	   ventricular	   contraction	   and	   relaxation	  
have	  been	  associated	  with	  a	  pro-­‐arrhythmogenic	  effect.53	  	  
	  
Several	   visualization	  methods	   of	   assessing	   the	   extent	   of	   ventricular	   dyssynchrony	  
have	   been	   proposed	   to	   overcome	   the	   above-­‐mentioned	   limitations,	   varying	   from	  
conventional	   echocardiographic	   techniques	   to	   more	   novel	   applications	   such	   as	  
Tissue	   Doppler	   imaging	   (TDI)	   and	   two-­‐dimensional	   strain	   echocardiography.	   TDI	  
initially	   showed	   promising	   results	   for	   the	   assessment	   of	   dyssynchrony	   in	   small	  
clinical	   trials.	   However,	   TDI	   is	   limited	   by	   several	   characteristics	   of	   Doppler-­‐based	  
techniques.	   Firstly,	   TDI	  measures	   only	   the	   vector	   of	  motion	   that	   is	   parallel	   to	   the	  
direction	  of	  the	  ultrasound	  beam	  and	  is	  thus	  inherently	  angle-­‐dependent.	  Secondly,	  
TDI	  measures	  absolute	  tissue	  velocity	  and	  is	  unable	  to	  discriminate	  passive	  motion	  
(related	   to	   translation	   or	   tethering)	   from	   active	   motion	   (fiber	   shortening	   or	  
lengthening).	  Recently,	  large,	  prospective	  randomized	  clinical	  trials	  have	  shown	  that	  
TDI	  is	  inadequate	  to	  predict	  response	  from	  CRT	  in	  patients	  with	  heart	  failure	  and	  is	  
associated	  with	  considerable	  intraobserver	  and	  interobserver	  variability.26,54,55	  	  
	  
Strain	   imaging	   derived	   from	   two-­‐dimensional	   speckle	   tracking	   echocardiography	  
enables	  quantification	  of	  regional	  myocardial	  function	  without	  tethering	  effect	  and	  
Doppler	   angle-­‐dependency.	   It	   measures	   the	   extent	   and	   timing	   of	   regional	  
myocardial	  deformation	  with	  high	  temporal	  and	  spatial	  resolution.	  Although	  2DSTE	  
is	   sensitive	   to	   signal	   noise,	   it	   may	   facilitate	   the	   detection	   of	   ventricular	  
dyssynchrony	  and	  the	  prediction	  of	  outcome	  after	  CRT.26	  A	  prospectively	  designed	  
study,	   performed	   by	   Suffoletto	   et	   al.,	   showed	   that	   2DSTE	   is	   able	   to	   quantify	  
dyssynchrony	   and	   predict	   immediate	   and	   long-­‐term	   response	   to	   CRT	   with	   good	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results.	  In	  addition,	  they	  demonstrated	  the	  feasibility	  of	  2DSTE	  to	  detect	  the	  site	  of	  
latest	   mechanical	   activation.	   Identification	   of	   the	   most	   delayed	   segment	   is	   of	  
importance,	   since	   previous	   reports	   have	   indicated	   that	   left	   ventricular	   lead	  
placement	   at	   the	   most	   delayed	   segment	   resulted	   in	   the	   greatest	   immediate	  
improvements	  from	  CRT.27,56	  Previous	  speckle	  tracking	  studies,	  in	  pediatric	  patients,	  
have	   revealed	   abnormal	   timing	   of	   systolic	   deformation	   in	   various	   congenital	   and	  
acquired	  cardiac	  conditions.	  These	  studies	  have	  indicated	  that	  various	  pathological	  
conditions	   are	   associated	   with	   a	   prolonged	   required	   amount	   of	   time	   to	   reach	  
maximum	   peak	   systolic	   strain,	   in	   addition	   to	   a	   greater	   extent	   of	   inter-­‐	   and	  
intraventricular	   dyssynchronous	   deformation.57,58,59,60,61	   If	   validated	   by	   additional	  
prospective	   studies,	   2DSTE	  may	  prove	  particularly	   helpful	   in	   selecting	   appropriate	  
candidates	  with	  congenital	  heart	  disease	  for	  CRT	  in	  whom	  conventional	  criteria	  are	  
not	   applicable.	   However,	   the	   application	   of	   2DSTE	   indices	   in	   the	   assessment	   of	  
ventricular	   dyssynchrony	   is	   dependent	   on	   establishing	   reference	   values	   across	   a	  
wide	   range	   of	   age	   groups;	   since	   both	   timing	   of	   myocardial	   deformation	   and	   the	  
extent	  of	  dyssynchrony	  between	  various	  ventricular	  segments	  appear	  to	  be	  related	  
to	  age.28,29,30	  	  
	  
While	  mapping	  of	  normal	  contraction	  times	  in	  the	  healthy	  (pediatric)	  heart	  may	  give	  
valuable	  insight	  into	  normal	  contraction	  patterns,	  data	  regarding	  the	  normal	  timing	  
of	   deformation	   and	   the	   extent	   of	   synchrony	   of	   contraction	   between	   ventricular	  
segments	   in	   healthy	   children	   and	   young	   adults	   were	   lacking.	   Therefore,	   in	   the	  
present	  study	  reference	  values	  for	  the	  normal	  timing	  of	  left	  ventricular	  deformation	  
in	  the	  pediatric	  and	  young	  adult	  age	  groups	  were	  assessed	  using	  2DSTE.	  	  
	  
Our	   results	   demonstrated	   a	   significant	   correlation	   between	   time	   to	   peak	   systolic	  
strain	   and	   age,	   as	   well	   as	   heart	   rate.	   The	   influence	   of	   heart	   rate	   on	   strain	  
measurements	  was	  previously	  described	  by	  others	  in	  a	  TDI	  study.62	  Since	  heart	  rate	  
decreases	   with	   age,	   we	   subsequently	   assessed	   the	   relationship	   between	   age	   and	  
time	  to	  peak	  systolic	  strain	  after	  correction	  for	  heart	  rate.	  As	  expected,	  the	  present	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study	  identified	  strong	  relationships	  between	  timing	  of	  myocardial	  deformation	  and	  
age,	  as	  well	  as	  multiple	  anthropometric	  variables	  and	  echocardiographic	  indices.	  No	  
significant	   sex-­‐related	   differences	   in	   time	   to	   peak	   systolic	   strain	   were	   found.	  
Surprisingly,	  we	  did	  not	  find	  a	  significant	  relation	  between	  timing	  of	  left	  ventricular	  
deformation	   and	   conventional	   echocardiographic	   functional	   indices	   such	   as	   left	  
ventricular	   ejection	   fraction,	   fractional	   shortening,	   and	   end-­‐systolic	   wall	   stress,	  
neither	  after	  correction	  of	  timing	  of	  deformation	  for	  heart	  rate.	  These	  findings	  are	  
in	  contrast	  to	  those	  of	  Rosen	  et	  al.30	  A	  possible	  explanation	  for	  these	  contradictory	  
findings	   could	   be	   that	   our	   study	   included	   only	   subjects	   free	   from	   risk	   factors	   for	  
cardiac	   disease	   in	   contrast	   to	   the	   study	   by	   Rosen	   et	   al.	   where	   the	   majority	   of	  
subjects	   had	   cardiovasculatory	   risk	   factors	   (such	   as	   smoking,	   diabetes	   mellitus,	  
hypertension,	   and	   obesity).	   Conventional	   echocardiographic	   functional	   indices	   in	  
our	  study	  showed	  little	  variation,	  which	  could	  offer	  an	  explanation	  for	  the	  absence	  
of	  a	  relation	  between	  these	  conventional	  parameters	  and	  2DSTE	  timing	   indices.	   In	  
all	   age	  groups,	   time	   to	  peak	   systolic	   longitudinal	   strain	  was	   shorter	   in	   the	   septum	  
than	  in	  the	  lateral	  wall,	  which	  is	   in	  accordance	  to	  previous	  reports.	  Zwanenburg	  et	  
al.	  showed	  an	  opposite	  spatial	  pattern	  of	  the	  onset	  of	  longitudinal	  deformation.	  As	  
a	   result,	   duration	   of	   deformation	   was	   longest	   in	   the	   lateral	   wall,	   for	   which	   it	   is	  
known	  that	  peak	  strains	  are	  largest.48,63	  	  
	  
Our	   results	   demonstrate	   that	   increased	  age	   is	   associated	  with	   a	   greater	   extent	  of	  
variation	   in	   timing	   of	   deformation	   among	   various	   left	   ventricular	   segments,	  
indicating	   that	   patterns	   of	   regional	   non-­‐uniformity	   of	  myocardial	   deformation	   are	  
altered	  with	  age.	  These	  findings	  are	   in	  agreement	  with	  previous	  studies	  describing	  
ventricular	   synchrony	   in	   healthy	   adult	   cohorts	   as	  well	   as	   animal	   studies,	  with	   the	  
exception	   of	   a	   study	   performed	   by	   Ng	   et	   al.	   which	   did	   not	   find	   decreased	  
synchronicity	   with	   advanced	   age.28,29,30,64,65,66	   Several	   possible	   explanations	   for	   a	  
decreasing	   extent	   of	   synchronicity	   with	   advancing	   age	   have	   been	   suggested	  
previously.	   A	   study	   by	   Kitzman	   et	   al.	   demonstrated	   age-­‐related	   alterations	   in	   left	  
ventricular	  diastolic	   function	  as	  an	   intrinsic	  biologic	  effect	  of	  aging,	   irrespective	  of	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other	   physiologic	   and	   pathologic	   changes	   that	   frequently	   accompany	   the	   aging	  
process	   such	   as	   hypertension,	   coronary	   artery	   disease	   and	   diabetes.67	   Others	  
described	  an	  age-­‐associated	  increase	  in	  the	  dynamic	  stiffness	  of	  the	  left	  ventricle	  in	  
addition	  to	  prolonged	  contraction	  duration	  due	  to	  a	  slower	  removal	  of	  calcium	  from	  
the	   contractile	   proteins,	   independent	  of	  myocardial	   catecholamine	   content.64,66	   In	  
elderly,	   delayed	   myocardial	   contraction	   and	   dyssynchrony	   may	   result	   from	  
myocardial	   fibrosis.	   Especially	   in	   hypertensive	   patients	   with	   silent	   ischemia	   or	  
infarction,	   potentially	   contributing	   to	   further	   electromechanical	   uncoupling.68	  
Importantly,	   increased	   ventricular	   dyssynchrony	   and	   prolonged	   duration	   of	  
contraction	   may	   impinge	   on	   early	   diastolic	   relaxation	   through	   increased	   post-­‐
systolic	  shortening	  and	  dyscoordinate	  myocardial	  strain.69	  	  
	  
3.6 STUDY LIMITATIONS 
	  
A	   technical	   limitation	   is	   that	   speckle-­‐tracking	   echocardiography	   is	   dependent	   on	  
frame	  rate,	  as	  well	  as	  image	  resolution	  and	  image	  quality.	  Low	  frame	  rates	  result	  in	  
a	   too	   high	   frame-­‐to-­‐frame	   change	   of	   the	   speckle	   pattern,	   which	   prevents	   the	  
precise	  characterization	  of	  regional	  myocardial	  deformation.	  However,	  since	  in	  this	  
study	  we	  are	  primarily	  interested	  in	  time	  to	  reach	  peak	  strain,	  low	  frame	  rates	  only	  
result	   in	   less	   resolution	   of	   the	   timing	   values,	   but	   not	   in	   incorrect	   estimation.	   The	  
optimal	   frame	   rate	   for	   precise	   detection	   of	   myocardial	   deformation	   has	   been	  
reported	   to	   be	   approximately	   60-­‐90	   Hz.24,27,40,41	   We	   used	   custom-­‐made	   software	  
which	   is	   not	   commercially	   available.	   The	   custom-­‐made	   software	   was	   specially	  
developed	   to	   improve	   the	   reliability	   of	   timing	   of	   peak	   estimations	   by	   averaging	  
strain	   curves,	   as	   well	   as	   to	   include	   peak	   systolic	   strain	  measurements	   that	   occur	  
(shortly)	  before	  aortic	  valve	  closure.	  This	  custom-­‐made	  software	  uses	  Q-­‐Q	  intervals	  
instead	  of	   the	  R-­‐R	   interval	   used	  by	   commercially	   available	   software.	  Although	   the	  
custom-­‐made	   software	   is	   not	   commercially	   available,	   this	   method	   can	   be	  
implemented	   in	  generally	  available	  software	  such	  as	  Matlab	   (The	  MathWorks	   Inc.,	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Natick,	  MA;	  see	  appendix	  for	  instructions).	  However,	  when	  not	  the	  strain	  curves	  are	  
averaged	  before	  calculating	  maximum	  strain	  and	  the	  time	  to	  reach	  these	  values,	  but	  
the	   timing	  parameters	  are	  calculated	   from	  the	   individual	   curves	  and	  are	  averaged	  
afterwards,	   similar	   values	   will	   be	   obtained.	   Comparison	   with	   an	   independent	  
external	   technique,	   such	   as	   tagged	  MRI,	  was	   not	   performed	   in	   the	   current	   study,	  
primarily	   because	   the	   validation	   of	   speckle-­‐tracking	   software	   has	   already	   been	  
compared	  with	  MRI	  previously	  with	  excellent	  results.70,71	  In	  addition,	  the	  frame	  rate	  
of	  tagged	  MRI	  cannot	  be	  as	  high	  as	  in	  echocardiography,	  which	  is	  of	  importance	  in	  
children	  in	  whom	  heart	  rate	  is	  higher	  compared	  with	  adults.	  Furthermore,	  in	  case	  of	  
(young)	   children	   it	   often	   indicates	   a	   need	   for	   sedation	   and	   anesthesia.	   Further	  
prospective	  studies	  are	  needed	  to	  compare	  the	  usefulness	  and	  prognostic	  value	  of	  




The	   present	   study	   provides	   reference	   values	   for	   timing	   of	   deformation	   assessed	  
with	  2DSTE	  in	  children	  and	  young	  adults.	  Our	  findings	  indicate	  that	  aging	  results	  in	  a	  
decrease	  of	  synchronicity	  of	  left	  ventricular	  systolic	  deformation.	  The	  results	  of	  the	  
present	  study	  should	  be	  further	  used	  to	  assess	  mechanical	  dyssynchrony	  in	  children	  
with	   various	   cardiac	   conditions.	   Since	   the	   currently	  used	   selection	   criteria	   for	  CRT	  
appear	   not	   very	   suitable	   for	   application	   in	   the	   pediatric	   age	   groups,	   it	   is	   possible	  
that	   2DSTE	   indices	   could	   provide	   valuable	   additional	   information	   on	   myocardial	  
synchrony	  and	  systolic	   function,	  which	  could	  be	  of	  assistance	   in	   selecting	  patients	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3.8 APPENDIX 
	  
Three	   consecutive	   cardiac	   cycles	   were	   analyzed.	   Results	   from	   all	   views	   and	  
segments	  were	  separately	  digitally	  stored	   into	  text	   files	  on	  the	   local	  Hard	  Drive	  of	  
the	  GE	  workstation	  (with	  disabled	  drift	  compensation).	  	  
The	  data	  files	  then	  were	  exported	  from	  the	  system	  and	  stored	  on	  the	  network	  for	  
further	  analysis	  in	  a	  custom-­‐made	  software	  package	  	  
“CardiacCurveAnalysisTool”	  (CCAT)	  using	  Matlab	  version	  7.4.0.287	  (r2007a).	  	  	  
	  
CUSTOM-­‐MADE	  SOFTWARE,	  STEP	  BY	  STEP:	  	  
	  
-­‐ automatic	  load	  of	  the	  three	  consecutive	  cardiac	  cycles	  results	  
-­‐ up	  sampling	  (cubic	  spline)	  to	  2000	  samples	  per	  cardiac	  cycle	  	  
-­‐ interactive	  QQ-­‐onset	  defining	  (on	  the	  three	  consecutive	  cardiac	  cycles)	  
-­‐ curve	  length	  check	  (If	  length	  difference	  is	  >10%	  then	  delete	  longest	  cycle)	  
-­‐ deletion	  of	  data	  before	  and	  after	  the	  selected	  QQ	  timestamps	  
-­‐ padding	  zeros	  (NaN’s)at	  the	  end	  of	  the	  diastolic	  phase	  for	  the	  shortest	  	  	  
cycles	  (to	  generate	  equal	  data	  lengths)	  
-­‐ curve	  averaging	  (using	  Matlab	  mean	  function)	  
-­‐ maximum	  detection	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Chapter 4 
Abnormal two-dimensional strain 
echocardiography findings in children with 
congenital valvular aortic stenosis 
Even	  in	  case	  of	  asymptomatic,	  mild	  stenosis	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4.1 ABSTRACT  
	  
Background:	  Congenital	  valvular	  aortic	  stenosis	  (VAS)	  causes	  a	  pressure	  overload	  to	  
the	   left	   ventricle.	   In	   the	   clinical	   setting,	   the	   severity	   of	   stenosis	   is	   graded	   by	   the	  
pressure	   drop	   over	   the	   stenotic	   valve	   (pressure	   gradient).	   This	   parameter	   is	  
dependent	   on	   the	   hemodynamic	   status	   and	   does	   not	   provide	   information	   on	  
myocardial	  performance.	  	  
	  
Aim:	  This	  study	  was	  undertaken	  to	  reveal	   the	  potentials	  of	   two-­‐dimensional	  strain	  
echocardiography	   (2DSTE)	   for	   the	  detection	  of	  myocardial	   functional	   changes	  due	  
to	  congenital	  VAS	  in	  children.	  	  
	  
Methods:	  A	  total	  of	  86	  patients	  (aged	  from	  birth	  to	  18	  years)	  with	  various	  degrees	  of	  
isolated	   congenital	   VAS	   were	   enrolled	   in	   this	   study.	   None	   of	   the	   patients	   had	  
undergone	  any	   form	  of	   surgical	   or	  balloon	   intervention.	  A	  number	  of	   139	  healthy	  
children	  served	  as	  a	  control	  group.	  Two-­‐dimensional	  cine-­‐loops	  recordings	  of	  apical	  
four-­‐chamber,	  midcavity	  short-­‐axis	  and	  basal	  short-­‐axis	  views	  were	  digitally	  stored	  
for	  offline	  analysis.	  Longitudinal,	  circumferential	  and	  radial	  peak	  systolic	  strain	  and	  
strain	  rate	  values	  were	  determined,	  as	  well	  as	  the	  time	  to	  peak	  systolic	  strain	  (T2P).	  
Two-­‐way	   analysis	   of	   variance	  was	   performed	   to	   assess	   the	   relation	   between	   VAS	  
severity	  and	  2DSTE	  parameters.	  	  
	  
Results:	   In	   all	   patients	   conventional	   echocardiographic	   findings	   did	   not	   indicate	  
systolic	  left	  ventricular	  dysfunction.	  All	  strain	  parameters	  of	  the	  control	  group	  were	  
significantly	   different	   from	   those	   of	   VAS	   patients.	   There	   was	   a	   statistically	  
significant,	   inverse	   relation	   between	   global	   peak	   systolic	   strain	   parameters	   in	   all	  
three	  directions	  and	  the	  degree	  of	  VAS	  (P<0.05).	  Local	  peak	  systolic	  strain	  (rate)	   in	  
the	  interventricular	  septum	  was	  most	  affected.	  T2P	  increased	  significantly	  with	  VAS	  
severity	  (P<0.05).	  The	  decline	  in	  LV	  longitudinal	  systolic	  performance	  preceded	  that	  
in	  other	  directions.	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Conclusion:	  2DSTE	  detects	  alterations	  in	  myocardial	  systolic	  deformation	  in	  children	  
diagnosed	  with	  congenital	  VAS,	  whose	  conventional	  echocardiographic	  findings	  did	  




Congenital	  isolated	  valvular	  aortic	  stenosis	  (VAS)	  is	  one	  of	  the	  most	  common	  forms	  
of	   congenital	   heart	   disease	   (CHD)	   with	   an	   incidence	   of	   1.1	   -­‐	   4.3	   per	   10,000	   live	  
births	   and	   an	   increasing	   prevalence	   with	   age,	   since	   certainly	   not	   all	   cases	   are	  
diagnosed	   at	   time	   of	   birth.	   It	   is	   a	   progressive	   disease	   with	   an	   overall	   25-­‐years	  
survival	  rate	  of	  85%	  after	  the	  diagnosis	  has	  been	  made	  and	  a	  worrisome	  potential	  
incidence	   of	   sudden	   cardiac	   death,	   which	   underscores	   the	   essential	   need	   for	  
lifelong,	  periodic	  cardiac	  evaluation	  and	  monitoring.1,2	  However,	  the	  survival	  rate	  of	  
85%	  is	  described	  for	  both	  symptomatic	  and	  asymptomatic	  patients	  and,	  therefore,	  
is	  not	  really	  reflective	  of	  the	  prognosis	  for	   just	  the	  asymptomatic	  patient	  group.	   In	  
clinical	   practice,	   the	   severity	   of	   stenosis	   is	   defined	   using	   the	   ultrasound	   Doppler-­‐
derived	  peak	   instantaneous	  aortic	   flow	  velocity	  or	   the	  Bernoulli	   equation-­‐	  derived	  
pressure	  drop	  across	  the	  stenotic	  aortic	  valve	  (pressure	  gradient).	  With	  this	  method,	  
mild	   stenosis	   is	   defined	  as	   a	  peak	   systolic	   flow	  velocity	  between	  2.5	   and	  3.0	  m/s,	  
moderate	  VAS	  between	  3.0	  and	  4.0	  m/s,	  while	  patients	  with	  a	  peak	   jet	  velocity	  of	  
more	  than	  4.0	  m/s,	  which	  corresponds	  to	  a	  peak	  pressure	  gradient	  of	  more	  than	  64	  
mmHg,	  are	  considered	  to	  have	  severe	  VAS.3	  
	  
In	   contrast	   to	   the	   adult	   population,	   there	   is	   little	   consensus	   and	   evidence	  
concerning	   the	   timing	   of	   intervention	   in	   children	   with	   VAS.1	  Most	   authors	   agree	  
that	   balloon	   valvuloplasty	   or	   surgery	   is	   indicated	   in	   symptomatic	   children	   or	   in	  
asymptomatic	   individuals	  with	   severe	   VAS.	   There	   is	   no	   consensus	   however,	   as	   to	  
whether,	   how	   and	  when	   to	   treat	   asymptomatic	   patients	  with	  moderate	   VAS.	   The	  
main	   reason	   for	   intervention	   in	   this	   subset	   of	   patients,	   even	   in	   the	   absence	   of	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electrocardiographic	  abnormalities	  or	  of	  echocardiographic	  signs	  of	   left	  ventricular	  
hypertrophy,	  is	  to	  avoid	  further	  deterioration	  and	  ultimately	  irreversible	  myocardial	  
damage.4	   Nevertheless,	   it	   remains	   a	   challenge	   to	   define	   which	   patients	   require	  
intervention.	  Both	  balloon	  and	  surgical	  valvulotomy	  are	   firmly	  established	  and	  are	  
comparable	  techniques	  in	  terms	  of	  immediate	  gradient	  relief,	  procedural	  mortality,	  
morbidity	   and	   long-­‐term	   survival.5,6	  However,	   the	  major	   concern,	  mainly	   in	   young	  
patients	   after	   any	   sort	   of	   valvulotomy,	   is	   severe	   valvular	   aortic	   regurgitation	  
(resulting	   in	  volume	  overload),	  which	   is	   less	  well	   tolerated	  than	  moderate	  residual	  
VAS	  (pressure	  overload).	  The	  decision	  concerning	  the	  timing	  of	  an	  intervention	  will	  
hopefully	   be	   greatly	   improved	   if	   an	   appropriate	   non-­‐invasive,	   easily	   applicable	  
(bedside)	   diagnostic	   tool	   to	   monitor	   left	   ventricular	   function	   becomes	   available.	  
Furthermore,	   it	   would	   enable	   accurate	   evaluation	   of	   the	   effectiveness	   of	   such	  
treatment,	   which	   would	   make	   it	   possible	   to	   adjust	   medical	   treatment	   to	   the	  
patient’s	  individual	  needs	  in	  a	  timely	  manner.	  
	  
Two-­‐dimensional	   speckle	   tracking	   echocardiography	   (2DSTE),	   a	   relatively	   new	  
echocardiographic	   technique	   to	   quantify	   myocardial	   strain	   (deformation),	  
represents	   a	   promising	   bedside	   tool	   for	   the	   careful	   evaluation	   of	   myocardial	  
function.	   The	   spectrum	   of	   potential	   clinical	   applications	   is	   very	   wide.	   Due	   to	   its	  
ability	   to	   differentiate	   between	   active	   and	   passive	   deformation	   of	   myocardial	  
segments,	   to	   quantify	   intraventricular	   dyssynchrony	   and	   to	   evaluate	   individual	  
components	   of	   myocardial	   function	   such	   as	   longitudinal	   myocardial	   shortening,	  
2DSTE	  is	  able	  to	  detect	  myocardial	  dysfunction	  at	  an	  early	  stage.7,8,9,10	  However,	  the	  
value	  and	  applicability	  of	  2DSTE	  in	  the	  evaluation	  of	  ventricular	  myocardial	  function	  
in	  children	  with	  CHD,	  such	  as	  VAS,	  have	  not	  been	  elucidated.	  We	  hypothesized	  that	  
regional	  myocardial	  function	  in	  congenital	  VAS	  is	  altered	  early,	  i.e.,	  before	  the	  overt	  
manifestation	   of	   cardiomyopathy	   and	   heart	   failure.	   The	   aim	   of	   this	   study	   is	   to	  
introduce	   2DSTE	   as	   a	   useful	   technique	   for	   the	   early	   detection	   of	   such	   subtle	  
(regional)	  myocardial	  dysfunction.	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4.3 MATERIAL AND METHODS 
4.3.1 STUDY POPULATION 
	  
All	  asymptomatic	  children	  with	  isolated	  congenital	  VAS	  visiting	  the	  outpatient	  clinic	  
at	   the	  Children’s	  Heart	   Centre	  Nijmegen	  between	   January	   1,	   2004	   and	  November	  
30,	   2009	   were	   analyzed	   for	   their	   eligibility	   for	   inclusion	   in	   the	   study.	   Inclusion	  
criteria	   consisted	   of	   an	   isolated	   congenital	   VAS	   (e.g.	   thickening	   of	   the	   valve	   or	  
functional	   bicuspid	   aortic	   valve),	   accompanied	   by	   a	   Doppler-­‐derived	   peak	  
instantaneous	   aortic	   flow	   velocity	   of	   at	   least	   2.5	   m/s	   (which	   corresponds	   to	   a	  
pressure	   gradient	   of	   25	   mmHg).	   Exclusion	   criteria	   were:	   (1)	   moderate	   or	   severe	  
aortic	  regurgitation	  (i.e.	  >	  grade	  1),	  (2)	  cardiac	  rhythms	  other	  than	  sinus	  rhythm,	  (3)	  
balloon	  and/or	   surgical	   valvulotomy	   in	   the	  past,	   (4)	  acute	  or	   chronic	   illness	  at	   the	  
time	   of	   echocardiographic	   evaluation,	   (5)	   diagnosis	   of	   a	  metabolic	   and/or	   genetic	  
syndrome.	  Demographic	   and	   anthropometric	   characteristics	  were	   collected	   at	   the	  
same	  time	  the	  echocardiographic	  study	  was	  performed.	  A	  complete	  history,	  as	  well	  
as	  physical	  examination	  and	  ECG	  were	  performed.	  This	  study	  was	  approved	  by	  the	  
local	  medical	  ethics	  committee.	  	  
	  
4.3.2 CONTROL GROUP 
	  
Subjects	   who	   were	   routinely	   referred	   for	   echocardiographic	   evaluation	   of	   an	  
asymptomatic,	   innocent	   heart	   murmur	   between	   May	   1,	   2005	   and	   November	   1,	  
2009,	  were	  retrospectively	  analyzed	  for	  their	  eligibility	  for	  inclusion	  in	  the	  study	  to	  
serve	   as	   a	   control	   group.	   Subjects	   with	   structural	   (congenital)	   heart	   disease,	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4.3.3 2DSTE DATA ACQUISITION 
	  
All	   subjects	   underwent	   a	   detailed	   transthoracic	   echocardiographic	   examination	   in	  
the	  left	  lateral	  position	  according	  to	  the	  recommendations	  of	  the	  American	  Society	  
of	   Echocardiography	   and	   a	   local	   research	   protocol	   previously	   described	   by	  
Mavinkurve-­‐Groothuis	  et	  al.11,12	  Every	  examination	  was	  performed	  at	  rest,	  without	  
using	   sedation.	   Images	   were	   obtained	   with	   a	   3.0-­‐MHz	   (S3)	   or	   a	   5.0-­‐MHz	   (S5)	  
phased-­‐array	   transducer	   using	   a	   commercially	   available	   system,	   the	   Vivid	   7	  
echocardiographic	   scanner	   (GE,	   Vingmed	   Ultrasound	   AS,	   Horten,	   Norway).	   The	  
choice	  of	   an	   S3	  or	   a	   S5	   transducer	  depended	  on	   the	  weight	   and	  age	  of	   the	   child.	  
Two-­‐dimensional	   multiframe	   B-­‐Mode	   (grayscale)	   images	   were	   obtained	   in	   the	  
parasternal	  apical	   four-­‐chamber	  (4C),	  midcavity	  short-­‐axis	  view	  (at	  the	   level	  of	  the	  
papillary	   muscle:	   PM)	   and	   basal	   short-­‐axis	   view	   (at	   the	   level	   of	   the	   mitral	   valve:	  
MV).	  A	  sector	  scan	  angle	  of	  30	  to	  60	  degrees	  was	  chosen	  and	  frame	  rates	  of	  60	  to	  
90	  Hz	  were	  used.	  Preferably	  images	  from	  five	  cardiac	  cycles	  triggered	  by	  the	  R	  wave	  
of	   the	  QRS	  complex	  were	  digitally	   saved	   in	  cineloop	   format.	  Offline	  strain	  analysis	  
was	  performed	  using	  software	  for	  echocardiographic	  quantification	  (Echopac	  6.1.0;	  
GE	  Vingmed	  Ultrasound	  AS,	  Horten,	  Norway).	  The	  timing	  of	  aortic	  valve	  closure	  and	  
mitral	   valve	   opening	   with	   respect	   to	   peak	   strain	   and	   peak	   systolic	   strain	   were	  
manually	   obtained,	   using	   single	   gated	   pulsed-­‐wave	   (PW-­‐)Doppler	   or	   continuous-­‐
wave	   (CW-­‐)	   Doppler	   images	   of	   the	   left	   ventricular	   outflow	   tract.	   For	   these	  
measurements,	  special	  care	  was	  taken	  to	  keep	  the	  heart	  rate	  in	  the	  same	  range	  as	  
during	   the	   2D	   grayscale	   imaging	   used	   for	   2D	   strain	   calculations.	   Endo-­‐myocardial	  
borders	   of	   the	   left	   ventricle	   were	   interactively	   tracked	   within	   the	   end-­‐systolic	  
frame.	  The	  second,	  epicardial,	  tracing	  was	  generated	  by	  the	  EchoPAC	  software	  and,	  
when	   necessary,	   manually	   adjusted	   to	   cover	   the	   whole	   myocardial	   wall.	   The	  
tracking	  algorithm	  then	   followed	   the	   speckles	   (the	  echographic	  pattern	  present	   in	  
an	  echogram)	  in	  the	  myocardium	  through	  the	  cardiac	  cycle.	  Tracking	  was	  accepted	  
only	   if	  both	  visual	   inspection	  as	  well	   as	   the	  EchoPAC	  software	   indicated	  adequate	  
tracking.	   The	   software	   automatically	   divided	   the	   cross-­‐sectional	   image	   into	   six	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segments,	   which	   were	   named	   and	   identified	   according	   to	   the	   statement	   of	   the	  
Cardiac	   Imaging	   Committee	   of	   the	   Council	   on	   Clinical	   Cardiology	   of	   the	   American	  
Heart	  Association.13	   The	   left	   ventricular	   segments	   to	  be	   analyzed	  were	   the	   apical,	  
middle	  and	  basal	  segments	  of	  the	  septal	  and	  the	  lateral	  wall	  of	  the	  4C	  view,	  as	  well	  
as	  the	  anteroseptal,	  anterior,	  lateral,	  posterior,	  inferior	  and	  septal	  segments	  of	  the	  
basal	   (MV)	   and	  midcavity	   (PM)	   short-­‐axis	   views.	   Strain	   (rate)	   curves	   of	   the	   three	  
consecutive	   cardiac	   cycles	   and	   values	   of	   the	  manual	   timing	  were	   imported	   into	   a	  
custom-­‐made	   software	   package	   for	   further	   analysis.	   The	   Q-­‐Q	   interval	   was	  
determined	   from	   the	   electrocardiogram	   signal	   to	   obtain	   cardiac	   cycle	   length.	   It	   is	  
known	  that	  the	  duration	  of	  the	  systolic	  phase	  of	  the	  cardiac	  cycle	   in	  rest	  does	  not	  
change	   with	   small	   changes	   in	   heart	   rate,	   in	   contrast	   to	   the	   diastolic	   phase.14	  
Therefore,	   the	   diastolic	   phase	   of	   the	   three	   cardiac	   cycles	   was	   automatically	  
extended	  and	  adjusted	  by	  the	  software	  package	  to	  the	  longest	  of	  the	  three	  cardiac	  
cycles.	  This	  intervention	  prevents	  a	  shift	  of	  the	  peak	  systolic	  strain	  while	  averaging	  
the	   three	   consecutive	   cardiac	   cycles.	   Cardiac	   cycles	   with	   lengths	   more	   than	   ten	  
percent	  different	   from	  the	  mean	   length	  of	   the	   three	  cardiac	  cycles	  were	  excluded	  
for	  further	  analysis.	  Myocardial	  longitudinal,	  radial	  and	  circumferential	  strain	  (-­‐rate)	  
values	  of	  each	  of	  the	  cardiac	  segments	  were	  obtained,	  as	  well	  as	  the	  time	  to	  reach	  
peak	  systolic	  strain.	  To	  determine	  global	  strain	  (-­‐rate),	  the	  strain	  (-­‐rate)	  values	  of	  the	  
six	   segments	  were	  averaged	   for	   the	  4C-­‐	   as	  well	   as	   the	   short-­‐axis	   views.	  All	   2DSTE	  
analyses	  were	  performed	  by	  the	  same	   investigator	   (K.A.M.)	   to	  avoid	   interobserver	  
variability.	  Intraobserver	  (and	  interobserver)	  reliability	  scores	  have	  been	  established	  
previously	   by	   our	   research	   group	   in	   children	   and	   young	   adults	   and	   are	   high	   for	  
almost	   all	   parameters.12	   Strain	   values	   are	   dimensionless	   and	   are	   expressed	   as	  
percentages.	  Strain-­‐rate	  is	  the	  time	  derivative	  of	  strain	  and	  is	  expressed	  as	  s-­‐1.	  Time	  
to	   peak	   systolic	   strain	   is	   expressed	   as	   milliseconds	   (ms).	   Negative	   strain	   values	  
reflect	   shortening/thinning,	   while	   positive	   strain	   values	   reflect	   lengthening	   or	  
thickening.	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4.3.4 CONVENTIONAL ECHOCARDIOGRAPHIC PARAMETERS 
	  
Quantification	  of	  cardiac	  chamber	  size,	  ventricular	  mass	  and	  systolic	  left	  ventricular	  
function	   were	   measured	   in	   accordance	   with	   the	   recommendations	   for	   chamber	  
quantification	   by	   the	   American	   Society	   of	   Echocardiography’.11	   Left	   ventricular	  
systolic	  function	  was	  characterized	  using	  fractional	  shortening	  (FS),	  ejection	  fraction	  
(EF),	  left	  ventricular	  myocardial	  performance	  index,	  or	  Tei	  index	  and	  rate-­‐corrected	  
velocity	  of	  circumferential	   fiber	  shortening	  (VCFc).	  Ejection	  fraction	  was	  calculated	  
using	   the	   modified	   Simpson’s	   rule.	   The	   PW-­‐Doppler-­‐derived	   myocardial	  
performance	   index	  was	  calculated	  as:	  Tei	  =	   (iso-­‐volumetric	   contraction	   time	  +	   iso-­‐
volumetric	  relaxation	  time)/	  ejection	  time.15	  VCFc	  was	  calculated	  using	  the	  formula	  
obtained	   from	  Colan	   and	   colleagues.16	   Left	   ventricular	  mass	   (LVM)	  was	   calculated	  
using	   the	   formula	   for	   estimation	   of	   LVM	   according	   to	   Devereux	   and	   Reichek	   and	  
was	  subsequently	  indexed	  to	  body	  surface	  area	  (BSA).17	  The	  obtained	  values	  of	  LVM	  
(corrected	   for	   BSA)	   were	   compared	   with	   those	   previously	   described	   in	   healthy	  
children.18,19	  	  
4.3.5 STATISTICAL ANALYSIS 
	  
All	   patients	   were	   divided	   in	   three	   groups	   according	   to	   VAS	   severity	   for	   further	  
analysis.	  Mild	   VAS	  was	   defined	   as	   a	   peak	   flow	   velocity	   between	   2.5	   and	   3.0	  m/s,	  
moderate	  VAS	  between	  3.0	  and	  4.0	  m/s,	  whereas	  patients	  with	  a	  peak	  jet	  velocity	  
of	   more	   than	   4.0	   m/s	   were	   considered	   to	   have	   severe	   VAS.3	   All	   demographic,	  
anthropometric,	  conventional	  echocardiographic	  and	  2D	  strain	  values	  are	  expressed	  
as	  mean	  ±	  standard	  deviation	  (SD)	  or	  median	  and	  range.	  A	  cohort	  consisting	  of	  139	  
healthy	  children	  was	  used	  as	  control	  group.	  The	  relation	  of	  VAS	  severity	  (none,	  mild,	  
moderate	  and	  severe)	  with	  each	  conventional	  echocardiographic	  parameter,	  as	  well	  
as	  with	   anthropometric	   characteristics	  was	   investigated	  using	  one-­‐way	   analysis	   of	  
variance	   (ANOVA)	   with	   the	   Bonferroni	   correction	   for	   multiple	   comparisons	   or	  
Kruskal-­‐Wallis	   nonparametric	   test	  when	   outcomes	  were	   not	   normally	   distributed.	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The	   relation	   between	   VAS	   severity	   (none,	   mild,	   moderate	   and	   severe)	   and	   each	  
global	   peak	   systolic	   strain	   (-­‐rate)	   parameter,	   as	   well	   as	   each	   time	   to	   global	   peak	  
systolic	  strain	  parameter	  was	  reported	  using	  two-­‐way	  analysis	  of	  variance	  with	  the	  
Bonferroni	  correction	  for	  multiple	  comparisons.	  A	  two-­‐way	  analysis	  of	  variance	  was	  
chosen	   to	   adjust	   for	   age,	   hereby	   avoiding	   possible	   bias	   caused	   by	   age.	   All	   2DSTE	  
parameters	   were	   normally	   distributed.	   To	   study	   the	   additional	   effect	   of	  
demographic,	  anthropometric	  and	  conventional	  echocardiographic	  parameters	  over	  
the	  effects	  of	  age	  and	  VAS	  severity,	  multiple	  linear	  regression	  analysis	  was	  used	  for	  
each	  global	  2DSTE	  variable	  taken	  as	  outcome	  variable.	  P-­‐values	  less	  than	  0.05	  were	  
considered	  to	  indicate	  significance.	  All	  statistical	  analyses	  were	  performed	  using	  the	  




4.4.1 DEMOGRAPHIC AND ANTHROPOMETRIC PARAMETERS 
	  
In	  total	  159	  children	  with	  congenital	  VAS	  were	  recruited	  from	  our	  outpatients	  clinic	  
for	   possible	   inclusion	   in	   the	   study.	   Seventy-­‐three	   of	   those	   patients	   were	  
subsequently	   excluded:	   in	   12	   cases	   VAS	   was	   accompanied	   by	   another	   congenital	  
heart	  defect,	  6	  patients	   suffered	   from	  moderate	   to	  severe	  aortic	   regurgitation,	  51	  
patients	   had	   a	   past	   history	   of	   valvuloplasty,	   3	   patients	   had	   been	   diagnosed	   with	  
Turner	   syndrome	  and	  one	  patient	   suffered	   from	  heart	   failure.	  Finally,	  86	  pediatric	  
patients	  aged	  0	  to	  18	  years	  were	  eligible	  for	  inclusion	  in	  the	  study.	  A	  group	  of	  139	  
healthy	   children	   (control	   group)	  with	   approximately	   the	   same	   age	   range	   (median	  
7.5	  years;	  range	  0.1	  –	  17.9	  for	  control	  group	  versus	  median:	  9.3	  years;	  range	  0.2	  –	  
17.9	  for	  VAS	  patient	  group)	  was	  included	  and	  examined.	  	  
Patient	  demographic	  characteristics	  and	  anthropometric	  parameters	  are	  described	  
in	  Table	  15,	  together	  with	  the	  data	  of	  the	  control	  group.	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Table 15 - Demographic and anthropometric characteristics (mean ± standard deviation 
or median and range) of study subjects categorized by VAS severity 






Number	   139	   45	   31	   10	  
Male	   82	  (59%)	   31	  (69%)	   23	  (74%)	   6	  (60%)	  
Age	  (y)	   7.5	  
(0.1	  –	  17.9)	  
10.2	  
(1.7	  –	  17.9)	  *	  
9.0	  
(0.4	  –	  17.0)	  
8.0	  
(0.2	  –	  15.7)	  
Weight	  (kg)	   28.4	  
(3.3	  –	  83.4)	  
36.2	  
(9.1	  –	  75.3)	  *	  
31.0	  
(7.0	  –	  86.0)	  
32.5	  
(6.4	  –	  58.2)	  
Height	  (cm)	   126	  ±	  38.5	   137	  ±	  29.6	  *	   133	  ±	  30.3	   128	  ±	  37.8	  
BSA	  (m2)	   0.99	  ±	  0.51	   1.20	  ±	  0.44	  *	   1.13	  ±	  0.45	   1.01	  ±	  0.43	  
BMI	  (kg/m2)	   16.8	  ±	  2.6	   17.9	  ±	  3.2	   18.1	  ±	  3.6	   16.7	  ±	  1.5	  
HR	  (bpm)	   90	  ±	  23	   81	  ±	  20	   83	  ±	  22	   90	  ±	  34	  
MAP	  (mmHg)	   71.7	  ±	  10.5	   74.6	  ±	  8.5	   76.0	  ±	  9.9	  *	   72.8	  ±	  7.6	  
Syst.BP	  (mmHg)	   98	  ±	  16	   103	  ±	  13	   100	  ±	  11	   100	  ±	  11	  
 
BMI: body mass index; BSA: body surface area; HR: heart rate; MAP: mean arterial blood 
pressure; Syst.BP: systolic blood pressure. *P < 0.05 statistically significant difference 
compared with control subjects determined by one-way analysis of variance with Bonferroni 
correction for multiple comparisons or Kruskal-Wallis nonparametric test. 
	  
4.4.2 CONVENTIONAL ECHOCARDIOGRAPHIC PARAMETERS 
	  
The	  conventional	  functional	  echocardiographic	  findings	  did	  not	  indicate	  systolic	  left	  
ventricular	  dysfunction	  and	  were	  all	  within	  normal	  limits.	  There	  were	  no	  statistically	  
significant	  differences	  in	  LVETc,	  VCFc,	  Tei	  index,	  FS,	  and	  LVEF	  between	  VAS	  severity	  
categories	   (none,	  mild,	  moderate	   and	   severe)	   as	   assessed	   by	   one-­‐way	   analysis	   of	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variance	   with	   Bonferroni	   correction	   for	   multiple	   comparisons.	   Only	   left	   ventricle	  
mass	  corrected	  for	  BSA	  increased	  significantly	  (P	  <0.001)	  with	  VAS	  severity,	  but	  did	  
not	   reach	   the	   threshold	   for	   left	   ventricular	  hypertrophy,	  not	  even	   in	   the	  group	  of	  
children	  with	  severe	  VAS	  (<	  90th	  percentile).	  Median	  z-­‐scores	  were	  normal,	   in	  both	  
control	  and	  patient	  groups.	  Conventional	  echocardiographic	   findings	  are	  described	  
in	  Table	  16.	  	  
	  
Table 16 – Conventional echocardiographic findings (mean ± standard  
deviation or median and range) of study subjects categorized by VAS severity 








(m/s)	   1.2	  (0.8	  –	  1.4)	   2.8	  (2.6	  –	  2.9)	  *	   3.4	  (3.1	  –	  3.9)	  *	  ¥	   4.5	  (4.1	  –	  6.2)	  *	  
¥	  
LVETc	  (s)	   0.31	  ±	  0.02	   0.31	  ±	  0.02	   0.32	  ±	  0.02	   0.32	  ±	  0.02	  
VCFc	  (circ/s)	   1.26	  ±	  0.20	   1.26	  ±	  0.18	   1.27	  ±	  0.16	   1.28	  ±	  0.25	  
Tei	  index	   0.38	  ±	  0.04	   0.38	  ±	  0.06	   0.39	  ±	  0.05	   0.39	  ±	  0.06	  
FS	   0.39	  ±	  0.05	   0.39	  ±	  0.04	   0.41	  ±	  0.05	   0.41	  ±	  0.05	  
LVEF	  biplane	   0.70	  ±	  0.06	   0.69	  ±	  0.05	   0.73	  ±	  0.06	   0.73	  ±	  0.10	  
LV	  mass/BSA	  
(g/m2)	   53.2	  ±	  16.3	   65.6	  ±	  18.7	  *	   74.0	  ±	  20.2	  *	   74.3	  ±	  18.3	  *	  
z-­‐score	  LV	  mass	  	   -­‐1.1	  	   -­‐1.2	  	   -­‐0.2	  	   0.3	  	  
(median	  –	  
range)	   (-­‐2.3	  -­‐1.8)	   (-­‐2.4	  –	  1.7)	   (-­‐2.5	  –	  2.3)	   (-­‐1.5	  –	  1.9)	  
	  
FS: fractional shortening; LVEF biplane: left ventricular ejection fraction measured by modified 
Simpson’s method; LVETc: left ventricular ejection time corrected for heart rate; LV 
mass/BSA: left ventricular mass corrected for body surface area; Peak velocity: peak 
instantaneous systolic flow velocity over the aortic valve; Tei index: left ventricular myocardial 
performance index; VCFc: heart-rate corrected velocity of circumferential fiber shortening.  
*P < 0.05 statistically significant difference when compared to control subjects; ¥ P < 0.05 
statistically significant difference when compared to previous VAS category; determined by 
one-way analysis of variance with Bonferroni correction for multiple comparisons or Kruskal-
Wallis nonparametric test. 
120	  |	  Chapter	  4	  
4.4.3 MYOCARDIAL STRAIN PARAMETERS 
	  
Tracking	  was	  feasible	  in	  98%	  of	  all	  segments	  of	  the	  four-­‐chamber	  view,	  in	  95%	  of	  all	  
segments	  in	  the	  short-­‐axis	  view	  at	  the	  level	  of	  the	  papillary	  muscle	  and	  in	  89%	  of	  all	  
segments	   in	   the	   short-­‐axis	   view	  at	   the	   level	   of	   the	  mitral	   valve.	   The	  most	   striking	  
observation	   was	   that	   all	   global	   systolic	   2DSTE	   parameters	   in	   VAS	   patients	   were	  
statistically	  significant	  different	  from	  those	  determined	  in	  the	  control	  group.	  There	  
was	  a	  statistically	  significant,	  inverse	  relation	  (P<0.001)	  between	  each	  of	  the	  global	  
peak	  systolic	  strain	  (-­‐rate)	  parameters	  and	  VAS	  severity,	  determined	  by	  means	  of	  a	  
two-­‐way	  analysis	  of	   variance	  with	  Bonferroni	   correction	   for	  multiple	   comparisons.	  
After	   adjustment	   for	   age	   and	   performing	   Bonferroni	   correction,	   there	   were	  
statistically	   significant	   differences	   (P<0.001)	   between	   most	   of	   the	   VAS	   severity	  
categories	  for	  all	  global	  peak	  systolic	  parameters	  (Table	  17).	  	  
	  
In	  children	  with	  VAS,	  the	  decline	   in	   left	  ventricular	   longitudinal	  peak	  systolic	  strain	  
values	  preceded	   that	   in	   the	  other	   two	  directions.	  Global	   longitudinal	  peak	  systolic	  
deformation	   was	   significantly	   lower	   in	   children	   with	   VAS	   among	   all	   degrees	   of	  
stenosis	   when	   compared	   to	   healthy	   subjects,	   even	   in	   case	   of	   mild	   stenosis	  
(P<0.001).	  The	  decline	   in	   longitudinal	   systolic	   strain	  as	  well	  as	   longitudinal	   systolic	  
strain	   rate	   was	   more	   pronounced	   in	   segments	   of	   the	   interventricular	   septum,	  
especially	   its	   basal	   parts.	   In	   children	   with	   severe	   VAS,	   global	   peak	   systolic	  
longitudinal	   strain	  was	  on	  average	  5.9%	  ±	  0.9	   lower	   in	   the	   interventicular	   septum	  
(6.2%	  ±	   0.9	   in	   the	  basal	   part)	   and	  4.5%	  ±	   1.3	   lower	   in	   the	   lateral	   free	  wall,	  when	  
compared	  to	  healthy	  age	  matched	  children	  (data	  not	  shown;	  P<0.001).	  
	  
The	  strain	  values	  in	  circumferential	  and	  radial	  direction	  decreased	  when	  the	  degree	  
of	   VAS	   was	   more	   severe.	   Significantly	   lower	   peak	   systolic	   strain	   values	   in	   the	  
circumferential	  plane	  were	  detected	  in	  children	  with	  moderate	  and	  severe	  VAS.	  The	  
radial	  peak	  systolic	  strain	  values	  were	  only	  significantly	  negatively	  affected	   in	  case	  
of	   severe	   VAS.	   Radial	   peak	   systolic	   strain	   appears	   to	   be	   relatively	   unaffected	   in	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children	  with	  moderate	  VAS.	  In	  contrast,	  in	  children	  with	  mild	  VAS	  global	  radial	  peak	  
systolic	  strain	  was	  increased	  compared	  with	  age-­‐matched	  reference	  values.	  	  
	  
The	  strain	  rate	  values	  among	  children	  with	  various	  degrees	  of	  VAS	  showed	  a	  pattern	  
comparable	   to	   that	   seen	   with	   global	   peak	   systolic	   strain.	   Left	   ventricular	  
longitudinal	   peak	   systolic	   strain	   rate	   was	   significantly	   lower	   in	   children	   with	  
congenital	   VAS,	   even	   in	   case	   of	  mild	   stenosis,	  when	   compared	   to	   healthy	   control	  
subjects	  (P	  <	  0.001).	  The	  lowest	  values	  of	  longitudinal	  strain	  rate	  were	  observed	  in	  
the	   group	   of	   children	   with	   severe	   VAS.	   Similar	   to	   circumferential	   strain,	  
circumferential	  peak	  systolic	  strain	  rate	  was	  significantly	  decreased	  in	  children	  with	  
moderate	   and	   severe	   VAS	   (P	   <	   0.001).	   In	   children	  with	   all	   degrees	   of	   VAS,	   radial	  
peak	  systolic	  strain	  rate	  values	  at	  the	  level	  of	  the	  papillary	  muscle	  were	  comparable	  
to	  those	  found	  in	  the	  healthy	  control	  subjects.	  At	  the	  level	  of	  the	  mitral	  valve,	  radial	  
peak	  systolic	  strain	  rate	  was	  significantly	  higher	   in	   the	  group	  of	  children	  with	  mild	  
VAS	  (P	  <	  0.01).	  
	  
Time	   to	   global	   peak	   systolic	   strain	   results	   in	   all	   three	   directions	   (longitudinal,	  
circumferential	   and	   radial)	   increased	   significantly	   (P	   <	   0.05)	   with	   increasing	   VAS	  
severity	   (none	   to	   severe),	   especially	   in	   severe	   VAS.	   Differences	   in	   timing	   of	  
deformation	   between	   the	   groups	   under	   investigation	   cannot	   be	   attributed	   to	  
differences	  in	  heart	  rate	  between	  the	  various	  groups	  of	  children	  (Table	  15).	  As	  with	  
strain	   parameter	   results,	   the	   time	   to	   peak	   systolic	   strain	   was	   most	   affected	   in	  
longitudinal	   direction,	   with	   abnormal	   timing	   of	  maximal	   deformation	   even	   in	   the	  
group	  of	  children	  with	  mild	  stenosis.	  Time	  to	  peak	  systolic	  circumferential	  and	  radial	  
strain	   was	   prolonged	   when	   the	   degree	   of	   stenosis	   was	   more	   severe	   (Table	   15;	  
Figure	  19).	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Table 17 – Global strain parameters (mean ± standard deviation) of study subjects 
categorized by severity of valvular aortic stenosis 
2DSTE	  	   	  	   Controls	   Mild	  VAS	   Moderate	  VAS	   Severe	  VAS	  
Parameters	   	  	   (n	  =	  139)	   (n	  =	  45)	   (n	  =	  31)	   (n	  =10)	  
Global	  S-­‐L	   (%)	   -­‐20.9	  ±	  1.9	   -­‐19.5	  ±	  1.2	  *	   -­‐18.4	  ±	  1.3	  ¥	  *	   -­‐15.5	  ±	  1.2	  ¥	  *	  
Global	  S-­‐CP	   (%)	   -­‐22.1	  ±	  2.8	   -­‐22.9	  ±	  1.5	   -­‐21.1	  ±	  2.0	  ¥	  *	   -­‐18.9	  ±	  2.2	  ¥	  *	  
Global	  S-­‐CM	   (%)	   -­‐20.3	  ±	  2.4	   -­‐20.9	  ±	  1.5	   -­‐19.0	  ±	  1.6	  ¥	  *	   -­‐16.3	  ±	  1.3	  ¥	  *	  
Global	  S-­‐RP	   (%)	   55.1	  ±	  6.8	   57.4	  ±	  2.3	   56.2	  ±	  2.7	   53.0	  ±	  2.2	  *	  
Global	  S-­‐RM	   (%)	   52.4	  ±	  5.4	   54.8	  ±	  2.8	  *	   53.3	  ±	  2.9	   50.0	  ±	  2.1	  *	  
T2P	  Global	  S-­‐L	   (ms)	   345	  ±	  39	   368	  ±	  26	  *	   383	  ±	  25	  *	   382	  ±	  26	  *	  
T2P	  Global	  S-­‐CP	   (ms)	   331	  ±	  35	   342	  ±	  33	   349	  ±	  31	  *	   376	  ±	  29	  *	  
T2P	  Global	  S-­‐CM	   (ms)	   347	  ±	  36	   350	  ±	  32	   366	  ±	  29	  *	   390	  ±	  28	  *	  
T2P	  Global	  S-­‐RP	   (ms)	   335	  ±	  31	   324	  ±	  27	   339	  ±	  24	  ¥	   365	  ±	  23	  ¥	  	  *	  
T2P	  Global	  S-­‐RM	   (ms)	   351	  ±	  29	   342	  ±	  27	   354	  ±	  23	  ¥	   391	  ±	  22	  ¥	  	  *	  
Global	  Sr-­‐L	   (s-­‐1)	   -­‐1.37	  ±	  0.1	   -­‐1.28	  ±	  0.2	  *	   -­‐1.12	  ±	  0.1	  ¥	  *	   -­‐0.93	  ±	  0.1	  ¥	  *	  
Global	  Sr-­‐CP	   (s-­‐1)	   -­‐1.90	  ±	  0.1	   -­‐	  1.91	  ±	  0.1	   -­‐1.67	  ±	  0.2	  ¥	  *	   -­‐1.59	  ±	  0.2	  *	  
Global	  Sr-­‐CM	   (s-­‐1)	   -­‐1.47	  ±	  0.2	   -­‐1.49	  ±	  0.2	   -­‐1.26	  ±	  0.2	  ¥	  *	   -­‐1.09	  ±	  0.3	  *	  
Global	  Sr-­‐RP	   (s-­‐1)	   3.47	  ±	  0.4	   3.65	  ±	  0.4	   3.50	  ±	  0.4	   3.19	  ±	  0.3	  
Global	  Sr-­‐RM	   (s-­‐1)	   3.23	  ±	  0.4	   3.49	  ±	  0.4	  *	   3.27	  ±	  0.5	   2.91	  ±	  0.3	  
	  
Global S-L: global peak systolic longitudinal strain; Global S-CP: global peak systolic 
circumferential strain at the level of the papillary muscle; Global S-CM: global peak systolic 
circumferential strain at the level of the mitral valve; Global S-RP: global peak systolic radial 
strain at the level of the papillary muscle; Global S-RM: global peak systolic radial strain at the 
level of the mitral valve; T2P: time to peak global systolic strain; Sr: strain-rate. * P < 0.05 
statistically significant difference when compared to control subjects ¥ P < 0.05 statistically 
significant difference when compared to previous VAS category; determined by two-way 
analysis of variance with Bonferroni correction for multiple comparisons. 
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Figure 19 - Bar plot of time to peak systolic strain (T2P) of study subjects in different 
directions of deformation according to VAS severity 
	  
	  
T2P: time to global peak systolic strain;  
S-L: global peak systolic longitudinal strain;  
S-CP: global peak systolic circumferential strain at the level of the papillary muscle;   
S-CM: global peak systolic circumferential strain at the level of the mitral valve;  
S-RP: global peak systolic radial strain at the level of the papillary muscle;  
S-RM: global peak systolic radial strain at the level of the mitral valve. 
	  
Linear	   regression	   analyses	   showed	   weak,	   but	   statistically	   significant,	   correlations	  
between	   2DSTE	   parameters	   and	   peak-­‐to-­‐peak	   pressure	   gradients.	   For	   each	   global	  
2DSTE	  variable	  multiple	   linear	  regression	  analysis	  was	  performed	  on	  demographic,	  
anthropometric	   and	   conventional	   echocardiographic	   parameters.	   This	   invariably	  
resulted	   in	   P	   values	   >	   0.05,	   indicating	   no	   additional	   effect,	   besides	   age	   and	   VAS	  
severity,	  on	  global	  peak	  systolic	  strain	  (-­‐rate)	  and	  time	  to	  global	  peak	  systolic	  strain	  
values.	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4.5 DISCUSSION 
	  
The	   rationale	   for	   intervention	   in	   children	   with	   moderate	   to	   severe	   congenital	  
valvular	   aortic	   stenosis	   is	   obvious	   when	   the	   patient	   is	   symptomatic	   and	  
intervention/surgery	  most	   likely	   improves	   the	   outcome	  of	   this	   subset	   of	   patients.	  
The	   decision	   is	   controversial	  when	   the	   patients	   are	   asymptomatic,	  which	   is	   often	  
the	  case	   in	  the	  pediatric	  population,	  even	   in	  case	  of	  severe	  stenosis.	  Although	  the	  
risk	   for	   sudden	   death	  might	   be	   overrated	   in	   historical	   retrospective	   studies,	   their	  
natural	   history	   has	   not	   been	   well	   described.	   Data	   to	   indicate	   intervention	   are	  
entirely	  based	  on	  pressure	  gradients	   in	  analogy	  with	   the	  data	   in	  adults,	   indicating	  
that	   when	   transvalvular	   gradients	   are	   more	   than	   50	   mmHg	   peak-­‐to-­‐peak	   an	  
increased	  risk	  for	  myocardial	  damage	  is	  present.	  	  
	  
Patients	   with	   valvular	   aortic	   stenosis	   are	   subjected	   to	   long-­‐standing	   pressure	  
overload	  of	  the	  left	  ventricle	  often	  leading	  to	  hypertrophy,	  fibrosis	  and	  myocardial	  
dysfunction.	  The	  pathophysiology	  of	  left	  ventricular	  dysfunction	  caused	  by	  pressure	  
or	  volume	  overload	   is	  only	  partially	  understood.	   In	  aortic	  stenosis,	   the	  decrease	   in	  
effective	   valve	   area	   results	   in	   a	   pressure	   gradient	   across	   the	   aortic	   valve	   and	   a	  
corresponding	  increase	  in	  afterload	  with	  a	  subsequent	  escalation	  in	  left	  ventricular	  
wall	   stress.	   The	   increased	   wall	   stress	   in	   turn	   stimulates	   the	   development	   of	  
concentric	   ventricular	   hypertrophy,	   an	   adaptation	   process	   in	   order	   to	   (try	   to)	  
normalize	   the	   wall	   stress.	   However,	   concentric	   hypertrophy	   compromises	  
ventricular	   tissue	  compliance	  as	  well	   as	   subendocardial	   (and	   sometimes	  coronary)	  
perfusion,	   which	   could	   lead	   to	   ischemia.	   The	   above-­‐mentioned	   changes,	   in	  
combination	   with	   ischemia	   induced	   replacement	   of	   contractile	   tissue	   by	   fibrous	  
tissue,	   lead	   to	   a	   limited	   functional	   capability	   of	   the	   ventricle.	   In	   adults,	   these	  
alterations	  eventually	   cause	  heart	   failure	  characterized	  by	  a	   triad	  comprising	   (1)	  a	  
cardiac	   abnormality,	   (2)	   exercise	   limitation	   and	   (3)	   neurohormonal	   activation,	  
particularly	   elevated	  N-­‐terminal	   pro	   brain	   natriuretic	   peptide	   (NT-­‐pro	  BNP)	   levels.	  
Patients	   with	   CHD	   manifest	   all	   the	   above-­‐mentioned	   criteria	   that	   constitute	   the	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chronic	   heart	   failure	   syndrome.	   It	  might	   therefore	   be	  more	   helpful	   to	   view	   heart	  
failure	   as	   a	   continuum	   from	   asymptomatic	   ventricular	   dysfunction	   with	   modest	  
neurohormonal	  activation	  to	  severe	  ventricular	  dysfunction	  with	  symptoms	  at	  rest	  
and	  marked	  neurohormonal	  activation.20	  Therefore,	  accurate	  detection	  of	   the	   first	  
signs	   of	   ventricular	   failure	   in	   CHD	   might	   be	   an	   important	   key	   factor	   for	   optimal	  
timing	  of	  intervention	  and	  hereby	  prevention	  of	  irreversible	  damage.	  	  
	  
Unfortunately,	   diagnostic	   modalities	   such	   as	   conventional	   echocardiographic	  
techniques,	  ECG	  and	  exercise	  testing,	  have	  failed	  to	  provide	  a	  reliable	  assessment	  of	  
ventricular	   function	   in	  children	  with	  CHD,	  e.g.,	  VAS.	  Doppler-­‐derived	  peak	  velocity	  
flow,	  which	  is	  commonly	  used	  to	  indicate	  VAS	  severity,	  is	  strongly	  dependent	  on	  the	  
hemodynamic	   status.	   Furthermore,	   these	   velocity-­‐based	   measurements	   do	   not	  
provide	   any	   information	   on	   the	   impact	   of	   the	   stenosis	   on	   the	   condition	   of	   the	  
myocardium.	   Other	   traditional	   echocardiographic	   methods,	   such	   as	   the	   one-­‐
dimensional	   M-­‐mode	   technique	   (e.g.,	   fractional	   shortening)	   and	   two-­‐dimensional	  
imaging	   (e.g.,	   ejection	   fraction),	   are	   frequently	   used	   to	   evaluate	   left	   ventricular	  
function	   in	   various	   (cardiac)	   conditions.	   Unfortunately,	   these	   methods	   are	   not	  
always	  applicable	  to	  pediatric	  patients	  with	  congenital	  malformations.	  The	  cardinal	  
reason	   for	   this	   is	   that	   they	  are	  based	  on	  geometric	  assumptions	  and	  overlook	   the	  
complex	  characteristics	  of	  congenital	  heart	  disease.21	  Furthermore;	  they	  provide	  no	  
information	   about	   regional	   alterations	   in	   ventricular	  myocardial	   contraction.	   Even	  
more	   importantly,	   in	  case	  of	  LV	  hypertrophy	   these	  conventional	   indices	  appear	   to	  
be	   relatively	   insensitive	   to	   impaired	   myocardial	   performance.22,23,24,25	   Left	  
ventricular	  ejection	   fraction	   is	   frequently	  normal	  even	   in	   the	  presence	  of	  a	   severe	  
pressure	   gradient	   across	   the	   stenotic	   valve	   and/or	   hypertrophy.	   One	   important	  
reason	  for	  this	   is	  that	  ejection	  fraction	  is	  not	  merely	  a	  function	  of	  myocardial	  fiber	  
shortening,	  but	  is	  also	  influenced	  by	  chamber’s	  morphology,	  especially	  relative	  wall	  
thickness.	  When	   left	   ventricular	   wall	   thickness	   increases,	   endocardial	   contraction	  
towards	  the	  cavity’s	  center	  can	  be	  obtained	  with	  lesser	  myocardial	  fiber	  shortening.	  
Because	   of	   this	   reciprocal	   relation	   between	   wall	   thickness	   and	   the	   amount	   of	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myocardial	   fiber	   shortening	   needed	   to	   cause	   a	   given	   displacement	   of	   the	  
endocardium,	   the	  magnitude	  of	   systolic	   shortening	  measured	  at	   the	  endocardium	  
does	  not	  directly	  reflect	   intramural	  shortening.23,26	   In	   light	  of	  these	  findings	   it	   is	  of	  
importance	   that	   reduced	   midwall	   shortening,	   but	   not	   endocardial	   shortening,	  
predicted	   fatal	   and	   non-­‐fatal	   cardiovascular	   events	   under	   pressure-­‐overloaded	  
conditions	  of	  the	  left	  ventricle.27	  
	  
The	   current	   reasons	   to	   intervene	  are	  based	  on	  extrapolated	  adult	   data.	  However,	  
the	   adaptation	  mechanisms	   in	   children	  might	   be	   different	   compared	   to	   adults.	   In	  
adults,	  it	  is	  evident	  that	  cardiac	  remodeling	  occurs	  early	  in	  the	  chronically	  pressure-­‐
overloaded	  heart.	  During	  childhood	  the	  LV	  has	  better	  compensation	  potentials	  as	  is	  
suggested	   by	   LV	   retraining	   data	   in	   patients	   with	   congenitally	   corrected	  
transposition.	   However,	   in	   children	   with	   VAS,	   the	   total	   amount	   of	   myocardial	  
collagen	   was	   significantly	   increased	   despite	   normal	   left	   ventricular	   myocardial	  
contractility	   and	   diastolic	   function	   assessed	   by	   means	   of	   standard	  
echocardiographic	  techniques.	  Left	  ventricular	  remodeling	  was	  abnormal	  in	  about	  a	  
quarter	   of	   the	   patients	   and	   none	   had	   more	   than	   mild	   hypertrophy	   despite	  
significant	   fibrosis.28	   These	   findings	   are	   in	   agreement	   with	   other	   studies	   that	  
describe	   fibrosis	   and	   myocyte	   enlargement	   in	   patients	   with	   even	   modest	   aortic	  
stenosis	   and	   normal	   conventional	   echocardiographic	   findings.29,30	   This	   is	   of	  
importance	   since	   fibrosis	   is	   not	   only	   a	  major	   determinant	   of	   diastolic	   and	   systolic	  
cardiac	  function,	  but	   it	   is	  also	  one	  of	  the	  structural	  substrates	  for	  arrhythmia.	  As	  a	  
result,	  fibrosis	  plays	  a	  major	  role	  in	  the	  occurrence	  of	  sudden	  cardiac	  death	  and	  the	  
progression	   to	   heart	   failure.31	   These	   findings	   together	   indicate	   that	   conventional	  
echocardiography	  is	  adequate	  in	  detecting	  (late)	  global	  LV	  dysfunction,	  whereas	  it	  is	  
not	  successful	  in	  the	  detection	  of	  early	  regional	  myocardial	  malfunction	  in	  (children	  
with)	  VAS.	  In	  the	  present	  study,	  we	  did	  not	  detect	  LV	  hypertrophy.	  However,	  strain-­‐
rate	   parameters,	   which	   more	   closely	   reflect	   contractility,	   were	   decreased	   in	   all	  
three	  principal	  directions	  of	  contraction.	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In	   animal	   studies,	   early	   normalization	   of	   loading	   conditions	   led	   to	   an	   immediate	  
complete	   recovery	   of	   myocardial	   velocities.	   In	   contrast,	   late	   normalization	   of	  
loading	   conditions,	   even	   in	   the	   presence	   of	   normal	   conventional	   indexes	   of	  
ventricular	  function,	  did	  not	  lead	  to	  a	  (complete)	  recovery	  of	  myocardial	  velocities.	  
This	   is	   probably	   due	   to	   extensive	   alterations	   in	   the	   LV	   myocardial	   architecture	  
leading	   to	   alterations	   in	   intrinsic	   myocardial	   contractility.32	   These	   findings	  
underscore	   the	   need	   for	   additional	   (preferably	   non-­‐invasive)	   parameters	   to	  
accurately	  detect	  deterioration	  of	  myocardial	  function.	   It	  would	  be	  desirable	  to	  be	  
able	   to	   detect	   myocardial	   changes	   at	   an	   early	   stage	   to	   optimize	   the	   timing	   of	  
intervention	  and	  hopefully	  prevent	  permanent	  damage	  of	  the	  cardiac	  muscle.	  Strain	  
imaging	  has	  proven	  to	  be	  a	  sensitive	  marker	  for	  ventricular	  dysfunction.	  A	  previous	  
report	  by	  Kiraly	  et	  al.	  showed	  that	  tissue	  Doppler	  strain	  imaging	  (TDI)	  indicated	  left	  
ventricular	  dysfunction	  in	   longitudinal	  direction	  in	  children	  with	  various	  degrees	  of	  
VAS	  and	  normal	  conventional	   indices	  of	  ventricular	  function	  (e.g.,	  ejection	  fraction	  
and	  shortening	  fraction).33	  However,	  TDI	  is	  limited	  by	  its	  inherently	  one-­‐dimensional	  
nature	  and	  is	  strongly	  dependent	  on	  the	  angle	  of	  insonation.	  
	  
2DSTE	   has	   emerged	   as	   a	   new	   index	   of	   local	   myocardial	   function.	   One	   important	  
advantage	  is	  that	  2DSTE	  is	  not	  limited	  by	  a	  dependency	  on	  the	  angle	  of	  insonation.	  
Furthermore,	  the	  speckle	  pattern	  can	  be	  tracked	  in	  multiple	  directions,	  which	  allows	  
for	  quantification	  of	  myocardial	  deformation	   in	  all	   three	  main	  directions	  of	   strain.	  
2DSTE	   can	   detect	   subtle	   changes	   in	   regional	   myocardial	   function	   in	   various	  
myocardial	   diseases	   at	   an	   earlier	   stage	   when	   compared	   to	   traditional	  
(echocardiographic)	   methods.	   Whether	   2DSTE	   is	   able	   to	   detect	   (regional)	  
myocardial	   dysfunction	   in	   children	   with	   congenital	   VAS	   has	   not	   been	   previously	  
investigated.	  In	  adults,	  strain	  imaging	  by	  means	  of	  TDI	  and	  2DSTE	  has	  proven	  to	  be	  
more	   sensitive	   than	   conventional	   echocardiography	   for	   assessing	   myocardial	  
dysfunction	  in	  isolated	  left	  ventricular	  pressure-­‐overload.22,24,34,35,36	  Strain	  and	  strain	  
rate	   parameters	   seemed	   to	   relate	   to	   LV	   function	   and	   VAS	   severity.	   Furthermore,	  
they	  appear	  to	  be	  superior	  to	  tissue	  velocity	  and	  conventional	  echocardiography	  in	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detecting	   subtle	   changes	   in	   myocardial	   function	   after	   normalization	   of	   loading	  
conditions.37	   Data	   on	   2D	   strain	   (-­‐rate)	   measurements	   in	   pediatric	   patients	   with	  
congenital	  VAS	  are	  still	  lacking.	  	  
	  
The	   present	   study	   in	   children	   with	   congenital	   VAS	   has	   included	   asymptomatic	  
subjects	   with	   various	   degrees	   of	   stenosis.	   Accordingly,	   it	   has	   covered	   different	  
stages	   of	   VAS,	   thus	   providing	   insight	   into	   the	   development	   of	   functional	  
abnormalities	   underlying	   the	  disease	  progression.	  Our	  main	   finding	  was	   a	   gradual	  
deterioration	   of	   left	   ventricular	   function	   characterized	   by	   decreased	   peak	   systolic	  
strain	   (-­‐rate)	   measurements	   even	   in	   children	   with	   moderate	   VAS	   and	   normal	  
conventional	   echocardiographic	   findings.	  We	  demonstrated	   that	   the	   decline	   in	   LV	  
longitudinal	   systolic	   performance	   precedes	   that	   in	   other	   directions,	   which	   is	   in	  
agreement	   with	   previous	   reports	   performed	   in	   pressure	   overloaded	   adults	   with	  
hypertension.38,39	  The	  decreased	  longitudinal	  systolic	  strain	  (-­‐rate)	  may	  be	  ascribed	  
to	   damage	   of	   subendocardial	  myocardial	   fibers,	   which	   are	  mainly	   responsible	   for	  
longitudinal	   function.	   These	   fibers	   are	   more	   vulnerable	   to	   increased	   wall	   stress,	  
stress-­‐induced	   ischemia,	   and	   microvascular	   dysfunction	   accompanying	   left	  
ventricular	  pressure	  overload.40	  Peak	  tissue	  pressures	   in	  the	  subendocardium	  have	  
been	  shown	  to	  exceed	  coronary	  perfusion	  pressures	  during	  one-­‐third	  of	  the	  cardiac	  
cycle.	   This	   increase	   in	   the	   extravascular	   component	   of	   coronary	   resistance	   is	  
sufficient	   to	   cause	   cessation	   of	   blood	   flow	   through	   this	   area	   during	   systole.	   As	   a	  
result,	   the	   subendocardium	   is	   poorly	   perfused	   at	   a	   time	   when	   its	   needs	   are	  
greatest.41,42	   Yet,	   the	  muscle	   fibers	   of	   the	   subendocardium	   are	   the	   longest	   in	   the	  
ventricular	   wall	   and	   perform	   the	   greatest	   work	   in	   the	   development	   of	   tension.	  
These	   two	   factors,	   the	   increased	   dependency	   of	   the	   subendocardium	  on	   diastolic	  
perfusion	  and	   the	   increased	  energy	   requirements,	   account	   for	   the	  vulnerability	  of	  
the	  subendocardial	  layer	  to	  ischemia.	  	  
	  
The	  mechanisms	  underlying	   the	  maintenance	  of	  normal	  or	   supra-­‐normal	   LV	   radial	  
function	   in	   the	  early	   stages	  of	  myocardial	   affection	  by	  VAS	  may	  be	   related	   to	   the	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augmented	   LV	   wall	   thickness.43	   In	   addition,	   the	   radius	   of	   curvature	   of	   the	  
circumferentially	  oriented	  myocardial	  fibers	  responsible	  for	  LV	  radial	  deformation	  is	  
smaller	   than	   that	   of	   longitudinal	   ones,	   which	   might	   entail	   lower	   stress	   and,	  
consequently	  delayed	  appearance	  of	  functional	  abnormalities.	  It	  is	  possible	  that	  the	  
increase	  in	  radial	  strain	  demonstrated	  in	  mild	  cases	  of	  stenosis	  (partly)	  compensates	  
for	   a	   reduction	   in	   longitudinal	   strain.	   In	   this	   light,	   a	   decline	   of	   radial	   strain	   in	   the	  
more	  advanced	  stages	  of	  VAS	  could	  be	  regarded	  as	  a	  form	  of	  decompensation.	  	  
	  
The	   decline	   in	   peak	   systolic	   strain	   (-­‐rate)	   was	   not	   equally	   distributed	   over	   the	  
different	  ventricular	  wall	  segments.	  In	  children	  with	  VAS,	  peak	  systolic	  strain	  (-­‐rate)	  
was	   most	   affected	   throughout	   the	   interventricular	   septum,	   especially	   its	   basal	  
segment.	  A	  possible	  explanation	  for	  this	  finding	  may	  be	  found	  in	  its	  geometry.	  The	  
interventricular	  septum,	  because	  of	  its	  flatter	  and	  more	  asymmetric	  contour	  with	  a	  
larger	   radius	   of	   curvature	   in	   the	   longitudinal	   plane,	   is	   subjected	   to	   a	   greater	  
increase	   in	   systolic	   wall	   stress	   than	   the	   lateral	   free	   wall.	   Consequently,	   both	  
myocardial	   hypertrophy	   and	   a	   decrease	   in	   systolic	   function	   produced	   by	   the	  
increase	   of	   afterload	   and	   subsequent	   exaggerated	   wall	   stress	   are	   predominantly	  
seen	  in	  the	  interventricular	  septum,	  particularly	  in	  its	  basal	  part.44	  
	  
Time	  to	  peak	  systolic	   strain	   increased	  significantly	  with	  disease	  severity.	  Especially	  
in	  patients	  with	  severe	  VAS,	  significantly	  more	  time	  elapsed	  to	  reach	  peak	  systolic	  
strain.	   These	   results	   are	   in	   agreement	   with	   previous	   reports	   which	   described	   an	  
abnormal	  pattern	  and	   timing	  of	   systolic	  deformation	   in	  adult	  pressure	  overloaded	  
left	  ventricles,	  as	  well	  as	  in	  rats	  with	  hypertensive	  disease.45,46	  As	  with	  peak	  systolic	  
strain	  (-­‐rate)	  measurements,	  time	  indices	  in	  our	  patient	  groups	  were	  most	  affected	  
in	   the	   longitudinal	   plane	   and	   less	   affected	   in	   the	   radial	   plane.	   The	   prolonged	  
duration	   of	   time	   to	  maximal	   deformation	   could	   be	   a	   consequence	   of	   progressive	  
fibrosis.	   Previous	   studies	   have	   indicated	   that	   changes	   in	   passive	   mechanical	  
characteristics	   caused	   by	   fibrosis	   and	   altered	   collagen	   deposition	   also	   affect	  
deformation	  when	  active	  force	  is	  developed	  within	  a	  myocardial	  segment.47	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In	  contrast	  to	  others,	  we	  did	  not	  find	  a	  significant	  relation	  between	  left	  ventricular	  
mass	   and	   2DSTE	   indices	   in	   our	   study	   group.46,48	   A	   possible	   explanation	   for	   this	  
finding	  could	  be	  that,	  despite	  the	  presence	  of	  severe	  valvular	  aortic	  stenosis	  in	  some	  
of	   the	   patients,	   our	   patient	   groups	   did	   not	   develop	   significant	   left	   ventricular	  
hypertrophy.	  
	  
Although	   we	   did	   find	   a	   statistically	   significant	   relation	   between	   transvalvular	  
pressure	   gradients	   and	   2DSTE	   parameters	   when	   analyzing	   the	   total	   group	   of	  
pediatric	   VAS	   patients,	   2DSTE	   parameters	   most	   likely	   more	   closely	   reflect	  
myocardial	  systolic	  performance	  in	  the	  individual	  patient.	  	  
	  
4.6 STUDY LIMITATIONS 
	  
We	   did	   not	   perform	   a	   validation	   study	   of	   the	   strain	   (-­‐rate)	   observations	   using	  
cardiac	   tagged	   magnetic	   resonance	   imaging	   studies	   or	   myocardial	   biopsies	   (for	  
ethical	  reasons).	  Both	  investigations	  could	  be	  useful	  for	  validation	  of	  the	  suspected	  
subclinical	  left	  ventricular	  systolic	  dysfunction	  and/or	  fibrosis.	  Since	  the	  clinical	  and	  
prognostic	   implications	   of	   the	   identified	   abnormalities	   in	  myocardial	   deformation	  
described	   in	   this	   study	   remain	   to	   be	   elucidated,	   their	   exact	   interpretation	   will	  




The	   present	   study	   demonstrates	   that	   asymptomatic	   children	  with	   congenital	   VAS	  
and	   preserved	   LV	   ejection	   fraction	   already	   exhibited	   decreased	   peak	   systolic	  
myocardial	   strain	   (-­‐rate)	   in	   all	   three	   directions	   (radial,	   circumferential	   and	  
longitudinal),	  even	  in	  case	  of	  mild	  VAS.	  We	  found	  that	  the	  decline	  in	  LV	  longitudinal	  
systolic	  performance	  precedes	  that	  in	  other	  directions.	  The	  2DSTE	  parameters	  could	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be	   useful	   for	   the	   early	   detection	   of	   subclinical	   LV	   myocardial	   dysfunction,	   which	  
remains	  otherwise	  undetected	  by	  conventional	  measurements	  of	  systolic	   function.	  
However,	  the	  prognostic	  implications	  of	  our	  findings	  remain	  to	  be	  assessed	  in	  future	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Chapter 5 
Persistent reduction in left ventricular strain using 
two-dimensional speckle tracking 
echocardiography after balloon valvuloplasty in 
children with congenital valvular aortic stenosis 
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5.1 ABSTRACT  
	  
Aim:	   Investigation	   of	   serial	   changes	   of	   myocardial	   deformation	   using	   two-­‐
dimensional	   speckle	   echocardiography	   (2DSTE)	   in	   children	   undergoing	   balloon	  
valvuloplasty	  for	  congenital	  valvular	  aortic	  stenosis	  (VAS).	  
	  
Methods:	   37	   children	   with	   isolated	   congenital	   VAS	   were	   enrolled	   in	   this	   study	  
prospectively.	  Patients	  underwent	  echocardiographic	  evaluation	  at	  three	  instances:	  
prior	   to	   balloon	   valvuloplasty,	   6	   months	   after	   intervention,	   and	   3	   years	   after	  
intervention.	  Longitudinal,	  circumferential	  and	  radial	  peak	  systolic	  strain	   (S)	  values	  
were	   determined,	   as	   well	   as	   systolic	   strain-­‐rate	   (Sr),	   and	   the	   time	   to	   peak	   global	  
systolic	   strain	   (T2P).	   Linear	  mixed	   statistical	  models	  were	   employed	   to	   assess	   the	  
change	   in	  2DSTE	  parameters	  after	  balloon	   intervention.	  With	  One	  Way	  Analysis	  of	  
Variance,	   2DSTE	   results	   at	   three	   years	   follow-­‐up	   were	   compared	   with	   2DSTE	  
measurements	   in:	   (1)	   74	   healthy	   age-­‐matched	   children	   (2)	   76	   children	   with	  
uncorrected	  VAS	  whose	  severity	  of	  stenosis	  corresponded	  with	  residual	  stenosis	  of	  
study	  subjects	  at	  three	  years	  follow-­‐up.	  
	  
Results:	  Global	  peak	  S	  and	  Sr	  measurements	  in	  all	  three	  directions	  were	  decreased	  
prior	   to	   intervention	   as	   compared	   to	   healthy	   children.	   Global	   peak	   S	   and	   Sr	  
measurements	   increased	   significantly	   (P<0.001)	   several	   months	   after	   balloon	  
valvuloplasty	  and	  continued	  to	  increase	  at	  three	  years	  follow-­‐up.	  However,	  at	  three	  
years	   follow-­‐up,	   global	   peak	   S	   and	   Sr	   in	   longitudinal	   and	   circumferential	   direction	  
were	   significantly	   lower	   (P<0.001)	   when	   compared	   to	   both	   control	   groups.	   T2P	  
measurements	   were	   significantly	   shorter	   at	   early	   follow-­‐up	   when	   compared	   to	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Conclusion:	  Shortly	  after	  balloon	  valvuloplasty	  for	  severe	  congenital	  VAS	  there	  is	  an	  
improvement	   in	   systolic	  myocardial	   deformation.	   However,	   2DSTE	   parameters	   do	  
not	   return	   to	   normal	   at	   three	   years	   follow-­‐up.	   These	   abnormalities	   in	   systolic	  




Patients	   with	   congenital	   valvular	   aortic	   stenosis	   (VAS)	   are	   subjected	   to	   long-­‐
standing	   pressure	   overload	   of	   the	   left	   ventricle	   (LV),	   leading	   to	   alterations	   in	   LV	  
architecture	   and	   myocardial	   dysfunction.1	   Previous	   reports	   in	   both	   children	   and	  
adults	   indicated	   that	   abnormal	   LV	   systolic	   function	   starts	   at	   an	   early	   stage	   of	   the	  
disease	  with	  progressive	  reduction	  of	  regional	  and	  global	  deformation.2,3	  However,	  
those	  early	  alterations	  in	  myocardial	  function	  have	  proven	  to	  be	  difficult	  to	  detect	  in	  
congenital	   VAS	   with	   conventional	   (echocardiographic)	   imaging	   modalities.	   Two-­‐
dimensional	  strain	  echocardiography	  or	  speckle	  tracking	  echocardiography	  (2DSTE)	  
has	  emerged	  as	  a	   relatively	  new	   index	  of	   regional	  and	  global	  myocardial	   function.	  
The	   spectrum	   of	   potential	   clinical	   applications	   is	   very	   wide.	   Due	   to	   its	   ability	   to	  
differentiate	   between	   active	   and	   passive	   deformation	   of	  myocardial	   segments,	   to	  
quantify	   intraventricular	   dyssynchrony	   and	   to	   evaluate	   individual	   components	   of	  
myocardial	   function	   such	   as	   longitudinal	   myocardial	   shortening,	   2DSTE	   is	   able	   to	  
detect	  myocardial	  dysfunction	  at	  an	  early	  stage.4,5,6,7	  Previous	  studies	  have	  indicated	  
that	  2DSTE	  is	  more	  sensitive	  than	  conventional	  echocardiography	  in	  detecting	  early	  
myocardial	  dysfunction	  in	  VAS.8,9,10,11	  Two-­‐dimensional	  strain	  parameters	  have	  been	  
shown	  to	  be	  abnormal	  even	   in	  children	  with	  asymptomatic,	  mild	  congenital	  aortic	  
stenosis.3	  In	  adults	  with	  degenerative	  VAS,	  these	  abnormal	  alterations	  in	  (regional)	  
deformation	   appear	   to	   be	   only	   partially	   reversible	   after	   aortic	   valve	   replacement	  
(AVR).10,11,12,13	   In	   children	  with	   congenital	   isolated	  VAS,	   the	   treatment	   of	   choice	   is	  
valvuloplasty,	   either	   surgical	   or	   balloon	   valvulotomy.	   The	   reversibility	   of	   systolic	  
myocardial	   dysfunction	   after	   valvulotomy	   in	   children	  with	   congenital	   VAS	   has	   not	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been	   established	   by	  means	   of	   2DSTE.	   The	   aim	   of	   the	   present	   study	  was	   twofold.	  
First,	   to	   assess	   the	   effects	   of	   balloon	   valvuloplasty	   on	   myocardial	   deformation	  
assessed	   with	   2DSTE	   in	   all	   three	   directions	   of	   deformation	   (longitudinal,	  
circumferential	  and	  radial)	  in	  children	  with	  isolated	  congenital	  VAS.	  Second,	  in	  case	  
of	   persistent	   abnormal	   2DSTE	   findings	   at	   three	   years	   follow-­‐up	   we	   aimed	   to	  
determine	   whether	   or	   not	   these	   abnormalities	   could	   be	   attributed	   to	   a	   residual	  
valvar	  stenosis.	  	  
	  
5.3 MATERIAL and METHODS 
5.3.1 STUDY POPULATION 
	  
All	   asymptomatic	   children	   with	   severe	   isolated	   congenital	   VAS	   visiting	   the	  
outpatient	   clinic	   at	   the	  Children’s	  Heart	   Centre	  Nijmegen	  between	  May	  2005	   and	  
May	   2009,	   who	   were	   scheduled	   for	   balloon	   valvuloplasty,	   were	   prospectively	  
analyzed	   for	   their	   eligibility	   for	   inclusion	   in	   the	   present	   study.	   Inclusion	   criteria	  
consisted	  of	  an	   isolated	  congenital	  VAS	   (e.g.,	   thickening	  of	   the	  valve	  or	   functional	  
bicuspid	   aortic	   valve),	   accompanied	   by	   a	   repeated	   Doppler-­‐derived	   peak	   systolic	  
instantaneous	   aortic	   flow	   velocity	   of	   at	   least	   4.0	   m/s	   (which	   corresponds	   to	   a	  
transvalvular	  pressure	  gradient	  of	  more	  than	  64	  mmHg)	  at	  subsequent	  visits.	  Peak	  
LV-­‐to-­‐peak-­‐aortic	   pressure	   gradient	   assessed	   during	   catheterization	   under	   general	  
anesthesia,	   had	   to	   be	   confirmative	   of	   aortic	   stenosis	   (according	   to	   the	   ACC/AHA	  
guidelines	   2006	   of	   the	   management	   of	   patients	   with	   valvular	   heart	   disease).14	  
Previous	  reports	  have	  indicated	  that	  general	  anesthesia	  results	  in	  a	  declined	  stroke	  
volume	   and	   lower	   pressure	   gradient	   estimations.15	   Exclusion	   criteria	   were:	   (1)	  
moderate	  or	  severe	  aortic	  regurgitation	  (i.e.	  >	  grade	  1),	   (2)	   (a	  history	  of	  repeated)	  
abnormal	   cardiac	   rhythm	   such	   as	   (supra)ventricular	   tachycardia,	   (3)	   previous	  
balloon	   and/or	   surgical	   valvulotomy,	   (4)	   acute	   or	   chronic	   illness	   at	   the	   time	   of	  
echocardiographic	   evaluation,	   (5)	   	   metabolic	   and/or	   genetic	   syndrome.16,17	  
Demographic	   and	   anthropometric	   characteristics,	   including	   age	   and	   gender	   were	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collected	  at	  the	  same	  time	  the	  echocardiographic	  study	  was	  performed.	  A	  complete	  
history,	  physical	  examination,	  ECG,	  as	  well	  as	  (2DST)	  echocardiographic	  examination	  
were	  performed	  at	  three	  times:	  (1)	  within	  one	  month	  prior	  to	  balloon	  valvuloplasty,	  
(2)	  6	  months	  after	  balloon	  intervention,	  (3)	  at	  three	  years	  follow-­‐up.	  	  
5.3.2 CONTROL GROUPS 
	  
1. Subjects	  who	  were	  routinely	  referred	  for	  echocardiographic	  evaluation	  of	  
an	  asymptomatic,	  innocent	  heart	  murmur	  or	  for	  screening	  purposes	  
between	  May	  1,	  2005	  and	  November	  1,	  2009,	  were	  retrospectively	  
analyzed	  for	  their	  eligibility	  for	  inclusion	  in	  the	  study	  to	  serve	  as	  a	  control	  
group.	  Subjects	  with	  structural	  (congenital)	  heart	  disease,	  abnormal	  
cardiac	  rhythms	  and/or	  (a	  past	  history	  of)	  chronic	  or	  acute	  illness	  were	  
excluded.	  A	  group	  of	  74	  healthy	  age-­‐matched	  children	  was	  included	  and	  
examined	  to	  provide	  normal	  reference	  values	  for	  conventional	  
echocardiographic	  and	  2DSTE	  parameters.	  
2. A	  total	  of	  76	  children,	  consisting	  of	  a	  cohort	  of	  45	  children	  with	  mild,	  
isolated	  congenital	  VAS	  (peak	  systolic	  instantaneous	  flow	  velocity	  between	  
2.5	  and	  3.0	  m/s)	  and	  a	  cohort	  of	  31	  children	  with	  moderate,	  isolated	  
congenital	  VAS	  (peak	  systolic	  instantaneous	  flow	  velocity	  between	  3.0	  and	  
4.0	  m/s)	  without	  prior	  surgical	  or	  balloon	  intervention	  were	  previously	  
analyzed	  and	  described	  by	  our	  research	  group.3	  In	  the	  present	  study,	  their	  
2DSTE	  results	  were	  compared	  with	  2DSTE	  findings	  in	  children	  with	  residual	  
aortic	  stenosis	  at	  late	  follow-­‐up	  after	  balloon	  intervention.	  	  
	  
This	  study	  was	  approved	  by	  the	  Local	  Ethics	  Committee	  and	  conforms	  to	  the	  
Declaration	  of	  Helsinki.	  Each	  participant	  and/or	  their	  parents	  gave	  consent.	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5.3.3 CONVENTIONAL ECHOCARDIOGRAPHIC PARAMETERS 
	  
All	   subjects	   underwent	   a	   detailed	   transthoracic	   echocardiographic	   examination	   in	  
the	  left	  lateral	  position	  according	  to	  the	  recommendations	  of	  the	  American	  Society	  
of	   Echocardiography	   and	   a	   local	   research	   protocol	   previously	   described	   by	  
Mavinkurve-­‐Groothuis	  et	  al.18,19	  Every	  examination	  was	  performed	  at	  rest,	  without	  
using	   sedation.	   Images	   were	   obtained	   with	   a	   3.0-­‐MHz	   (S3)	   or	   a	   5.0-­‐MHz	   (S5)	  
phased-­‐array	   transducer	   using	   a	   commercially	   available	   system,	   the	   Vivid	   7	  
echocardiographic	   scanner	   (GE,	   Vingmed	   Ultrasound	   AS,	   Horten,	   Norway).	   The	  
choice	   for	  a	  S3	  or	  a	  S5	   transducer	  depended	  on	   the	  age	  and	  posture	  of	   the	  child.	  
Quantification	  of	  cardiac	  chamber	  size,	  ventricular	  mass	  and	  systolic	  left	  ventricular	  
function	   were	   measured	   in	   accordance	   with	   the	   recommendations	   for	   chamber	  
quantification	   by	   the	   American	   Society	   of	   Echocardiography.18	   Left	   ventricular	  
systolic	  function	  was	  characterized	  using	  fractional	  shortening	  (FS),	  ejection	  fraction	  
(EF),	   pulsed-­‐wave	   Doppler-­‐derived	   left	   ventricular	   myocardial	   performance	   index	  
(or	   Tei	   index)	   and	   rate-­‐corrected	   velocity	   of	   circumferential	   fiber	   shortening	  
(VCFc).20,21,22	  Ejection	  fraction	  was	  calculated	  using	  the	  modified	  Simpson’s	  rule.	  The	  
obtained	   values	   of	   left	   ventricular	  mass	   (corrected	   for	   BSA)	   were	   compared	  with	  
those	  previously	  described	  in	  healthy	  children.23,24	  
	  
5.3.4 2DSTE DATA ACQUISITION 
	  
Two-­‐dimensional	   multiframe	   B-­‐Mode	   (grayscale)	   images	   were	   obtained	   from	   the	  
apical	   four-­‐chamber	  (4C),	   the	  parasternal	  midcavity	  short-­‐axis	  view	  (at	  the	   level	  of	  
the	  papillary	  muscle:	  PM)	  and	  parasternal	  basal	  short-­‐axis	  view	  (at	  the	  level	  of	  the	  
mitral	   valve:	  MV).	  A	   sector	   scan	  angle	  of	  30	   to	  60	  degrees	  was	   chosen	  and	   frame	  
rates	  of	  60	  to	  90	  Hz	  were	  used	  since	  these	  rates	  are	  considered	  to	  be	  optimal	  for	  2D	  
speckle	  tracking.7	  Data	  were	  stored	  at	  the	  same	  frame	  rate	  as	  the	  acquisition	  frame	  
rate.	  Preferably,	  images	  from	  five	  cardiac	  cycles	  triggered	  by	  the	  R	  wave	  of	  the	  QRS	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complex	   were	   digitally	   saved	   in	   cineloop	   format.	   Offline	   strain	   analysis	   was	  
performed	   using	   speckle	   tracking	   software	   for	   echocardiographic	   quantification	  
(EchoPAC	  6.1.0;	  GE	  Vingmed	  Ultrasound	  AS,	  Horten,	  Norway).	  The	  timing	  of	  aortic	  
valve	  closure	  and	  mitral	  valve	  opening	  with	  respect	  to	  peak	  strain	  and	  peak	  systolic	  
strain	   were	   manually	   obtained,	   using	   single	   gated	   pulsed-­‐wave	   (PW-­‐)Doppler	   or	  
continuous-­‐wave	   (CW-­‐)Doppler	   blood	   flow	   velocity	   images	   of	   the	   left	   ventricular	  
outflow	   tract.	   For	   these	  measurements,	   special	   care	  was	   taken	   to	   keep	   the	   heart	  
rate	   in	   the	   same	   range	   as	   during	   the	   2D	   grayscale	   imaging	   used	   for	   2D	   strain	  
calculations.	   Endomyocardial	   borders	   of	   the	   left	   ventricle	   were	   manually	   tracked	  
within	  the	  end-­‐systolic	  frame.	  The	  second,	  epicardial	  tracing	  was	  generated	  by	  the	  
EchoPAC	   software	   and,	   when	   necessary,	   manually	   adjusted	   to	   cover	   the	   whole	  
myocardial	   wall.	   The	   tracking	   algorithm	   then	   followed	   the	   myocardial	   speckles	  
through	   the	   cardiac	   cycle.	   Tracking	  was	   accepted	  only	   if	   both	   visual	   inspection	   as	  
well	  as	  EchoPAC	  software	   indicated	  adequate	  tracking.	  The	  software	  automatically	  
divided	   the	   cross-­‐sectional	   image	   into	   six	   segments,	   which	   were	   named	   and	  
identified	   according	   to	   the	   statement	   of	   the	   Cardiac	   Imaging	   Committee	   of	   the	  
Council	   on	   Clinical	   Cardiology	   of	   the	   American	   Heart	   Association.25	   The	   left	  
ventricular	  segments	  to	  be	  analyzed	  were	  the	  apical,	  middle	  and	  basal	  segments	  of	  
the	  septal	  and	  the	  lateral	  wall	  of	  the	  4C	  view,	  as	  well	  as	  the	  anteroseptal,	  anterior,	  
lateral,	  posterior,	  inferior	  and	  septal	  segments	  of	  the	  basal	  (MV)	  and	  midcavity	  (PM)	  
short-­‐axis	  views.	  Strain	  curves	  of	  the	  three	  consecutive	  cardiac	  cycles	  and	  values	  of	  
the	   manual	   timing	   were	   imported	   into	   a	   custom-­‐made	   software	   package	   for	  
averaging	   the	   strain	   curves	   of	   three	   consecutive	   cycles.	   The	   Q-­‐Q	   interval	   was	  
determined	   from	   the	   electrocardiogram	   signal	   to	   obtain	   cardiac	   cycle	   length.	  
Cardiac	  cycles	  with	   lengths	  more	  than	  ten	  percent	  different	  from	  the	  mean	   length	  
of	   the	   three	   cardiac	   cycles	   were	   excluded	   from	   averaging	   and	   thus	   for	   further	  
analysis.	   Myocardial	   longitudinal,	   radial	   and	   circumferential	   strain	   values	   were	  
obtained,	   as	   well	   as	   peak	   systolic	   strain-­‐rate	   and	   the	   time	   to	   reach	   peak	   systolic	  
strain.	   To	   determine	   global	   strain	   (-­‐rate),	   the	   strain	   (-­‐rate)	   values	   of	   the	   six	  
segments	  were	  averaged	  for	  the	  four-­‐chamber	  as	  well	  as	  for	  the	  short-­‐axis	  views.	  All	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2DSTE	   analyses	   were	   performed	   by	   the	   same	   investigator	   (K.A.M.)	   to	   avoid	  
interobserver	   variability.	   Intraobserver	   variability	   scores	   have	   been	   previously	  
described	   by	   our	   research	   group.19,26	   Strain	   values	   are	   dimensionless	   and	   are	  
expressed	   as	   percentages	   (%).	   Strain-­‐rate	   is	   the	   time	   derivative	   of	   strain	   and	   is	  
expressed	   as	   per	   second	   (s-­‐1).	   Time	   to	   peak	   systolic	   strain	   is	   expressed	   as	  
milliseconds	  (ms).	  Negative	  strain	  values	  reflect	  shortening/thinning,	  while	  positive	  
strain	  values	  reflect	  lengthening/thickening.	  
	  
5.3.5 STATISTICAL ANALYSIS 
	  
All	   normally	   distributed	   demographic,	   anthropometric,	   conventional	  
echocardiographic	  and	  2D	  strain	  values	  are	  expressed	  as	  mean	  ±	  standard	  deviation	  
(SD),	   all	   non-­‐normally	   distributed	   data	   as	   median	   and	   range.	   Conventional	  
echocardiographic	  as	  well	  as	  2DSTE	  measurements	  derived	   from	  the	  children	  with	  
severe	   VAS	   prior	   to	   intervention	   were	   compared	   with	   those	   acquired	   at	  
intermediate	   and	   late	   follow-­‐up.	   The	   change	   in	   each	   standard	   echocardiographic	  
finding	   as	  well	   as	   each	   2DSTE	  parameter	  was	   reported	  using	   linear	  mixed	  models	  
and	   Bland-­‐Altman	   plots.	   Since	   it	   is	   possible	   that	   changes	   in	   2DSTE	   results	   after	  
intervention	   (especially	  at	   late	   follow-­‐up)	   could	  be	   (partly)	  biased	  by	  maturational	  
changes,	   all	   2DSTE	   results	   were	   compared	   with	   pediatric	   reference	   values	  
established	  by	  our	   research	  group.26	   For	  all	   individual	  2DSTE	   results	  of	  each	   study	  
subject	   (pre-­‐intervention	   and	   at	   follow-­‐up),	   the	   deviation	   from	   normal	   was	  
calculated	   (2DSTE	   result	   of	   the	   individual	   patient	  minus	  mean	   reference	   value	   of	  
2DSTE	  parameter	  at	   the	  same	  age).	  The	  change	   in	  deviation	  from	  normal	   for	  each	  
2DSTE	  parameter	  at	  follow-­‐up	  was	  determined	  by	  using	  linear	  mixed	  models.	  2DSTE	  
measurements	   at	   late	   follow-­‐up	   were	   compared	   with	   respective	   findings	   in	   both	  
control	  groups:	  (1)	  a	  cohort	  of	  74	  healthy	  age-­‐matched	  children	  and	  (2)	  76	  children	  
with	  mild	   (45)	   or	  moderate	   (31)	   isolated	   congenital	   VAS	  without	   prior	   surgical	   or	  
balloon	  intervention.	  For	  the	  latter	  comparison,	  VAS	  patients	  at	  late	  follow-­‐up	  were	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divided	  according	   to	   residual	  VAS	  prior	   to	   further	   analysis.	  None	   to	  mild	  VAS	  was	  
defined	  as	  a	  peak	  systolic	   flow	  velocity	  <	  3.0	  m/s,	  moderate	  VAS	  between	  3.0	  and	  
4.0	  m/s,	   whereas	   patients	   with	   a	   systolic	   peak	   jet	   velocity	   of	  more	   than	   4.0	  m/s	  
were	   considered	   to	   have	   severe	   VAS.14	   Subsequently,	   global	   peak	   systolic	   strain,	  
global	   peak	   systolic	   strain-­‐rate	   and	   T2P	   measurements	   were	   compared	   with	  
respective	   findings	   in	   children	   with	   corresponding	   peak	   systolic	   flow	   velocity	  
measurements	   but	   no	   prior	   balloon	   intervention	   as	   well	   as	   healthy	   age-­‐matched	  
children.	   To	   determine	   their	   relation,	   one-­‐way	   analysis	   of	   variance	   (ANOVA)	   was	  
used	   with	   the	   Bonferroni	   correction	   for	   multiple	   comparisons.	   To	   determine	   the	  
relation	   between	   individual	   2DSTE	   parameters	   and	   aortic	   regurgitation	   at	   late	  
follow-­‐up,	   one-­‐way	   analysis	   of	   variance	   (ANOVA)	   was	   performed.	   Relations	  
between	  pre-­‐interventional	  conventional	  echocardiographic	  and	  2DSTE	  parameters	  
and	   respective	   post-­‐interventional	   findings	   were	   expressed	   in	   terms	   of	   linear	  
regression	  analyses.	  All	  2DSTE	  parameters	  were	  normally	  distributed.	  P-­‐values	   less	  
than	   0.05	   were	   considered	   to	   indicate	   significance.	   All	   statistical	   analyses	   were	  
performed	   using	   the	   Statistical	   Package	   for	   Social	   Sciences	   for	   Windows,	   version	  
16.0	  (SPSS	  Inc,	  Chicago,	  IL).	  	  	  
	  
5.4 RESULTS 
5.4.1 STUDY POPULATION  
	  
A	   total	   of	   51	   children	  who	   underwent	   a	   balloon	   valvuloplasty	   to	   relieve	   pressure	  
overload	  due	  to	  severe	  congenital	  VAS	  was	  identified	  from	  our	  outpatient	  clinic	  for	  
possible	  inclusion	  in	  the	  present	  study.	  	  
Fourteen	   of	   those	   patients	   were	   subsequently	   excluded:	   in	   two	   cases	   VAS	   was	  
accompanied	   by	   another	   congenital	   heart	   defect,	   three	   patients	   suffered	   from	  
moderate	   to	   severe	   aortic	   regurgitation,	   eight	   patients	   had	   a	   past	   history	   of	  
valvuloplasty	   prior	   to	   the	   present	   valvuloplasty,	   and	   one	   patient	   had	   been	  
diagnosed	  with	  Turner	   syndrome.	  Finally,	  37	  pediatric	  patients	  aged	  0	   to	  15	  years	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were	   eligible	   for	   inclusion	   in	   the	   study.	   Their	  Doppler-­‐derived	  peak	   instantaneous	  
systolic	  flow	  velocity	  across	  the	  aortic	  valve	  prior	  to	  intervention	  was	  on	  average	  4.8	  
m/s,	   corresponding	   to	   a	   pressure	   gradient	   across	   the	   stenotic	   valve	   of	   91	  mmHg.	  
The	  peak-­‐to-­‐peak	  gradient	  at	  catheterization	  was	  64	  mmHg	  (range	  51	  –	  75	  mmHg).	  
All	  catheterizations	  were	  performed	  under	  general	  anesthesia.	  Of	  those	  37	  patients,	  
one	  patient	  underwent	  balloon	  valvuloplasty	  less	  than	  one	  year	  prior	  to	  the	  end	  of	  
the	   inclusion	  period	  and	  therefore	  no	   information	  regarding	   three	  years	   follow-­‐up	  
findings	  are	  available	  for	  this	  particular	  patient.	  	  
5.4.2 HISTORY, PHYSICAL EXAMINATION AND ECG 
	  
History	   and	   physical	   examination	   pre-­‐intervention	   were	   unremarkable	   with	   the	  
exception	   of	   a	   systolic	   murmur.	   All	   were	   asymptomatic	   and	   in	   New	   York	   Heart	  
Association	  functional	  class	  I.	  ECG	  findings	  did	  not	  reveal	  abnormal	  cardiac	  rhythm,	  
conduction	   disorders	   or	   signs	   of	   ischemia.	   There	   were	   no	   T-­‐wave	   abnormalities	  
indicative	  of	  cardiac	  strain	  at	  rest.	   In	   five	  patients	  ECG	  findings	  were	  suggestive	  of	  
left	  ventricular	  hypertrophy,	  with	  increased	  LV	  forces	  and	  leftward	  deviation	  of	  the	  
QRS	  axis.	  Echocardiography	  confirmed	   the	  presence	  of	   LV	  hypertrophy	   in	   three	  of	  
these	   patients.	   At	   intermediate	   follow-­‐up	   (5.8±1.5	   months	   after	   balloon	  
intervention)	  and	   late	   follow-­‐up	  (3.4±0.7	  years	  after	  balloon	   intervention)	  patients	  
were	   free	   from	   cardiac	   symptoms.	   As	   expected,	   several	   anthropometric	  
characteristics	  of	   the	   study	   subjects	  were	   statistically	   significant	  different	   (P<0.05)	  
at	   three	   years	   follow-­‐up	   when	   compared	   to	   pre-­‐interventional	   measurements	   by	  
linear	  mixed	  models.	  These	  small,	  but	  statistically	  significant	  differences	  can	  be	  fully	  
explained	   by	   maturational	   changes.	   Patient	   demographic	   characteristics	   and	  
anthropometric	  parameters	  pre-­‐intervention	  and	  at	  follow-­‐up	  are	  listed	  in	  Table	  18.	  
Demographic	   and	   anthropometric	   characteristics	   of	   control	   subjects	   and	   study	  
subjects	  at	  three	  years	  follow-­‐up	  are	  described	  in	  Table	  19.	  There	  were	  no	  statistical	  
significant	  differences	  in	  anthropometric	  parameters	  between	  the	  various	  groups	  of	  
children	  under	  investigation	  (e.g.,	  children	  with	  severe	  VAS	  at	  three	  years	  follow-­‐up	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after	   balloon	   valvuloplasty,	   healthy	   control	   subjects,	   VAS	   patients	   without	   prior	  
intervention).	  	  
	  
Table 18 – Demographic and anthropometric characteristics (mean ± standard 














Male	   25	  (68%)	   25	  (68%)	   -­‐	   25	  (68%)	   -­‐	  
Age	  (y)	  
6.7	  
(0.0	  –	  15.5)	  
7.3	  





Height	  (cm)	   114	  ±	  42	   121	  ±	  39	   0.35	   139	  ±	  30	   0.08	  
Weight	  (kg)	  
26.5	  
(2	  –	  65)	  
30.4	  
(5	  –	  66)	  
0.38	  
38.8	  
(12	  –	  73)	  
0.14	  
BSA	  (m2)	   0.90	  ±	  0.51	   0.99	  ±	  0.51	   0.37	   1.20	  ±	  0.46	   0.11	  
BMI	  (kg/m2)	   17.1	  ±	  2.9	   17.5	  ±	  3.9	   0.58	   18.3	  ±	  4.5	   0.45	  
HR	  (bpm)	   99	  ±	  32	   95	  ±	  32	   0.45	   86	  ±	  21	   0.38	  
MAP	  (mmHg)	   64	  ±	  10	   67	  ±	  9	   0.17	   74	  ±	  9	   0.002*	  
Syst.BP	  
(mmHg)	  
91	  ±	  13	   94	  ±	  11	   0.30	   103	  ±	  13	   0.003*	  
Diast.BP	  
(mmHg)	  
51	  ±	  10	   54	  ±	  9	   0.13	   60	  ±	  8	   0.005*	  
	  
BMI: body mass index; HR: heart rate; BSA: body surface area; Diast.BP: diastolic blood 
pressure; MAP: mean arterial blood pressure; Syst.BP: systolic blood pressure. * P < 0.05   
when compared with the same parameter at the prior examination by linear mixed models. 
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Table 19 – Demographic and anthropometric characteristics (mean ± standard 
deviation or median and range) of study subjects and control groups at late follow-up 
Subject	   Late	  follow-­‐up	   Late	  follow-­‐up	   No	  prior	  intervention	  
No	  prior	  









Mild	  VAS	   Moderate	  VAS	  
Number	   17	   19	   45	   31	   74	  
Male	  	   11	  (65%)	   12	  (64%)	   31	  (69%)	   23	  (74%)	   50	  (68%)	  
Age	  (y)	   10.2	  (3	  –	  18)	   10.3	  (3	  –	  19)	   10.2	  (2	  –	  18)	   9.0	  (0	  –	  17)	   10.3	  (3	  –	  19)	  
Height	  (cm)	   140	  ±	  30	   139	  ±	  31	   137	  ±	  30	   133	  ±	  30	   141	  ±	  30	  
Weight	  (kg)	   37.4	  (12	  –	  68)	   40.0	  (14	  –	  73)	   36.2	  (9	  –	  75)	   31.0	  (7	  –	  86)	   38.7	  (13	  –	  70)	  
BSA	  (m2)	   1.19	  ±	  0.44	   1.22	  ±	  0.48	   1.20	  ±	  0.44	   1.13	  ±	  0.45	   1.21	  ±	  0.47	  
BMI	  (kg/m2)	   17.6	  ±	  3.1	   18.9	  ±	  5.4	   17.9	  ±	  3.2	   18.1	  ±	  3.6	   17.8	  ±	  2.9	  
HR	  (bpm)	   79	  ±	  19	   83	  ±	  23	   81	  ±	  20	   83	  ±	  22	   79	  ±	  16	  
MAP	  (mmHg)	   76	  ±	  7	   73	  ±	  10	   75	  ±	  9	   76	  ±	  10	   74	  ±	  9	  
Syst.BP	  (mmHg)	   106	  ±	  11	   101	  ±	  14	   103	  ±	  13	   100	  ±	  11	   103	  ±	  12	  
Diast.BP	  (mmHg)	   61	  ±	  7	   59	  ±	  9	   60	  ±	  8	   61	  ±	  11	   60	  ±	  6	  
	  
BMI: body mass index; BSA: body surface area; Diast.BP: diastolic blood pressure; HR: heart 
rate; MAP: mean arterial blood pressure; Syst.BP: systolic blood pressure. 
 
5.4.3 CONVENTIONAL ECHOCARDIOGRAPHIC PARAMETERS 
	  
Conventional	   echocardiographic	   findings	   are	   shown	   in	   Table	   20.	   Prior	   to	  
intervention,	   echocardiographic	   findings	   indicated	   significant	   left	   ventricular	  
hypertrophy	  in	  three	  patients.	  At	  that	  time,	  mild	  aortic	  regurgitation	  was	  present	  in	  
11	  out	  of	  37	  patients.	  Conventional	  systolic	  echocardiographic	  indices	  were	  normal	  
in	   all	   echocardiographic	   examinations	   performed	   prior	   to	   intervention.	   At	  
intermediate	   and	   three	   years	   follow-­‐up,	   none	   of	   the	   patients	   had	   significant	   left	  
ventricular	   hypertrophy.	   Mild	   aortic	   regurgitation	   was	   present	   in	   19	   out	   of	   37	  
patients,	  whereas	  moderate	  aortic	  regurgitation	  was	  revealed	  in	  two	  patients.	  Post-­‐
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intervention,	   conventional	   functional	   echocardiographic	   findings	   did	   not	   indicate	  
systolic	   left	   ventricular	   dysfunction	   and	   were	   all	   within	   normal	   limits.	   Each	  
conventional	   echocardiographic	   finding	   of	   the	   pre-­‐interventional	   examination	  was	  
similar	   to	   respective	   echocardiographic	   findings	   at	   follow-­‐up	   as	   determined	   by	  
linear	   mixed	   models.	   Peak	   instantaneous	   systolic	   flow	   velocity	   across	   the	   aortic	  
valve	  and	  the	  Bernoulli	  equation	  derived	  peak	  pressure	  gradient	  across	  the	  stenotic	  
valve	   were	   the	   only	   conventional	   parameters	   that	   changed	   after	   balloon	  
valvuloplasty.	   Both	   declined	   significantly	   (P<0.001)	   within	   6	  months	   after	   balloon	  
valvuloplasty	  and	  remained	  stable	  at	  three	  years	  follow-­‐up.	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Table 20 – Conventional echocardiographic findings (mean ± standard deviation or 
median and range) of study subjects and significance (P-value) of change during 
follow-up after intervention 
Parameters	   Pre-­‐intervention	  
Intermediate	  
Follow-­‐up	   P	  value	   Late	  follow-­‐up	   P	  value	  
	  	   (n=37)	   (n=37)	   	  	   (n=36)	   	  	  
Peak	  velocity	  




91	  (67	  –	  154)	   42	  (18	  –	  68)	   <0.001*	   39	  (14	  –	  61)	   0.49	  
Mitral	  A	  
velocity	   0.59	  ±	  0.12	   0.58	  ±	  0.12	   0.72	   0.57	  ±	  0.14	   0.88	  
Mitral	  E	  
velocity	   1.00	  ±	  0.17	   0.98	  ±	  0.17	   0.50	   1.03	  ±	  0.17	   0.19	  
Mitral	  EA	  
Ratio	   1.75	  ±	  0.41	   1.74	  ±	  0.39	   0.91	   1.85	  ±	  0.33	   0.27	  
LVETc	  (s)	   0.30	  ±	  0.02	   0.30	  ±	  0.02	   0.83	   0.30	  ±	  0.02	   0.76	  
VCFc	  (circ/s)	   1.30	  ±	  0.14	   1.29	  ±	  0.10	   0.49	   1.27	  ±	  0.10	   0.21	  
Tei	  index	   0.39	  ±	  0.02	   0.38	  ±	  0.02	   0.64	   0.39	  ±	  0.02	   0.58	  
FS	   0.40	  ±	  0.04	   0.39	  ±	  0.02	   0.16	   0.38	  ±	  0.03	   0.22	  
LVEF	  biplane	   0.74	  ±	  0.04	   0.73	  ±	  0.05	   0.36	   0.72	  ±	  0.05	   0.92	  
LVM	  (g)	   68.1	  ±	  37	   71.2	  ±	  39	  
0.88	  
84.9	  ±	  42	  
0.26	  
z-­‐score	   +	  0.85	  	   +	  0.54	   -­‐	  0.03	  
	  	  
(-­‐0.30	  to	  +2.45)	   (-­‐0.76	  to	  +1.70)	   (-­‐1.14	  to	  +1.33)	  
LVM/BSA	  
(g/m2)	   75.7	  ±	  18	   71.9	  ±	  14	   0.52	   70.8	  ±	  16	   0.83	  
	  
Peak velocity: Doppler-derived peak instantaneous systolic flow velocity over the aortic valve; 
Peak pressure: peak pressure gradient across aortic valve; LVETc: left ventricular ejection 
time corrected for heart rate; VCFc: heart-rate corrected velocity of circumferential fiber 
shortening; Tei index: left ventricular myocardial performance index; FS: fractional shortening; 
LVEF biplane: left ventricular ejection fraction measured by modified Simpson’s method; LV 
mass/BSA: left ventricular mass corrected for body surface area. * P < 0.05 when compared 
with the same echocardiographic parameter at the prior examination by linear mixed models. 
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5.4.4 MYOCARDIAL STRAIN PARAMETERS 
	  
Tracking	  was	  feasible	  in	  98%	  of	  all	  segments	  of	  the	  four	  chamber	  view,	  in	  97%	  of	  all	  
segments	  in	  the	  short	  axis	  view	  at	  the	  level	  of	  the	  papillary	  muscle	  and	  in	  93%	  of	  all	  
segments	  in	  the	  short	  axis	  view	  at	  the	  level	  of	  the	  mitral	  valve.	  The	  2DSTE	  findings	  
prior	  to	   intervention	  and	  at	   follow-­‐up	  are	  presented	   in	  Table	  21	  and	  Figure	  20-­‐22.	  
One	   important	   observation	   was	   a	   strong,	   statistically	   significant	   change	   in	   2DSTE	  
parameters	   after	   balloon	   valvuloplasty.	   At	   intermediate	   follow-­‐up,	   global	   peak	  
systolic	   strain	   in	   all	   three	   directions	   (longitudinal,	   circumferential	   and	   radial)	  
improved	   significantly	   when	   compared	   to	   pre-­‐interventional	   measurements	   by	  
means	  of	  linear	  mixed	  models.	  Peak	  systolic	  strain	  in	  all	  three	  directions	  continued	  
to	   change	   thereafter.	   At	   three	   years	   follow-­‐up	   peak	   systolic	   strain	   in	   all	   three	  
direction	   was	   significantly	   improved	   when	   compared	   to	   findings	   at	   intermediate	  
follow-­‐up.	  Time	  to	  global	  peak	  systolic	  strain	  values	  at	  intermediate	  follow-­‐up	  were	  
significantly	   shorter	   in	   radial	   direction	   when	   compared	   to	   pre-­‐interventional	  
measurements.	   On	   the	   contrary,	   T2P	   values	   at	   three	   years	   follow-­‐up	   were	  
significantly	   longer	   (in	   all	   three	   directions	   of	   contraction)	   when	   compared	   to	  
findings	   at	   intermediate	   follow-­‐up	   and	   T2P	   results	   acquired	   prior	   to	   intervention.	  
The	   latter	   finding	   could	   be	   the	   effect	   of	   maturational	   changes	   in	   heart	   rate	  
(prolongation	  of	  R-­‐R	  interval)	  since	  regression	  analysis	  showed	  a	  strong,	  statistically	  
significant,	  relation	  between	  T2P	  indices	  and	  R-­‐R	  interval	  (R2	  0.65;	  P	  <	  0.0001).	  	  
Global	   peak	   systolic	   strain-­‐rate	   in	   longitudinal	   and	   circumferential	   direction	  
improved	   significantly	   at	   intermediate	   follow-­‐up	   when	   compared	   to	   pre-­‐
interventional	  measurements.	  At	   three	  years	   follow-­‐up	  global	  peak	   systolic	   strain-­‐
rate	   results	   were	   similar	   to	   those	   acquired	   at	   intermediate	   follow-­‐up	   in	   all	   three	  
directions	  of	  deformation.	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Figure 20 - Box and Whisker plots of global peak systolic strain values 
	  
	  
Global SL: Global peak systolic longitudinal strain (%); 0 (red): baseline data acquired in VAS 
patients prior to balloon valvuloplasty; 1 (blue): data acquired in VAS patients following balloon 
valvuloplasty at six months follow-up; 2 (green): data acquired in VAS patients at three years 
follow-up; normal (yellow): data acquired in healthy controls. * P < 0.05 when compared with 
the adjacent data group. 
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Figure 21 - Box and Whisker plots of global peak systolic strain values 
	  
	  
Global SCP: Global peak systolic circumferential strain at the level of the papillary muscle (%); 
0 (red): baseline data acquired in VAS patients prior to balloon valvuloplasty; 1 (blue): data 
acquired in VAS patients following balloon valvuloplasty at six months follow-up; 2 (green): 
data acquired in VAS patients at three years follow-up; normal (yellow): data acquired in 
healthy controls. * P < 0.05 when compared with the adjacent data group. 
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Figure 22 - Box and Whisker plots of global peak systolic strain values 
	  
	  
Global SCP: Global peak systolic radial strain at the level of the papillary muscle (%); 0 (red): 
baseline data acquired in VAS patients prior to balloon valvuloplasty;  1 (blue): data acquired 
in VAS patients following balloon valvuloplasty at six months follow-up; 2 (green): data 
acquired in VAS patients at three years follow-up; normal (yellow): data acquired in healthy 
controls. * P < 0.05 when compared with the adjacent data group. 
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Table 21 - 2DSTE findings (mean ± standard deviation) of study subjects 









Global	  SL	  (%)	   -­‐14.7	  ±	  1.0	   -­‐16.2	  ±	  1.6	  *	   -­‐17.2	  ±	  1.2	  ¥	  
Global	  SC-­‐P	  (%)	   -­‐18.2	  ±	  2.2	   -­‐19.4	  ±	  2.0	  ¥	   -­‐20.7	  ±	  1.4	  ¥	  
Global	  SC-­‐M	  (%)	   -­‐16.0	  ±	  1.3	   -­‐17.7	  ±	  1.8	  *	   -­‐18.5	  ±	  1.6	  
Global	  SR-­‐P	  (%)	   51.7	  ±	  2.5	   53.3	  ±	  2.6	  ¥	   54.8	  ±	  2.0	  ¥	  
Global	  SR-­‐M	  (%)	   49.2	  ±	  2.5	   51.0	  ±	  2.6	  ¥	   52.5	  ±	  2.2	  ¥	  
T2P	  global	  SL	  (ms)	   374	  ±	  58	   363	  ±	  48	   393	  ±	  31	  ¥	  
T2P	  global	  SC-­‐P	  (ms)	   347	  ±	  60	   335	  ±	  52	   366	  ±	  30	  ¥	  
T2P	  global	  SC-­‐M	  (ms)	   363	  ±	  55	   353	  ±	  45	   375	  ±	  22	  ¥	  
T2P	  global	  SR-­‐P	  (ms)	   354	  ±	  55	   324	  ±	  37	  ¥	   344	  ±	  23	  ¥	  
T2P	  global	  SR-­‐M	  (ms)	   401	  ±	  51	   352	  ±	  52	  ¥	   353	  ±	  41	  
Global	  SrL	  (s-­‐1)	   -­‐0.9	  ±	  0.1	   -­‐1.1	  ±	  0.2	  *	   -­‐1.1	  ±	  0.1	  
Global	  SrC-­‐P	  (s-­‐1)	   -­‐1.4	  ±	  0.2	   -­‐1.6	  ±	  0.2	  ¥	   -­‐1.6	  ±	  0.2	  
Global	  SrC-­‐M	  (s-­‐1)	   -­‐1.0	  ±	  0.3	   -­‐1.2	  ±	  0.3	  ¥	   -­‐1.2	  ±	  0.3	  
Global	  SrR-­‐P	  (s-­‐1)	   3.1	  ±	  0.5	   3.4	  ±	  0.4	   3.4	  ±	  0.5	  
Global	  SrR-­‐M	  (s-­‐1)	   2.9	  ±	  0.5	   3.1	  ±	  0.4	   3.0	  ±	  0.6	  
	  
SL: global peak systolic longitudinal strain; SC: global peak systolic circumferential strain; -P: 
the level of the papillary muscle; -M: at the level of the mitral valve; SR: global peak systolic 
radial strain; T2P: time to global peak systolic strain; SrL: global peak systolic longitudinal 
strain-rate; SrC: global peak systolic circumferential strain-rate; SrR: global peak systolic radial 
strain-rate; * P < 0.0001 when compared with the same 2DSTE parameter at the prior 
examination by linear mixed models; ¥ P < 0.05 when compared with the same 2DSTE 
parameter at the prior examination by linear mixed models. 
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DEVIATION	  FROM	  NORMAL	  2DSTE	  REFERENCE	  VALUES:	  	  
	  
All	   2DSTE	   results	   were	   compared	   with	   pediatric	   reference	   values	   to	   correct	   for	  
possible	  bias	   caused	  by	  maturational	   changes.26	   For	  all	   individual	  2DSTE	   results	  of	  
the	   study	   subjects	   (pre-­‐intervention	   and	   at	   follow-­‐up),	   the	   deviation	   from	  normal	  
was	  calculated	  (2DSTE	  result	  of	  the	   individual	  patient	  minus	  mean	  reference	  value	  
of	   2DSTE	   parameter	   for	   age).	   The	   deviation	   from	   normal	   for	   all	   individual	   strain	  
parameters	  was	  significantly	  (P<0.0001)	  reduced	  at	  intermediate	  follow-­‐up.	  At	  three	  
years	  follow-­‐	  up,	  there	  was	  no	  significant	  further	  reduction	  in	  deviation	  from	  normal	  
observed	  and	  similar	  values	  as	  at	  intermediate	  follow	  up	  were	  found	  (Table	  22	  and	  
Fure	  23-­‐25).	  The	  decline	  in	  longitudinal	  systolic	  strain	  as	  well	  as	  longitudinal	  systolic	  
strain	   rate	   prior	   to	   intervention	   was	   more	   pronounced	   in	   segments	   of	   the	  
interventricular	  septum,	  especially	   its	  basal	  parts.	  Global	  peak	  systolic	   longitudinal	  
strain	  was	  on	  average	  6.8%	  ±	  1.0	  lower	  in	  the	  interventicular	  septum	  (7.2%	  ±	  0.9	  in	  
the	   basal	   part)	   and	   5.0%	   ±	   1.2	   lower	   in	   the	   lateral	   free	   wall,	   when	   compared	   to	  
healthy	   age	   matched	   children	   (P<0.001).	   In	   contrast	   to	   longitudinal	   deformation,	  
were	  circumferential	  and	  radial	  strain	  (-­‐rate)	  values	  equally	  affected	  throughout	  the	  
interventricular	  septum	  and	  left	  ventricular	  lateral	  wall	  segments.	  	  
	  
In	  the	  individual	  patient	  with	  aortic	  stenosis	  under	  investigation,	  pre-­‐interventional	  
global	  peak	  systolic	  strain	  was	  abnormal	  (below	  5th	  percentile	  of	  normal	  according	  
to	  previously	  mentioned	  reference	  values)	  in	  97%	  of	  patients	  for	  longitudinal	  strain,	  
65%	  of	   patients	   for	   circumferential	   strain	   at	   the	   level	   of	   the	   papillary	  muscle	   and	  
68%	  of	  patients	   for	   circumferential	   strain	  at	   the	   level	  of	   the	  mitral	   valve.26	  Global	  
peak	  systolic	  radial	  strain	  was	  abnormal	  at	  the	  level	  of	  the	  papillary	  muscle	  in	  24%	  
of	  the	  patients	  versus	  16%	  of	  patients	  at	  the	  level	  of	  the	  mitral	  valve.	  	  
	  
As	  for	  the	  post-­‐intervention	  2DSTE	  measurements	  at	  three	  years	  follow-­‐up,	  97%	  of	  
patients	  persisted	  to	  show	  an	  abnormal	  peak	  systolic	  longitudinal	  deformation,	  38%	  
of	  patients	  for	  circumferential	  strain	  at	  the	  level	  of	  the	  papillary	  muscle	  and	  36%	  of	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patients	   for	   circumferential	   strain	   at	   the	   level	   of	   the	   mitral	   valve.	   Global	   peak	  
systolic	  radial	  strain	  was	  abnormal	  at	  the	  level	  of	  the	  papillary	  muscle	  in	  10%	  of	  the	  
patients	  versus	  8%	  of	  the	  patients	  at	  the	  level	  of	  the	  mitral	  valve.	  
	  
Figure 23 – Deviation from normal reference values for age of global peak systolic 
strain values (%) pre-intervention and at follow-up 
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Figure 24 – Deviation from normal reference values for age of time to global peak 
systolic strain values (ms) pre-intervention and at follow-up 
	  
	  
Figure 25 – Deviation from normal reference values for age of global peak systolic 
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Table 22 – Deviation from normal reference values according to age of each 2DSTE 
parameter (absolute values: mean ± standard deviation) 
Deviation	  from	  reference	  










Δ	  Global	  SL	  (%)	   5.8	  ±	  0.9	   4.5	  ±	  1.3	  *	   4.4	  ±	  1.0	  
Δ	  Global	  SC-­‐P	  (%)	   3.5	  ±	  0.8	   2.6	  ±	  1.2	  ¥	   2.4	  ±	  1.3	  
Δ	  Global	  SC-­‐M	  (%)	   4.0	  ±	  1.0	   2.5	  ±	  1.3	  *	   2.3	  ±	  1.2	  
Δ	  Global	  SR-­‐P	  (%)	   -­‐3.1	  ±	  1.0	   -­‐1.8	  ±	  0.9	  *	   -­‐1.4	  ±	  0.5	  
Δ	  Global	  SR-­‐M	  (%)	   -­‐3.0	  ±	  1.3	   -­‐1.3	  ±	  0.6	  *	   -­‐1.0	  ±	  0.4	  
Δ	  T2P	  global	  SL	  (ms)	   40	  ±	  8	   22	  ±	  10	  *	   19	  ±	  9	  
Δ	  T2P	  global	  SC-­‐P	  (ms)	   26	  ±	  9	   9	  ±	  4	  *	   11	  ±	  5	  
Δ	  T2P	  global	  SC-­‐M	  (ms)	   25	  ±	  7	   11	  ±	  5	  *	   7	  ±	  3	  
Δ	  T2P	  global	  SR-­‐P	  (ms)	   18	  ±	  4	   8	  ±	  3	  *	   8	  ±	  2	  
Δ	  T2P	  global	  SR-­‐M	  (ms)	   36	  ±	  13	   15	  ±	  6	  *	   -­‐5	  ±	  2	  ¥	  
Δ	  Global	  SrL	  (s-­‐1)	   0.5	  ±	  0.1	   0.3	  ±	  0.2	  *	   0.3	  ±	  0.2	  
Δ	  Global	  SrC-­‐P	  (s-­‐1)	   0.5	  ±	  0.2	   0.3	  ±	  0.2	  *	   0.3	  ±	  0.2	  
Δ	  Global	  SrC-­‐M	  (s-­‐1)	   0.5	  ±	  0.3	   0.3	  ±	  0.3	  ¥	   0.3	  ±	  0.3	  
Δ	  Global	  SrR-­‐P	  (s-­‐1)	   -­‐0.4	  ±	  0.5	   -­‐0.1	  ±	  0.4	  ¥	   -­‐0.1	  ±	  0.5	  
Δ	  Global	  SrR-­‐M	  (s-­‐1)	   -­‐0.3	  ±	  0.5	   -­‐0.1	  ±	  0.4	   -­‐0.2	  ±	  0.6	  
	  
SL: global peak systolic longitudinal strain; SC: global peak systolic circumferential strain; -P: 
the level of the papillary muscle; -M: at the level of the mitral valve; SR: global peak systolic 
radial strain; T2P: time to global peak systolic strain; SrL: global peak systolic longitudinal 
strain-rate; SrC: global peak systolic circumferential strain-rate; SrR: global peak systolic radial 
strain-rate; * P < 0.0001 when compared with the same 2DSTE parameter at the prior 
examination by linear mixed models; ¥ P < 0.05 when compared with the same 2DSTE 
parameter at the prior examination by linear mixed models. 
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THREE	  YEARS	  FOLLOW-­‐UP	  2DSTE	  FINDINGS	  COMPARED	  WITH	  THOSE	  IN	  CONTROL	  
GROUPS:	  	  
	  
The	  2DSTE	  findings	  in	  study	  subjects	  at	  three	  years	  follow-­‐up	  compared	  with	  those	  
found	   in	   both	   control	   groups	   are	   shown	   in	   Table	   23.	   Determined	   with	   One	  Way	  
Analysis	   Of	   Variance	   (ANOVA),	   each	   global	   peak	   systolic	   strain	   and	   global	   peak	  
systolic	   strain-­‐rate	   parameter	   at	   three	   years	   follow-­‐up	   was	   significantly	   lower	  
(P<0.001)	   in	   longitudinal	   and	   circumferential	   direction	   when	   compared	   to	   both	  
healthy	   age-­‐matched	   controls	   and	   age-­‐matched	   children	  with	   an	   equal	   degree	   of	  
stenosis	  but	  no	  prior	  intervention.	  Radial	  2DSTE	  parameters	  at	  three	  years	  follow-­‐up	  
as	   well	   as	   T2P	   values	   in	   all	   three	   directions	   were	   similar	   to	   those	   found	   in	   both	  
control	   groups.	   There	  was	  no	   statistically	   significant	   relation	  between	   global	   peak	  
systolic	   strain	   (-­‐rate)	   results	   or	   T2P	   values	   and	   aortic	   regurgitation	   as	   assessed	  by	  
means	   of	   One	   Way	   Analysis	   of	   Variance	   (P	   0.72).	   The	   relation	   between	   various	  
conventional	   echocardiographic	   parameters	   and	   longitudinal	   and	   circumferential	  
strain	   indices	   determined	   at	   three	   years	   follow-­‐up	   was	   assessed	   by	   means	   of	  
regression	  analysis	  (Table	  24).	  LVEF	  and	  FS	  at	  baseline	  appeared	  not	  to	  be	  related	  to	  
strain	   (-­‐rate)	  measurements	   at	   follow-­‐up.	  On	   contrast,	   peak	   flow	   velocity	   at	   base	  
line	   and	   follow-­‐up	   showed	   strong,	   statistically	   significant	   (P	   <0.001),	   relationships	  
with	  deformation	  at	  three	  years	  follow-­‐up.	  The	  reduction	  of	  peak	  flow	  velocity	  (pre-­‐
interventional	  measurement	  minus	  peak	  flow	  velocity	  at	  three	  years	  follow	  up)	  was	  
statistically	  significant	  related	  to	  the	  increment	  in	  peak	  systolic	  strain	  (difference	  in	  
peak	  systolic	  strain	  between	  pre-­‐interventional	  assessment	  and	  post-­‐interventional	  
assessment	  at	   three	   years	   follow	  up):	  R2	  0.41	   for	   global	   SL	   (P	   <0.001),	  R2	   0.38	   for	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Table 23 - 2DSTE findings (mean ± standard deviation) of study subjects at late follow-
up and control groups 
	  
Peak velocity: peak instantaneous systolic flow velocity over the aortic valve; AR: aortic 
regurgitation; SL: peak systolic longitudinal strain; SC: peak systolic circumferential strain; -P: 
at the level of the papillary muscle; -M: at the level of the mitral valve; SR: peak systolic radial 
strain; T2P: time to peak systolic strain; SrL: peak systolic longitudinal strain-rate; SrC: peak 
systolic circumferential strain-rate; SrR: peak systolic radial strain-rate; P values with respect 
to pair wise comparison of the means of two adjacent groups, resulting from one-way ANOVA 
with Bonferroni correction.  
	  











































































Number 45 17 74 19 31
No.#patients#with#AR 10#(22%) 10#(59%) 0 11#(58%) 6#(19%)
Peak#velocity#(m/s) 2.8#±#0.2 1.00 2.6#±#0.3 0 3.5#±#0.3 1.00 3.4#±#0.3
Global#SL#(%) 019.5#±#1.2 <0.001 017.8#±#1.2 <0.001 021.6#±#1.4 <0.001 016.7#±#1.0 <0.001 018.4#±#1.3
Global#SC0P#(%) 022.9#±#1.5 <0.01 021.0#±#1.3 <0.001 023.3#±#2.0 <0.001 019.8#±#1.5 <0.01 021.1#±#2.0
Global#SC0M#(%) 020.9#±#1.5 <0.01 019.3#±#1.5 <0.001 021.2#±#2.1 <0.001 017.8#±#1.2 0.22 019.0#±#1.6
Global#SR0P#(%) 57.4#±#2.3 0.87 55.4#±#2.2 1.00 55.9#±#5.5 1.00 54.3#±#1.7 0.94 56.2#±#2.7
Global#SR0M#(%) 54.8#±#2.8 1.00 53.6#±#2.2 1.00 53.7#±#5.7 0.57 51.6#±#1.6 1.00 53.3#±#2.9
T2P#global#SL#(ms) 368#±#26 0.37 390#±#31 0.79 373#±#31 0.08 396#±#28 1.00 383#±#25
T2P#global#SC0P#(ms) 342#±#33 0.81 360#±#28 1.00 355#±#38 0.83 371#±#32 0.34 349#±#31
T2P#global#SC0M#(ms) 350#±#32 1.00 365#±#32 1.00 357#±#36 0.06 380#±#23 1.00 366#±#29
T2P#global#SR0P#(ms) 324#±#27 0.22 341#±#22 1.00 339#±#36 1.00 345#±#23 1.00 339#±#24
T2P#global#SR0M#(ms) 342#±#27 1.00 349#±#22 1.00 341#±#43 0.43 356#±#44 1.00 354#±#23
Global#SrL#(s01) 01.3#±#0.2 <0.01 01.2#±#0.1 <0.001 01.4#±#0.1 <0.001 00.9#±#0.1 <0.001 01.1#±#0.1
Global#SrC0P#(s01) 01.9#±#0.1 <0.01 01.7#±#0.2 <0.01 01.9#±#0.1 <0.001 01.4#±#0.2 <0.01 01.7#±#0.2
Global#SrC0M#(s01) 01.5#±#0.2 <0.01 01.3#±#0.1 <0.01 01.5#±#0.2 <0.001 01.2#±#0.3 1.00 01.3#±#0.2
Global#SrR0P#(s01) 3.6#±#0.4 1.00 3.5#±#0.5 1.00 3.5#±#0.4 0.36 3.2#±#0.5 0.29 3.5#±#0.4
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P	  <	  0.001	  
R2	  0.46	  
P	  <	  0.001	  
R2	  0.42	  
P	  <	  0.001	  
R2	  0.59	  
P	  <	  0.001	  
R2	  0.47	  
P	  <	  0.001	  
R2	  0.38	  
P	  <	  0.001	  





































at	  T0	  minus	  
Peak	  velocity	  
at	  T2	  	  
R2	  0.65	  	  
P	  <	  0.001	  
R2	  0.51	  
P	  <	  0.001	  
R2	  0.48	  
P	  <	  0.001	  
R2	  0.66	  
P	  <	  0.001	  
R2	  0.53	  
P	  <	  0.001	  
R2	  0.44	  




P	  <	  0.001	  
R2	  0.29	  
P	  <	  0.001	  
R2	  0.28	  
P	  <	  0.001	  
R2	  0.36	  
P	  <	  0.001	  
R2	  0.30	  
P	  <	  0.001	  
R2	  0.22	  
P	  <	  0.004	  
	  
Global SL: global peak systolic longitudinal strain; Global SC: Global peak systolic 
circumferential strain; -P: at the level of the papillary muscle; -M: at the level of the mitral 
valve; Global SrL: Global peak systolic longitudinal strain rate; Global SrC: Global peak 
systolic circumferential strain rate; peak velocity: Doppler-derived peak instantaneous systolic 
flow velocity over the aortic valve; LVM; left ventricular mass; LVEF: left ventricular ejection 
fraction measured by modified Simpson’s method; FS: fractional shortening; T0: baseline (pre-
intervention); T2: late follow-up; R2: coefficient of determination assessed by means of linear 
regression analysis. 
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5.5 DISCUSSION 
	  
Congenital	   isolated	   VAS	   is	   one	   of	   the	   most	   common	   forms	   of	   congenital	   heart	  
disease	  with	  an	  estimated	  incidence	  of	  3.8	  per	  10,000	  live	  births	  and	  an	  increasing	  
prevalence	   with	   age,	   since	   certainly	   not	   all	   cases	   are	   diagnosed	   at	   time	   of	   birth.	  
Previous	  reports	  suggest	  that	  congenital	  VAS	  is	  a	  progressive	  disease	  with	  an	  overall	  
25-­‐year	   survival	   rate	   of	   85%	   after	   the	   diagnosis	   has	   been	  made	   and	   a	  worrisome	  
incidence	  of	  sudden	  cardiac	  death.27,28	  	  
	  
Although	  these	  figures	  might	  be	  overrated,	  lifelong,	  periodic	  cardiac	  evaluation	  and	  
monitoring	   is	   clearly	   indicated.	   The	   rationale	   for	   intervention	   in	   children	   with	  
moderate	  to	  severe	  congenital	  valvular	  aortic	  stenosis	  is	  obvious	  when	  the	  patient	  is	  
symptomatic	   and	   (surgical)	   intervention	  most	   likely	   improves	   the	   outcome	  of	   this	  
subset	   of	   patients.	   The	   decision	   is	   controversial	   when	   the	   patients	   are	  
asymptomatic,	  which	   is	  often	  the	  case	   in	   the	  pediatric	  population,	  even	   in	  case	  of	  
severe	   stenosis.	   In	   addition	   to	   symptomatic	   status,	   current	   criteria	   to	   indicate	  
intervention	   are	   entirely	   based	   on	   the	   pressure	   gradient	   in	   analogy	  with	   adults.27	  
Thus,	  indicating	  that	  when	  transvalvular	  peak	  pressure	  gradients	  exceed	  50	  mmHg,	  
an	  increased	  risk	  for	  myocardial	  damage	  is	  present.	  	  
	  
Unfortunately,	   adequate	   monitoring	   of	   myocardial	   function	   and	   remodeling	   in	  
children	  with	  congenital	  VAS	  imposes	  a	  challenge.	  Conventional	  diagnostic	  imaging	  
modalities	  such	  as	  standard	  echocardiographic	  techniques,	  have	  failed	  to	  provide	  a	  
reliable	  assessment	  of	  ventricular	  function	  in	  this	  subset	  of	  patients.	  Although	  they	  
are	   appropriate	   to	   detect	   global	   LV	   dysfunction	   at	   advanced	   stages	   of	   cardiac	  
disease,	   they	   are	   not	   able	   to	   identify	   subclinical	   (regional)	   systolic	   myocardial	  
abnormalities.	  	  
	  
Previous	  reports	  on	  adults	  with	  degenerative	  VAS	  have	  clearly	  illustrated	  that	  strain	  
imaging	  more	  carefully	   reflects	  myocardial	   systolic	   function	   in	  VAS.9,29,30,31,32	  Strain	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parameters	   seemed	   to	   relate	   to	   LV	   function	  as	  well	   as	   to	   the	   severity	  of	   stenosis.	  
Furthermore,	   they	   have	   proven	   to	   be	   superior	   to	   tissue	   velocity	   imaging	   and	  
conventional	  echocardiography	   in	  detecting	   subtle	   changes	   in	  myocardial	   function	  
after	   intervention	   and	   are	   predictive	   of	   (post-­‐operative)	   morbidity	   and	  
mortality.8,11,13,33,34,35	  	  
	  
Several	   studies	   in	   adults	   with	   degenerative	   VAS	   aimed	   to	   assess	   the	   changes	   in	  
regional	  myocardial	   function	   due	   to	   aortic	   valve	   surgery.	   At	   short-­‐term	   follow-­‐up	  
after	   AVR,	   improvement	   of	   strain	   values	   was	   evident	   immediately	   after	  
intervention.	  This	  early	   recovery	   in	  global	  and	  regional	  LV	   function	  within	   the	   first	  
24	  hours	  after	  surgery	  suggests	  an	  important	  negative	  impact	  of	  increased	  afterload	  
on	  regional	  systolic	  function.	  Although	  regional	  and	  global	  myocardial	  deformation	  
improved,	   strain	   parameters	   did	   not	   normalize	   at	   short-­‐term	   follow-­‐up.10,13,36	  
Concerning	   the	   long-­‐term	   effects	   of	   AVR	   on	   the	   recovery	   of	   systolic	   ventricular	  
performance	   in	   adults,	  most	   studies	   are	   indicative	   of	   incomplete	   recovery	  with	   a	  
persistent	  decline	  in	  strain	  parameters.10,11	  	  
	  
The	   latter	   findings	   are	   in	   agreement	   with	   an	   animal	   study	   in	   which	   rats	   were	  
exposed	   to	   pathological	   pressure-­‐overload	   of	   the	   left	   ventricle.	   In	   these	   animals,	  
abnormal	   regional	   myocardial	   velocities	   were	   detected	   as	   well	   as	   significantly	  
increased	   collagen	   density.	   These	   abnormalities	   were	   present	   despite	   normal	  
conventional	   indices	   of	   systolic	   ventricular	   function.	   Subsequently,	   early	  
normalization	  of	   loading	  conditions	   led	  to	  an	  immediate	  and	  complete	  recovery	  of	  
myocardial	   velocities.	   In	   contrast,	   late	   normalization	   of	   loading	   condition	   did	   not	  
lead	   to	   a	   (complete)	   recovery,	   probably	   due	   to	   extensive	   alterations	   in	   the	   LV	  
myocardial	   architecture	   leading	   to	   alterations	   in	   intrinsic	   myocardial	  
contractility.37,38	  	  
	  
Weidemann	   et	   al.	   described	   similar	   findings	   in	   adult	   VAS	   patients	   in	   a	   Tissue	  
Doppler	   imaging	  study.	  Their	  data	  suggested	  that	  aortic	  valve	   replacement	   fails	   to	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reduce	  the	  degree	  of	  replacement	  fibrosis.	  Patients	  without	  fibrosis	  experienced	  the	  
greatest	  clinical	   functional	   improvement,	  which	  was	  accompanied	  by	  an	   increased	  
myocardial	   deformation.	   However,	   in	   patients	   with	   myocardial	   fibrosis	   both	  
functional	   status	   and	   abnormal	   deformation	   appeared	   not	   to	   be	   reversible	   after	  
AVR.	  These	  findings	  suggest	  that	  improvement	  of	  regional	  deformation	  and	  clinical	  
outcome	   is	   limited	  by	  permanent	  myocardial	  alterations	   such	  as	   fibrosis	   (which	   in	  
turn	  is	  related	  to	  severity	  and	  duration	  of	  disease).11	  
	  
Information	  on	  (regional)	  myocardial	  systolic	  dysfunction	  in	  children	  with	  congenital	  
VAS	  is	  limited.	  A	  study	  by	  Kiraly	  et	  al.	  was	  the	  first	  to	  indicate	  a	  decline	  in	  regional	  
deformation	   in	   various	  degrees	  of	   congenital	  VAS	  as	   assessed	  by	  means	  of	   Tissue	  
Doppler	  Imaging.39	  Recently,	  a	  study	  performed	  by	  our	  research	  group	  showed	  that	  
2DSTE	   parameters	  were	   significantly	   related	   to	   the	   severity	   of	   congenital	   valvular	  
aortic	  stenosis,	  with	  abnormal	   longitudinal	  deformation	  even	   in	  patients	  with	  mild	  
stenosis.3	   Whether	   these	   signs	   of	   myocardial	   dysfunction	   are	   reversible	   by	  
normalization	  of	  loading	  conditions	  has	  not	  been	  elucidated.	  Myocardial	  reaction	  to	  
pressure	   overload	   can	   be	   quite	   different	   in	   children,	   especially	   of	   younger	   ages,	  
when	   compared	   to	   adults.	   The	  myocardial	   cells	   of	   young	   children	   have	   yet	   some	  
multiplication	   potential	   and	   vascular	   growth	   can	   more	   flexibly	   follow	   the	  
hypertrophy	  process.40	   It	   is	  possible	   therefore	   that	   in	  children	   the	  elasticity	  of	   the	  
heart	   wall	   may	   be	   preserved	   and	   permanent	   myocardial	   alterations	   will	   only	  
develop	   after	   a	   relatively	   long	   period	   of	   time.	   Thus,	   findings	   in	   adults	   with	  
degenerative	  VAS	   cannot	   be	   expected	   to	   be	   the	   same	   in	   children	  with	   congenital	  
VAS.	  We	  aimed	  to	  assess	  the	  reversibility	  of	  changes	  in	  (regional)	  myocardial	  systolic	  
deformation	  as	  determined	  by	  means	  of	  2DSTE	  in	  this	  subset	  of	  patients.	  	  
	  
The	   present	   study	   revealed	   significant	   decreased	   deformation	   indices	   in	   nearly	   all	  
VAS	  patients	  prior	  to	  balloon	  valvuloplasty	  when	  compared	  to	  healthy	  subjects.	  The	  
decline	   in	   peak	   systolic	   longitudinal	   deformation	  was	   not	   equally	   distributed	   over	  
the	  different	  ventricular	  wall	  segments.	  Peak	  systolic	  longitudinal	  strain	  (-­‐rate)	  was	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most	  affected	  throughout	  the	  interventricular	  septum,	  especially	  its	  basal	  segment.	  
A	   possible	   explanation	   for	   this	   finding	   may	   be	   found	   in	   its	   geometry.	   The	  
interventricular	  septum,	  because	  of	  its	  flatter	  and	  more	  asymmetric	  contour	  with	  a	  
larger	   radius	   of	   curvature	   in	   the	   longitudinal	   plane,	   is	   subjected	   to	   a	   greater	  
increase	   in	   systolic	   wall	   stress	   than	   the	   lateral	   free	   wall.	   Consequently,	   both	  
myocardial	   hypertrophy	   and	   a	   decrease	   in	   systolic	   function	   produced	   by	   the	  
increase	   of	   afterload	   and	   subsequent	   exaggerated	   wall	   stress	   are	   predominantly	  
seen	   in	   the	   interventricular	   septum,	   particularly	   in	   its	   basal	   part.41	   Conventional	  
echocardiographic	  parameters	  to	  assess	  systolic	  function	  prior	  to	  intervention	  were	  
within	   normal	   limits.	   Several	   months	   after	   balloon	   valvuloplasty	   significant	  
improvement	  of	  2DSTE	  parameters	   in	  all	   three	  principal	  directions	  of	  deformation	  
was	  observed.	  When	  corrected	  for	  maturational	  changes,	   these	  changes	  remained	  
statistically	  significant.	  The	  deviation	  from	  normal	  reference	  values	  for	  all	  individual	  
strain	  parameters	  was	  significantly	  reduced	  at	  six	  months	  follow-­‐up.	  The	  improved	  
myocardial	   deformation,	   observed	   following	   balloon	   valvuloplasty,	   is	   probably	   at	  
least	  partially	  caused	  by	  a	  reduced	  pressure-­‐overload	  and	  a	  decline	  of	   its	  negative	  
effects	   on	   myocardial	   function.42	   However,	   when	   2DSTE	   results	   at	   three	   years	  
follow-­‐up	  were	   corrected	   for	  maturational	   changes	  with	   use	   of	   normal	   reference	  
values,	  no	  statistically	   significant	   further	   reduction	   in	  deviation	   from	  normal	  could	  
be	   identified.	   These	   findings	   indicate	   that	   recovery	   of	   left	   ventricular	   systolic	  
deformation	   in	   children	   with	   severe	   congenital	   VAS	   primarily	   occurs	   in	   the	   first	  
months	  after	  balloon	  valvuloplasty.	  Thereafter,	  no	  significant	  further	   improvement	  
can	  be	  anticipated	  using	  two-­‐dimensional	  strain	  parameters.	  
	  
Although	   there	   is	   substantial	   recovery	   of	   myocardial	   deformation	   after	   balloon	  
intervention,	   our	   results	   indicate	   incomplete	   recovery	   of	   longitudinal	   and	  
circumferential	   myocardial	   function.	   Global	   peak	   systolic	   strain	   values	   and	   global	  
peak	   systolic	   strain-­‐rate	   in	   the	   longitudinal	   and	   circumferential	   plane	   were	  
significantly	   lower	   at	   three	   years	   follow-­‐up	   when	   compared	   with	   healthy	   age-­‐
matched	  children.	  More	   importantly,	   these	   respective	   strain	   values	  at	   three	  years	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follow-­‐up	   were	   also	   significantly	   lower	   when	   compared	   to	   age-­‐matched	   children	  
with	  an	  uncorrected	  aortic	  valve	  stenosis	  similar	  to	  the	  residual	  stenosis	  in	  our	  study	  
subjects.	   These	   latter	   results	   could	   indicate	   fixed	   structural	  myocardial	   alterations	  
(e.g.,	  myocardial	   replacement	   fibrosis)	  of	  at	   least	   the	  subendocardial	   layers	  of	   the	  
myocardium,	   which	   are	   mainly	   responsible	   for	   longitudinal	   function.11,43	   These	  
findings	  are	  in	  agreement	  with	  other	  strain	  imaging	  studies	  that	  have	  indicated	  that	  
impairment	   of	   longitudinal,	   and	   to	   a	   lesser	   extend	   circumferential	   function,	  
precedes	   radial	   dysfunction	   in	   VAS	   as	  well	   as	   other	   conditions	   characterized	   by	   a	  
pressure	  overload	  of	   the	   left	  ventricle.3,10,31,34,42,44	  The	   reason	   for	   this	   is	   that	   these	  
subendocardial	   fibers	  are	  more	  vulnerable	   to	   increased	  wall	   stress,	   stress-­‐induced	  
ischemia,	   and	   microvascular	   dysfunction	   accompanying	   left	   ventricular	   pressure	  
overload.45	  In	  contrast,	  myocardial	  function	  in	  radial	  direction	  as	  well	  as	  most	  of	  the	  
time	   to	   global	   peak	   systolic	   strain	   values	   fully	   normalized	   after	   balloon	  
valvuloplasty.	   Neither	   left	   ventricular	   ejection	   fraction,	   nor	   fractional	   shortening	  
prior	   to	   intervention,	  was	  predictive	  of	   systolic	  deformation	   indices	  at	   three	  years	  
follow-­‐up.	  In	  contrast,	  peak	  transvalvular	  velocity	  across	  the	  stenotic	  valve	  prior	  to	  
balloon	   valvuloplasty	   as	   well	   as	   the	   extent	   to	   which	   the	   pressure	   gradient	   was	  
reduced	   after	   intervention	   were	   significantly	   related	   to	   peak	   systolic	   strain	  
parameters	  at	  three	  years	  follow-­‐up.	  	  
	  
5.6 STUDY LIMITATIONS 
	  
Post-­‐interventional	   echocardiographic	   examinations	   revealed	   significantly	   more	  
frequent	   aortic	   regurgitation	   which	   is	   a	   well	   recognized	   complication	   following	  
aortic	   valvuloplasty.	   Theoretically	   the	   higher	   incidence	   of	   aortic	   regurgitation	   can	  
also	   account	   for	   incomplete	   recovery	   of	   myocardial	   performance	   as	   assessed	   by	  
2DSTE.	   However,	   with	   multiple	   regression	   analysis	   such	   a	   relation	   was	   not	  
identified,	  perhaps	  due	   to	   the	   limited	  number	  of	  patients.	   It	   is	   uncertain	  whether	  
the	   persistent	   abnormalities	   in	   myocardial	   systolic	   deformation	   at	   late	   follow-­‐up	  
168	  |	  Chapter	  5	  
after	  balloon	  valvuloplasty	  are	  the	  result	  of	   irreversible	  myocardial	  alterations	  due	  
to	   longstanding	   pressure	   overload	   or	   merely	   part	   of	   the	   congenital	   heart	   defect	  
where	   developmental	   abnormalities	   result	   in	   alterations	   in	   functional	   capacity.	  
Whether	  earlier	   timing	  of	   intervention	  might	   influence	  the	  recovery	   is	  beyond	  the	  
scope	   of	   our	   study.	   The	   clinical	   and	   prognostic	   implications	   of	   the	   identified	  
persistent	  abnormalities	   in	  myocardial	  deformation	  described	   in	   this	   study	   remain	  
to	  be	  elucidated.	  Longer	  follow-­‐up	  studies	  will	  hopefully	  provide	  an	  answer	  to	  these	  
questions.	  The	  relation	  between	  decreased	  myocardial	  strain	  (rate)	  parameters	  and	  
myocardial	   fibrosis	   could	   not	   be	   sustained	   by	   myocardial	   biopsies	   due	   to	   ethical	  
reasons.	   Furthermore,	   at	   the	   time	   of	   the	   present	   study,	   tagged	   MRI	   in	   young	  
children	  was	   not	   available	   for	   research	  purposes.	  However,	   previous	   studies	   have	  
clearly	   indicated	   the	   relation	   between	   persistent	   abnormal	   deformation	   and	  
replacement	   fibrosis.11,37	  Although	  myocardial	   replacement	   fibrosis	  due	   to	   chronic	  
pressure-­‐overload	   affects	   systolic	   as	   well	   as	   diastolic	   ventricular	   function,	   we	   did	  
not	  investigate	  left	  ventricular	  diastolic	  function	  by	  means	  of	  2DSTE.	  At	  present,	  the	  
optimal	  frame	  rate	  for	  speckle	  tracking	  appears	  to	  be	  60-­‐90	  FPS.	  As	  a	  consequence,	  
two-­‐dimensional	   strain	   echocardiography	   is	   less	   suitable	   for	   the	  measurement	   of	  
shorter	  events	  such	  as	  deformation	  during	  the	  diastolic	  rapid	  filling	  phase,	  especially	  




Echocardiographic	   examination	   after	   balloon	   valvuloplasty	   for	   severe	   VAS	   in	  
children	   shows	   a	   reduction	   of	   transvalvular	   pressure	   gradients	   and	   normal	  
myocardial	  performance	  as	  assessed	  with	  conventional	  echocardiographic	  indices	  of	  
left	  ventricular	  systolic	   function.	  However,	   there	   is	  an	   incomplete	  recovery	  of	  pre-­‐
interventional,	   decreased,	   systolic	   two-­‐dimensional	   strain	   parameters.	   The	   latter	  
might	   be	   indicative	   of	   (fixed)	   myocardial	   alterations.	   The	   clinical	   and	   prognostic	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implications	   of	   persistent	   abnormal	   deformation	   in	   the	   longitudinal	   and	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Chapter 6 
Early detection of myocardial dysfunction in 
children with mitochondrial disease 
An	  ultrasound	  and	  two-­‐dimensional	  strain	  echocardiography	  study	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6.1 ABSTRACT  
	  
Background:	   Myocardial	   dysfunction	   in	   children	   diagnosed	   with	   mitochondrial	  
disease	   is	   an	   ominous	   sign	   and	   has	   been	   associated	   with	   substantial	   increased	  
mortality	   rates.	   Early	   detection	   of	   cardiac	   involvement	   would	   therefore	   be	  
desirable.	  Two	  dimensional	  strain	  echocardiography	  (2DSTE)	  has	  proven	  to	  be	  more	  
sensitive	  than	  conventional	  echocardiography	  for	  the	  detection	  of	  early	  myocardial	  
dysfunction	  in	  various	  conditions.	  	  
	  
Aim:	   To	  determine	   left	   ventricular	   systolic	   function	   in	   children	  with	  mitochondrial	  
disorders	   by	   means	   of	   physical	   examination,	   electrocardiography	   (ECG),	  
conventional	  echocardiography	  and	  2DSTE.	  	  
	  
Methods:	  A	  total	  of	  27	  children	  with	  established	  mitochondrial	  disease	  and	  54	  age-­‐
matched	   control	   subjects	   underwent	   cardiac	   evaluation.	   Global	   longitudinal,	  
circumferential	  and	  radial	  peak	  systolic	  strain	  (S)	  values	  were	  determined	  as	  well	  as	  
global	  peak	  systolic	  strain-­‐rate	  (Sr)	  and	  the	  global	  time	  to	  peak	  systolic	  strain	  (T2P).	  
One-­‐way	  analysis	  of	  variance	  was	  performed	  to	  assess	  the	  influence	  of	  the	  presence	  
of	  mitochondrial	  disease	  on	  conventional	  echocardiographic	  and	  2DSTE	  outcomes.	  	  
	  
Results:	   Conventional	   echocardiographic	   findings	   did	   not	   indicate	   systolic	   left	  
ventricular	   dysfunction.	   Global	   peak	   S,	   Sr	   and	   T2P	   measurements	   in	   all	   three	  
directions	  were	  significantly	  lower	  in	  children	  with	  mitochondrial	  disease	  (P<0.001)	  
when	  compared	  to	  controls.	  	  
	  
Conclusion:	   2DSTE	   detects	   alterations	   in	   myocardial	   systolic	   function	   in	   children	  
diagnosed	   with	   mitochondrial	   disease,	   whose	   conventional	   echocardiographic	  
findings	  did	  not	  indicate	  ventricular	  systolic	  dysfunction.	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6.2 BACKGROUND 
	  
Mitochondrial	   oxidative	   phosphorylation	   (OXPHOS)	   defects	   are	   the	  most	   common	  
inborn	  errors	  of	  metabolism,	  with	   a	  prevalence	  of	   1	   :	   5000.1	   The	  OXPHOS	   system	  
consists	  of	  five	  enzyme	  complexes	  and	  uses	  the	  trans-­‐membrane	  proton	  gradient	  to	  
produce	   adenosine	   triphosphate	   (ATP).2	   Mutations	   in	   either	   nuclear	   or	  
mitochondrial	  genes	  encoding	  structural	  or	  facilitating	  mitochondrial	  proteins	  cause	  
a	   suboptimal	   production	   of	   ATP,	   affecting	   mostly	   organs	   with	   a	   high	   energy	  
demand.2	  	  	  
The	   clinical	   presentation	   of	  mitochondrial	   disorders	   is	   extremely	   variable,	   ranging	  
from	   isolated	  myopathies	   to	   complex	  multisystem	  syndromes.3	  The	  heart,	  being	  a	  
highly	   energy-­‐dependent	   tissue,	   is	   frequently	   affected	   by	   mitochondrial	  
dysfunction.	   The	   identification	   of	   cardiac	   involvement	   in	   (children	   suspected	   of)	  
mitochondrial	   disorders	   is	   important,	   since	  mitochondrial	   cardiomyopathies	   (MIC)	  
are	  a	  diagnostic	  criterion	  in	  several	  mitochondrial	  syndromes.4	  The	  need	  for	  timely	  
identification	  of	  MIC	  is	  further	  illustrated	  by	  its	  adverse	  clinical	  course	  attributed	  to	  
progressive	   biventricular	   dysfunction	   which	   is	   associated	   with	   a	   substantial	  
increased	   mortality	   rate.5,6	   MIC	   is	   usually	   identified	   by	   means	   of	   conventional	  
echocardiographic	  examination.	  With	  use	  of	  this	  modality,	  MIC	   is	  diagnosed	   in	  20-­‐
25%	   of	   children	   with	   mitochondrial	   disease.5,7	   Unfortunately,	   these	   conventional	  
echocardiographic	  techniques	  provide	  no	   information	  about	  regional	  alterations	   in	  
ventricular	  myocardial	   contraction	   and	   have	   proven	   to	   be	   relatively	   insensitive	   to	  
impaired	   myocardial	   performance	   in	   various	   (primary	   or	   secondary)	   cardiac	  
conditions.8	  Occult	  LV	  dysfunction	  in	  children	  with	  mitochondrial	  disease	  could	  have	  
important	  implications	  for	  morbidity	  and	  mortality.	  Therefore,	  it	  would	  be	  clinically	  
valuable	  to	  detect	  such	  subclinical	  dysfunction.	  	  
	  
Two-­‐dimensional	  strain	  echocardiography	  (2DSTE)	  has	  emerged	  as	  a	  relatively	  new	  
index	   of	   regional	   and	   global	   myocardial	   function.	   This	   ultrasound-­‐based	  modality	  
investigates	  regional	  as	  well	  as	  global	  myocardial	  deformation	  (e.g.,	  stretching	  and	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shortening	  versus	  thickening	  and	  thinning	  of	  the	  myocardial	  wall).	  The	  spectrum	  of	  
potential	   clinical	   applications	   is	   very	   broad.	   Due	   to	   its	   ability	   to	   differentiate	  
between	   active	   and	   passive	   deformation	   of	   myocardial	   segments,	   to	   quantify	  
intraventricular	  dyssynchrony	  and	  to	  evaluate	  individual	  components	  of	  myocardial	  
function	   such	   as	   longitudinal	   myocardial	   shortening,	   2DSTE	   is	   able	   to	   detect	  
myocardial	  dysfunction	  at	  an	  early	  stage.9,10,11	  Previous	  studies	  have	  indicated	  that	  
2DSTE	   is	   more	   sensitive	   than	   conventional	   echocardiography	   for	   detecting	   early	  
myocardial	   dysfunction	   in	   a	   wide	   variety	   of	   clinical	   disorders.12,13,14	   However,	   the	  
value	  and	  applicability	  of	  2DSTE	  in	  the	  evaluation	  of	  ventricular	  systolic	  myocardial	  
function	  in	  children	  with	  mitochondrial	  disease	  have	  not	  been	  elucidated.	  	  
	  
We	   hypothesized	   that	   abnormal	   regional	   myocardial	   systolic	   function	   in	   children	  
with	  mitochondrial	  disease	  can	  be	  detected,	  even	  before	  the	  overt	  manifestation	  of	  
cardiomyopathy	  and	  heart	  failure.	  The	  aim	  of	  this	  study	  is	  to	  introduce	  2DSTE	  as	  a	  
useful	   technique	   for	   the	   early	   detection	   of	   such	   subtle	   alterations	   in	   myocardial	  
function.	  	  
	  
6.3 MATERIAL and METHODS 
6.3.1 STUDY POPULATION 
	  
Between	  December	   2008	   and	  December	   2009	  we	   prospectively	   included	   children	  
who	  were	  previously	  diagnosed	  with	  mitochondrial	  disease,	  visiting	  the	  outpatient	  
clinic	   of	   the	   Institute	   for	   Metabolic,	   Genetic	   and	   Endocrine	   Disorders	   of	   the	  
Radboud	   University	   Nijmegen	   Medical	   Centre,	   The	   Netherlands.	   Mitochondrial	  
disease	   had	  been	   established	   according	   to	   the	   following	   protocol.	   Patients	  with	   a	  
clinically	  and	  metabolically	  suspected	  oxidative	  phosphorylation	  disorder	  were	  first	  
evaluated	   based	   on	   the	   Mitochondrial	   Disease	   Criteria	   (MDC).15	   The	   biochemical	  
and	   genetic	   characteristics	   were	   consecutively	   obtained	   by	   using	   standard	  
diagnostic	  protocols.16	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The	  MDC	   score	   is	   a	   screening	   instrument	   for	   mitochondrial	   disease,	   which	   has	   a	  
high	   specificity	   in	   distinguishing	   between	   mitochondrial	   and	   other	   multisystem	  
disorders	   in	   children.17	   Following	   the	   first	   outpatient	   visit,	   all	   children	   undergo	   a	  
standard	   diagnostic	   protocol	   of	   multiple	   investigations	   including	   anthropometric	  
measurements,	   electrocardiogram,	   chest	   X-­‐ray,	   electroencephalogram,	   brain	  
auditory	  evoked	  potential,	  visual	  evoked	  potential,	  sensory	  evoked	  potentials	  and	  a	  
cranial	   magnetic	   resonance	   imaging	   prior	   to	   the	   muscle	   biopsy.	   Serial	   lactic	   acid	  
measurements,	  pyruvic	  acid	  levels,	  blood	  gas,	  serum	  acyl-­‐carnitine,	  amino	  acid	  and	  
urine	  organic	  acid	  profiles	  are	  analysed	  in	  all	  children.	  The	  MDC	  score	  is	  calculated	  
based	   on	   clinical	   symptoms,	   metabolic	   alterations	   and	   abnormal	   neuro-­‐imaging	  
features.	   A	   score	   of	   2-­‐4	   suggest	   a	   “possible	   mitochondrial	   disorder”,	   5-­‐7	   are	  
comparable	  with	   a	   “probable	  mitochondrial	   disorder”	   and	   score	   8-­‐12	   confirm	   the	  
diagnosis	  “definite	  mitochondrial	  disorder”.	  
	  
According	  to	  the	  standard	  clinical	  practice	  patients	  with	  an	  MDC	  score	  above	  4	  are	  
admitted	  for	  surgical	  muscle	  and	  skin	  biopsy	  under	  generalized	  anesthesia.	  Parallel	  
with	   routine	   immune-­‐histological	   and	   electron-­‐microscopic	   analysis,	   oxidation	  
ratios,	   ATP-­‐production	   from	   pyruvate	   oxidation	   and	   the	   activity	   of	   pyruvate	  
dehydrogenase	   complex	   (PDHc)	   and	   the	   respiratory	   enzyme	   complexes	   I-­‐V	   are	  
measured	  in	  the	  fresh	  muscle	  sample.	  ATP-­‐production	  from	  pyruvate	  oxidation	  and	  
the	   activity	   of	   the	   respiratory	   enzyme	   complexes	   I-­‐V	   are	   also	   determined	   in	  
fibroblasts	  according	  to	  the	  methods	  described	  previously.16	  Based	  on	  the	  complex	  
deficiencies,	   histological	   findings	   and	   the	   clinical	   features	   appropriate	   genetic	  
studies	  are	  initiated.4	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The	   diagnosis	   mitochondrial	   disease	   was	   confirmed	   when	   one	   of	   the	   following	  
criteria	  was	  met:	  	  
	  
1. A	  mitochondrial	  disease	  score	  of	  (more	  than)	  eight.	  
2. An	  identified	  deficiency	  of	  at	  least	  one	  of	  the	  respiratory	  chain	  enzyme	  
complexes:16	  
• OXPHOS	  complex	  deficiency	  in	  muscle	  biopsy	  and/or	  in	  fibroblast	  
culture.	  
• Enzyme	  histochemical	  evidence	  of	  OXPHOS	  complex	  deficiency	  in	  
muscle.	  
3. A	  significantly	  decreased	  ATP	  synthesis	  rate	  from	  pyruvate	  oxidation	  in	  
fresh	  muscle	  biopsy	  specimen	  (≤	  20	  nmol/h/mU	  CS;	  normal	  reference	  
values:	  42-­‐81	  nmol/h/mU	  CS).16	  	  
4. The	  presence	  of	  a	  known	  pathogenic	  mutation	  of	  mitochondrial	  DNA	  or	  
nuclear	  DNA,	  together	  with	  compatible	  clinical	  symptoms.	  	  
	  
Exclusion	  criteria	   consisted	  of:	   (1)	   congenital	  heart	  disease	   (2)	   valvular	   stenosis	  or	  
regurgitation	   (3)	   acute	   illness	   at	   the	   time	   of	   echocardiographic	   evaluation.	  
Demographic	   and	   anthropometric	   characteristics,	   including	   age	   and	   gender	   were	  
collected	  at	  the	  same	  time	  the	  echocardiographic	  study	  was	  performed.	  A	  complete	  
history,	  physical	  examination,	  ECG	  as	  well	   as	  echocardiographic	  examination	  were	  
performed	  as	  part	  of	  hospital	  policy.	  	  
6.3.2 CONTROL GROUP 
	  
Subjects	   who	   were	   routinely	   referred	   for	   echocardiographic	   evaluation	   of	   an	  
asymptomatic,	   innocent	  heart	  murmur	  or	   for	   screening	  purposes	  between	  May	  1,	  
2005	  and	  November	  1,	   2009,	  were	   retrospectively	   analysed	   for	   their	   eligibility	   for	  
inclusion	   in	   the	   study	   to	   serve	   as	   a	   control	   group.	   Subjects	   with	   structural	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(congenital)	   heart	   disease,	   abnormal	   cardiac	   rhythms	   and/or	   (a	   past	   history	   of)	  
chronic	  or	  acute	  illness	  were	  excluded.	  
6.3.3 CONVENTIONAL ECHOCARDIOGRAPHIC PARAMETERS  
	  
All	   subjects	   underwent	   a	   detailed	   transthoracic	   echocardiographic	   examination	   in	  
the	  left	  lateral	  position	  according	  to	  the	  recommendations	  of	  the	  American	  Society	  
of	   Echocardiography	   and	   a	   local	   research	   protocol	   previously	   described	   by	  
Mavinkurve-­‐Groothuis	  et	  al.18,19	  Every	  examination	  was	  performed	  at	  rest,	  without	  
using	   sedation.	   Images	   were	   obtained	   with	   a	   3.0-­‐MHz	   (S3)	   or	   a	   5.0-­‐MHz	   (S5)	  
transducer	   using	   a	   commercially	   available	   system,	   the	   Vivid	   7	   echocardiographic	  
scanner	   (GE,	   Vingmed	   Ultrasound	   AS,	   Horten,	   Norway).	   Quantification	   of	   cardiac	  
chamber	  size,	  ventricular	  mass	  and	  systolic	  left	  ventricular	  function	  were	  measured	  
in	   accordance	   with	   the	   recommendations	   for	   chamber	   quantification	   by	   the	  
American	   Society	   of	   Echocardiography.18	   Left	   ventricular	   systolic	   function	   was	  
characterized	  using	  fractional	  shortening	  (FS),	  ejection	  fraction	  (EF),	  left	  ventricular	  
myocardial	   performance	   index,	   or	   Tei	   index,	   end-­‐systolic	   wall	   stress	   (ESWS)	   and	  
rate-­‐corrected	  velocity	  of	   circumferential	   fiber	   shortening	   (VCFc).	   Ejection	   fraction	  
was	   calculated	   using	   the	   modified	   Simpson’s	   rule.	   The	   PW-­‐Doppler-­‐derived	  
myocardial	   performance	   index	   (Tei	   index)	  was	   calculated	   as:	   Tei	   =	   (iso-­‐volumetric	  
contraction	  time	  +	  iso-­‐volumetric	  relaxation	  time)	  /	  ejection	  time.20	  Left	  ventricular	  
end-­‐systolic	  wall	  stress	  was	  calculated	  using	  the	  modified	  formula	  of	  Rowland	  and	  
Gutgesell.21	   VCFc	   was	   calculated	   using	   the	   formula	   obtained	   from	   Colan	   and	  
colleagues.22	   Left	   ventricular	   mass	   (LVM)	   was	   calculated	   using	   the	   formula	   for	  
estimation	   of	   LVM	   according	   to	   Devereux	   and	   Reichek	   and	   was	   subsequently	  
indexed	  to	  body	  surface	  area	  (BSA).23	  
6.3.4 2DSTE DATA ACQUISITION 
	  
Two-­‐dimensional	  multiframe	  B-­‐mode	  (grayscale)	  images	  were	  obtained	  in	  the	  apical	  
four-­‐chamber	   (4C),	   and	   parasternal	   midcavity	   short-­‐axis	   view	   (at	   the	   level	   of	   the	  
182	  |	  Chapter	  6	  
papillary	   muscle:	   PM)	   and	   basal	   short-­‐axis	   view	   (at	   the	   level	   of	   the	   mitral	   valve:	  
MV).	  A	  sector	  scan	  angle	  of	  30	  to	  60	  degrees	  was	  chosen	  and	  frame	  rates	  of	  60	  to	  
90	  Hz	  were	  used.	  Preferably	  images	  from	  five	  cardiac	  cycles	  triggered	  by	  the	  R	  wave	  
of	   the	  QRS	  complex	  were	  digitally	   saved	   in	  cineloop	   format.	  Offline	  strain	  analysis	  
was	  performed	  using	  software	  for	  echocardiographic	  quantification	  (EchoPAC	  6.1.0;	  
GE	  Vingmed	  Ultrasound	  AS,	  Horten,	  Norway).	  The	  timing	  of	  aortic	  valve	  closure	  and	  
mitral	   valve	   opening	   with	   respect	   to	   peak	   strain	   and	   peak	   systolic	   strain	   were	  
manually	   obtained,	   using	   single	   gated	   pulsed-­‐wave	   (PW-­‐)Doppler	   or	   continuous-­‐
wave	   (CW-­‐)Doppler	   images	   of	   the	   left	   ventricular	   outflow	   tract.	   For	   these	  
measurements,	  special	  care	  was	  taken	  to	  keep	  the	  heart	  rate	  in	  the	  same	  range	  as	  
during	   the	   2D	   grayscale	   imaging	   used	   for	   2D	   strain	   calculations.	   Endomyocardial	  
borders	  of	  the	  left	  ventricle	  were	  manually	  traced	  within	  the	  end-­‐systolic	  frame.	  The	  
second,	   epicardial	   tracing	   was	   generated	   by	   the	   computer	   algorithm	   and,	   when	  
necessary,	   manually	   adjusted	   to	   cover	   the	   whole	   myocardial	   wall.	   The	   tracking	  
algorithm	   then	   followed	   the	   endocardial	   and	   myocardial	   speckles	   through	   the	  
cardiac	   cycle.	   Tracking	   was	   accepted	   only	   if	   both	   visual	   inspection	   as	   well	   as	  
EchoPAC	  software	  indicated	  adequate	  tracking.	  The	  software	  automatically	  divided	  
the	   cross-­‐sectional	   image	   into	   six	   segments,	   which	   were	   named	   and	   identified	  
according	   to	   the	   statement	   of	   the	   Cardiac	   Imaging	   Committee	   of	   the	   Council	   on	  
Clinical	   Cardiology	   of	   the	   American	   Heart	   Association.24	   The	   left	   ventricular	  
segments	  to	  be	  analysed	  were	  the	  apical,	  middle	  and	  basal	  segments	  of	  the	  septal	  
and	   the	   lateral	   wall	   of	   the	   4C	   view,	   as	  well	   as	   the	   anteroseptal,	   anterior,	   lateral,	  
posterior,	  inferior	  and	  septal	  segments	  of	  the	  basal	  (MV)	  and	  midcavity	  (PM)	  short-­‐
axis	   views.	   Strain	   curves	  of	   the	   three	   consecutive	   cardiac	   cycles	  and	  values	  of	   the	  
manual	   timing	   were	   imported	   into	   a	   custom-­‐made	   software	   package	   for	   further	  
analysis.	   The	   Q-­‐Q	   interval	   was	   determined	   from	   the	   electrocardiogram	   signal	   to	  
obtain	  cardiac	  cycle	  length.	  It	  is	  known	  that	  the	  duration	  of	  the	  systolic	  phase	  of	  the	  
cardiac	  cycle	  in	  rest	  does	  not	  change	  with	  small	  changes	  in	  heart	  rate,	  in	  contrast	  to	  
the	  diastolic	  phase.25	  Therefore,	  the	  diastolic	  phase	  of	  the	  three	  cardiac	  cycles	  was	  
automatically	  extended	  and	  adjusted	  by	  the	  software	  package	  to	  the	  longest	  of	  the	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three	   cardiac	   cycles.	   This	   intervention	   prevents	   a	   shift	   of	   the	   peak	   systolic	   strain	  
with	  averaging	  of	   the	  three	  consecutive	  cardiac	  cycles.	  Cardiac	  cycles	  with	   lengths	  
more	   than	   ten	  percent	  different	   from	  the	  mean	   length	  of	   the	   three	  cardiac	  cycles	  
were	   excluded	   from	   averaging	   and	   thus	   for	   further	   analysis.	   Myocardial	  
longitudinal,	  radial	  and	  circumferential	  strain	  values	  were	  obtained,	  as	  well	  as	  peak	  
systolic	   strain-­‐rate	  and	   the	   time	   to	   reach	  peak	  systolic	   strain.	  To	  determine	  global	  
strain	  (-­‐rate),	  the	  strain	  (-­‐rate)	  values	  of	  the	  six	  segments	  were	  averaged	  for	  the	  4C	  
as	  well	  as	  the	  short-­‐axis	  views.	  All	  2D	  strain	  analyses	  were	  performed	  by	  the	  same	  
investigator	   (K.A.M.)	   to	   avoid	   interobserver	   variability.	   Intraobserver	   (and	  
interobserver)	   variability	   scores	   have	   been	   described	   by	   our	   research	   group	  
previously.19	   Strain	   values	   are	   dimensionless	   and	   are	   expressed	   as	   percentages.	  
Strain-­‐rate	   is	   the	   time	   derivative	   of	   strain	   and	   is	   expressed	   as	   s-­‐1.	   Time	   to	   peak	  
systolic	   strain	   is	   expressed	   as	   milliseconds.	   Negative	   strain	   values	   reflect	  
shortening/thinning,	  while	  positive	  strain	  values	  reflect	  lengthening/thickening.	  	  	  
6.3.5 STATISTICAL ANALYSIS 
	  
All	   normally	   distributed	   demographic,	   anthropometric,	   conventional	  
echocardiographic	   and	   2DSTE	   values	   are	   expressed	   as	  mean	   ±	   standard	   deviation	  
(SD),	   non-­‐normally	   distributed	   data	   as	   median	   and	   range.	   Demographic	   and	  
anthropometric	   characteristics	  of	   the	  patient	   group	  were	   compared	  with	   those	  of	  
the	   control	   group	   using	   one-­‐way	   analysis	   of	   variance	   or	   Kruskal-­‐Wallis	  
nonparametric	  test	  when	  outcomes	  were	  not	  normally	  distributed.	  All	  demographic	  
and	   anthropometric	   parameters	   were	   all	   normally	   distributed	   except	   for	   age.	  
Conventional	   echocardiographic	   as	   well	   as	   2DSTE	   measurements	   established	   in	  
children	  with	  mitochondrial	  disease	  were	  compared	  with	  respective	  measurements	  
acquired	   from	   healthy	   age-­‐matched	   control	   subjects.	   The	   relation	   between	   the	  
presence	   or	   absence	   of	   mitochondrial	   disease	   and	   individual	   conventional	  
echocardiographic	   findings,	   as	   well	   as	   each	   global	   2DSTE	   parameter	   (global	   peak	  
systolic	  strain,	  global	  peak	  systolic	  strain-­‐rate,	  time	  to	  global	  peak	  systolic	  strain	   in	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longitudinal,	   circumferential	   and	   radial	   direction)	   was	   investigated	   using	   one-­‐way	  
analysis	   of	   variance	   (ANOVA)	   and	   linear	   regression	   analysis.	   The	   relation	  between	  
the	   type	   of	   mitochondrial	   dysfunction	   (i.e.,	   different	   types	   of	   respiratory	   chain	  
enzyme	  complex	  deficiencies),	  as	  well	  as	  the	  presence	  of	  multiple	  enzyme	  complex	  
deficiencies	   in	   the	   same	  patient	  and	  each	  2DSTE	  parameter	  was	  assessed	  by	  one-­‐
way	   analysis	   of	   variance	   with	   Bonferroni	   correction	   for	   multiple	   comparisons.	  	  
P-­‐values	   less	   than	   0.05	   were	   considered	   to	   indicate	   significance.	   All	   statistical	  
analyses	   were	   performed	   using	   the	   Statistical	   Package	   for	   Social	   Sciences	   for	  
Windows,	  version	  16.0	  (SPSS	  Inc,	  Chicago,	  IL).	  	  
	  
6.4 RESULTS 
6.4.1 STUDY POPULATION 
	  
In	  total	  100	  children	  referred	  to	  the	  outpatient	  clinic	  of	  the	  Institute	  for	  Metabolic,	  
Genetic	   and	   Endocrine	   Disorders	   of	   the	   Radboud	   University	   Nijmegen	   Medical	  
Centre,	  The	  Netherlands,	  for	  investigation	  of	  mitochondrial	  disease	  were	  evaluated	  
for	   possible	   inclusion	   in	   the	   study.	   Of	   those	   children	   73	   were	   subsequently	  
excluded:	   in	   63	   cases	   mitochondrial	   disease	   was	   not	   confirmed	   by	   subsequent	  
investigations	   (MDC	   score	  was	  not	  diagnostic,	   or	   a	  mitochondrial	   dysfunction	  was	  
detected,	  without	  a	  severely	  decreased	  ATP	  production;	  see	  diagnostic	  criteria),	  10	  
children	  were	  diagnosed	  with	  a	  congenital	  heart	  defect	  or	  valvular	  disease.	  Finally,	  
27	   pediatric	   patients	   aged	   0	   to	   15	   years	   with	   established	   respiratory	   chain	  
dysfunction	  were	   eligible	   for	   inclusion	   in	   the	   study.	   Since	   this	   is	   a	   cross	   sectional	  
study,	  patients	  were	  evaluated	  at	  various	   times	  after	  disease	  onset	  and	  diagnosis.	  
The	  median	   time	   after	   diagnoses	   was	   3.0	   years	   (range	   0.0	   –	   13.7	   years).	   Clinical	  
phenotype	  and	  diagnostic	  findings	  are	  described	  in	  Table	  25.	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Table 25 - Clinical phenotype and diagnostic findings of 27 children with established 
mitochondrial dysfunction 
Clinical	  phenotype	   Myopathy	   Encephalomyopathy	   Encephalopathy	  
n	  (%)	   5	  (18)	   21	  (78)	   1	  (4)	  
MDC	  score	  ≥	  8	   2	   11	   1	  
Decreased	  ATP	  synthesis	   3	   9	   1	  
Pyruvate	  oxidation	  deficiency	   4	   9	   1	  
Complex	  I	  deficiency	   3	   13	   1	  
Complex	  II	  deficiency	   1	   4	   -­‐	  
Complex	  III	  deficiency	   2	   7	   1	  
Complex	  IV	  deficiency	   -­‐	   5	   -­‐	  
Multiple	  complex	  deficiencies	   2	   8	   1	  
Mt/nucl.	  DNA	  alterations	   1	   6	   -­‐	  
	  
MDC score: mitochondrial disease criteria score; Mt/nucl. DNA mutation: mutation in 
mitochondrial or nuclear DNA 
6.4.2 GENETIC RESULTS 
	  
Genetic	   analysis	   revealed	   alterations	   in	   the	   mitochondrial	   DNA	   in	   5	   patients.	   An	  
unreported	  homoplasmic	   alteration	  was	   found	   in	   three	   siblings	   and	   their	   affected	  
mother	   in	   the	   12S	   ribosomal	   RNA	   gene	   (m.1008A>T)	   in	   combination	   with	   a	  
polymorphism	   (m.14574C>T)	   in	   the	   gene	   encoding	   the	   NADH	   dehydrogenase	   6	  
subunit	   (part	   of	   complex	   I).	   The	   pathogenicity	   of	   the	   alterations	   was	   not	   yet	  
confirmed.	  Mitochondrial	  DNA	  analysis	  in	  a	  fourth	  patient	  revealed	  a	  homoplasmic	  
mutation	   in	  12S	   ribosomal	  RNA	  MTRN1	   (m.01484C>T).	   In	   the	   fifth	  patient	  with	  an	  
identified	  mitochondrial	  DNA	  mutation,	  genetic	  analysis	  revealed	  a	  point	  mutation	  
in	  the	  ATPase	  6	  gene	  (MTATP6;	  m.	  8993T>G)	  causing	  Leigh	  syndrome.	  Nuclear	  DNA	  
mutations,	   resulting	   in	   mitochondrial	   dysfunction,	   were	   identified	   in	   two	   other	  
patients.	   The	   first	   was	   an	   X-­‐linked	   mutation	   in	   exon	   10	   of	   the	   pyruvate	  
dehydrogenase	  complex	  (PDHc)	  E1	  α-­‐gene	  (PDHA1;	  924G>T).	  The	  second	  patient	  in	  
whom	   nuclear	   DNA	  mutations	   were	   identified,	   was	   finally	   diagnosed	  with	   a	   non-­‐
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mitochondrial	   mutation	   underlying	   the	   phenotypical	   and	   biochemical	   features	   of	  
severe	   mitochondrial	   dysfunction	   due	   to	   compound	   heterozygous	   PLA2G6	   gene	  
mutations	   in	   exon	   11	   (c1445G>A)	   and	   exon	   16	   (c2222G>A),	   resulting	   in	   a	  
progressive	   neurodegenerative	   disorder:	   the	   infantile	   form	   of	   dystonia	  
parkinsonism	  (MIM	  25660).	  	  
6.4.3 CONTROL GROUP 
	  
A	   group	   of	   54	   healthy	   age-­‐	   and	   gender-­‐matched	   children	   was	   included	   and	  
examined	   to	   provide	   us	   with	   normal	   reference	   values	   for	   conventional	  
echocardiographic	  and	  2DSTE	  parameters.	  	  
6.4.4 HISTORY AND PHYSICAL EXAMINATION  
	  
History	   and	   physical	   examination	   of	   both	   patients	   diagnosed	   with	   mitochondrial	  
disease	   and	   control	   subjects	   were	   not	   indicative	   of	   cardiovascular	   disease.	   None	  
used	  medications	  for	  cardiac	  disease.	  Demographic	  and	  anthropometric	  findings	  in	  
children	  with	  mitochondrial	  dysfunction	  were	  comparable	  to	  those	  found	  in	  control	  
subjects	   using	   one-­‐way	   analysis	   of	   variance.	   Patient	   demographic	   characteristics	  
and	  anthropometric	  parameters	  are	  described	  in	  Table	  26,	  together	  with	  the	  data	  of	  
the	  control	  group.	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Table 26 - Demographic and anthropometric characteristics (mean ± standard deviation 





(n	  =	  27)	  
Control	  subjects	  
(n	  =	  54)	  
P	  value	  
Male	  	   19	  (70%)	   38	  (70%)	   1.00	  
Age	  (y)	   4.8	  (0.8	  –	  15.3)	   4.8	  (0.7	  –	  15.4)	   1.00	  
Height	  (cm)	   107	  ±	  19	   112	  ±	  26	   0.38	  
Weight	  (kg)	   18.6	  ±	  8	   22.0	  ±	  7	   0.22	  
BSA	  (m2)	   0.74	  ±	  0.22	   0.82	  ±	  0.33	   0.26	  
BMI	  (kg/m2)	   15.5	  ±	  1.9	   16.2	  ±	  1.8	   0.14	  
HR	  (bpm)	   103	  ±	  20	   97	  ±	  21	   0.10	  
MAP	  (mmHg)	   68	  ±	  6	   67	  ±	  7	   1.00	  
Syst.BP	  (mmHg)	   95	  ±	  8	   94	  ±	  8	   1.00	  
Diast.BP	  (mmHg)	   55	  ±	  5	   53	  ±	  5	   1.00	  
	  
BMI: body mass index; BSA: body surface area; Diast.BP: diastolic blood pressure; HR: heart 
rate; MAP: mean arterial blood pressure; Syst.BP: systolic blood pressure; characteristics of 
the patient group were compared with those of the control group using one-way analysis of 
variance or Kruskal-Wallis nonparametric test when outcomes were not normally distributed. 
	  
6.4.5 ECG FINDINGS 
	  
Electrocardiographic	  examination	  did	  not	  reveal	  abnormalities.	  There	  were	  no	  signs	  
of	  ischemia	  or	  conduction	  disturbances.	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6.4.6 CONVENTIONAL ECHOCARDIOGRAPHIC PARAMETERS 
	  
Conventional	  systolic	  echocardiographic	  indices	  were	  normal	  in	  all	  children.	  In	  none	  
of	   the	   children	   diagnosed	   with	   mitochondrial	   disease,	   echocardiographic	   findings	  
indicated	   left	   ventricular	   hypertrophy	   and/or	   dilation.26	   One-­‐way	   analysis	   of	  
variance	   did	   not	   indicate	   statistically	   significant	   differences	   in	   standard	  
echocardiographic	   indices	   between	  patients	   and	  healthy	   controls.	  However,	   there	  
was	  a	  trend	  towards	  lower	  left	  ventricular	  mass	  (corrected	  for	  body	  surface	  area	  as	  
well	  as	  indexed	  to	  height)	  in	  children	  with	  mitochondrial	  disorders	  (P	  0.06	  and	  0.08	  
resp.).	  Conventional	  echocardiographic	  findings	  are	  described	  in	  Table	  27.	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Table 27 – Conventional echocardiographic findings (mean ± standard deviation) of 





(n	  =	  27)	  
Control	  
subjects	  
(n	  =	  54)	  
P	  value	  
LVPWd	  (mm)	   4.7	  ±	  1.2	   5.0	  ±	  1.4	   0.35	  
IVSd	  (mm)	   4.3	  ±	  0.7	   4.5	  ±	  1.2	   0.53	  
LVIDd	  (mm)	   34	  ±	  5	   36	  ±	  6	   0.22	  
Mitral	  A	  velocity	   0.55	  ±	  0.17	   0.56	  ±	  0.11	   0.98	  
Mitral	  E	  velocity	   1.08	  ±	  0.13	   1.07	  ±	  0.15	   0.98	  
Mitral	  EA	  Ratio	   1.96	  ±	  0.36	   1.97	  ±	  0.41	   0.97	  
LVETc	  (s)	   0.32	  ±	  0.02	   0.31	  ±	  0.02	   1.00	  
VCFc	  (circ/s)	   1.27	  ±	  0.13	   1.27	  ±	  0.20	   1.00	  
Tei	  index	   0.38	  ±	  0.05	   0.37	  ±	  0.02	   0.55	  
FS	   0.38	  ±	  0.03	   0.38	  ±	  0.05	   0.97	  
LVEF	  biplane	   0.69	  ±	  0.04	   0.70	  ±	  0.07	   0.59	  
ESWS	  (g/cm2)	   41.6	  ±	  13	   43.8	  ±	  12	   0.45	  
LVM/BSA	  (g/m2)	   45.7	  ±	  11	   51.7	  ±	  13	   0.06	  
LVM/height2.7	  (g/m2.7)	   27.7	  ±	  7	   31.3	  ±	  8	   0.08	  
	  
LVPWd: diastolic left ventricular posterior wall thickness; IVSd: diastolic interventricular septal 
thickness; LVIDd: diastolic left ventricular diameter; LVETc: left ventricular ejection time 
corrected for heart rate; VCFc: heart-rate corrected velocity of circumferential fiber shortening; 
Tei index: left ventricular myocardial performance index; FS: fractional shortening; LVEF 
biplane: left ventricular ejection fraction measured by modified Simpson’s method; ESWS: 
end-systolic wall stress; LV mass/BSA: left ventricular mass corrected for body surface area; 
echocardiographic parameters of the patient group were compared with those of the control 
group using one-way analysis of variance. 
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6.4.7 MYOCARDIAL STRAIN PARAMETERS 
	  
Tracking	  was	   feasible	   in	  98%	  of	  all	   segments	  of	   the	  4	  chamber	  view,	   in	  98%	  of	  all	  
segments	  in	  the	  short-­‐axis	  view	  at	  the	  level	  of	  the	  papillary	  muscle	  and	  in	  94%	  of	  all	  
segments	  in	  the	  short-­‐axis	  view	  at	  the	  level	  of	  the	  mitral	  valve.	  	  
	  
The	   most	   important	   observations	   were	   statistically	   significant	   	   (P	   <	   0.001)	  
differences	  of	  global	  peak	  systolic	  strain	  values	  and	  global	  peak	  systolic	  strain-­‐rate	  
measurements	  in	  all	  three	  directions	  between	  patients	  with	  mitochondrial	  disorders	  
and	  healthy	  control	  subjects	  as	  determined	  by	  one-­‐way	  analysis	  of	  variance.	  Linear	  
regression	   analysis	   revealed	   that	   the	   presence	   or	   absence	   of	   mitochondrial	  
dysfunction	  explained	  21	  to	  62%	  of	  variation	  in	  global	  peak	  systolic	  strain	  and	  global	  
peak	  systolic	  strain-­‐rate	  values.	  Time	  to	  peak	  global	  systolic	  strain	  values	  was	  similar	  
to	  those	  found	  in	  healthy	  children.	  Evaluation	  of	  time	  to	  peak	  systolic	  strain	  values	  
in	   the	   different	   left	   ventricular	   segments	   did	   not	   indicate	   intraventricular	  
dyssynchrony.	   There	   were	   no	   statistically	   significant	   differences	   in	   2DSTE	  
parameters	  between	  the	  various	  types	  of	  respiratory	  chain	  enzyme	  deficiencies.	  The	  
presence	   of	   multiple	   complex	   deficiencies	   in	   the	   same	   patient	   did	   not	   influence	  
2DSTE	   values	   as	   assessed	   by	   one-­‐way	   analysis	   of	   variance	   with	   Bonferroni	  
correction	   for	   multiple	   comparisons.	   There	   was	   no	   relation	   between	   2DSTE	  
parameters	  and	  MDC-­‐score.	  	  
	  
In	  the	  individual	  patient	  with	  mitochondrial	  disease	  under	  investigation,	  global	  peak	  
systolic	  strain	  was	  abnormal	  (below	  5th	  percentile	  of	  normal	  according	  to	  reference	  
values	  established	  by	  our	  research	  group)	  in	  56%	  of	  patients	  for	  longitudinal	  strain,	  
69%	  of	   patients	   for	   circumferential	   strain	   at	   the	   level	   of	   the	   papillary	  muscle	   and	  
46%	  of	  patients	   for	   circumferential	   strain	  at	   the	   level	  of	   the	  mitral	   valve.27	  Global	  
peak	  systolic	  radial	  strain	  was	  abnormal	  at	  the	  level	  of	  the	  papillary	  muscle	  in	  15%	  
of	  the	  patients	  versus	  39%	  of	  patients	  at	  the	  level	  of	  the	  mitral	  valve.	  As	  for	  global	  
peak	   systolic	   strain-­‐rate,	   44%	   of	   patients	   showed	   an	   abnormal	   longitudinal	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deformation-­‐rate,	  65%	  of	  patients	  for	  circumferential	  strain	  rate	  at	  the	  level	  of	  the	  
papillary	  muscle	  and	  31%	  of	  patients	   for	  circumferential	   strain	   rate	  at	   the	   level	  of	  
the	  mitral	  valve.	  Global	  peak	  systolic	  radial	  strain-­‐rate	  was	  abnormal	  at	  the	  level	  of	  
the	  papillary	  muscle	  in	  73%	  of	  the	  patients	  versus	  58%	  of	  the	  patients	  at	  the	  level	  of	  
the	  mitral	  valve.	  Two-­‐dimensional	  strain	  echocardiography	  findings	   in	  patients	  and	  
healthy	  control	  subjects	  are	  described	  in	  Table	  28.	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Table 28 - 2DSTE-findings (mean ± standard deviation) of children with mitochondrial 
disease and healthy control subjects 
2DSTE	  parameters	   Mitochondria
l	  Disease	  
(n	  =	  27)	  
Control	  	  
subjects	  
(n	  =	  54)	  
P	  value	   R2	  
Global	  SL	  (%)	   -­‐17.9	  ±	  2.3	   -­‐21.2	  ±	  1.3	   <0.001*	   0.44	  
Global	  SC-­‐P	  (%)	   -­‐16.8	  ±	  2.7	   -­‐22.3	  ±	  2.3	   <0.001*	   0.54	  
Global	  SC-­‐M	  (%)	   -­‐16.4	  ±	  1.7	   -­‐20.5	  ±	  2.0	   <0.001*	   0.51	  
Global	  SR-­‐P	  (%)	   51.7	  ±	  10	   55.0	  ±	  7	   0.10	   -­‐	  
Global	  SR-­‐M	  (%)	   43.1	  ±	  10	   51.0	  ±	  6	   <0.001*	   0.21	  
T2P	  global	  SL	  (ms)	   346	  ±	  42	   337	  ±	  41	   0.37	   -­‐	  
T2P	  global	  SC-­‐P	  (ms)	   324	  ±	  46	   321	  ±	  43	   0.81	   -­‐	  
T2P	  global	  SC-­‐M	  (ms)	   336	  ±	  43	   330	  ±	  43	   0.61	   -­‐	  
T2P	  global	  SR-­‐P	  (ms)	   340	  ±	  39	   333	  ±	  38	   0.44	   -­‐	  
T2P	  global	  SR-­‐M	  (ms)	   379	  ±	  48	   358	  ±	  54	   0.09	   -­‐	  
Global	  SrL	  (s-­‐1)	   -­‐1.1	  ±	  0.1	   -­‐1.4	  ±	  0.1	   <0.001*	   0.55	  
Global	  SrC-­‐P	  (s-­‐1)	   -­‐1.5	  ±	  0.3	   -­‐1.9	  ±	  0.2	   <0.001*	   0.37	  
Global	  SrC-­‐M	  (s-­‐1)	   -­‐1.2	  ±	  0.2	   -­‐1.6	  ±	  0.2	   <0.001*	   0.30	  
Global	  SrR-­‐P	  (s-­‐1)	   2.2	  ±	  0.7	   3.5	  ±	  0.4	   <0.001*	   0.62	  
Global	  SrR-­‐M	  (s-­‐1)	   2.2	  ±	  0.5	   3.3	  ±	  0.4	   <0.001*	   0.57	  
	  
SL: peak systolic longitudinal strain; SC: peak systolic circumferential strain; -P: at the level of 
the papillary muscle; -M: at the level of the mitral valve; SR: peak systolic radial strain; T2P: 
time to peak systolic strain; SrL: peak systolic longitudinal strain-rate; SrC: peak systolic 
circumferential strain-rate; SrR: peak systolic radial strain-rate; * P < 0.05 determined by one-
way analysis of variance and linear regression analysis; R2: coefficient of determination 
indicating the proportion of variability accounted for by the presence or absence of 
mitochondrial disease. 
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6.5 DISCUSSION 
	  
Mitochondrial	   disorders,	   although	   genetically	   diverse,	   share	   the	   common	   cellular	  
consequences	  of	  decreased	  ATP	  production,	  increased	  reliance	  on	  anaerobic	  energy	  
sources	   and	   increased	   production	   of	   reactive	   oxygen	   species.	   Since	   the	   extent	   of	  
dysfunction	   is	   dependent	   upon	   the	   aerobic	   energy	   requirements	   of	   each	   tissue,	  
highly	   energy-­‐dependent	   tissues,	   such	   as	   the	   central	   nervous	   system	   and	   skeletal	  
and	  cardiac	  muscle,	  are	  commonly	  involved.3	  However,	  there	  is	  no	  strict	  correlation	  
between	   the	   genetic	   background,	   biochemistry,	   system	   involvement	   and	  
symptomatic	  status	  .28	  The	  same	  biochemical	  and	  genetic	  defect	  can	  be	  associated	  
with	   completely	   different	   phenotypes.	   This	   phenomenon,	   in	   some	  of	   the	   patients	  
carrying	   mitochondrial	   DNA	   mutations,	   can	   be	   explained	   by	   unique	   features	   of	  
mitochondrial	   disorders.	   A	   condition	   known	   as	   heteroplasmy	   allows	   mutated	  
mitochondrial	  DNA	  to	  coexist	  with	  normal	  mitochondrial	  genomes	  in	  the	  same	  cell.	  
Furthermore,	  different	  cells	  and	  tissues	  may	  contain	  vastly	  different	  percentages	  of	  
mutant	   mitochondrial	   DNA.29,30	   Together,	   these	   characteristics	   result	   in	   a	  
remarkable	   phenotypic	   variation	   in	   expression,	   even	   within	   the	   same	   family.	   No	  
obvious	  explanation	  exists	  however	  for	  the	  surprising	  phenotypic	  variability	  in	  most	  
patients	  diagnosed	  with	  a	  mitochondrial	  disorder	  due	  to	  nuclear	  mutations.	  Due	  to	  
this	   variable	   expression	   it	   is	   difficult	   to	   predict	   if	   and	   when	   cardiomyopathy	   will	  
occur	  in	  a	  patient	  diagnosed	  with	  mitochondrial	  dysfunction.	  What	  we	  do	  know	  for	  
certain,	   is	   such	   a	   patient	   to	   be	   at	   increased	   risk	   of	   developing	   myocardial	  
malfunction.	  	  
	  
The	  molecular	  events	  linking	  respiratory	  chain	  defects	  to	  cardiac	  hypertrophy	  have	  
not	   been	   completely	   elucidated.	   It	   appears	   that	   multiple	   factors	   contribute	   to	  
myocardial	   dysfunction.	   First,	   experimental	   models	   suggest	   that	   both	   energy	  
derangements	   and	   increase	   of	   mitochondrial-­‐derived	   reactive	   oxygen	   species	   are	  
important	   steps	   in	  developing	   cardiac	  malfunction	   in	  mitochondrial	  disease.31,32	   In	  
addition,	   mitochondrial	   proliferation	   per	   se,	   a	   well-­‐recognized	   compensatory	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mechanism	  in	  mitochondrial	  disease,	  could	  interfere	  with	  sarcomere	  alignment	  and	  
contraction	   through	   ultrastructural	   remodeling.33	   Finally,	   mitochondrial	   disorders	  
have	   been	   associated	   with	   angiopathy	   independently	   of	   the	   presence	   of	   cardiac	  
hypertrophy.	   It	   has	   been	   speculated	   that	   mitochondrial	   proliferation	   leads	   to	  
narrowing	  of	   the	   lumen	  of	  arterioles,	  which	  might	  be	  responsible	   for	   the	   ischemic	  
findings	   observed	   by	   means	   of	   scintigraphy.34	   Combined,	   these	   pathologic	  
alterations	  lead	  to	  myocardial	  dysfunction	  which	  can	  present	  itself	  in	  various	  forms.	  
Although	   concentric	   hypertrophic	   non-­‐obstructive	   cardiomyopathy	   is	   observed	  
most	   frequently,	   dilated	   and	   noncompaction	   cardiomyopathy	   have	   been	  
reported.4,5,35,36	  
Many	   cases	   of	   MIC	   are	   associated	   with	   both	   myopathy	   and	   neuropathy.	   Cardiac	  
involvement	  rarely	  causes	  the	   initial	  symptoms	  of	  mitochondrial	  disease.	   In	   just	  5-­‐
10%	   of	   children	   diagnosed	   with	   MIC,	   cardiomyopathy	   was	   the	   first	   sign	   of	  
mitochondrial	  dysfunction.5,36	  The	  onset	  of	  MIC	  as	  sole	  presenting	  symptom	  occurs	  
predominantly	  early	  in	  childhood	  and	  is	  characterized	  by	  a	  rapid	  downward	  course.	  
Frequently,	  these	  patients	  die	  before	  diagnosis	  can	  be	  made.	  In	  general,	  the	  median	  
age	   at	   onset	   of	   cardiac	   symptoms	   in	   patients	   who	   presented	   with	   extracardiac	  
symptoms	   is	  5-­‐24	  months,	   ranging	   from	  birth	   to	  27	  years.5,6,36,37	   It	   is	   important	   to	  
note	   that	   myocardial	   dysfunction	   can	   develop	   long	   after	   the	   diagnosis	  
mitochondrial	   disease	   has	   been	   made.	   Even	   when	   previous	   (traditional	  
echocardiographic)	  investigations	  revealed	  no	  cardiac	  abnormalities.5	  
	  
Cardiomyopathy	  is	  a	  hallmark	  of	  several	  mitochondrial	  syndromes.	  Barth	  syndrome	  
(MGA	   type	   II;	   MIM	   302060)	   caused	   by	   defects	   of	   the	   TAZ	   gen	   presents	   with	   3-­‐
methylglutaconic	   aciduria,	   mitochondrial	   dysfunction,	   cyclic	   neutropenia	   and	  
dilated	   cardiomyopathy.	  Mutations	   of	   the	  DNAJC19	   gene,	   also	   associated	  with	   3-­‐
methylglutaconic	   aciduria,	   (MGA	   type	   V;	   MIM610198)	   is	   a	   syndrome	   of	   dilated	  
cardiomyopathy	   and	   ataxia.4	   In	   the	   clinically	   variable	   group	   of	   mitochondrial	  
complex	   V	   (ATPase)	   deficiency,	   specific	   mutations	   in	   the	   mitochondrial-­‐encoded	  
MTATP6	   (MIM	   516060)	   and	   MTATP8	   (MIM	   516070)	   genes,	   or	   nuclear-­‐encoded	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TMEM70	  gene	  (MIM	  612418),	  share	  the	  same	  phenotypic	  features	  such	  as	  profound	  
hypotonia,	  lactic	  acidemia,	  failure	  to	  thrive	  and	  hypertrophic	  cardiomyopathy.38,39	  	  
Cardiac	   involvement	   in	   patients	   diagnosed	   with	   other	   forms	   of	   mitochondrial	  
disease	  has	  been	  reported	  in	  several	  series	  with	  varying	  prevalence.5,6,7,36,37,40,41	  The	  
frequency	  of	  MIC	  in	  the	  cited	  studies	  ranges	  from	  14	  to	  40%	  of	  patients.	  Since	  there	  
is	   some	   difficulty	   in	   comparing	   the	   results	   of	   these	   studies	   in	   light	   of	   possible	  
ascertainment	   biases	   as	   a	   result	   of	   different	   inclusion	   criteria	   used,	   the	   true	  
prevalence	  of	  cardiac	  involvement	  remains	  unclear.	  The	  same	  problem	  arises	  when	  
estimating	   the	  prognosis	  of	  MIC	  once	  myocardial	   dysfunction	  has	  been	   identified,	  
although	   most	   reports	   agree	   that	   MIC	   is	   associated	   with	   an	   adverse	   clinical	  
course.5,6,35,37	   The	   disease	   may	   be	   stable	   for	   many	   years,	   however,	   rapid	  
deterioration	   and	   sudden	   cardiac	   death	   have	   been	   observed.	   In	   a	   study	   by	  
Holmgren	  et	   al.	   10	   of	   17	   children	   diagnosed	  with	  MIC	   died	   from	   a	   cardiac	   cause.	  
Which	   is	   in	   agreement	   with	   other	   reports.5,35,37	   This	   poor	   prognosis	   is	   further	  
illustrated	   by	   a	   marked	   increased	   mortality	   rate	   in	   children	   with	   myocardial	  
involvement	  when	  compared	  to	  those	  without	  cardiac	  manifestations.	  Holmgren	  et	  
al.	   reported	   that	   mortality	   increased	   from	   26%	   to	   71%,	   whereas	   Scaglia	   et	   al.	  
described	  an	  incline	  from	  5%	  to	  82%	  when	  myocardial	  dysfunction	  was	  present.5,6	  	  
These	   figures	   indicate	   that	  MIC	   is	   an	   ominous	   finding	   in	   children	   diagnosed	   with	  
mitochondrial	  disease.	  Timely	  identification	  of	  deterioration	  of	  myocardial	  function	  
is	   important	   since	   early	   and	   aggressive	   supportive	   therapy	   might	   improve	   the	  
chances	  of	  survival.	  	  
	  
Conventional	   diagnostic	   cardiac	   imaging	   modalities	   such	   as	   standard	  
echocardiographic	   techniques	   are	   appropriate	   to	   detect	   global	   LV	   dysfunction	   at	  
advanced	   stages	   of	   cardiac	   disease.	   However,	   they	   are	   often	   not	   able	   to	   identify	  
subclinical	   systolic	   (regional)	   myocardial	   abnormalities	   in	   children	   with	   various	  
conditions.	   Previous	   reports	   have	   illustrated	   that	   strain	   imaging	   more	   carefully	  
reflects	  myocardial	  systolic	  function.	  With	  this	  study	  we	  aimed	  to	  assess	  myocardial	  
systolic	   function	   in	   children	   with	   mitochondrial	   disease.	   Our	   results	   indicate	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significant	   subclinical	   systolic	   myocardial	   dysfunction	   in	   the	   presence	   of	   normal	  
conventional	  echocardiographic	  indices	  and	  normal	  electrocardiographic	  findings.	  In	  
none	   of	   the	   patients	   mitochondrial	   cardiomyopathy	   was	   identified	   with	  
conventional	   echocardiographic	   techniques.	   However,	   global	   peak	   systolic	   strain	  
values	   and	   global	   peak	   systolic	   strain-­‐rate	   measurements	   in	   all	   three	   directions	  
were	   significantly	   lower	   in	   patients	   when	   compared	   to	   healthy	   age-­‐matched	  
children	   indicating	   abnormal	   myocardial	   deformation	   in	   the	   first	   cohort.	   Time	   to	  
global	   peak	   systolic	   strain	   values	   in	   the	   patient	   group	   did	   not	   differ	   significantly	  
from	  those	  found	  in	  control	  subjects.	  
	  
The	  clinical	  and	  prognostic	  implications	  of	  the	  identified	  abnormalities	  in	  myocardial	  
deformation	  described	  in	  this	  study	  remain	  to	  be	  elucidated.	  Since	  all	  patients	  were	  
asymptomatic	  they	  were	  not	  treated	  for	  heart	  failure,	  e.g.	  with	  beta-­‐blocker	  and/or	  
ACE	   inhibitor.	  Currently	  we	  cannot	  predict	   the	  clinical	   course	  of	   the	  patient	  group	  
under	   investigation	   whose	   echocardiographic	   findings	   suggest	   abnormal	   systolic	  
deformation.	  Future	  longitudinal	  follow-­‐up	  studies	  will	  hopefully	  provide	  an	  answer	  
to	   this	   question.	   However,	   previous	   reports	   have	   indicated	   that	   abnormal	  
myocardial	  deformation	  is	  associated	  with	  an	  increased	  risk	  of	  cardiovascular	  events	  
in	  several	  other	  (cardiac)	  conditions,	  even	  in	  the	  absence	  of	  conventional	  functional	  
echocardiographic	  abnormalities.42,43	  	  
	  
6.6 STUDY LIMITATIONS 
	  
Abnormal	  global	  peak	  systolic	  strain	  (-­‐rate)	   finding	  could	  not	  be	  related	  to	  specific	  
enzyme	   defects	   or	   mitochondrial	   disease	   score.	   It	   is	   possible	   that	   the	   relatively	  
small	  number	  of	  patients	  prevents	  the	  identification	  of	  such	  a	  relation.	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6.7 CONCLUSION 
	  
Our	  results	   indicate	  subclinical	  systolic	  myocardial	  deformation	  abnormalities	   in	  all	  
three	  directions	  of	  myocardial	  contraction	  (longitudinal,	  circumferential	  and	  radial)	  
in	   children	   with	   mitochondrial	   disease	   in	   the	   presence	   of	   normal	   conventional	  
echocardiographic	  indices.	  Since	  myocardial	  dysfunction	  in	  mitochondrial	  disorders	  
is	   an	   ominous	   sign,	   these	   findings	   emphasize	   the	   need	   for	   repeated	   cardiac	  
assessment	   as	   part	   of	   monitoring	   disease	   progression	   in	   patients	   with	   confirmed	  
mitochondrial	  disorders.	  Our	  findings	  illustrate	  the	  additional	  value	  of	  2DSTE	  in	  the	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7.1 ABSTRACT  
	  
Background:	  Prader-­‐Willi	  syndrome	  (PWS)	  is	  associated	  with	  a	  substantial	  increased	  
risk	   of	   cardiovascular	   death	   and	   morbidity,	   which	   most	   likely	   cannot	   be	   entirely	  
attributed	  to	  obesity-­‐related	  risk	  factors.	  
	  
Aim:	   Cardiac	   evaluation	   in	   children	   with	   PWS	   based	   on	   history,	   physical	  
examination,	   electrocardiography	   (ECG),	   conventional	   echocardiography	   and	   two-­‐
dimensional	  strain	  echocardiography	  (2DSTE).	  
	  
Methods:	  Physical	  examination,	  ECG	  recordings	  and	  transthoracic	  echocardiograms	  
were	   performed	   and	   evaluated	   in	   the	   Children’s	   Heart	   centre	   of	   the	   Radboud	  
University	  Hospital	  Nijmegen,	  the	  Netherlands.	   In	  total	  19	  children	  diagnosed	  with	  
PWS	   and	   38	   age-­‐matched	   control	   subjects	   underwent	   cardiac	   evaluation.	   Main	  
outcome	  measures	  consisted	  of	  physical	  characteristics,	  ECG	  findings,	  conventional	  
echocardiographic	  indices	  and	  2DSTE	  parameters.	  Longitudinal,	  circumferential	  and	  
radial	  peak	  systolic	  strain	  (S)	  values	  were	  determined	  as	  well	  as	  peak	  systolic	  strain-­‐
rate	   (Sr)	   and	   the	   time	   to	   peak	   global	   systolic	   strain	   (T2P).	   Systolic	   deformation	  
appeared	  more	  affected	  in	  case	  of	  maternal	  uniparental	  disomy.	  	  
	  
Results:	  Abnormal	  ECG	  findings	  were	  detected	  in	  nine	  PWS	  patients.	  Mild	  structural	  
cardiac	   abnormalities	   were	   found	   in	   two	   patients	   by	   echocardiography.	  
Conventional	   echocardiographic	   findings	   did	   not	   indicate	   systolic	   left	   ventricular	  
dysfunction,	  in	  contrast	  to	  2DSTE	  examination.	  Global	  peak	  S	  and	  Sr	  measurements	  
in	  all	   three	  directions	  of	  contraction	  were	  significantly	   lower	   in	  children	  with	  PWS	  
(P<0.001)	   compared	   with	   healthy	   age-­‐matched	   children,	   indicating	   abnormal	   left	  
ventricular	   deformation.	   In	   two-­‐thirds	   of	   the	   patients,	   2DSTE	   revealed	   abnormal	  
systolic	  deformation	  (peak	  systolic	  strain	  as	  well	  as	  strain	  rate).	  T2P	  values	   in	  PWS	  
patients	  were	  similar	  to	  control	  subject.	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Conclusion:	  Cardiac	  evaluation,	  including	  2DSTE,	  detected	  alterations	  in	  myocardial	  
systolic	   function	   in	   children	   diagnosed	   with	   PWS,	   whose	   conventional	  
echocardiographic	   findings	   did	   not	   indicate	   ventricular	   systolic	   dysfunction.	   Since	  
cardiovascular	  morbidity	  and	  mortality	   is	   substantial	   in	  PWS,	  especially	   adults,	  we	  




Prader-­‐Willi	   syndrome	   (PWS)	   was	   the	   first	   recognized	   human	   disorder	   related	   to	  
genomic	   imprinting,	  which	  means	  that	  genes	  are	  expressed	  differentially	  based	  on	  
the	   parent	   of	   origin.	   In	   PWS,	   symptoms	   result	   from	   failure	   of	   expression	   of	  
paternally	  inherited	  genes	  in	  the	  PWS	  region	  of	  chromosome	  15.1	  It	  is	  characterized	  
by	  a	  recognizable	  pattern	  of	  dysmorphic	  features	  and	  major	  neurological,	  cognitive,	  
endocrine	   and	   behavioral	   disturbances.	   These	   disturbances	   include	   severe	  
hypotonia	  and	  feeding	  difficulties	  in	  early	  infancy,	  followed	  by	  excessive	  eating	  and	  
gradual	   development	   of	   morbid	   obesity	   when	   the	   child	   is	   older,	   unless	   eating	   is	  
controlled	   by	   dietary	   restriction	   or	   behavior	   modification.	   Endocrine	   features	   of	  
PWS	   are	   related	   to	   hypothalamic	   dysfunction	   and	   include	   hypogonadotrophic	  
hypogonadism,	   central	   adrenal	   insufficiency	   and	   growth	   hormone	   deficiency	  
resulting	  in	  short	  stature.	  Several	  reports	  and	  surveys	  within	  large	  cohorts	  indicate	  
that	  PWS	  is	  associated	  with	  a	  high	  incidence	  of	  sudden	  death	  in	  both	  children	  and	  
adults,	   suspected	   to	   be	   cardiopulmonary	   in	   origin.2,3,4	   Traditionally,	   cardiovascular	  
death	   in	   PWS	   has	   been	   attributed	   to	   obesity-­‐related	   risk	   factors.2,3	   Patel	   et	   al.	  
described	   microcirculatory	   dysfunction	   and	   raised	   levels	   of	   the	   inflammatory	  
marker	  high-­‐sensitivity	  CRP	  in	  adult	  PWS	  patients,	  both	  of	  which	  are	  associated	  with	  
coronary	   artery	   disease.5,6	   Recently,	   awareness	   is	   rising	   that	   critical	   illness	   and	  
sudden	  cardiac	  death	  in	  PWS	  may	  not	  be	  entirely	  caused	  by	  obesity	  alone.4,7,8	  It	  has	  
been	  postulated	  that	  the	  above	  mentioned	  endocrine	  disturbances	  associated	  with	  
PWS,	   as	   well	   as	   structural	   and	   functional	   cardiac	   abnormalities	   contribute	   to	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increased	   cardiovascular	   morbidity	   and	   mortality.	   However,	   the	   structural	   and	  
functional	   changes	   that	  may	   occur	   in	   the	   heart	   or	   vasculature,	   predisposing	   PWS	  
patients	   to	   myocardial	   dysfunction,	   remain	   to	   be	   elucidated.	   The	   few	   previous	  
studies	   that	   have	   addressed	   this	   issue	   have	   focused	   on	   adults	  with	   PWS	   entirely.	  
These	   reports	   describe	   decreased	   myocardial	   mass	   and	   lower	   ejective	   and	  
chronotropic	  response	  to	  dobutamine	  when	  compared	  to	  healthy	  obese	  controls.5,7	  	  	  	  
	  
Two-­‐dimensional	  strain	  echocardiography	  (2DSTE)	  has	  emerged	  as	  a	  relatively	  new	  
index	   of	   regional	   and	   global	   myocardial	   function.	   The	   technique	   uses	   two-­‐
dimensional	   ultrasound	   multiframe	   images	   to	   determine	   myocardial	   deformation	  
(i.e.,	  strain)	   in	  all	  three	  principal	  directions	  (longitudinal,	  circumferential	  and	  radial	  
direction)	  per	  cardiac	  segment	  over	  time.	  Due	  to	  its	  ability	  to	  differentiate	  between	  
active	  and	  passive	  deformation	  of	  myocardial	  segments,	  to	  quantify	  intraventricular	  
dyssynchrony	  and	  to	  evaluate	  individual	  components	  of	  myocardial	  function,	  2DSTE	  
is	   able	   to	   detect	   myocardial	   dysfunction	   at	   an	   early	   stage.9,10,11	   Previous	   studies	  
have	  indicated	  that	  2DSTE	  is	  more	  sensitive	  than	  conventional	  echocardiography	  for	  
detecting	  early	  myocardial	  dysfunction	  in	  a	  wide	  variety	  of	  clinical	  disorders.12,13,14,15	  
The	   aim	   of	   the	   present	   study	   was	   to	   assess	   cardiac	   anatomy	   and	   myocardial	  
function	  in	  children	  with	  PWS.	  	  
	  
7.3 MATERIAL and METHODS 
7.3.1 STUDY POPULATION 
	  
All	   consecutive	   children	   previously	   diagnosed	   with	   Prader-­‐Willi	   syndrome	   visiting	  
the	  outpatient	  clinic	  of	  the	  Pediatric	  Endocrinology	  and	  Metabolism	  Department	  of	  
the	   Radboud	   University	   Nijmegen	   Medical	   Centre,	   The	   Netherlands,	   between	  
October	   1,	   2008	   and	   May	   31,	   2010,	   were	   included	   in	   the	   study.	   DNA	   diagnostic	  
testing	  was	  previously	  performed	   in	  all	   patients	  and	   confirmative	  of	   the	  diagnosis	  
PWS.	   All	   patients	   showed	   the	   absence	   of	   a	   paternal	   methylation	   pattern	   by	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methylation	   specific	   polymerase	   chain	   reaction	   (MS-­‐PCR),	   or	   Southern	   blot	  
analysis.16	  In	  order	  to	  identify	  the	  underlying	  genetic	  defect,	  follow-­‐up	  studies	  using	  
FISH,	  microsatellite	   analysis	   or	  methylation	   sensitive	  multiplex	   ligation-­‐dependent	  
probe	  amplification	  were	  performed	   (MS-­‐MLPA;	  ME028-­‐B1	  kit	   from	  MRC	  Holland;	  
http://www.mrc-­‐holland.com).	   A	   complete	   history,	   physical	   examination	   by	   a	  
pediatric	   cardiologist,	  12-­‐lead	  ECG	  as	  well	   as	  echocardiographic	  examination	  were	  
performed	  as	  part	  of	  the	  clinical	  evaluation.	  	  
7.3.2 CONTROL GROUP 
	  
A	  group	  of	  healthy,	  age-­‐	  and	  gender-­‐matched	  children	  were	  prospectively	  recruited	  
to	  serve	  as	  a	  control	  group.	  These	  children	  underwent	  the	  same	  cardiac	  evaluation	  
as	   the	  group	  of	   the	  children	  diagnosed	  with	  PWS.	   Informed	  consent	  was	  obtained	  
from	  each	  participant	  and	  their	  parents.	  	  
7.3.3 CONVENTIONAL ECHOCARDIOGRAPHIC PARAMETERS 
	  
All	   subjects	   underwent	   a	   detailed	   transthoracic	   echocardiographic	   examination	   in	  
the	  left	  lateral	  position	  according	  to	  the	  recommendations	  of	  the	  American	  Society	  
of	   Echocardiography	   and	   a	   previous	   described	   local	   research	   protocol	  
previously.17,18	   Every	   examination	  was	   performed	   at	   rest,	   without	   using	   sedation.	  
Images	   were	   obtained	   with	   a	   3.0-­‐MHz	   (S3)	   or	   a	   5.0-­‐MHz	   (S5)	   phased-­‐array	  
transducer	   using	   a	   commercially	   available	   system,	   the	   Vivid	   7	   echocardiographic	  
scanner	  (GE,	  Vingmed	  Ultrasound	  AS,	  Horten,	  Norway).	  The	  choice	  of	  an	  S3	  or	  a	  S5	  
transducer	  depended	  on	  the	  age	  and	  posture	  of	  the	  child.	  Quantification	  of	  cardiac	  
chamber	  size,	  ventricular	  mass	  and	  systolic	  left	  ventricular	  function	  were	  measured	  
in	   accordance	   with	   the	   recommendations	   for	   chamber	   quantification	   by	   the	  
American	   Society	   of	   Echocardiography.17	   Left	   ventricular	   systolic	   function	   was	  
characterized	  using	  fractional	  shortening	  (FS),	  ejection	  fraction	  (EF),	  left	  ventricular	  
myocardial	   performance	   index,	   or	   Tei	   index,	   end-­‐systolic	   wall	   stress	   (ESWS)	   and	  
rate-­‐corrected	  velocity	  of	  circumferential	  fiber	  shortening	  (VCFc).19,20,21,22	  	  	  
208	  |	  Chapter	  7	  
7.3.4 DSTE DATA ACQUISITION 
	  
Two-­‐dimensional	   strain	   echocardiography	   measurements	   were	   performed	  
according	   to	   a	   previous	   described	   protocol.18,23	   In	   short:	   two-­‐dimensional	  
multiframe	   B-­‐Mode	   images	   were	   obtained	   from	   the	   apical	   four-­‐chamber,	  
parasternal	  midcavity	  short-­‐axis	  view	  (at	  the	  level	  of	  the	  papillary	  muscle:	  PM),	  and	  
parasternal	  basal	  short-­‐axis	  view	  (at	  the	  level	  of	  the	  mitral	  valve:	  MV).	  Offline	  strain	  
analysis	   was	   performed	   using	   speckle	   tracking	   software	   for	   echocardiographic	  
quantification	   (EchoPAC	   6.1.0;	   GE	   Vingmed	   Ultrasound	   AS,	   Horten,	   Norway).	  
Myocardial	  longitudinal,	  radial	  and	  circumferential	  peak	  systolic	  strain	  (-­‐rate)	  values	  
were	  obtained,	  as	  well	  as	  the	  time	  to	  reach	  peak	  systolic	  strain.	  To	  determine	  global	  
strain	  (-­‐rate),	  the	  strain	  (-­‐rate)	  values	  of	  the	  six	  segments	  were	  averaged	  for	  each	  of	  
the	  views.	  All	  2D	  strain	  analyses	  were	  performed	  by	  the	  same	  investigator	  (K.A.M.)	  
to	  avoid	  interobserver	  variability.	   Intraobserver	  variability	  scores	  as	  well	  as	  normal	  
reference	  values	  have	  been	  described	  by	  our	   research	  group	  previously.18,23	  Strain	  
values	  are	  dimensionless	  and	  are	  expressed	  as	  percentages.	  Strain-­‐rate	   is	  the	  time	  
derivative	  of	  strain	  and	  is	  expressed	  as	  s-­‐1.	  Time	  to	  peak	  systolic	  strain	  is	  expressed	  
as	   milliseconds.	   Negative	   strain	   values	   reflect	   shortening/thinning,	   while	   positive	  
strain	  values	  reflect	  lengthening/thickening.	  	  
7.3.5 STATISTICAL ANALYSIS 
	  
All	   values	   are	   expressed	   as	  mean	   ±	   standard	   deviation	   (SD)	   or	  median	   and	   range	  
when	   outcomes	  were	   not	   normally	   distributed.	   Demographic	   and	   anthropometric	  
characteristics,	   as	   well	   as	   conventional	   and	   2DSTE	   measurements	   of	   the	   patient	  
group	   were	   compared	   with	   those	   of	   the	   control	   group	   with	   one-­‐way	   analysis	   of	  
variance	   or	   Kruskal-­‐Wallis	   nonparametric	   test	   when	   outcomes	  were	   not	   normally	  
distributed.	   The	   relation	   between	   PWS	   and	   individual	   conventional	  
echocardiographic	   findings	   as	   well	   as	   each	   global	   2DSTE	   parameter	   (global	   peak	  
systolic	  strain,	  global	  peak	  systolic	  strain-­‐rate,	  time	  to	  peak	  global	  systolic	  strain	   in	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longitudinal,	   circumferential	   and	   radial	   direction)	   was	   investigated	   using	   one-­‐way	  
analysis	   of	   variance	   and	   multivariate	   analysis.	   The	   relation	   between	   the	   genetic	  
defect	  (paternal	  deletion	  or	  maternal	  uniparental	  disomy),	  gender	  as	  well	  as	  growth	  
hormone	   therapy	   (GHT)	   and	   each	   2DSTE	   parameter	   was	   assessed	   by	   one-­‐way	  
analysis	   of	   variance	   and	   multivariate	   analysis.	   Two-­‐dimensional	   strain	  
echocardiography	   measurements	   in	   children	   with	   PWS	   were	   compared	   with	  
previously	  described	  reference	  values.23	  P-­‐values	  less	  than	  0.05	  were	  considered	  to	  
indicate	   significance.	   All	   statistical	   analyses	   were	   performed	   using	   the	   Statistical	  
Package	  for	  Social	  Sciences	  for	  Windows,	  version	  16.0	  (SPSS	  Inc,	  Chicago,	  IL).	  	  
	  
7.4 RESULTS 
7.4.1 STUDY POPULATION  
	  
In	  total	  19	  children	  diagnosed	  with	  PWS	  by	  MS-­‐PCR	  or	  Southern	  blot	  analysis	  were	  
included.	  Follow-­‐up	  studies	  using	  FISH,	  microsatellite	  analysis	  or	  MS-­‐MLPA	  showed	  
a	  deletion	  of	  the	  paternally	  inherited	  chromosomal	  15q11.2-­‐q13	  region	  in	  12	  (63%)	  
patients.	  In	  7	  (37%)	  others,	  maternal	  uniparental	  disomy	  15	  was	  detected.	  	  
7.4.2 CONTROL GROUP 
	  
A	   group	   of	   38	   healthy	   age-­‐	   and	   gender-­‐matched	   children	   was	   included	   and	  
examined	   to	   provide	   us	   with	   normal	   reference	   values	   for	   conventional	  
echocardiographic	  and	  2DSTE	  parameters.	  	  
7.4.3 HISTORY AND PHYSICAL EXAMINATION  
	  
History	   and	   physical	   examination	   of	   patients	   diagnosed	   with	   PWS	   and	   control	  
subjects,	  were	  not	   indicative	  of	  cardiovascular	  disease.	  None	  used	  medications	  for	  
cardiac	   disease.	   Eleven	   patients	   received	   GHT	   (median	   duration	   GHT:	   4.6	   years;	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range:	   1.6	   –	   15.7	   years).	   Of	   those	   patients	   treated	   with	   growth	   hormone,	   five	  
patients	   also	   received	   thyroxine	   treatment.	   Eight	   PWS	   patients	   received	   neither	  
GHT,	   nor	   other	   medication.	   All	   were	   free	   from	   hypertension.	   Demographic	   and	  
anthropometric	  findings	  in	  children	  with	  PWS	  were	  similar	  to	  those	  found	  in	  control	  
subjects.	  There	  were	  no	  statistically	  significant	  differences	  between	  both	  groups.	  An	  
important	  observation	  was	   that	  body	  mass	   index	   (BMI)	  was	   increased	   in	  only	  one	  
PWS	   patient	   (30.5	   kg/m2:	   z-­‐score	   3).	   Patient	   demographic	   characteristics	   and	  
anthropometric	  parameters	  are	  described	  in	  Table	  29,	  together	  with	  the	  data	  of	  the	  
control	  group.	  	  
7.4.4 ECG FINDINGS  
	  
Electrocardiographic	   examinations	   were	   normal	   in	   all	   control	   subjects.	   In	   the	  
patient	  group,	  abnormalities	  were	  identified	  in	  nine	  PWS	  patients.	  High	  voltages	  in	  
the	   left	   (two	   patients)	   and	   right	   (two	   patients)	   precordial	   leads,	   first	   degree	  
atrioventricular	   block	   with	   PR	   interval	   lengthened	   beyond	   0.2	   s	   (one	   patient),	  
pathological	  Q	  wave	   in	   lead	   III	  and	  aVF	  (one	  patient:	  Figure	  26)	  and	  prolonged	  QT	  
interval	  corrected	  for	  heart	  rate	  of	  0.52	  -­‐	  0.55	  s	  (three	  patients).	  There	  were	  no	  ST	  
segment	   or	   T-­‐wave	   abnormalities	   detected.	   Electrocardiographic	   abnormalities	  
were	  equally	  distributed	  among	  patients	  with	  uniparental	  disomy	   (4	  patients)	  and	  
patients	  with	  a	  deletion	  (5	  patients).	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Table 29 – Demographic and anthropometric characteristics (mean ± standard 
deviation or median and range) of patients with PWS and control subjects 
Subject	   PWS	  patients	   Control	  subjects	  
P	  value	  
Characteristics	   (n	  =	  19)	   (n	  =	  38)	  
Male	  	   12	  (63%)	   24	  (63%)	   1.00	  
Age	  (y)	   5.8	  (0.3	  –	  19.9)	   5.8	  (0.3	  –	  19.1)	   1.00	  
Height	  (cm)	   120	  ±	  41	   126	  ±	  44	   0.64	  
Weight	  (kg)	   30.0	  (5	  –	  71)	   27.8	  (6	  –	  83)	   0.89	  
BSA	  (m2)	   1.04	  ±	  0.59	   1.06	  ±	  0.61	   0.92	  
BMI	  (kg/m2)	   18.9	  (12.5	  –	  30.5)	   17.9	  (14.3	  -­‐	  28.7)	   0.18	  
BMI	  z-­‐score	   0.20	  (-­‐2	  –	  3)	   -­‐0.10	  (-­‐2	  –	  2)	   0.19	  
HR	  (bpm)	   95	  ±	  34	   92	  ±	  30	   0.77	  
MAP	  (mmHg)	   70	  ±	  11	   69	  ±	  11	   0.69	  
Syst.BP	  (mmHg)	   97	  ±	  14	   96	  ±	  12	   0.88	  
Diast.BP	  (mmHg)	   57	  ±	  10	   57	  ±	  9	   0.71	  
	  
BMI: body mass index; BSA: body surface area; Diast.BP: diastolic blood pressure; HR: heart 
rate; MAP: mean arterial blood pressure; Syst.BP: systolic blood pressure. Patient group and 
control subjects were compared using one-way analysis of variance or Kruskal Wallis 
nonparametric test when data were not normally distributed. 
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Figure 26 –Pathological Q waves in lead III and aVF in one pediatric PWS patient 
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7.4.5 CONVENTIONAL ECHOCARDIOGRAPHIC PARAMETERS 
	  
Conventional	   echocardiographic	   findings	   are	   described	   in	   Table	   30.	  
Echocardiographic	   examination	   revealed	   an	   atrial	   septum	   defect	   of	   the	   ostium	  
secundum	   type	   in	   one	   PWS	   patient	   accompanied	   by	   increased	   right	   ventricular	  
internal	   diameters	   at	   both	   end-­‐systole	   and	   end-­‐diastole.	   In	   a	   second	   patient,	   a	  
moderate-­‐severe	  pulmonary	  valve	  stenosis	  was	   identified	  without	  right	  ventricular	  
hypertrophy.	   Both	   patients	   were	   diagnosed	   with	   a	   deletion.	   Conventional	  
echocardiographic	  indices	  to	  indicate	  ventricular	  systolic	  function	  were	  normal	  in	  all	  
children	  with	  PWS	  as	  well	  as	  healthy,	  age-­‐matched	  children.	  In	  none	  of	  the	  children	  
echocardiographic	   findings	   were	   indicative	   of	   left	   and/or	   right	   ventricular	  
hypertrophy.	   One-­‐way	   analysis	   of	   variance	   did	   not	   indicate	   statistically	   significant	  
differences	   in	   standard	   echocardiographic	   indices	   between	   patients	   and	   healthy	  
controls.	   In	   children	   diagnosed	   with	   PWS,	   there	   was	   a	   statistically	   significant	  
difference	  (P	  0.003)	  in	  left	  ventricular	  mass	  corrected	  for	  body	  surface	  area	  among	  
patients	  who	  received	  GHT	  (n=11)	  compared	  to	  those	  without	  GHT	  (n=	  8)	  with	  one-­‐
way	  analysis	  of	  variance	  (63	  ±	  11	  versus	  45	  ±	  7	  g/m2	  respectively).	  	  
7.4.6 MYOCARDIAL STRAIN PARAMETERS 
	  
Tracking	  was	  feasible	  in	  98%	  of	  all	  segments	  of	  the	  four-­‐chamber	  view,	  in	  94%	  of	  all	  
segments	   in	   the	  midventricular	   short-­‐axis	   view	   and	   in	   94%	  of	   all	   segments	   in	   the	  
basal	   short-­‐axis	   view.	   In	   one	   patient	   two-­‐dimensional	   strain	   analysis	   was	   not	  
possible	   since	   the	  quality	  of	   the	  B-­‐Mode	   images	  was	   too	   low.	   Interestingly,	  global	  
peak	  systolic	  strain	  values	  and	  global	  peak	  systolic	  strain-­‐rate	  measurements	   in	  all	  
three	   directions	   showed	   statistically	   significant	   (P	   <0.001)	   differences	   between	  
patients	  with	  PWS	  and	  healthy	  control	  subjects	  as	  determined	  by	  one-­‐way	  analysis	  
of	  variance	  (Table	  31).	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Multivariate	  analysis	  revealed	  that	  the	  presence	  or	  absence	  of	  PWS	  explained	  22	  to	  
57%	   of	   variation	   in	   global	   peak	   systolic	   strain	   and	   global	   peak	   systolic	   strain-­‐rate	  
values.	  Time	  to	  peak	  global	  systolic	  strain	  values	  was	  comparable	  to	  those	  found	  in	  
healthy	   children.	   There	   were	   no	   statistically	   significant	   differences	   in	   2DSTE	  
parameters	   between	   PWS	   patients	   who	   received	   GHT	   and	   those	   without	   growth	  
hormone	  replacement	  as	  assessed	  by	  one-­‐way	  analysis	  of	  variance.	  There	  were	  no	  
gender	   differences	   identified.	   We	   did,	   however,	   detect	   statistically	   significant	  
differences	   between	   2DSTE	   parameters	   that	   could	   be	   attributed	   to	   different	  
genotypes,	   i.e.	   maternal	   uniparental	   disomy	   or	   deletion.	   Although	   global	   peak	  
systolic	  strain	  values	  and	  global	  peak	  systolic	  strain-­‐rate	  measurements	  in	  all	  three	  
directions	  were	  significantly	  lower	  in	  children	  with	  PWS	  when	  compared	  to	  healthy	  
control	  subjects,	  irrespective	  of	  their	  specific	  genetic	  defect,	  radial	  systolic	  strain	  (-­‐
rate)	   parameters	   were	  more	   affected	   in	   PWS	   patients	   with	   maternal	   uniparental	  
disomy	   (detected	   by	   means	   of	   one-­‐way	   analysis	   of	   variance	   with	   Bonferroni	  
correction	   for	   multiple	   comparisons).	   Global	   peak	   systolic	   radial	   strain	   and	   radial	  
peak	  systolic	  strain-­‐rate	  (both	  at	  the	  level	  of	  the	  papillary	  muscle	  and	  at	  the	  level	  of	  
the	  mitral	  valve)	  were	  significantly	   (P	  <	  0.05)	   lower	   in	  PWS	  patients	  with	  maternal	  
uniparental	  disomy.	  	  
	  
In	   the	   individual	   patient	  with	   PWS	   under	   investigation,	   global	   peak	   systolic	   strain	  
was	   abnormal	   (below	   5th	   percentile	   of	   normal	   according	   to	   reference	   values	  
established	  by	  our	  research	  group)	  in	  67%	  of	  patients	  for	  longitudinal	  strain,	  78%	  of	  
patients	   for	   midventricular	   circumferential	   strain	   and	   67%	   of	   patients	   for	   basal	  
circumferential	  strain.	  Global	  peak	  systolic	  radial	  strain	  was	  abnormal	  in	  44%	  of	  the	  
patients,	   both	   at	   the	   level	   of	   the	   papillary	   muscle	   and	   at	   the	   level	   of	   the	   mitral	  
valve.23	   Global	   peak	   systolic	   strain	   rate	   was	   abnormal	   in	   72%	   of	   patients	   for	  
longitudinal	  strain	  rate,	  50%	  of	  patients	  for	  circumferential	  strain	  rate,	  both	  at	  the	  
level	  of	  the	  papillary	  muscle	  and	  at	  the	  level	  of	  the	  mitral	  valve.	  Global	  peak	  systolic	  
radial	   strain	   rate	   was	   abnormal	   in	   77%	   of	   the	   PWS	   patients	   at	   the	   level	   of	   the	  
papillary	  muscle	  and	  72%	  of	  patients	  at	  the	  level	  of	  the	  mitral	  valve.23	  
Chapter	  7	  	  |	  215	  
Table 30 – Conventional echocardiographic findings (mean ± standard deviation) of 
children with PWS and healthy control subjects 
Conventional	   PWS	  patients	   Control	  subjects	   P	  value	  
Parameters	   (n	  =	  19)	   (n	  =	  38)	  
LVPWd	  (mm)	   5.9	  ±	  1.8	  	   5.5	  ±	  2.0	   0.52	  
IVSd	  (mm)	   5.4	  ±	  1.5	   5.0	  ±	  1.7	   0.43	  
LVIDd	  (mm)	   37	  ±	  10	   39	  ±	  10	   0.62	  
Mitral	  A	  velocity	   0.62	  ±	  0.18	   0.61	  ±	  0.19	   0.87	  
Mitral	  E	  velocity	   0.98	  ±	  0.09	   0.97	  ±	  0.15	   0.86	  
Mitral	  EA	  Ratio	   1.70	  ±	  0.49	   1.71	  ±	  0.46	   0.96	  
LVETc	  (s)	   0.31	  ±	  0.03	   0.30	  ±	  0.03	   0.23	  
VCFc	  (circ/s)	   1.24	  ±	  0.20	   1.27	  ±	  0.22	   0.71	  
Tei	  index	   0.37	  ±	  0.02	   0.38	  ±	  0.03	   0.24	  
FS	   0.38	  ±	  0.05	   0.37	  ±	  0.05	   0.54	  
LVEF	  biplane	   0.69	  ±	  0.05	   0.67	  ±	  0.15	   0.64	  
ESWS	  (g/cm2)	   39	  ±	  8	   43	  ±	  12	   0.22	  
LVM/BSA	  (g/m2)	   57	  ±	  13	   56	  ±	  16	   0.74	  
LVM/height2.7	  (g/m2.7)	   37	  ±	  12	  	   32	  ±	  10	   0.15	  
	  
LVPWd: diastolic left ventricular posterior wall thickness; IVSd: diastolic interventricular septal 
thickness; LVIDd: diastolic left ventricular diameter; LVETc: left ventricular ejection time 
corrected for heart rate; VCFc: heart-rate corrected velocity of circumferential fiber shortening; 
Tei index: left ventricular myocardial performance index; FS: fractional shortening; LVEF 
biplane: left ventricular ejection fraction measured by modified Simpson’s method; ESWS: 
end-systolic wall stress; LV mass/BSA: left ventricular mass corrected for body surface area. 
Statistically significant differences between patient group and control subjects were assessed 
by one-way analysis of variance. 
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Table 31 - 2DSTE findings (mean ± standard deviation) of children with PWS and 
healthy control subjects 
2DSTE	  parameters	   PWS	   Control	  subjects	   P	  value	  
	  	   (n	  =	  18)	   (n	  =	  38)	  
Global	  SL	  (%)	   -­‐17.3	  ±	  2.1	   -­‐21.2	  ±	  2.0	   <0.001	  *	  
Global	  SC-­‐P	  (%)	   -­‐17.2	  ±	  1.8	   -­‐23.1	  ±	  2.8	   <0.001	  *	  
Global	  SC-­‐M	  (%)	   -­‐16.1	  ±	  2.2	   -­‐20.7	  ±	  2.3	   <0.001	  *	  
Global	  SR-­‐P	  (%)	   46.2	  ±	  10	   56.4	  ±	  6	   <0.01	  *	  
Global	  SR-­‐M	  (%)	   44.8	  ±	  7	   53.7	  ±	  6	   <0.01	  *	  
T2P	  global	  SL	  (ms)	   341	  ±	  57	   335	  ±	  69	   0.79	  
T2P	  global	  SC-­‐P	  (ms)	   325	  ±	  55	   315	  ±	  57	   0.60	  
T2P	  global	  SC-­‐M	  (ms)	   342	  ±	  57	   335	  ±	  54	   0.68	  
T2P	  global	  SR-­‐P	  (ms)	   372	  ±	  62	   360	  ±	  65	   0.88	  
T2P	  global	  SR-­‐M	  (ms)	   379	  ±	  48	   358	  ±	  54	   0.56	  
Global	  SrL	  (s-­‐1)	   -­‐1.0	  ±	  0.2	   -­‐1.4	  ±	  0.1	   <0.001*	  
Global	  SrC-­‐P	  (s-­‐1)	   -­‐1.3	  ±	  0.4	   -­‐1.9	  ±	  0.2	   <0.001*	  
Global	  SrC-­‐M	  (s-­‐1)	   -­‐1.2	  ±	  0.2	   -­‐1.6	  ±	  0.3	   <0.01*	  
Global	  SrR-­‐P	  (s-­‐1)	   2.5	  ±	  0.4	   3.5	  ±	  0.4	   <0.001*	  
Global	  SrR-­‐M	  (s-­‐1)	   2.4	  ±	  0.4	   3.2	  ±	  0.3	   <0.001*	  
	  
SL: peak systolic longitudinal strain; SC-P: peak systolic circumferential strain at the level of 
the papillary muscle; SC-M: peak systolic circumferential strain at the level of the mitral valve; 
SR-P: peak systolic radial strain at the level of the papillary muscle; SR-M: peak systolic radial 
strain at the level of the mitral valve; T2P: time to peak systolic strain; SrL: peak systolic 
longitudinal strain-rate; SrC-P: peak systolic circumferential strain-rate at the level of the 
papillary muscle; SrC-M: peak systolic circumferential strain-rate at the level of the mitral 
valve; SrR-P: peak systolic radial strain-rate at the level of the papillary muscle; SrR-M: peak 
systolic radial strain-rate at the level of the mitral valve; * P < 0.05 determined by one-way 
analysis of variance and multivariate analysis. 
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7.5 DISCUSSION 
	  
It	   is	  well	   recognized	  that	  pediatric	  as	  well	  as	  adult	  PWS	  patients	  are	  at	  substantial	  
risk	  of	  sudden,	  premature	  death.3,4	  A	  retrospective	  study,	  performed	  by	  Whittington	  
et	  al.	  reported	  annual	  mortality	  rates	  of	  3%	  across	  all	  ages	  and	  7%	  in	  patients	  older	  
than	  thirty	  years,	  compared	  to	  an	  overall	  annual	  mortality	  of	  0.13%	  for	  the	  general	  
population	   below	   55	   years.2	   Cardiovascular	   illness	   is	   the	   main	   cause	   of	   death	   in	  
adolescents	   and	   adults	   with	   PWS,	   whereas	   mortality	   in	   early	   childhood	   is	  
predominantly	   related	   to	   respiratory	   and	   gastro-­‐intestinal	   infections.4,24,25	   In	   the	  
latter	  group	  of	  young	  children	  with	  PWS,	  it	  has	  been	  postulated	  that	  (unrecognized)	  
adrenal	  insufficiency	  could	  offer	  an	  explanation	  for	  increased	  mortality	  rates	  during	  
relatively	   mild	   to	   moderate	   infections.26	   In	   addition	   to	   fatal	   infections,	   life	  
threatening	  circulatory	  complications,	  such	  as	  sudden	  cardiac	  death	  or	  progressive	  
heart	   failure,	  are	  not	  uncommon	   in	  PWS	  throughout	  whole	  childhood.27,28	  Despite	  
the	  established	  substantial	  increased	  risk	  of	  cardiovascular	  morbidity	  and	  mortality	  
in	  (pediatric)	  patients	  with	  PWS,	  cardiac	  structure	  and	  myocardial	  function	  has	  not	  
been	  investigated	  previously	  in	  children	  diagnosed	  with	  PWS.	  	  
	  
In	   the	   present	   study	   we	   conducted	   a	   thorough	   cardiovascular	   assessment	   in	  
children	  with	  PWS.	  Electrocardiographic	  examination	  revealed	  mild	  abnormalities	  in	  
nine	   out	   of	   nineteen	   PWS	   patients	   (47%).	   In	   four	   patients	   electrocardiographic	  
findings	   were	   indicative	   of	   ventricular	   hypertrophy,	   which	   was	   not	   confirmed	   by	  
means	   of	   echocardiography.	   This	   was	   not	   surprising,	   since	   it	   is	   well-­‐known	   that	  
electrocardiography	   is	   associated	   with	   a	   relatively	   low	   accuracy	   in	   assessing	  
ventricular	  hypertrophy	   in	  children.29,30	   In	   five	  other	  patients,	  electrocardiographic	  
abnormalities	   necessitated	   future	   cardiac	   follow-­‐up	   due	   to	   asymptomatic	  
pathologic	  Q	  waves,	  a	  first	  degree	  atrioventricular	  block	  and	  a	  prolonged	  QT	  interval	  
which	  could	  indicate	  pathologic	  myocardial	  alterations.	  	  
	  
218	  |	  Chapter	  7	  
Conventional	   echocardiographic	   examination	   detected	   mild	   structural	   cardiac	  
anomalies	  in	  two	  of	  the	  nineteen	  (11%)	  children	  diagnosed	  with	  PWS,	  both	  of	  which	  
require	   long-­‐term	   cardiac	   follow-­‐up.	   One	   patient	   had	   a	   valvular	   pulmonary	   valve	  
stenosis,	   whereas	   in	   another	   patient	   an	   atrial	   septum	   defect	   of	   the	   ostium	  
secundum	   type	   was	   identified.	   In	   the	   latter	   patient,	   ECG	   findings	   indicated	   right	  
ventricular	   hypertrophy,	   which	   was	   not	   confirmed	   by	   conventional	  
echocardiography.	   Other	   morphological	   abnormalities	   were	   not	   detected.	   It	   is	  
important	  to	  note	  that	  left	  ventricular	  mass	  (indexed	  for	  body	  surface	  area	  as	  well	  
as	  height),	   left	  ventricular	   internal	  diameter	  as	  well	  as	  the	   interventricular	  septum	  
thickness	  in	  PWS	  patients,	  irrespective	  of	  GHT,	  were	  equal	  to	  respective	  findings	  in	  
healthy,	   age-­‐matched	   children.	   These	   findings	   are	   in	   contrast	   to	   previous	   reports	  
indicating	   a	   reduced	   left	   ventricular	  mass	   and	   left	   ventricular	   internal	   diameter	   in	  
adult	   PWS	  patients	   and	   adults	  with	   growth	  hormone	  deficiency	   (GHD).7,31,32,33	  We	  
did	   however	   find	   a	   difference	   in	   left	   ventricular	  mass	   corrected	   for	   body	   surface	  
area	   in	   children	   diagnosed	   with	   PWS	   when	   children	   who	   received	   GHT	   were	  
compared	  to	  those	  who	  did	  not	  receive	  GH	  replacement.	  Left	  ventricular	  mass	  was	  
significantly	   higher	   in	   the	   group	   of	   patients	   receiving	   GH	   substitution.	   This	   is	   in	  
agreement	  with	  a	  study	  performed	  by	  Marzullo	  et	  al.,	  which	  described	  that	  GHT	  in	  
adult	  PWS	  patients	  resulted	  in	  an	  increased	  left	  ventricular	  mass.34	  	  	  
Using	  conventional	  echocardiographic	   techniques	   to	  assess	   left	  ventricular	   systolic	  
function,	  we	  did	  not	  identify	  myocardial	  dysfunction	  in	  children	  with	  PWS.	  All	  tested	  
conventional	  systolic	  indices	  were	  within	  normal	  limits	  and	  similar	  to	  those	  found	  in	  
age-­‐matched	   control	   subjects.	   It	   is	   well	   known	   that	   standard	   echocardiographic	  
techniques	   are	   appropriate	   to	   detect	   global	   LV	   dysfunction	   at	   advanced	   stages	   of	  
cardiac	  disease.	  However,	  in	  children	  with	  various	  conditions	  these	  modalities	  have	  
not	  been	  able	  to	  identify	  subclinical	  systolic	  (regional)	  myocardial	  abnormalities.	  	  
	  
Previous	   reports	   have	   illustrated	   that	   strain	   imaging	   more	   carefully	   reflects	  
myocardial	   systolic	   function.11,12,13,15	   Our	   results	   indicate	   significant	   subclinical	  
systolic	   myocardial	   dysfunction	   in	   the	   presence	   of	   normal	   conventional	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echocardiographic	   indices	   in	   children	   diagnosed	   with	   PWS.	   Global	   peak	   systolic	  
strain	   values	   and	   global	   peak	   systolic	   strain-­‐rate	   measurements	   in	   all	   three	  
directions	   were	   significantly	   lower	   in	   PWS	   patients	   compared	   with	   healthy,	   age-­‐
matched	  children.	  Time	  to	  global	  peak	  systolic	  strain	  values	  in	  the	  patient	  group	  did	  
not	  differ	  significantly	  from	  those	  found	  in	  control	  subjects.	  Two-­‐dimensional	  strain	  
echocardiography	  measurements	  did	  not	  differ	  between	  boys	  and	  girls,	  nor	  did	  we	  
identify	  a	  relation	  with	  GHT.	  It	   is	  possible	  that	  the	  number	  of	  children	  investigated	  
in	   the	   present	   study	   is	   too	   small	   to	   detect	   such	   a	   relation.	   In	   contrast	   to	  
electrocardiographic	   and	   conventional	   echocardiographic	   abnormalities,	   which	  
were	   equally	   distributed	   among	   PWS	   patients	   with	   a	   deletion	   and	   maternal	  
uniparental	   disomy,	   2DSTE	   findings	   indicated	   more	   severe	   systolic	   dysfunction	   in	  
PWS	   patients	   with	   uniparental	   disomy.	   Radial	   peak	   systolic	   strain	   (-­‐rate)	  
measurement	   were	   significantly	   more	   affected	   in	   PWS	   patients	   with	   maternal	  
uniparental	   disomy	  when	   compared	   to	   the	   group	   of	   patients	   in	  whom	   a	   deletion	  
was	  detected.	  Interestingly,	  a	  previous	  report	  described	  an	  increased	  cardiovascular	  
fatality	  rate	  in	  adult	  PWS	  patients	  with	  maternal	  uniparental	  disomy	  compared	  with	  
fatality	   rates	   of	   PWS	   patients	   with	   a	   deletion.4	   The	   reason	   for	   this	   (possible)	  
increased	   risk	   of	   cardiovascular	   complications	   in	   PWS	   patients	   with	   maternal	  
uniparental	   disomy	   is	   unknown.	   Smith	   et	   al.	   hypothesize	   that	   another	   gene	   on	  
chromosome	  15	  (besides	  the	  q11-­‐q13	  region)	  is	  maternally	  imprinted	  and,	  when	  no	  
paternal	  copy	  is	  present,	  leads	  to	  deleterious	  effects	  on	  cardiac	  function.4	  
	  
Together,	   our	   results	   indicate	   that	   structural	   and	   functional	   cardiac	   abnormalities	  
are	  common	  in	  children	  diagnosed	  with	  PWS.	  Traditionally,	  cardiovascular	  fatalities	  
in	   PWS	   have	   been	   ascribed	   to	   obesity-­‐related	   complications,	   such	   as	   diabetes	  
mellitus,	   sleep	   apnea,	   arterial	   hypertension,	   and	   coronary	   artery	   disease.3,5,35	   This	  
has	  prompted	  many	   investigators	   to	  recommend	  strict	  control	  on	  calorie	   intake	   in	  
order	  to	  improve	  life	  expectancy.36	  Currently,	  there	  is	  an	  increasing	  awareness	  that	  
other	   factors,	   besides	   obesity,	   may	   contribute	   to	   poor	   health	   outcome	   and	  
circulatory	  fatalities	  in	  PWS.4,28	  The	  findings	  of	  the	  present	  study	  support	  the	  latter	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hypothesis	   since	  cardiac	  abnormalities	  were	   frequently	  present	  despite	   the	  virtual	  
absence	  of	  obesity	  in	  our	  PWS	  patients.	  	  
In	  this	  context,	  GHD	  has	  been	  suggested	  as	  a	  possible	  contributing	  factor	  leading	  to	  
increased	   risk	  of	   cardiovasculatory	   complications.	  Reduced	  GH	   secretion	  has	  been	  
documented	  in	  both	  children	  and	  adults	  with	  PWS.37,38,39,40	  It	  is	  known	  that	  patients	  
with	   childhood-­‐onset	  GHD	  often	   suffer	   both	   from	   structural	   cardiac	   abnormalities	  
and	  functional	  myocardial	   impairment,	   that	  combine	  to	  reduce	  diastolic	   filling	  and	  
impair	  left	  ventricular	  response	  to	  peak	  exercise.32	  Experimental	  and	  clinical	  studies	  
have	  provided	  evidence	  that	  both	  GH	  and	  its	  anabolic	  mediator,	  insulin-­‐like	  growth	  
factor-­‐1	   (IGF-­‐1)	   are	   implicated	   in	   cardiac	   development	   and	   function.41,42	   Left	  
ventricular	  mass	  and	   LV	  diameter	  are	   reduced	   in	  GHD	  patients	  proportionately	   to	  
the	   duration	   of	   GHD	   or	   to	   IGF-­‐I	   levels.33	   In	   large	   cohorts,	   cardiac	   dysfunction	   has	  
been	   reported	   proportionately	   to	   the	   severity	   of	   GHD,	   with	   systolic	   and	   diastolic	  
abnormalities	  affecting	  45–78%	  of	  GHD	  patients.43	  Another	  point	  that	  should	  not	  be	  
disregarded	   in	  patients	  with	  GHD	   is	   the	  presence	  of	  endothelial	  dysfunction.	  GHD	  
patients	   often	   have	   an	   increased	   vascular	   intima-­‐media	   thickness	   and	   a	   higher	  
occurrence	  of	  atheromatous	  plaques,	  that	  can	  further	  aggravate	  the	  hemodynamic	  
conditions	   and	   contribute	   to	   increased	   cardiovascular	   risk.44	   Epidemiological	   data	  
suggest	   that	   adults	   with	   hypopituitarism	   have	   reduced	   life	   expectancy	   compared	  
with	   healthy	   controls,	   with	   a	   greater	   than	   twofold	   increase	   mortality	   for	  
cardiovascular	   disease.45	   In	   patients	   with	   PWS,	   a	   GH/IGF-­‐I-­‐mediated	   control	   of	  
cardiac	   risk	   has	   been	   reported.	   A	   study	   by	   Marzullo	   et	   al.	   described	   decreased	  
cardiac	  mass	  and	  lower	  ejective	  and	  chronotropic	  response	  to	  dobutamine	  in	  adult	  
PWS	  patients	  compared	  with	  healthy	  obese	  controls.7	  Several	  lines	  of	  evidence	  have	  
suggested	   that	   the	   cardiovascular	   abnormalities	   can	   be	   partially	   reversed	   by	   GH	  
replacement	   therapy	   in	   GHD	   patients.	   The	   reversibility	   of	   cardiovascular	  
abnormalities	   after	   GH	   replacement	   in	   PWS	   and	   its	   effect	   on	   circulatory-­‐related	  
mortality	  have	  not	  been	  investigated.	  However,	  it	  has	  been	  reported	  that	  one	  year	  
of	  GHT	  in	  adult	  PWS	  patients	  results	  in	  improved	  LV	  mass	  without	  significant	  effects	  
on	   cardiac	   function.34	   A	   second	   factor,	   possibly	   contributing	   to	   circulatory	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complications	   in	   PWS	   is	   autonomic	   dysfunction	   characterized	   by	   diminished	  
parasympatic	   nervous	   system	   activity.46	   A	   disturbance	   in	   sympathovagal	   tone	   has	  
been	   implicated	   in	   the	   development	   of	   arrhythmia	   and	   sudden	   death	   in	   different	  
patient	  groups.47	  	  	  
	  
7.6 STUDY LIMITATIONS 
	  
This	   cross	   sectional	   study	   was	   conducted	   in	   a	   relatively	   small	   cohort	   of	   patients.	  
Despite	   the	   small	   number	   of	   patients,	   statistical	   significant	   differences	   in	   systolic	  
deformation	   between	   healthy	   individuals	   and	   patients	   with	   PWS	   were	   detected.	  
The	  clinical	  and	  prognostic	  implications	  of	  the	  identified	  abnormalities	  in	  myocardial	  
deformation	  described	   in	   this	   study	   remain	   to	  be	  elucidated.	  Currently	  we	  cannot	  
predict	   the	   clinical	   course	   of	   the	   patient	   group	   under	   investigation	   whose	  
echocardiographic	   findings	   suggest	   abnormal	   systolic	   deformation.	   Future	  
longitudinal	   follow-­‐up	   studies	   will	   hopefully	   provide	   an	   answer	   to	   this	   question.	  
However,	  previous	  reports	  have	  indicated	  that	  abnormal	  myocardial	  deformation	  is	  
associated	  with	  an	  increased	  risk	  of	  cardiovascular	  events	  in	  several	  other	  (cardiac)	  





Our	   results	   indicate	   structural,	   electrocardiographic	   and	   subclinical	   systolic	  
myocardial	   deformation	   abnormalities	   in	   all	   three	   directions	   (longitudinal,	  
circumferential	   and	   radial)	   in	   children	   with	   PWS.	   Systolic	   myocardial	   function	  
appears	  more	  affected	  in	  case	  of	  maternal	  uniparental	  disomy.	  Since	  cardiovascular	  
morbidity	  and	  mortality	   is	   substantial	   in	  PWS,	  especially	  adults,	  we	  emphasize	   the	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need	   for	   (repeated)	   cardiac	   assessment	   in	   PWS.	   Our	   findings	   indicate	   that	   2DSTE	  
could	  be	  of	  additional	  value.	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Chapter 8 
Myocardial 2D strain echocardiography and 
cardiac biomarkers in children during and shortly 
after anthracycline therapy for Acute 
Lymphoblastic Leukemia (ALL) 
A	  prospective	  study	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8.1 ABSTRACT  
	  
Background:	   Anthracycline-­‐induced	   cardiotoxicity	   can	   lead	   to	   severe	   heart	   failure	  
and	  is	  a	  growing	  problem	  in	  survivors	  of	  childhood	  cancer.	  
	  
Aim:	   The	   aim	   of	   this	   study	   was	   to	   investigate	   the	   additive	   value	   of	   cardiac	  
biomarkers	  and	  myocardial	  2D	  strain	  echocardiography	  in	  the	  assessment	  of	  cardiac	  
function	   in	   children	   with	   Acute	   Lymphoblastic	   Leukemia	   (ALL)	   during	   and	   shortly	  
after	  treatment	  with	  anthracyclines.	  	  
	  
Methods:	   Cardiac	   function	   of	   60	   children	   with	   ALL	   was	   prospectively	   studied	   by	  
means	   of	   cardiac	   Troponin	   T	   (cTnT)	   and	   N-­‐Terminal-­‐pro-­‐brain	   natriuretic	   peptide	  
(NT-­‐pro-­‐BNP)	   measurements,	   as	   well	   as	   conventional	   and	   myocardial	   2D	   strain	  
echocardiography.	   Cardiac	   assessment	   was	   performed	   at	   three	   instances:	   before	  
start	   of	   anthracycline	   therapy	   (T=0),	   after	   three	  months	   (T=1)	   and	   after	   one	   year	  
(T=2).	   Echocardiographic	   data	   were	   compared	   to	   respective	   measurements	  
acquired	  from	  60	  healthy,	  age-­‐matched	  controls.	  	  
	  
Results:	   None	   of	   the	   patients	   showed	   clinical	   signs	   of	   cardiac	   failure.	   Fractional	  
shortening	   (FS)	   remained	   normal.	   Cardiac	   function,	   as	   indicated	   by	   strain	   indices,	  
decreased	  significantly	  during	  treatment	  and	  was	  significantly	  decreased	  compared	  
to	   normal	   controls.	   cTnT	   levels	  were	   abnormal	   in	   11%	  of	   the	   patients	   at	   T=1	   and	  
were	   significantly	   related	   to	   increased	   time	   to	   global	   peak	   systolic	   longitudinal	  
strain	  at	  T=2	  (P	  =	  0.003).	  NT-­‐pro-­‐BNP	  levels	  were	  abnormal	  in	  13%	  of	  patients	  at	  T=1	  
and	  in	  20%	  at	  T=2.	  Absolute	  values	  of	  NT-­‐pro-­‐BNP	  increased	  throughout	  treatment	  
in	  59%	  of	  the	  patients.	  Predictors	  for	  abnormal	  cardiac	  biomarkers	  and	  myocardial	  
2D	   strain	   parameters	   at	   T=2	   were	   cumulative	   anthracycline	   dose,	   z-­‐score	   of	   the	  
diastolic	  left	  ventricular	  internal	  diameter	  and	  FS	  at	  baseline,	  abnormal	  NT-­‐pro-­‐BNP	  
at	  T=0	  and	  T=1,	  and	  global	  peak	  systolic	  longitudinal	  strain	  (-­‐rate)	  at	  T=1.	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Conclusion:	   Cardiac	   biomarkers	   and	   myocardial	   2D	   strain	   echocardiography	   are	  




Cardiotoxicity	   is	   a	   well-­‐known	   side	   effect	   of	   anthracycline	   therapy.	   Early-­‐onset	  
anthracycline-­‐induced	   cardiotoxicity	   occurs	   during	   or	   within	   the	   first	   year	   after	  
anthracycline	   treatment.	   It	   is	   a	   risk	   factor	   for	   the	   development	   of	   late-­‐onset	  
anthracycline-­‐induced	  cardiotoxicity,	  which	  is	  known	  to	  cause	  serious	  cardiac	  health	  
problems	  in	  a	  growing	  number	  of	  cancer	  survivors.1,2,3,4,5,6	  
	  
Cardiac	  biomarkers	  are	  increasingly	  used	  for	  the	  detection	  of	  anthracycline-­‐induced	  
cardiotoxicity.7,8,9,10,11,12,13,14,15,16,17	   Release	   of	   cardiac	   troponins	   is	   indicative	   for	  
myocardial	   necrosis.	   Natriuretic	   peptides	   are	   released	   by	   the	   myocardium	   in	  
response	  to	  volume	  and	  pressure	  overload	  and	  have	  shown	  to	  be	  sensitive	  markers	  
of	  left	  ventricular	  dysfunction.7,8	  The	  value	  of	  myocardial	  strain	  echocardiography	  in	  
early-­‐onset	  anthracycline-­‐induced	  cardiotoxicity	  has	  been	  studied	  by	  tissue	  Doppler	  
imaging	   and	   by	   means	   of	   2D	   speckle	   tracking.15,16,17	   These	   studies	   indicated	  
abnormal	   myocardial	   deformation	   during	   anthracycline	   therapy	   and	   years	   after	  
anthracycline	  therapy,	  with	  relatively	  preserved	  fractional	  shortening.15,16,17,18,19	  
	  
In	   the	   present,	   prospective	   study,	  we	   aim	   (1)	   to	   document	   cTnT	   and	  NT-­‐pro-­‐BNP	  
levels,	   as	   well	   as	   conventional	   and	   myocardial	   2D	   strain	   echocardiographic	  
parameters	   before,	   during	   and	   shortly	   after	   treatment	   with	   anthracyclines	   in	  
children	   with	   newly	   diagnosed	   ALL,	   (2)	   to	   find	   predictors	   for	   abnormal	   cardiac	  
function	   at	   one	   year	   after	   anthracycline	   treatment	   and	   (3)	   to	   compare	   cardiac	  
performance	   of	   children	   with	   ALL	   after	   one	   year	   of	   anthracycline	   treatment	   to	  
cardiac	  function	  of	  healthy	  controls.	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8.3 MATERIAL and METHODS 
8.3.1 STUDY POPULATION 
	  
Consecutive,	   newly	   diagnosed	   patients	   with	   childhood	   ALL	   and	   their	  
parents/guardians	   were	   asked	   informed	   consent	   to	   participate	   in	   our	   study	  
between	   January	   2006	   and	   March	   2009.	   Exclusion	   criteria	   consisted	   of	   cardiac	  
disease	  prior	  to	  therapy	  and	  renal	  failure.	  	  	  
	  
The	   first	   cardiac	  evaluation	  was	  performed	   in	   the	   first	  week	  of	  ALL	   treatment,	   i.e.	  
before	   the	   first	   anthracycline	   dose	   (T=0).	   The	   second	   cardiac	   evaluation	   was	  
performed	   at	   the	   end	   of	   the	   induction	   phase	   of	   the	   ALL	   treatment,	   which	   is	   ten	  
weeks	   after	   start	   of	   treatment	   and	   five	  weeks	   after	   the	   latest	   anthracycline	   dose	  
(T=1).	   The	   third	   cardiac	   evaluation	   was	   performed	   one	   year	   after	   start	   of	   ALL	  
treatment,	  which	  is	  at	   least	  two	  weeks	  after	  the	  last	  anthracycline	  dose	  (T=2).	  The	  
study	   was	   approved	   by	   the	   local	   ethics	   committee.	  
	  
8.3.2 CONTROL GROUP 
	  
As	  a	  control	  group,	  we	  included	  the	  conventional	  echocardiographic	  and	  2D	  speckle	  
tracking	  data	  of	  60	  healthy	  age-­‐matched	   controls	   that	  were	   routinely	   referred	   for	  
echocardiographic	   evaluation	   of	   an	   asymptomatic,	   innocent	   heart	   murmur	   or	   for	  
screening	  purposes.	  Subjects	  with	  structural	  (congenital)	  heart	  disease	  or	  abnormal	  
cardiac	  rhythms	  were	  excluded.	  Other	  exclusion	  criteria	  consisted	  of	  hypertension,	  
chronic	   illness,	   recent	   acute	   illness	   or	   poor	   echocardiographic	   image	   quality.	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8.3.3 ANTHRACYCLINE TREATMENT AS PART OF THE ANTILEUKEMIC 
THERAPY 
	  
Treatment	   according	   to	   the	   DCOG-­‐ALL-­‐10	   protocol	   is	   based	   the	   DCOG-­‐ALL-­‐8	  
protocol.	   Patients	   are	   stratified	   in	   three	   treatment	   groups;	   standard	   risk	   (SR),	  
medium	   risk	   (MR)	   and	   high	   risk	   (HR)	   patients,	   largely	   based	   on	   response	   to	  
treatment.20	   The	   total	   duration	   of	   treatment	   is	   two	   years,	   but	   shorter	   for	   HR	  
patients	  who	  are	  eligible	  for	  stem	  cell	  transplantation	  (SCT).	  At	  T=1,	  the	  cumulative	  
anthracycline	  dose	  of	  all	  patients	  is	  120	  mg/m2.	  At	  T=2,	  SR	  patients	  have	  received	  a	  
cumulative	   anthracycline	   dose	   of	   120	   mg/m2,	   MR	   patients	   300	   mg/m2	   and	   HR	  
patients	  a	  maximum	  cumulative	  anthracycline	  dose	  of	  240	  mg/m2	  and	  an	  additional	  
52,5	  mg/m2	  of	  mitoxantrone	  and	  18	  mg/m2	  of	  idarubicin,	  depending	  on	  (timing	  of)	  
SCT.	  All	  SCT	  patients	  received	  total	  body	  irradiation	  (TBI).	  
8.3.4 CARDIAC BIOMARKERS 
	  
Blood	  samples	  were	  obtained	  from	  ALL	  patients	  at	  T=0,	  T=1	  and	  T=2	  from	  a	  central	  
venous	   line.	   Cardiac	   TnT	   levels	   were	   assessed	   by	   the	   Elecsys	   Troponin	   T	   STAT	  
Immunoassay,	   performed	   on	   a	   Modular	   E	   immunoassay	   analyzer	   (Roche	  
Diagnostics,	  Mannheim,	  Germany).21	  A	  level	  of	  ≤	  0.01	  ng/ml	  was	  defined	  as	  normal.	  
NT-­‐pro-­‐BNP	  was	  measured	  using	  an	  electrochemiluminescence	  immunoassay,	  using	  
the	   NT-­‐pro-­‐BNP	   kit	   (Roche	   Diagnostics,	   Mannheim,	   Germany).	   Normal	   values	   for	  
children	  were	  based	  on	  age-­‐dependent	  reference	  values	  (97.5th	  percentile).22	  	  	  
8.3.5 CONVENTIONAL ECHOCARDIOGRAPHY 
	  
Transthoracic	   echocardiography	   in	   left	   lateral	   position	   was	   performed	   at	   rest,	  
without	   using	   sedation.	   Images	   were	   obtained	   with	   a	   3.0-­‐MHz	   and	   a	   5.0-­‐MHz	  
transducer,	  depending	  on	  the	  age	  and	  weight	  of	  the	  study	  subjects,	  using	  a	  Vivid	  7	  
echographic	   scanner	   (GE,	   Vingmed	   Ultrasound,	   Horten,	   Norway).	   Frame	   rate	   was	  
kept	   between	   70	   and	   100	   frames	   per	   second	   (fps).23,24	   Quantification	   of	   cardiac	  
234	  |	  Chapter	  8	  
chamber	  size,	   left	  ventricular	  mass	   (LVM)	  and	  systolic	  and	  diastolic	   left	  ventricular	  
function	   were	   measured	   in	   accordance	   with	   the	   recommendations	   for	   chamber	  
quantification	   by	   the	   American	   Society	   of	   Echocardiography.25	   Z-­‐scores	   of	   left	  
ventricular	   dimensions	   and	   LVM	   were	   calculated	   based	   on	   normal	   values	   of	   M	  
mode	  measurements.26,27	  The	   left	   ventricular	   systolic	   function	  was	   indicated	  using	  
fractional	  shortening	  (FS).	  Left	  ventricular	  diastolic	  function	  was	  indicated	  using	  the	  
E/A	   ratio,	   E/E’	   ratio	   and	   the	   isovolumic	   relaxation	   time.28,29	   Left	   ventricular	   mass	  
was	  calculated	  according	  to	  the	  formula	  of	  Devereux.30	  	  
8.3.6 2DSTE DATA ACQUISITION 
	  
Two-­‐dimensional	   grayscale	   images	   were	   obtained	   from	   the	   parasternal	   apical	   4-­‐
chamber	   and	   midcavity	   short-­‐axis	   (at	   the	   level	   of	   the	   papillary	   muscle)	   views.	   A	  
sector	  scan	  angle	  of	  30-­‐60	  degrees	  was	  chosen	  and	  	  frame	  rates	  of	  60-­‐90	  Hz	  were	  
used	  since	  these	  rates	  are	  considered	  to	  be	  optimal	  for	  speckle	  tracking.	  Cine	  loops	  
of	   three	  cardiac	   cycles	   triggered	  by	   the	  R	  wave	  of	   the	  QRS	  complex	  were	  digitally	  
saved.	   Off-­‐line	   analysis	   was	   performed	   using	   software	   for	   echocardiographic	  
quantification	   (EchoPAC	   6.1.0,	   GE	  Medical	   Systems,	   Horten,	   Norway).	   Separately,	  
timing	  of	   aortic	   valve	   closure	   and	  mitral	   valve	  opening	  was	  obtained,	   using	   single	  
gated	   pulsed	   Doppler	   or	   continuous	   wave	   Doppler	   images.	   These	   images	   were	  
acquired	   just	   after	   the	   2D	   strain	   grayscale	   images	   and	   special	   care	   was	   taken	   to	  
ensure	   that	   the	   heart	   rate	   was	   in	   the	   same	   range.	   Myocardial	   segments	   were	  
named	  and	  localized	  according	  to	  the	  statement	  of	  the	  Cardiac	  Imaging	  Committee	  
of	   the	   Council	   on	   Clinical	   Cardiology	   of	   the	  American	  Heart	  Association.31	  Manual	  
tracking	  of	   the	   endomyocardial	   borders	  was	  performed	  at	   the	   end-­‐systolic	   frame.	  
An	   automatic	   generation	   of	   the	   second	   epicardial	   tracing	   was	   created	   by	   the	  
software.	  The	  software	  automatically	  divided	   the	   image	   into	  six	   segments.	  Quality	  
of	   the	   tracking	   was	   verified	   for	   each	   segment	   and	   adjusted	  when	   needed.	   Strain	  
curves	   of	   three	   consecutive	   cardiac	   cycles	   and	   values	   of	   the	  manual	   timing	  were	  
imported	  into	  a	  custom-­‐made	  software	  package	  for	  further	  analysis.	  Cardiac	  cycles	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with	  a	   length	  more	   than	   ten	  percent	  different	   from	   the	  mean	   length	  of	   the	   three	  
cardiac	   cycles	   were	   excluded	   for	   further	   analysis.	   The	   average	   values	   of	   peak	  
systolic	  longitudinal	  (SL),	  radial	  (SR)	  and	  circumferential	  (SC)	  strain	  and	  strain	  rate	  of	  
the	   three	   imported	   curves	  were	   calculated	   by	   the	   custom	  made	   software.	   Global	  
strain	  and	  strain	  rate	  were	  calculated	  by	  averaging	  the	  six	  segments	  of	  each	  view.	  
Measurements	  of	  time	  to	  global	  peak	  systolic	  strain	  were	  expressed	  as	  a	  percentage	  
of	   the	  duration	  of	   the	   complete	   cardiac	   cycle	   (i.e.,	   R-­‐R	   interval).	   Strain	   values	   are	  
dimensionless	  and	  are	  expressed	  as	  percentages,	  whilst	  strain	  rate	  is	  denoted	  as	  s-­‐1.	  
Negative	   strain	   (-­‐rate)	   values	   reflect	   shortening/thinning,	   while	   positive	   strain	  
values	   reflect	   lengthening/thickening.	  We	   recently	   showed	   that	  myocardial	   strain	  
imaging	   with	   2D	   echocardiography	   can	   produce	   scores	   with	   high	   interobserver,	  
intraobserver	  and	  intrapatient	  reliability.32	  Abnormal	  global	  peak	  systolic	  SL,	  -­‐SR	  and	  
-­‐SC	  were	  defined	  as	   values	  below	   the	  5th	  percentile	  of	  normal	  pediatric	   reference	  
values	  according	  to	  age.33	  
8.3.7 STATISTICAL ANALYSIS 
	  
Characteristics	   of	   the	   study	   population	   and	   biomarker	   levels	   are	   reported	   using	  
median	  and	  range.	  Conventional	  echocardiographic	  and	  2D	  strain	  parameters	  were	  
summarized	  by	  using	  mean	  and	  standard	  deviation	  (SD).	  The	  biomarker	  levels	  were	  
studied	  at	  T=1	  and	  T=2	  for	  available	  paired	  observations	  using	  the	  McNemar	  test	  for	  
abnormal	   biomarkers	   levels	   and	   the	  Wilcoxon	   signed	   ranks	   test	   for	   the	   absolute	  
biomarker	   levels.	   The	   echocardiographic	   data	   in	   the	   patient	   group	   were	   studied	  
using	  Linear	  Mixed	  Models	  and	  Generalized	  Estimating	  Equations	  (GEE)	  to	  account	  
for	  correlations	  between	  different	  points	  in	  time.	  Echocardiographic	  parameters	  of	  
patients	   and	   controls	  were	   compared	   using	   the	   independent	   t-­‐test.	   Using	   logistic	  
regression	   analysis	   we	   searched	   for	   possible	   predictors	   at	   baseline	   and	   T=1	   for	  
abnormal	  cardiac	  biomarkers	  and	  2D	  myocardial	  global	  SL,	  SR	  and	  SC	  at	  T	  =	  2.	  We	  
refrained	  from	  multiple	  regression	  analysis	  because	  of	  the	  small	  number	  of	  subjects.	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Statistical	  analyses	  were	  performed	  using	  the	  Statistical	  Package	  for	  Social	  Sciences	  
(SPSS)	  for	  Windows,	  version	  16.0	  and	  SAS,	  version	  8.2.	  A	  P-­‐value	  less	  than	  0.05	  was	  
considered	  to	  indicate	  significance.	  	  
8.4 RESULTS 
8.4.1 SUBJECT CHARACTERISTICS 
	  
Seventy	   children	   and	   their	   parents	   were	   asked	   to	   give	   informed	   consent	   for	  
participation	   in	  this	  study.	  Parents	  of	   four	  patients	  refused	   informed	  consent.	  One	  
patient	   was	   excluded	   because	   of	   congenital	   heart	   disease	   (atrial	   septal	   defect).	  
Consequently,	   65	   patients	  were	   included	   in	   the	   study.	   Before	   T=1,	   three	   patients	  
altered	   treatment	   because	   of	   treatment	   related	   (non-­‐cardiac)	   toxicity	   and	   two	  
patients	   died	   (progressive	   disease	   and	   sepsis,	   respectively).	   Further	   analysis	   was	  
done	   in	   the	   remaining	   60	   patients.	   Three	   patients	   died	   after	   T=1	   (one	   sepsis	   and	  
two	  relapses,	  respectively)	  and	  one	  patient	  was	  lost	  to	  follow-­‐up	  by	  moving	  abroad.	  
Parents	  of	  one	  SR	  patient	  refused	  echocardiography	  and	  biomarker	  sampling	  at	  T=2.	  
In	   six	   patients,	   follow-­‐up	   was	   not	   available	   at	   T=2.	   Six	   patients	   in	   the	   HR-­‐group	  
completed	   T=2.	   Four	   of	   them	   received	   the	   full	   dose	   of	   anthracyclines,	   two	   were	  
eligible	  for	  SCT;	  one	  received	  a	  cumulative	  anthracycline	  dose	  of	  120	  mg/m2,	  one	  a	  
cumulative	  anthracycline	  dose	  of	  120	  mg/m2	  plus	  18	  mg/m2	  of	  idarubicin	  and	  26.25	  
mg/m2	   of	   mitoxantrone.	   None	   of	   the	   patients	   showed	   clinical	   symptoms	   (e.g.,	  
rhythm	  disorders,	  acute	  heart	  failure)	  of	  acute	  anthracycline-­‐induced	  cardiotoxicity	  
and	  none	  of	  them	  used	  cardiac	  medication.	  
	  
Hyperhydration,	  i.e.,	  the	  infusion	  of	  3000	  ml/m2/day	  of	  glucose	  2.5%/NaCl	  0.45%,	  as	  
part	  of	  the	  supportive	  care	  to	  prevent	  tumor	  lysis	  syndrome	  was	  given	  in	  95%	  of	  the	  
patients	  at	  T=0,	  but	  in	  none	  at	  T=1	  and	  T=2.	  The	  characteristics	  of	  ALL	  patients	  and	  
the	  healthy	  controls	  are	  described	  in	  table	  32.	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Table 32 - Characteristics of the study population 
	  
Values are expressed as median and range.   
*Hemoglobin, †Total Leucocyte Count. ‡Mann-Whitny-U analysis. 
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8.4.2 CARDIAC BIOMARKERS 
	  
The	  biomarker	  levels	  at	  T=0,	  T=1	  and	  T=2	  are	  shown	  in	  Table	  33.	  Levels	  of	  cTnT	  were	  
normal	   in	   all	   patients	   before	   start	   of	   anthracycline	   treatment	   (T=0).	   At	   T=1,	   cTnT	  
levels	  were	  abnormal	  in	  11%	  of	  the	  patients	  (5/45)	  and	  normalized	  in	  all	  at	  T=2.	  In	  
one	  MR-­‐patient,	  cTnT	  became	  abnormal	  at	  T=2	  (i.e.	  after	  a	  cumulative	  anthracycline	  
dose	  of	  300	  mg/m2).	  	  
NT-­‐pro-­‐BNP	  levels	  were	  abnormal	  in	  26%	  of	  the	  patients	  (12/46)	  at	  T=0.	  Ninety-­‐five	  
percent	   of	   the	   patients	   received	   hyperhydration	   at	   T=0,	  when	   plasma	   samples	   of	  
NT-­‐pro-­‐BNP	  and	  cTnT	  were	  obtained.	  The	  median	  NT-­‐pro-­‐BNP	   level	  at	  T=0	  was	  13	  
pmol/l	  (range	  2-­‐185).	  Abnormal	  NT-­‐pro-­‐BNP	  levels	  were	  not	  significantly	  related	  to,	  
but	   showed	   a	   tendency	   towards	   lower	   hemoglobin	   (Hb)	   levels,	   higher	   total	  
leucocyte	   counts	   (TLC)	   and	   hyperhydration	   (data	   not	   shown).	   NT-­‐pro-­‐BNP	   levels	  
were	   abnormal	   in	   13%	   6/45)	   at	   T=1	   and	   in	   20%	   of	   the	   patients	   (8/41)	   at	   T=2.	  
Absolute	  NT-­‐pro-­‐BNP	  levels	  increased	  during	  treatment	  in	  59%	  of	  the	  patients.	  	  
8.4.3 CONVENTIONAL ECHOCARDIOGRAPHIC PARAMETERS 
	  
Conventional	   echocardiographic	   parameters	   during	   treatment	   are	   shown	   in	   table	  
34.	  None	  of	  the	  patients	  had	  a	  FS	  below	  28%	  at	  any	  point.	  In	  23%	  of	  the	  patients	  FS	  
decreased	   more	   than	   10%	   between	   T	   =	   1	   and	   T	   =	   2.	   As	   a	   group,	   FS	   decreased	  
significantly	  after	  the	  first	  120	  mg/m2	  of	  anthracyclines	  (P	  <0.0001).	  Z-­‐scores	  of	  left	  
ventricular	  dimensions	  and	  LVM	  all	  changed	  significantly	  over	  time.	  	  
	  
Table	  35	  describes	  the	  echocardiographic	  data	  of	  ALL	  patients	  at	  T=2	  compared	  to	  
that	   of	   healthy	   controls.	   Conventional	   echocardiographic	   parameters	   of	   patients	  
showed	   significant	   lower	   FS,	   and	   increased	   IVRT	   compared	   to	  healthy	   controls.	   Z-­‐
scores	  of	  left	  ventricular	  dimensions	  and	  LVM	  were	  not	  significantly	  different	  from	  
healthy	  controls.	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Table 33 – Cardiac biomarkers in ALL patients during treatment with anthracyclines 
	  	   T	  =	  0	   T	  =	  1	   T	  =	  2	   P	  value	  
Number	  of	  patients	  (N)	   60	   60	   49	   	  	  
Number	  of	  biomarker	  
samples	  (N)	  	   46	   45	   41	   	  	  
Abnormal	  cTnT	  (%)	  [N]	  	   0	  (0)	   11	  (5)	   2	  (1)	   0.2*	  
cTnT	  (ng/ml)	   0.01	   0.01	  	  (0.01	  –	  0.04)	  
0.01	  	  
(0.01	  –	  0.02)	   0.08†	  
Abnormal	  NT-­‐pro-­‐BNP	  
(%)	  [N]	   26	  (12)	   13	  (6)	   20	  (8)	   0.5*	  
NT-­‐pro-­‐BNP	  (pmol/l)	   13	  (2	  –	  185)	   10	  (1	  –	  45)	   11	  (1	  –	  68)	   0.5†	  
 
Values are expressed as median and range, *McNemar test based on 37 paired available 
observations at T=1 and T=2, † Wilcoxon signed ranks test on 37 paired available 
observations at T=1 and T=2 
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Table 34 – Conventional echocardiographic 
Parameter	   T	  =	  0	   T	  =	  1	   T	  =	  2	   P	  value	  	  *	  
Number	  of	  patients	   60	   60	   49	   	  	  
FS	  (%)	   40	  ±	  5	   36	  ±	  3	   35	  ±	  3	   <	  0.0001	  
z-­‐score	  LVIDd	   0.14	  ±	  1.15	   0.63	  ±	  0.82	   0.48	  ±	  0.88	   0.005	  
z-­‐	  score	  LVPWd	   -­‐0.07	  ±	  1.14	   -­‐0.36	  ±	  0.88	   -­‐0.59	  ±	  1.28	   0.04	  
z-­‐score	  IVSd	   -­‐0.80	  ±	  1.05	   -­‐0.59	  ±	  0.98	   -­‐1.09	  ±	  1.05	   0.02	  
z-­‐score	  LVM	   -­‐2.23	  ±	  1.58	   -­‐1.61	  ±	  1.12	   -­‐2.20	  ±	  1.62	   0.007	  
IVRT	  (msec)	   72	  ±	  12	   67	  ±	  9	   71	  ±	  10	   0.01	  
E/A	  ratio	   1.8	  ±	  0.6	   1.8	  ±	  0.5	   1.8	  ±	  0.6	   0.80	  
E/E’	  ratio	   10.1	  ±	  4.8	   12.4	  ±	  3.9	   11.6	  ±	  5.7	   0.11	  
	  
Values are expressed as mean and standard deviation. * P values with respect to differences 
between time points are based on linear mixed model analyses. FS = fractional shortening; 
LVIDd = diastolic left ventricular internal diameter; LVPWd = diastolic left ventricular posterior 
wall thickness; IVSd = diastolic intraventricular septum diameter; LVM = left ventricular mass; 
IVRT = isovolumic relaxation time 
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Table 35 – Conventional echocardiographic parameters in ALL patients at T = 2 
compared to healthy controls 
Parameter	   Controls	   Patients	  at	  T	  =	  2	   P	  value	  	  *	  
Number	  of	  patients	   60	   49	   	  	  
FS	  (%)	   38	  ±	  4	   35	  ±	  3	   0.002	  
z-­‐score	  LVIDd	   0.51	  ±	  1.00	   0.48	  ±	  0.88	   0.86	  
z-­‐	  score	  LVPWd	   -­‐0.34	  ±	  1.42	   -­‐0.59	  ±	  1.28	   0.40	  
z-­‐score	  IVSd	   -­‐0.92	  ±	  1.14	   -­‐1.09	  ±	  1.05	   0.42	  
z-­‐score	  LVM	   -­‐2.03	  ±	  1.38	   -­‐2.20	  ±	  1.62	   0.56	  
IVRT	  (msec)	   47	  ±	  5	   71	  ±	  10	   <	  0.0001	  
E/A	  ratio	   2.0	  ±	  0.5	   1.8	  ±	  0.6	   0.03	  
E/E’	  ratio	   12.0	  ±	  5.0	   11.6	  ±	  5.7	   0.60	  
	  
Values are expressed as mean and standard deviation. * P values with respect to differences 
to ALL patients and controls are calculated using the independent t-test. FS = fractional 
shortening; LVIDd = diastolic left ventricular internal diameter; LVPWd = diastolic left 
ventricular posterior wall thickness; IVSd = diastolic intraventricular septum diameter; LVM = 
left ventricular mass; IVRT = isovolumic relaxation time 
	  
8.4.4 MYOCARDIAL STRAIN PARAMETERS 
	  
All	   myocardial	   2D	   strain	   parameters	   altered	   during	   anthracycline	   treatment;	   a	  
statistically	  significant	  decrease	  was	  observed	  for	  global	  SrL,	  global	  SR	  and	  global	  SC	  
(P	   =	   0.03,	   0.004	   and	   0.01,	   respectively)	   and	   all	   time	   to	   peak	   systolic	   strain	  
parameters	   increased	  significantly	   (P	  <0.001).	  Global	  SL,	  SrL	  and	  SR	  were	   inversely	  
related	  to	  cumulative	  anthracycline	  dose	  (P	  =	  0.004,	  0.03	  and	  0.006,	   respectively).	  
Patients	  with	  abnormal	  cTnT	  level	  at	  T=1	  had	  a	  significant	  longer	  time	  to	  peak	  global	  
SL	  at	  T=2	  (P	  =	  0.003).	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In	   contrast,	   all	   myocardial	   global	   peak	   systolic	   strain	   (-­‐rate)	   parameters	   were	  
significantly	  decreased	   in	  patients	  compared	   to	  healthy	  controls,	  except	   for	  global	  
SR.	   Time	   to	   peak	   global	   SL,	   SR	   and	   SC	   was	   significantly	   prolonged	   in	   patients	  
compared	  to	  healthy	  controls	  (P	  <0.0001).	  
	  
The	  2DSTE	  parameters	  in	  ALL	  patients	  during	  treatment	  are	  shown	  in	  table	  36.	  Table	  
37	   describes	   the	   2DSTE	   data	   of	   ALL	   patients	   at	   T=2	   compared	   to	   that	   of	   healthy	  
controls.	  
	  
8.4.5 PREDICTORS FOR ABNORMAL CARDIAC BIOMARKERS AND 
MYOCARDIAL STRAIN PARAMETERS 
	  
Cardiac	  biomarkers	  and	  2D	  myocardial	  global	  SL,	  SR	  and	  SC	  were	  defined	  as	  normal	  
and	  abnormal	  at	  T=2	  based	  on	  age-­‐dependent	  reference	  values.	  
-­‐ Predictors	  for	  abnormal	  global	  SL	  at	  T=2	  were	  cumulative	  anthracycline	  
dose	  (P	  <0.05,	  OR	  associated	  with	  an	  increase	  of	  100	  mg/m2	  =	  2.25,	  95%CI	  
[1.02-­‐4.93]),	  LVIDd	  z-­‐score	  at	  baseline	  (P	  =	  0.03,	  OR	  =	  1.95,	  95%CI	  [1.05-­‐
3.62])	  and	  FS	  at	  baseline	  (P	  <0.05,	  OR	  =	  1.17,	  95%CI	  [1.00-­‐1.36]).	  	  
-­‐ Predictors	  for	  abnormal	  global	  SC	  at	  T=2	  were	  global	  SL	  (P	  =0.02,	  OR	  =	  1.33,	  
95%CI	  [1.05-­‐1.68])	  and	  global	  SrL	  (P	  =	  0.04,	  OR	  =	  24.96,	  95%CI	  [1.22-­‐510])	  
at	  T=1.	  	  
-­‐ Predictors	  for	  abnormal	  NT-­‐pro-­‐BNP	  at	  T=2	  were	  an	  abnormal	  NT-­‐pro-­‐BNP	  
at	  T=0	  and	  T=1	  (P	  =	  0.01,	  OR	  =	  11.0,	  95%CI	  [1.6-­‐73.5]).	  	  
-­‐ Predictors	  for	  a	  decreased	  FS	  of	  more	  than	  10%	  at	  T=2	  were	  FS	  (P	  =	  0.01,	  
OR	  =	  1.5,	  95%CI	  [1.1-­‐2.0]),	  LVM	  z-­‐score	  (P	  =	  0.01,	  OR	  =	  3.8,	  95%CI	  [1.3-­‐10.7]	  
and	  z-­‐score	  of	  the	  diastolic	  left	  ventricular	  septum	  (P	  <0.01,	  OR	  =	  4.2	  95%CI	  
[1.6-­‐11.1])	  and	  z-­‐score	  of	  LVPWd	  (P	  =	  0.004,	  OR	  =	  4.1,	  95%CI	  [1.6-­‐10.9]	  at	  
T=1.	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Table	  36	  -­‐	  Strain	  parameters	  in	  ALL	  patients	  during	  treatment	  with	  anthracyclines	  
Parameter	   T	  =	  0	   T	  =	  1	   T	  =	  2	   P	  value	  	  *	  
Number	  of	  patients	   60	   60	   49	   	  	  
Global	  SL	  (%)	   -­‐18.2	  ±	  3.1	   -­‐17.3	  ±	  3.6	   -­‐16.7	  ±	  5.2	   0.5	  
Global	  SR	  (%)	   66.8	  ±	  12	   53.5	  ±	  13	   55.2	  ±	  16	   0.004	  
Global	  SC	  (%)	   -­‐19.4	  ±	  4.3	   -­‐17.1	  ±	  3.7	   -­‐16.9	  ±	  3.1	   0.01	  
Global	  SrL	  (s-­‐1)	   -­‐1.4	  ±	  0.3	   -­‐1.3	  ±	  0.3	   -­‐1.2	  ±	  0.4	   0.03	  
Global	  SrR	  (s-­‐1)	   2.6	  ±	  0.5	   2.4	  ±	  0.5	   2.3	  ±	  0.6	   0.1	  
Global	  SrC	  (s-­‐1)	   -­‐1.7	  ±	  0.3	   -­‐1.6	  ±	  0.3	   -­‐1.5	  ±	  0.2	   0.08	  
Time	  to	  global	  SL	  (%)	   43	  ±	  8	   51	  ±	  6	   48	  ±	  8	   <0.0001	  
Time	  to	  global	  SR	  (%)	   45	  ±	  8	   53	  ±	  8	   52	  ±	  8	   <0.0001	  
Time	  to	  global	  SC	  (%)	   43	  ±	  8	   50	  ±	  7	   48	  ±	  7	   <0.0001	  
Abnormal	  global	  SL	  (%)	   45	   52	   42	   0.51	  (GEE)	  
Abnormal	  global	  SR	  (%)	   3	   15	   15	   0.01	  (GEE)	  
Abnormal	  global	  SC	  (%)	   15	   35	   35	   0.002	  (GEE)	  
	  
Values are expressed as mean and standard deviation. * P values with respect to differences 
between time points are based on linear mixed model analyses or generalized estimating 
equations (GEE) analysis as indicated. Global SL: global peak systolic longitudinal strain; 
global SR: global peak systolic radial strain; global SC: global peak systolic circumferential 
strain; global SrL: global peak systolic longitudinal strain rate; global SrR: global peak systolic 
radial strain rate; global SrC: global peak systolic circumferential strain rate; time to global 
peak systolic strain is expressed as percentage of cardiac cycle (percentage of R-R interval). 
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Table 37 – Strain parameters in ALL patients at T = 2 compared to healthy controls 
Parameter	   Controls	   Patients	  at	  T	  =	  2	   P	  value	  	  	  
Number	  of	  patients	   60	   49	   	  	  
Global	  SL	  (%)	   -­‐20.9	  ±	  1.3	   -­‐16.7	  ±	  5.2	   <0.0001	  
Global	  SR	  (%)	   54.3	  ±	  6	   55.2	  ±	  16	   0.60	  
Global	  SC	  (%)	   -­‐22.5	  ±	  2.1	   -­‐16.9	  ±	  3.1	   <0.0001	  
Global	  SrL	  (s-­‐1)	   -­‐1.3	  ±	  0.1	   -­‐1.2	  ±	  0.4	   0.01	  
Global	  SrR	  (s-­‐1)	   3.4	  ±	  0.4	   2.3	  ±	  0.6	   <0.0001	  
Global	  SrC	  (s-­‐1)	   -­‐1.9	  ±	  0.2	   -­‐1.5	  ±	  0.2	   <0.0001	  
Time	  to	  global	  SL	  (%)	   43	  ±	  3	   48	  ±	  8	   <0.0001	  
Time	  to	  global	  SR	  (%)	   42	  ±	  4	   52	  ±	  8	   <0.0001	  
Time	  to	  global	  SC	  (%)	   43	  ±	  4	   48	  ±	  7	   <0.0001	  
	  
Values are expressed as mean and standard deviation. * P values with respect to differences 
to ALL patients and controls are calculated using the independent t-test. Global SL: global 
peak systolic longitudinal strain; global SR: global peak systolic radial strain; global SC: global 
peak systolic circumferential strain; global SrL: global peak systolic longitudinal strain rate; 
global SrR: global peak systolic radial strain rate; global SrC: global peak systolic 
circumferential strain rate; time to global peak systolic strain is expressed as percentage of 




Summary	  of	  study	  findings.	  In	  children	  with	  ALL	  treated	  with	  a	  relatively	  low	  dose	  of	  
cumulative	  anthracyclines,	   cardiac	   function	  deteriorated	  over	   time	  as	   indicated	  by	  
conventional	   and	   2D	   strain	   echocardiography.	   Comparison	   of	   echocardiographic	  
parameters	   of	   the	   patients	   at	   one	   year	   after	   anthracycline	   therapy	   with	   healthy	  
controls	  showed	  that	  mainly	  deformation	  parameters	  were	  affected.	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Biomarkers.	  Cardiac	  TnT	  levels	  were	  all	  normal	  before	  start	  of	  treatment	  (T=0)	  and	  
became	  abnormal	   in	  11%	  of	  patients	  after	  a	  cumulative	  anthracycline	  dose	  of	  120	  
mg/m2	   (at	   T=1).	   Release	   of	   cTnT	   during	   therapy	   or	   directly	   after	   anthracycline	  
therapy	  might	  reflect	  direct	  injury	  of	  cardiomyocytes.	  The	  present	  study	  shows	  that	  
even	  after	  a	  cumulative	  anthracycline	  dose	  of	  120	  mg/m2,	  which	  is	  considered	  to	  be	  
a	   relatively	   safe	  dose,	   damage	  of	   the	   cardiomyocytes	   occurs	   as	   indicated	  by	   cTnT	  
levels.34,35	   The	   fact	   that	   most	   of	   the	   patients	   had	   their	   last	   anthracycline	   dose	   6	  
months	  before	  T=2,	  might	  explain	  the	  absence	  of	  abnormal	  cTnT	  levels	  in	  all	  except	  
for	   one	   patient	   at	   that	   moment.	   The	   absolute	   levels	   of	   the	   abnormal	   cTnT	  
measurements	   in	   our	   patients	   were	   in	   the	   lower	   ranges.	   Measurement	   of	   high	  
sensitive	   cTnT	   is	   a	   newer	   method	   to	   detect	   troponin	   release	   at	   even	   lower	  
concentrations	   than	   that	   is	   detectable	   now.36	   This	  might	   be	   an	   interesting	   future	  
method	  to	  evaluate	  in	  our	  patients.	  Our	  results	  indicated	  that	  abnormal	  cTnT	  levels	  
at	  T=1	  were	  significantly	  related	  to	  increased	  time	  to	  reach	  the	  global	  peak	  systolic	  
longitudinal	   strain	   at	   T=2	   (P	   =	   0.003).	   A	   recent	   study	   of	   Sawaya	   and	   colleagues	  
showed	  a	  similar	  relation	  between	  cardiac	  Troponin	  I	  (cTnI)	  and	  longitudinal	  strain.	  
They	  concluded	  that	  abnormal	  cTnI	  levels	  and	  longitudinal	  strain	  were	  predictive	  of	  
cardiotoxicity	   in	   patients	   with	   breast	   cancer	   treated	   with	   anthracyclines	   and	  
trastuzumab.37	  	  
	  
In	   our	   study,	   an	   interesting	   finding	   was	   the	   unexpected	   high	   percentage	   of	  
abnormal	   NT-­‐pro-­‐BNP	   levels	   in	   patients	   (26%)	   before	   receiving	   anthracyclins.	   Our	  
hypothesis	  is	  that	  in	  children	  with	  ALL,	  release	  of	  NT-­‐pro-­‐BNP	  might	  be	  addressed	  to	  
commonly	   occurring	   symptoms	   as	   severe	   anemia,	   leucocytosis	   and	   to	  
hyperhydration	   to	   prevent	   tumor	   lysis	   syndrome.	   A	   tendency	   towards	   lower	   Hb	  
levels,	   higher	   leucocyte	   counts	   and	   hyperhydration	   was	   seen	   in	   our	   patients;	  
however	  this	  relation	  was	  not	  statistically	  significant.	  	  
	  
The	   number	   of	   patients	   with	   abnormal	   NT-­‐pro-­‐BNP	   levels	   increased	   throughout	  
treatment	  from	  13%	  at	  T=1	  to	  20%	  at	  T=2.	  Absolute	  values	  of	  NT-­‐pro-­‐BNP	  increased	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throughout	   treatment	   in	  59%	  of	   the	  patients.	  We	   recently	   showed	   that	   in	   a	   large	  
group	  of	  asymptomatic	  long-­‐term	  survivors	  of	  childhood	  cancer,	  none	  of	  them	  had	  
abnormal	   cTnT	   levels	   15	   years	   after	   anthracycline	   treatment	   and	   concluded	   that	  
assessment	   of	   cTnT	   levels	   does	   not	   contribute	   to	   the	   detection	   of	   subclinical	  	  
late-­‐onset	  anthracyline-­‐induced	  cardiotoxicity.	  On	  the	  other	  hand,	  abnormal	   levels	  
of	  NT-­‐pro-­‐BNP	  were	  detected	  in	  13%	  of	  patients	   in	  this	  group	  and	  were	  related	  to	  
cumulative	  anthracycline	  dose.38	  	  
	  
The	  predictive	  role	  of	  biomarkers	  in	  chemotherapy-­‐induced	  cardiotoxicity	  has	  been	  
reviewed	   before.39	   These	   data	   indicate	   that	   increased	   troponin	   levels	   appears	  
related	  to	  a	  high	  probability	  of	  major	  cardiac	  events	  within	  the	  first	  year	  of	  follow-­‐
up.	   Patients	   with	   a	   persistent	   normal	   troponin	   value	   would	   most	   likely	   not	   have	  
cardiac	   complications,	   with	   a	   negative	   predictive	   value	   of	   99%.	   The	   role	   of	  
natriuretic	   peptides	   in	   the	   prediction	   of	   anthracycline-­‐induced	   cardiotoxicity	  
seemed	   less	   clear.39	   Long-­‐term	   follow-­‐up	   of	   our	   patients	   might	   clarify	   this	   topic.	  
Biomarkers	   reflecting	   fibrosis	   of	   the	  myocardium,	   such	   as	   galectin-­‐3,	  might	   be	   of	  
additional	  use	  in	  the	  assessment	  of	  anthracycline-­‐induced	  cardiotoxicity.40	  
	  
Myocardial	  2D	  strain.	  None	  of	  the	  patients	  had	  clinical	  signs	  of	  acute	  and/or	  early-­‐
onset	  anthracycline-­‐induced	  cardiotoxicity;	  all	  cardiac	  changes	  in	  our	  patients	  were	  
subclinical.	   Although	   FS	   decreased	   significantly	   after	   120	   mg/m2	   of	   cumulative	  
anthracycline	   dose	   in	   our	   cohort,	   none	   of	   the	   patients	   had	   abnormal	   FS.	   FS	  
decreased	  more	  than	  10%	  in	  23%	  of	  the	  patients.	  Predictors	  for	  a	  10%	  decrease	  of	  
FS	  were	  decreased	  z-­‐scores	  of	  left	  ventricular	  dimensions	  and	  LVM.	  The	  cumulative	  
anthracycline	  dose	  correlated	  negatively	  with	  global	  peak	  systolic	  longitudinal	  strain	  
(P	   =	   0.004)	   and	   global	   peak	   systolic	   longitudinal	   strain	   rate	   (P	   =	   0.03)	   and	   global	  
peak	  systolic	  radial	  strain	  (P	  =	  0.006),	  but	  not	  with	  conventional	  echocardiographic	  
parameters,	  including	  FS.	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Increasing	   data	   suggest	   that	   systolic	   strain	   and	   especially	   strain	   rate	   are	   strong	  
indices	  of	  left	  ventricular	  contractility.41,42	  In	  addition,	  a	  growing	  number	  of	  studies	  
report	   on	   the	   usefulness	   of	  myocardial	   2D	   strain	   echocardiography	   in	  monitoring	  
anthracycline-­‐induced	   cardiotoxicity.15,16,17,18,19	   In	   our	   previous	   study	   in	   long-­‐term	  
survivors	   of	   childhood	   cancer	   treated	   with	   anthracyclines,	   we	   also	   showed	   that	  
strain	   parameters	   were	   lower	   as	   compared	   to	   healthy	   controls.16	   Similar	   findings	  
were	   reported	   by	   Tsai	   and	   colleagues,	   who	   studied	   cardiac	   function	   in	   long-­‐term	  
survivors	  of	  Hodgkin’s	   lymphoma.17	   Interestingly,	   Cheung	  and	   colleagues	   reported	  
impaired	   left	   ventricular	  myocardial	   deformation	   and	  mechanical	   dyssynchrony	   in	  
ALL	   patients	   after	   more	   than	   one	   year	   of	   treatment	   as	   compared	   to	   healthy	  
controls.	   They	   showed	   that	   synchronicity	   of	  myocardial	   deformation	  may	   provide	  
additional	  insights	  into	  the	  alteration	  of	  left	  ventricular	  mechanics.19	  In	  our	  present	  
study,	  we	  also	   assessed	   time	   to	   reach	  global	   peak	   systolic	   longitudinal,	   radial	   and	  
circumferential	   strain	   which	   was	   significantly	   longer	   as	   compared	   to	   healthy	  
controls.	   The	   increased	   time	   to	   peak	   systolic	   strain	   seems	   to	   occur	   during	  
anthracycline	   treatment.	   Reduced	   strain	   parameters	   and	   increased	   time	   to	   peak	  
systolic	   strain,	   in	   the	  presence	  of	   reduced	  wall	   dimensions,	   can	  be	  attributable	   to	  
loss	   of	   myocytes	   and	   increased	   collagen	   deposit,	   which	  may	   result	   in	  myocardial	  
fibrosis.	  This	  phenomenon	  is	  already	  reported	  in	  adults	  with	  heart	  failure.43	  	  
	  
8.6 STUDY LIMITATIONS 
	  
Due	  to	  disease	  related	  complications,	  a	  complete	  follow-­‐up	  of	  all	  patients	  was	  not	  
possible.	   Abnormal	   cardiac	   function	   before	   start	   of	   treatment	   for	   ALL	   might	   not	  
reflect	   the	   patients’	   normal	   cardiac	   function,	   due	   to	   disease	   related	   anemia	   and	  
leucocytosis	  and	  hyperhydration	  which	  might	  influence	  myocardial	  function.	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8.7 CONCLUSION 
	  
Children	   with	   newly	   diagnosed	   ALL	   showed	   a	   decline	   of	   systolic	   and	   diastolic	  
function	   during	   treatment	   with	   anthracyclines	   using	   conventional	   and	  myocardial	  
2D	   strain	   echocardiography.	   The	   use	   of	   cardiac	   biomarkers	   in	   combination	   with	  
myocardial	   2D	   strain	   echocardiography	   provides	   additive	   information	   in	   the	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9.1 SUMMARY & GENERAL DISCUSSION  
	  
Accurate	   knowledge	   of	   myocardial	   function	   is	   essential	   to	   the	   management	   of	  
cardiac	  disease,	  and	  the	  quest	  continues	   for	  an	  optimal,	  quantitative	   technique	  to	  
assess	   myocardial	   contractile	   function.	   Previous	   studies	   indicated	   that	   strain	  
analysis	   can	   provide	   important	   additional	   information	   regarding	   quantification	   of	  
myocardial	  function.	  Applications	  are	  found	  primarily	  in	  research,	  but	  also	  already	  in	  
clinical	  settings.	  	  
	  
The	   assessment	   of	   myocardial	   deformation	   might	   have	   potential	   benefits	   for	  
patients	   in	   whom	   the	   cardiac	   anatomy	   obstructs	   quantification	   of	   ventricular	  
function	  using	  M-­‐mode	  or	  two-­‐dimensional	  volumetric	  techniques.	  Investigating	  the	  
myocardium	   directly	   renders	   the	   strain-­‐based	   techniques	   geometry-­‐independent,	  
allowing	   the	   quantification	  of	   right	   ventricular	   performance	   as	  well	   as	   uni-­‐	   or	   left	  
ventricular	   systolic	   function	   in	   children	   with	   complex	   congenital	   heart	   disease.	   A	  
second	  advantage	  of	  myocardial	   deformation	   techniques	   is	   that	   these	   are	   able	   to	  
quantify	   regional	  myocardial	   function	   in	  addition	   to	  global	   cardiac	   function.	  Third,	  
unlike	  velocity-­‐based	  parameters,	  strain	  calculations	  are	  not	  affected	  by	  movement	  
due	  to	  global	  cardiac	  motion	  within	  the	  chest	  (cardiac	  translation)	  nor	  by	  the	  effect	  
(pulling	   or	   tethering)	   of	   surrounding	   segments	   on	   the	   segment	   of	   interest.	   This	  
characteristic	   of	   strain	   discriminates	   passive	  movement	   from	   true	   shortening	   and	  
stretching	  of	  the	  myocardial	  region	  under	  investigation.	  
	  
A	   relatively	   new	   application	   to	   assess	   myocardial	   deformation,	   is	   known	   as	   two-­‐
dimensional	   strain	   echocardiography	   (2DSTE)	   or	   ‘speckle	   tracking’.	   This	  
echocardiographic	  technique	  uses	  two-­‐dimensional	  multi-­‐frame	  B-­‐Mode	  (grayscale)	  
images	  to	  quantify	  strain	  and	  strain-­‐rate.	  	  
	  
In	   CHAPTER	   2	   and	   CHAPTER	   3	   we	   provide	   reference	   values	   for	   two-­‐dimensional	  
strain	  echocardiography	  parameters	  in	  children	  and	  young	  adults.	  The	  availability	  of	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pediatric	  reference	  values	  is	  a	  mandatory	  prerequisite	  for	  its	  use	  in	  clinical	  practice.	  
Previous	   studies	   were	   conducted	   in	   small	   cohorts	   of	   children	   and	   included	   peak	  
systolic	   strain	   measurements	   in	   just	   one	   or	   two	   directions	   without	   providing	  
information	   on	   the	   timing	   of	   peak	   systolic	   deformation.	   For	   these	   reasons,	   we	  
aimed	  at	  evaluating	  left	  ventricular	  myocardial	  strain	  in	  all	  three	  principal	  directions	  
of	   deformation	   (longitudinal,	   circumferential	   and	   radial)	   assessed	  with	   2DSTE	   in	   a	  
large,	   healthy	   pediatric	   and	   young	   adult	   cohort	   (birth	   to	   40	   years	   of	   age).	   Using	  
2DSTE	  we	   established	   reference	   values	   and	   determined	   the	   influence	   of	   age	   and	  
growth	   on	   these	   2DSTE	   parameters.	   Our	   results	   indicate	   that	   global	   peak	   systolic	  
strain	   in	   all	   three	   directions	   is	   lowest	   on	   both	   ends	   of	   the	   age	   spectrum	   under	  
investigation	   and	   reaches	   the	   maximum	   value	   around	   an	   age	   of	   18	   years.	   These	  
findings	   illustrate	   the	   importance	  of	  using	  age-­‐dependent	  reference	  values	   for	   the	  
adequate	   interpretation	   of	   2DSTE	   measurements,	   since	   left	   ventricular	   systolic	  
deformation	  alters	  during	  growth	  and	  development.	  	  	  
	  
Furthermore,	   we	   observed	   that	   deformation	   is	   not	   homogenously	   distributed	  
throughout	   the	   left	   ventricular	   wall	   and	   interventricular	   septum.	   Successive	  
contraction	   and	   relaxation	   of	   the	   ventricular	   myocardial	   band	   produces	   several	  
fundamental	   movements	   of	   the	   left	   ventricle,	   such	   as	   narrowing	   and	   shortening	  
(with	  torsion	  or	  twisting).	  Nonhomogenous	  deformation	  of	  the	  basal,	  mid	  and	  apical	  
ventricular	  segments	  provides	  coordinated	  left	  ventricular	  contraction.	  This	  uneven	  
distribution	  is	  illustrated	  by	  nonequal	  maximum	  systolic	  strain	  values	  among	  various	  
left	   ventricular	   segments,	   as	   well	   as	   regional	   differences	   in	   the	   required	   time	   to	  
reach	  the	  maximum	  deformation.	  These	   latter	  variations	   in	   timing	  of	  peak	  systolic	  
strain	   between	   left	   ventricular	  myocardial	   segments	   are	   different	   for	   various	   age	  
groups.	   Our	   findings	   indicate	   that	   aging	   results	   in	   a	   decreased	   extent	   of	  
synchronicity	   of	   left	   ventricular	   systolic	   deformation,	   even	   after	   correction	   for	  
differences	  in	  heart	  rate.	  The	  reference	  values	  provided	  in	  this	  study	  could	  be	  used	  
to	   assess	   mechanical	   dyssynchrony	   in	   various	   congenital	   and	   acquired	   cardiac	  
diseases.	   It	   is	   possible	   that	   2DSTE	   indices	   could	   provide	   valuable	   additional	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information	   on	   myocardial	   synchrony	   and	   systolic	   function	   which	   could	   be	   of	  
assistance	   in	  selecting	  patients	  who	  might	  benefit	   from	  “cardiac	  resynchronization	  
therapy”	  (CRT).	  The	  reason	  for	  this	  is	  that	  previous	  studies	  in	  adults	  have	  indicated	  
that	   2DSTE	   is	   a	   promising	   tool	   to	   predict	   which	   patients	   respond	   to	   CRT.	  
Furthermore,	   in	   the	   pediatric	   age	   groups	   the	   currently	   used	   selection	   criteria	   for	  
CRT,	  which	  are	  based	  on	  clinical	  status	  and	  QRS	  duration,	  appear	  not	  very	  suitable.	  	  	  
	  
In	   the	   subsequent	   section	  we	   investigated	   the	  potential	  of	  2DSTE	   in	   children	  with	  
different	  congenital	  or	  inherited	  cardiac	  diseases.	  	  
	  
In	   CHAPTER	   4	   we	   evaluate	   two-­‐dimensional	   strain	   echocardiographic	   findings	   in	  
children	  diagnosed	  with	  isolated	  congenital	  valvular	  aortic	  stenosis.	  These	  children	  -­‐	  
without	  prior	  intervention	  to	  relief	  pressure	  overload	  of	  the	  left	  ventricle	  -­‐	  suffered	  
from	   various	   degrees	   of	   stenosis.	   Our	   findings	   demonstrate	   that	   asymptomatic	  
children	   with	   congenital	   valvular	   aortic	   stenosis	   and	   preserved	   left	   ventricular	  
ejection	   fraction	  already	  exhibited	  decreased	  peak	   systolic	  myocardial	   strain	   in	   all	  
three	  principal	  directions	  of	  deformation	   (radial,	   circumferential	   and	   longitudinal),	  
even	   in	   case	   of	   mild	   stenosis.	   We	   found	   that	   the	   decline	   in	   longitudinal	   systolic	  
performance	   precedes	   that	   in	   other	   directions.	   These	   observations	   suggest	   that	  
2DSTE	   parameters	   could	   be	   useful	   for	   the	   early	   detection	   of	   subclinical	   left	  
ventricular	   myocardial	   dysfunction,	   which	   remains	   otherwise	   undetected	   by	  
conventional	  measurements	  of	  systolic	  function.	  	  
	  
In	   CHAPTER	   5	   we	   investigate	   the	   recovery	   of	   left	   ventricular	   myocardial	   systolic	  
performance	   using	   conventional	   and	   two-­‐dimensional	   strain	   echocardiography	  
before	  and	  after	  balloon	  valvuloplasty	  for	  severe,	  isolated	  congenital	  valvular	  aortic	  
stenosis.	   After	   balloon	   valvuloplasty	   we	   observed	   an	   incomplete	   recovery	   of	   left	  
ventricular	  deformation	   that	  cannot	  be	  completely	  attributed	   to	  concurrent	  aortic	  
regurgitation	  or	  residual	  stenosis.	  It	  is	  possible	  that	  these	  findings	  provide	  evidence	  
of	   irreversible	   myocardial	   damage.	   The	   clinical	   and	   prognostic	   implications	   of	  
Chapter	  9	  	  |	  257	  
permanent	   abnormal	   deformation	   in	   longitudinal	   and	   circumferential	   directions	  
remain	  to	  be	  elucidated.	   It	   is	  uncertain	   if	  earlier	  (surgical	  or	  catheter)	   intervention	  
will	  lead	  to	  complete	  recovery	  of	  myocardial	  strain.	  	  
	  
In	   CHAPTER	   6	   we	   describe	   left	   ventricular	   myocardial	   performance	   assessed	   by	  
means	   of	   physical	   examination,	   electrocardiography,	   conventional	  
echocardiography	  and	  2DSTE	  in	  a	  group	  of	  children	  with	  established	  mitochondrial	  
disease.	   Our	   results	   indicate	   subclinical	   systolic	   myocardial	   deformation	  
abnormalities	   in	   all	   three	   directions	   of	   deformation	   (longitudinal,	   circumferential	  
and	  radial)	  in	  the	  presence	  of	  normal	  conventional	  echocardiographic	  indices.	  Since	  
myocardial	  dysfunction	  in	  mitochondrial	  disorders	  is	  an	  ominous	  sign,	  these	  findings	  
emphasize	   the	  need	   for	   repeated	  cardiac	  assessment	  as	  part	  of	   the	  monitoring	  of	  
disease	   progression	   in	   patients	   with	   confirmed	   mitochondrial	   disorders.	   Our	  
findings	  illustrate	  that	  2DSTE	  could	  be	  of	  additional	  value	  in	  the	  cardiac	  assessment	  
in	  children	  diagnosed	  with	  mitochondrial	  disease.	  	  
	  
In	  CHAPTER	  7	  we	  evaluate	  cardiac	  anatomy	  and	  left	  ventricular	  myocardial	  systolic	  
function	   in	   children	  previously	  diagnosed	  with	  Prader-­‐Willi	   syndrome.	  Prader-­‐Willi	  
syndrome	  is	  associated	  with	  a	  substantial	   increased	  risk	  at	  (sudden)	  cardiovascular	  
death	   and	   morbidity,	   which	   cannot	   be	   entirely	   attributed	   to	   obesity-­‐related	   risk	  
factors.	   Cardiac	   structure	   and	   myocardial	   deformation	   has	   not	   been	   investigated	  
previously	   in	   (pediatric)	  patients	  with	  Prader-­‐Willi	   syndrome.	  Cardiac	  evaluation	   in	  
the	   current	   study	   consisted	   of	   physical	   examination,	   electrocardiography,	  
conventional	   echocardiography	   and	   2DSTE.	   Our	   results	   indicate	   few	   minor	  
structural	   (atrial	   septum	   defect	   and	   a	   pulmonary	   valve	   stenosis)	   as	   well	   as	  	  
electrocardiographic	   abnormalities.	   However,	   subclinical	   systolic	   myocardial	  
deformation	   abnormalities	   in	   all	   three	   directions	  were	   frequent.	   In	   approximately	  
70%	   of	   PWS	   patients	   under	   investigation,	   deformation	   appeared	   to	   be	   abnormal	  
(below	  5th	  percentile	  of	  previously	  established	  reference	  values	  according	  to	  age).	  
Systolic	   myocardial	   deformation	   appeared	   more	   affected	   in	   case	   of	   maternal	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uniparental	   disomy.	   Long-­‐term	   follow-­‐up	   studies	   in	   larger	   groups	   of	   patients	   are	  
required	   to	   determine	   the	   clinical	   and	   prognostic	   implications	   of	   the	   identified	  
abnormalities	   in	   myocardial	   deformation	   in	   pediatric	   Prader-­‐Willi	   patients.	   Since	  
cardiovascular	  morbidity	   and	  mortality	   is	   substantial	   in	   patients	   with	   Prader-­‐Willi	  
syndrome,	   especially	   in	   adults,	   we	   emphasize	   the	   need	   for	   (repeated)	   cardiac	  
assessment.	  Our	  findings	  indicate	  that	  2DSTE	  could	  be	  of	  additional	  value.	  	  
	  
In	  CHAPTER	  8	  we	  describe	  how	  2DSTE,	   in	  addition	   to	  Troponin	  T	  and	  N-­‐Terminal-­‐
pro-­‐brain	  natriuretic	  peptide	  assays,	  could	  be	  of	  assistance	  in	  the	  detection	  of	  early-­‐
onset	  anthracycline-­‐induced	  cardiotoxicity.	  Cardiotoxicity	  is	  a	  well-­‐known	  side	  effect	  
of	   anthracycline	   therapy.	   Early-­‐onset	   anthracycline-­‐induced	   cardiotoxicity	   occurs	  
during	  or	  within	  the	  first	  year	  after	  anthracycline	  treatment.	  It	  forms	  a	  risk	  factor	  for	  
the	   development	   of	   late-­‐onset	   anthracycline-­‐induced	   cardiotoxicity,	   which	   is	  
associated	   with	   serious	   cardiac	   morbidity	   and	   mortality	   in	   a	   growing	   number	   of	  
cancer	   survivors.	   In	   the	   current	   study	   we	   prospectively	   evaluated	   myocardial	  
performance	  using	  conventional	  echocardiographic	  modalities,	  2DSTE	  and	  through	  
the	   assessment	   of	   biomarkers	   (i.e.,	   cardiac	   Troponin	   T	   and	   N-­‐	   Terminal-­‐pro-­‐brain	  
natriuretic	   peptide)	   before	   start,	   after	   three	   months	   and	   after	   one	   year	   of	  
anthracycline	   therapy.	   The	   study	   population	   consisted	   of	   children	   recently	  
diagnosed	  with	  acute	   lymphoblastic	   leukemia	   in	   addition	   to	  healthy,	   age-­‐matched	  
controls.	   Our	   results	   indicate	   that	   myocardial	   systolic	   function,	   as	   assessed	   with	  
2DSTE,	   declined	   significantly	   during	   anthracycline	   treatment	   and	  was	   significantly	  
decreased	   compared	   to	   healthy,	   age-­‐matched	   controls.	   Predictors	   for	   abnormal	  
cardiac	  biomarkers	  and	  2D	  myocardial	  strain	  parameters	  after	  one	  year	  of	  therapy	  
were:	  cumulative	  anthracycline	  dose,	  diastolic	   left	  ventricular	   internal	  diameter	  (z-­‐
score),	   fractional	   shortening,	   cardiac	   biomarker	   levels	   and	   global	   peak	   systolic	  
longitudinal	  strain(-­‐rate)	  at	  baseline.	  These	  findings	  indicate	  that	  myocardial	  2DSTE	  
and	   cardiac	   biomarkers	   are	   useful	   in	   the	   detection	   of	   subclinical	   myocardial	  
alterations	  indicative	  of	  early-­‐onset	  anthracycline-­‐induced	  cardiotoxicity.	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9.2 FUTURE PERSPECTIVES 
	  
This	   relatively	   new	  method	   of	   2D-­‐strain	   imaging	   by	   using	   speckle	   tracking	   is	   still	  
evolving	   through	   research	   and	   development.	   Currently,	   this	   technique	   is	   not	   yet	  
considered	  part	  of	  a	   routine	  clinical	  echocardiographic	  examination.	  However,	   the	  
amount	  of	  research	  using	  this	  technology	   is	  escalating	  and	  the	  clinical	  applications	  
of	  this	  technique	  are	  likely	  to	  expand	  rapidly	  over	  the	  coming	  years.	  	  
	  
In	  our	  experience,	  speckle	   tracking	  could	  provide	  valuable	  additive	   information	  on	  
myocardial	  function	  in	  a	  variety	  of	  conditions.	  For	  example,	  in	  children	  with	  cardiac	  
disease	  without	  overt	   signs	  of	  heart	   failure,	   since	  2DSTE	  has	  proven	   to	  be	  able	   to	  
identify	   subclinical	   myocardial	   dysfunction	   at	   an	   earlier	   stage	   when	   compared	   to	  
conventional	   echocardiographic	   techniques.	   Second,	   since	   2DSTE	   determines	  
myocardial	  deformation	  independently	  of	  cardiac	  geometry,	  this	  technique	  may	  be	  
especially	   useful	   for	   the	   evaluation	   of	   myocardial	   performance	   of	   ventricles	   with	  
variable	  morphology	  (e.g.,	  congenital	  heart	  disease).	  Third,	  the	  regional	  assessment	  
of	   deformation	   is	   of	   potential	   value	   in	   ischemic	   heart	   disease.	   This	   may	   be	  
important	   in	   congenital	   lesions	   where	   coronary	   artery	   anomalies	   are	   present	   or	  
where,	   during	   cardiac	   surgery,	   the	   coronary	   artery	   flow	   was	   altered	   (e.g.,	   re-­‐
implanted).	   In	   addition,	   2DSTE	   could	   identify	   cardiac	   electromechanical	  
dyssynchrony	  which,	   depending	   on	   the	   underlying	   substrate,	   can	   be	   treated	  with	  
cardiac	   resynchronization	   therapy,	   even	   before	   dyssynchrony	   is	   accompanied	   by	  
overt	  heart	  failure.	  
	  
However,	  several	  unresolved	  issues	  remain	  which	  future	  research	  and	  development	  
should	  address.	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9.2.1 TECHNICAL ISSUES 
	  
IMAGE	  QUALITY	  
Adequate	  speckle	  tracking	  relies	  on	  the	  quality	  of	  grayscale	  B-­‐mode	  images	  used	  for	  
speckle	  tracking.	  For	  instance,	  acoustic	  shadowing	  or	  reverberations	  might	  influence	  
strain	   estimates.	   Furthermore,	   since	   2DSTE	   is	   influenced	   by	   signal	   noise,	   filtering	  
algorithms	   are	   used.	   However,	   filtering	   represents	   a	   compromise	   between	  
resolution	   and	  precision.	   If	   long	  windows	  are	  used	  or	   strain	   estimates	  of	  multiple	  
small	   windows,	   the	   standard	   deviation	   of	   the	   estimates	   decreases.	   However,	   the	  
resolution	  decreases	  also	  since	  the	  estimate	  represents	  a	  larger	  region.	  	  
In	   addition,	   in	   case	   of	   large	   ventricles	   it	   may	   be	   difficult	   to	   image	   the	   entire	  
myocardium	   in	   one	   frame,	   especially	   the	   apical	   segments.	   However,	   apical	  
foreshortening	   seriously	   affects	   the	   results	   of	   2DSTE,	   and	   should	   therefore	   be	  
minimized.	  	  
	  
UNKNOWN	  SOFTWARE	  ALGORITHMS	  	  
To	   track	   speckles	   and	   to	   compute	   deformation	   values,	   filtering	   and	   search	  
algorithms	  are	  used.	  The	  effects	  of	  these	  speckle	  tracking	  algorithms	  on	  the	  results	  
represents	  a	  ‘black	  box’	  and	  may	  vary	  from	  vendor	  to	  vendor,	  especially	  when	  radial	  
strain	   is	   concerned.	  Differences	   among	  vendors	   are	  driven	  by	   the	   fact	   that	   2DSTE	  
analysis	  is	  performed	  on	  data	  stored	  in	  a	  proprietary	  scan	  line	  format,	  which	  cannot	  
be	  analyzed	  by	  other	  vendor’s	  software.	  At	  present	  it	  is	  yet	  unclear	  how	  values	  from	  
different	   scanners	   and	   software	   versions	   compare.	   This	   issue	   needs	   further	  
investigation	   through	   cross-­‐platform	   comparisons	   before	   2DSTE	   can	   become	   a	  
mainstream	  methodology.	   Currently	   there	   is	   a	   joint	   effort	   between	   the	   American	  
Society	   of	   Echocardiography	   (ASE),	   European	   Association	   of	   Echocardiography	  
(EAE),	  and	  the	  industry	  to	  address	  this	  issue.	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9.2.2 STANDARDIZATION ISSUES 
	  
To	   enable	   the	   comparison	   of	   research	   outcomes	   as	   well	   as	   to	   facilitate	   clinical	  
utility,	  standardization	  of	  2DSTE	  examination	  is	  needed.	  For	  instance:	  
-­‐ What	  should	  be	  measured:	  	  
o How	   many	   myocardial	   segments	   and	   which	   ones	   should	   be	  
measured?	  
Different	   vendors	   use	   various	   numbers	   of	   myocardial	   segments	  
and	   different	   nomenclature.	   These	   differences	   among	   software	  
vendors	   attribute	   to	   the	   difficulties	   in	   comparing	   2DSTE	   results	  
assessed	  with	  different	  software	  packages.	  
o Peak	   strain	   (-­‐rate)	   and	   its	   timing	   during	   cardiac	   cycle	   is	   not	  
uniform	  across	  publications.	  Peak	  strain	  can	  be	  measured	  as	  peak	  
systolic	   strain,	   peak	   strain	   at	   end-­‐systole	   (at	   time	  of	   aortic	   valve	  
closure),	   or	   peak	   strain	   regardless	   of	   timing	   during	   cardiac	   cycle	  
(in	  systole	  or	  diastole).	  	  
-­‐ Standardized	  reporting	  of	  measurements.	  	  
-­‐ An	  echocardiographic	  study	  that	  incorporates	  2DSTE	  can	  yield	  a	  plethora	  of	  
data	   points	   that	   need	   to	   be	   processed	   in	   the	   framework	   of	   busy	   clinical	  
practice	  and	  synthesized	  into	  a	  coherent	  picture	  that	  is	  readily	  understood	  
by	  the	  clinician	  who	  may	  not	  be	  familiar	  with	  these	  methods.	  
9.2.3 PROGNOSTIC IMPLICATIONS 
	  
It	  is	  now	  time	  to	  establish	  the	  usefulness	  of	  2DSTE	  examination	  for	  clinical	  decision-­‐
making.	   Further	   research	   is	   needed	   to	   determine	   the	   sensitivity	   and	   specificity	   of	  
the	  measurements	   obtained	   using	   this	   technique	   and	   to	   define	   its	   strengths	   and	  
limitations	  in	  various	  cardiac	  conditions.	  In	  particular,	  whether	  the	  measured	  values	  
correlate	   well	   with	   clinical	   outcome	   needs	   to	   be	   established	   in	   longitudinal	  
interventional	   studies.	   A	   primary	   goal	   will	   be	   the	   definition	   of	   cut-­‐off	   values	   for	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medical	   decision-­‐making	   and	   to	   correlate	   these	   with	   hard	   end-­‐points.	   This	   will	  
require	   larger	   prospective	   studies,	   as	   well	   as	   an	   effort	   to	   standardize	   2DSTE	  
examinations,	   address	   the	   problems	   listed	   above,	   and	   finally	   incorporate	   two-­‐
dimensional	  strain	  echocardiography	  into	  the	  realities	  of	  routine	  clinical	  practice.	  	  
	  
9.3 TO CONCLUDE 
	  
What	   is	   clear	   is	   that	   further	   work	   is	   needed	   before	   this	   technique	   can	   be	   fully	  
applied	  in	  the	  clinical	  setting,	  but	  we	  believe	  that	  the	  future	  appears	  bright	  for	  2D-­‐
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10.1 SAMENVATTING & DISCUSSIE 
	  
Accurate	  kennis	  van	  het	  functionerend	  vermogen	  van	  de	  hartspier	  is	  van	  essentieel	  
belang	   voor	   de	   behandeling	   van	   hartziekten.	   Tot	   op	   heden	   is	   het	   echter	   lastig	  
gebleken	  om	  de	  cardiale	   functie	   in	  diverse	  patiëntengroepen	  op	  een	  betrouwbare	  
wijze	  in	  kaart	  te	  brengen.	  De	  zoektocht	  naar	  een	  optimale	  techniek	  om	  de	  kwaliteit	  
van	   het	   functioneren	   van	   de	   hartspier	   in	   mate	   en	   getal	   uit	   te	   drukken	   zet	   zich	  
hiermee	  voort.	  	  
	  
Uit	   voorgaand	   onderzoek	   is	   gebleken	   dat	   een	   relatief	   nieuwe	   techniek,	   genaamd	  
’strain	  analyse’	  belangrijke,	  toegevoegde	  informatie	  lijkt	  te	  bieden	  over	  de	  mate	  van	  
functioneren	   van	   de	   hartspier.	   Deze	   techniek	   wordt	   momenteel	   al	   toegepast,	  
hoewel	  vooralsnog	  voornamelijk	  in	  het	  kader	  van	  onderzoek.	  	  
	  
Deze	   techniek,	   die	   de	  mate	   van	   vervorming	   (strain)	   van	   de	   hartspier	   bepaalt,	   zou	  
met	   name	   van	   grote	   aanvullende	   waarde	   kunnen	   zijn	   bij	   patiënten	   met	   een	  
afwijkende	  bouw	  en	  vorm	  van	  de	  hartkamer(s).	  De	  huidige	  echotechnieken	  om	  de	  
cardiale	  functie	  weer	  te	  geven	  zijn	  namelijk	  niet	  goed	  toepasbaar	  in	  deze	  categorie	  
patiënten.	   Aangezien	   door	   middel	   van	   strain	   analyses	   het	   functioneren	   van	   de	  
hartspier	  onafhankelijk	   van	   zijn	   vorm	  bepaald	  kan	  worden,	   kan	  deze	   techniek	  ook	  
toegepast	  worden	   in	   het	   geval	   van	   complexe	   aangeboren	   hartafwijkingen	  waarbij	  
de	  bouw	  van	  de	  hartkamer(s)	  abnormaal	  is.	  	  
	  
Een	   tweede	   voordeel	   van	   strain	   analyse	   is	   dat	   deze	   techniek	   naast	   de	   globale	  
functie	  van	  de	  hartkamer(s)	  ook	  de	  regionale	  functie	  kan	  weergeven,	  iets	  wat	  tot	  op	  
heden	   zeer	   moeilijk	   is	   gebleken.	   Ten	   derde,	   in	   tegenstelling	   tot	   parameters	   die	  
gebaseerd	  zijn	  op	  snelheid,	  worden	  strain	  berekeningen	  (gebaseerd	  op	  vervorming	  
van	   de	   hartspier)	   niet	   tot	   nauwelijks	   beïnvloed	   door	   globale	   bewegingen	   van	   het	  
hart	  in	  de	  borstkas	  noch	  door	  het	  effect	  (trekkrachten)	  van	  omliggende	  weefsels	  op	  
het	  gebied	  van	  de	  hartspier	  dat	  men	  wil	  onderzoeken.	  Deze	  kenmerken	  van	  strain	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analyse	   zorgen	   ervoor	   dat	   deze	   techniek	   passieve	   bewegingen	   van	   de	   hartspier	  
onderscheid	  van	  ware	  contractie	  (actieve	  beweging).	  	  	  
Een	  relatief	  nieuwe	  techniek	  om	  strain	  te	  bepalen	  is	  bekend	  als	  ‘twee-­‐dimensionale	  
strain	   echocardiografie	   (2DSTE)	   of	   speckle	   tracking’.	   De	   echocardiografische	  
methode	  maakt	  gebruik	  van	  twee-­‐dimensionale	  multiframe	  B-­‐mode	  plaatjes	  om	  de	  
mate	  en	  frequentie	  van	  vervorming	  van	  de	  hartspier	  te	  bepalen.	  	  
	  
In	   HOOFDSTUK	   2	   en	   HOOFDSTUK	   3	   worden	   referentiewaardes	   voor	   2DSTE	  
parameters	  weergegeven	  in	  kinderen	  en	  jong	  volwassenen,	  welke	  tot	  op	  heden	  nog	  
niet	  waren	   vastgesteld.	  De	  beschikbaarheid	   van	   referentiewaardes	   is	   een	   vereiste	  
voor	   gebruik	   in	   de	   klinische	   praktijk.	   Voorgaand	   onderzoek	   op	   dit	   gebied	   werd	  
uitgevoerd	   in	  kleine	  groepen	  kinderen	  en	  beschreef	  enkel	  strain	  bepalingen	  in	  één	  
of	  twee	  richtingen	  zonder	  informatie	  te	  bieden	  over	  de	  timing	  van	  het	  bereiken	  van	  
de	  maximale	  vervorming	  gedurende	  de	  hartcyclus.	  Om	  deze	  reden	  was	  ons	  streven	  
om	  de	  normale	  vervorming	  van	  de	  linker	  hartkamer	  gedurende	  de	  hartcyclus	  in	  drie	  
richtingen	   in	   kaart	   te	   brengen	   in	   een	   grote	   groep	   gezonde	   kinderen	   en	   jong	  
volwassenen	   (0	   tot	   40	   jaar)	   door	   middel	   van	   2DSTE.	   Ons	   doel	   was	   om	   op	   deze	  
manier	  referentiewaardes	  vast	  te	  stellen	  voor	  deze	  leeftijdscategorie	  en	  de	  invloed	  
van	   leeftijd	   en	   groei	   te	   bepalen.	   Onze	   resultaten	   tonen	   aan	   dat	   de	   maximale	  
vervorming	  van	  de	   linker	  hartkamer	   in	  alle	  3	  de	   richtingen	  het	   laagst	   is	  aan	  beide	  
uiteinden	   van	   het	   onderzochte	   leeftijdsspectrum.	   De	   maximale	   waardes	   werden	  
gevonden	   rond	   de	   leeftijd	   van	   18	   jaar.	   Zowel	   de	   zuigelingen	   als	   de	   dertigers	  
vertoonden	   een	   lagere	   maximale	   vervorming	   in	   vergelijking	   met	   tieners.	   Deze	  
resultaten	   onderstrepen	   het	   belang	   van	   het	   gebruik	   van	   leeftijdsspecifieke	  
referentiewaardes	   voor	   een	   adequate	   interpretatie	   van	   2DSTE	   bepalingen	  
aangezien	  de	  mate	  vervorming	  lijkt	  te	  veranderen	  gedurende	  groei	  en	  ontwikkeling.	  	  
	  
Daarnaast	   zagen	   we	   ook	   dat	   de	   mate	   en	   timing	   van	   vervorming	   van	   de	  
hartspierwanden	   van	   de	   linker	   hartkamer	   niet	   overal	   gelijk	   is.	   Segmenten	   aan	   de	  
basis	  van	  de	  kamer,	  in	  het	  midden	  en	  de	  apicale	  segmenten	  trekken	  in	  verschillende	  
268	  |	  Chapter	  10	  
mate	  en	  op	  verschillende	  tijdstippen	  samen.	  Hierdoor	  ontstaat	  een	  gecoördineerde	  
contractie	  van	  de	  hartspier.	  Onze	  onderzoeksresultaten	  laten	  zien	  dat	  de	  onderlinge	  
verschillen	   tussen	   de	   diverse	   segmenten	   van	   de	   linker	   hartkamer,	  met	   betrekking	  
tot	   het	   tijdstip	   waarop	   de	   maximale	   vervorming	   wordt	   bereikt,	   niet	   voor	   alle	  
leeftijdsgroepen	   gelijk	   is.	   Naar	   mate	   de	   leeftijd	   stijgt,	   neemt	   de	   mate	   van	  
synchroniteit	   van	   deformatie	   af.	   Deze	   verschillen	   in	   synchronie	   tussen	   de	   diverse	  
leeftijdsgroepen	  blijven	  ook	  bestaan	  na	  correctie	  voor	  variatie	  in	  hartfrequentie.	  	  
De	   referentiewaardes	   die	   in	   deze	   studie	   beschreven	   worden	   zouden	   gebruikt	  
kunnen	  worden	  om	  de	  mate	  van	  mechanische	  dyssynchronie	  vast	  te	  stellen	  van	  de	  
linker	   hartkamer	   in	   diverse	   cardiale	   aandoeningen.	   Het	   is	   zeer	   goed	  mogelijk	   dat	  
2DSTE	  parameters	  waardevolle,	  aanvullende	  informatie	  zouden	  kunnen	  bieden	  ten	  
aanzien	   van	   myocardiale	   synchronie	   en	   systolische	   functie,	   hetgeen	   nuttig	   zou	  
kunnen	  blijken	  bij	  de	  selectie	  van	  patiënten	  voor	  cardiale	  resynchronisatie	  therapie	  
(CRT).	  	  
	  
In	   de	   hierop	   volgende	   sectie	   hebben	   we	   de	   potentiele	   waarde	   van	   2DSTE	  
onderzocht	   bij	   het	   in	   kaart	   brengen	   van	   de	   cardiale	   functie	   bij	   kinderen	   met	  
verschillende	  aangeboren	  hartafwijkingen	  en	  erfelijke	  aandoeningen.	  	  
	  
In	  HOOFDSTUK	   4	   hebben	   we	   door	   middel	   van	   conventionele	   echotechnieken	   en	  
met	  behulp	  van	  2DSTE	  het	  functioneren	  van	  de	  linker	  hartspier	  in	  kaart	  gebracht	  bij	  
een	  groep	  kinderen	  met	  een	  geïsoleerde	  aangeboren	  vernauwing	  van	  de	  aortaklep.	  
Geen	   van	   deze	   kinderen	   had	   op	   het	  moment	   van	   onderzoek	   in	   het	   verleden	   een	  
ingreep	  ondergaan	  (in	  een	  poging	  tot)	  om	  deze	  vernauwing	  te	  verhelpen.	  De	  ernst	  
van	   vernauwing	   was	   niet	   uniform	   waardoor	   een	   breed	   spectrum	   van	   deze	  
aandoening	  onderzocht	  kon	  worden.	  Onze	  bevindingen	  tonen	  aan	  dat	  de	  mate	  van	  
vervorming	  van	  de	  linker	  hartkamer	  in	  deze	  kinderen	  afwijkend	  is	  in	  vergelijking	  met	  
gezonde	  kinderen.	  Deze	  bevindingen	  werden	  gedaan	  ondanks	  het	  feit	  dat	  geen	  van	  
deze	  kinderen	  klachten	  ondervond	  van	  de	  klepvernauwing	  en	  ondanks	  het	  feit	  dat	  
de	   conventionele	   indices	   om	   het	   functioneren	   van	   de	   linker	   hartkamer	   weer	   te	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geven	  niet	  afwijkend	  waren.	  Opvallend	  was	  de	  strain	  parameters	  afwijkend	  waren,	  
zelfs	  in	  de	  groep	  met	  een	  milde	  vernauwing	  van	  de	  aortaklep.	  In	  het	  geval	  van	  een	  
ernstige	  vernauwing	  van	  de	  aortaklep	  was	  de	  vervorming	  afwijkend	   in	  alle	  drie	  de	  
richtingen	   van	   contractie,	   echter	   in	   het	   geval	   van	   milde	   vernauwing	   enkel	   in	   de	  
lengterichting	  van	  de	  hart	  as	   (longitudinaal).	  Deze	  resultaten	  tonen	  aan	  dat	  2DSTE	  
van	   toegevoegde	   waarde	   zou	   kunnen	   zijn	   bij	   het	   vroegtijdig	   opsporen	   van	  
verminderd	   functioneren	   van	   de	   linker	   hartkamer	   welke	   door	   conventionele	  
echotechnieken	  onopgemerkt	  zou	  blijven.	  Echter,	  de	  prognostische	   implicaties	  van	  
deze	   bevindingen	   moeten	   nog	   worden	   vastgesteld	   door	   middel	   van	   toekomstig	  
longitudinaal	  onderzoek.	  	  
	  
In	   HOOFDSTUK	   5	   onderzoeken	   we	   het	   herstel	   van	   de	   werking	   van	   de	   linker	  
hartkamer	   door	   middel	   van	   conventionele	   echotechnieken	   en	   2DSTE	   vóór	   en	   na	  
correctie	   (ballondilatatie	  door	  middel	  van	  katheterisatie)	  van	  de	  drukbelasting	  van	  
de	  linker	  hartkamer	  in	  kinderen	  met	  een	  ernstige	  vorm	  van	  aortaklep	  vernauwing.	  	  
Na	  de	  ingreep	  zagen	  we	  een	  incompleet	  herstel	  van	  de	  linker	  ventrikel	  vervorming	  
welke	  niet	  (geheel)	  toegeschreven	  kan	  worden	  aan	  een	  restant	  vernauwing	  dan	  wel	  
het	  optreden	  van	  kleplekkage.	  Het	  is	  mogelijk	  dat	  deze	  bevindingen	  het	  gevolg	  zijn	  
van	   onherstelbare	   schade	   die	   veroorzaakt	   is	   door	   langdurige	   blootstelling	   van	   de	  
hartspier	  aan	  een	  verhoogde	  weerstand	  of	  dat	  het	  een	  uiting	   is	  van	  een	   intrinsiek	  
aanlegstoornis.	   De	   klinische	   en	   prognostische	   implicaties	   van	   deze	   persisterend	  
afwijkende	   vervorming	   moet	   nog	   worden	   bepaald	   in	   prospectief	   (interventie)	  
onderzoek.	  Het	  is	  onzeker	  of	  eerder	  ingrijpen	  wel	  zal	  leiden	  tot	  compleet	  herstel.	  	  
	  
In	  HOOFDSTUK	  6	  beschrijven	  we	  de	  functie	  van	  de	  linker	  hartkamer	  in	  kinderen	  met	  
een	  aangetoonde	  stoornis	   in	  de	  energie	  huishouding	  (mitochondriële	  stoornis).	  De	  
functie	   van	   de	   linker	   hartkamer	   hebben	   we	   in	   deze	   groep	   patiënten	   in	   beeld	  
gebracht	  door	  middel	  van	  lichamelijk	  onderzoek,	  elektrocardiografie,	  conventionele	  
echocardiografie	   en	   door	   middel	   van	   2DSTE.	   Onze	   resultaten	   geven	   aan	   dat	   de	  
vervorming	  van	  de	  linker	  hartspier	  in	  deze	  groep	  kinderen	  abnormaal	  is	  in	  alle	  drie	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de	   richtingen	  zonder	  dat	   ze	  hiervan	  duidelijk	  merkbare	  klachten	  ondervinden.	  Het	  
lichamelijk	   onderzoek,	   elektrocardiografisch	   en	   de	   conventionele	   echotechniek	  
indices	   vertoonden	   geen	   afwijkingen.	  Aangezien	  het	   verminderd	   functioneren	   van	  
de	  hartspier	  bij	  patiënten	  met	  een	  energie	  stofwisselingstoornis	  een	  omineus	  teken	  
is	   en	   gepaard	   gaat	   met	   een	   sterk	   verminderde	   levensverwachting,	   onderstrepen	  
deze	  bevindingen	  het	  belang	  van	  herhaaldelijk	  onderzoek	  van	  de	  hartspier	  functie	  in	  
deze	  patiëntengroep.	  Het	   is	   zeer	  goed	  mogelijk	  dat	  2DSTE	  hierbij	   van	  aanvullende	  
waarde	  zou	  kunnen	  zijn.	  	  
	  
In	  HOOFDSTUK	   7	   onderzoeken	   we	   de	   bouw	   (anatomie)	   en	   functie	   van	   de	   linker	  
hartkamer	   in	   kinderen	   die	   eerder	   gediagnosticeerd	   zijn	   met	   het	   Prader-­‐Willi	  
syndroom.	  Dit	  syndroom	  wordt	  geassocieerd	  met	  een	  substantieel	  verhoogd	  risico	  
op	   (acuut)	   cardiovasculair	   overlijden	   en	   chronisch	   hart-­‐en-­‐vaat	   lijden.	   Voorheen	  
schreef	  men	  dit	   voornamelijk	   toe	  aan	  het	   feit	  dat	  deze	  patiënten	  vaak	  obees	   zijn.	  
Tegenwoordig	   is	   men	   echter	   steeds	   meer	   van	   mening	   dat	   obesitas-­‐gerelateerde	  
risicofactoren	  niet	  de	  volledige	  lading	  dekken.	  De	  cardiale	  anatomie	  en	  de	  mate	  van	  
vervorming	  van	  de	  hartspier	  is	  nog	  niet	  eerder	  onderzocht	  bij	  kinderen	  die	  aan	  het	  
Prader-­‐Willi	  syndroom	  lijden.	  Ons	  doel	  was	  daarom	  om	  de	  bouw	  en	  functie	  van	  het	  
hart	   bij	   deze	   groep	   kinderen	   in	   beeld	   te	   brengen.	   Dit	   hebben	   we	   gedaan	   door	  
middel	   van	   lichamelijk	   onderzoek,	   elektrocardiografie,	   conventionele	  
echocardiografie	  en	  2DSTE.	  Met	  deze	  onderzoektechnieken	  toonden	  wij	  aan	  dat	  er	  
in	   enkele	   gevallen	   sprake	   was	   van	   (milde)	   structurele	   hartafwijkingen	   en	  
elektrocardiografische	  afwijkingen.	  Een	  abnormale	  vervorming	  van	  de	  hartspier	  van	  
de	   linker	   hartkamer	   zonder	   dat	   deze	   patiënten	   hier	   (merkbaar)	   klachten	   van	  
ondervonden	  kwam	  echter	  frequenter	  voor.	  In	  70%	  van	  de	  patiënten	  was	  er	  sprake	  
van	   een	   abnormale	   vervorming	   van	   de	   hartspier	   (<5e	   percentiel	   van	   de	   eerder	  
vastgestelde	  referentiewaarden).	  De	  vervorming	  van	  de	  hartspier	  was	  afwijkend	  in	  
alle	  drie	  de	  richtingen.	  Opvallend	  was	  dat	  de	  mate	  van	  vervorming	  vooral	  afwijkend	  
was	   in	   het	   geval	   van	   maternale	   uniparentale	   disomie,	   wat	   een	   specifieke	   DNA	  
afwijking	  is	  welke	  in	  sommige	  gevallen	  de	  genetische	  oorzaak	  is	  van	  het	  Prader-­‐Willi	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syndroom.	  Lange	  termijn	  follow-­‐up	  studies	  in	  grotere	  patiënten	  groepen	  zijn	  nodig	  
om	   de	   klinische	   en	   prognostische	   betekenis	   van	   de	   aangetoonde	   afwijkingen	   te	  
achterhalen.	  Echter	  gezien	  de	  cardiovasculaire	  morbiditeit	  en	  mortaliteit,	   zeker	  bij	  
volwassenen,	   adviseren	   wij	   (herhaaldelijk)	   cardiaal	   onderzoek	   bij	   patiënten	  
gediagnostiseerd	   met	   het	   Prader-­‐Willi	   syndroom.	   Hierbij	   zou	   2DSTE	   aanvullende	  
informatie	  kunnen	  bieden	  ten	  aanzien	  van	  de	  werking	  van	  de	  hartspier.	  	  
	  
In	  HOOFDSTUK	  8	  beschrijven	  we	  dat	  2DSTE,	   in	  combinatie	  met	  Troponine	  T	  en	  N-­‐
Terminal-­‐pro-­‐brain	  natriuretic	  peptide	  bepalingen,	  gebruikt	  kan	  worden	  om	  in	  een	  
vroeg	  stadium	  anthracycline	  geïnduceerde	  cardiotoxiciteit	  aan	  te	  tonen	  bij	  kinderen	  
met	  acute	  lymfatische	  leukemie.	  	  
In	  de	  huidige,	  prospectieve	  studie	  evalueren	  we	  de	  myocardiale	  functie	  door	  middel	  
van	   conventionele	   echotechnieken,	   2DSTE	   en	   het	   bepalen	   van	   de	  
serumconcentratie	  van	  biomarkers	  (Troponine	  T	  en	  N-­‐Terminal-­‐pro-­‐brain	  natriuretic	  
peptide)	   op	   3	  meetmomenten:	   voor	   de	   start	   van,	   na	   3	  maanden	   en	   1	   jaar	   na	   de	  
start	  van	  anthracycline	  therapie.	  Onze	  bevindingen	  wijzen	  uit	  dat	  de	  functie	  van	  de	  
linker	   hartkamer,	   weergegeven	   door	   2DSTE	   parameters,	   achteruit	   gaat	   tijdens	   de	  
behandeling	  met	   anthracyclines.	   Bovendien	   is	   de	   systolische	   functie	   van	   de	   linker	  
hartkamer	   bij	   deze	   groep	   kinderen	   significant	   lager	   in	   vergelijking	   met	   gezonde	  
leeftijdsgenoten.	   Voorspellende	   parameters	   voor	   afwijkende	   biomarker	  
concentraties	  en	  abnormale	  strain	  indices	  na	  1	  jaar	  chemotherapie	  zijn:	  cumulatieve	  
anthracycline	   dosis,	   diastolische	   interne	   diameter	   van	   de	   linker	   hartkamer,	  
fractionele	   verkorting,	   biomarker	   concentratie	   en	   globale	   piek	   systolische	  
longitudinale	  strain	  (-­‐rate)	  vóór	  de	  start	  van	  anthracycline	  therapie.	  Deze	  resultaten	  
geven	   aan	   dat	   2DSTE	   en	   cardiale	   biomarkers	   gebruikt	   kunnen	   worden	   om	  
subklinische	   veranderingen	   in	  de	  myocardiale	   functie	   aan	   te	   tonen,	  welke	   zouden	  
kunnen	  duiden	  op	  anthracycline	  geïnduceerde	  cardiotoxiciteit.	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10.2 TOEKOMSTPERSPECTIEVEN 
	  
Tweedimensionale	   echocardiografie	   is	   zich	   als	   techniek	   om	   de	   werking	   van	   de	  
hartspier	   in	   kaart	   te	   brengen	   nog	   steeds	   aan	   het	   ontwikkelen	   door	   onderzoek	   en	  
technische	  ontwikkelingen.	  Op	  dit	  moment	  kan	  deze	  techniek	  nog	  niet	  beschouwd	  
worden	   als	   onderdeel	   van	   een	   routine	   echocardiografisch	   onderzoek.	   Echter,	  
onderzoek	   op	   het	   terrein	   van	   2DSTE	   neemt	   hand	   over	   hand	   toe	   en	   het	   is	  
waarschijnlijk	  dat	  de	  klinische	  toepasbaarheid	   in	  de	  komende	   jaren	  zich	  verder	  zal	  
uitbreiden.	  	  
	  
Wij	   zijn	   van	  mening	  dat	  2DSTE	  aanvullende	   informatie	  kan	  bieden	  met	  betrekking	  
tot	  de	  functie	  van	  de	  hartspier	  in	  een	  groot	  scala	  aan	  cardiale	  ziektes.	  Bijvoorbeeld	  
in	   kinderen	  met	   een	   primair	   of	   secundair	   gestoorde	  werking	   van	   het	   hart	   zonder	  
overduidelijke	  tekenen	  van	  hartfalen.	  Het	  is	  in	  deze	  groep	  patiënten	  waarbij	  2DSTE	  
heeft	   aangetoond	   subklinisch	   abnormaal	   functioneren	   van	  de	  hartspier	   te	   kunnen	  
detecteren	   voordat	   conventionele	   echotechnieken	   afwijkende	   waardes	   vertonen.	  
Daarnaast	  zou	  2DSTE	  van	  grote	  waarde	  kunnen	  zijn	  bij	  kinderen	  met	  een	  abnormale	  
bouw	  van	  de	  hartkamer(s)	  aangezien	  deze	  techniek,	   in	  tegenstelling	  tot	  de	  huidige	  
echotechnieken	   om	   de	   werking	   van	   de	   hartspier	   te	   kwantificeren,	   de	   mate	   en	  
timing	   van	   vervorming	   bepaalt	   onafhankelijk	   van	   de	   geometrie.	   Aanvullend,	   biedt	  
het	  feit	  dat	  2DSTE	  het	  mogelijk	  maakt	  om	  niet	  alleen	  de	  globale	  hartspierwerking	  te	  
detecteren	  maar	  ook	  de	  regionale	  verschillen	  hierin	  nieuwe	  mogelijkheden.	  Zo	  kan	  
het	   in	   kaart	   brengen	   van	   de	   werking	   van	   de	   verschillende	   segmenten	   van	   de	  
hartkamer(s)	   zeer	   nuttig	   zijn	   bij	   ischemische	   hartziekten.	   Voorbeelden	   hiervan	   bij	  
kinderen	   zijn	   onder	   andere	   aangeboren	   afwijkingen	   van	   de	   kransslagaders	   en	  
aangeboren	  hartafwijkingen	  waarbij	  gedurende	  de	  operatieve	  correctie	  hiervan	  de	  
kransslagaders	   opnieuw	   geïmplanteerd	   zijn.	   Tot	   slot,	   zou	   2DSTE	   cardiale	  
elektromechanische	  dyssynchroniteit	  kunnen	  aantonen,	  hetgeen	  afhankelijk	  van	  de	  
oorzaak	  behandeld	  zou	  kunnen	  worden	  met	  resynchronisatie	  therapie.	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Dit	   alles	   tezamen	   evaluerend	   zou	   2DSTE	   nieuwe	   inzichten	   kunnen	   leveren	   in	   het	  
mechanisme	   van	   diverse	   cardiale	   aandoeningen	   en	   wellicht	   hiermee	  
aanknopingspunten	   kunnen	   bieden	   voor	   het	   optimaliseren	   van	   diens	  
behandelingen.	  	  
	  
Echter,	  verschillende	  probleemstukken	  moeten	  hiervoor	  eerst	  een	  oplossing	  vinden	  
door	  middel	  van	  toekomstig	  onderzoek	  en	  verdere	  technische	  ontwikkelingen.	  	  
	  
10.2.1 TECHNISCHE PROBLEMEN 
	  
BEELDKWALITEIT	  
Een	  betrouwbare	  2DSTE	  analyse	  is	  sterk	  afhankelijk	  van	  de	  beeldkwaliteit	  van	  de	  B-­‐
mode	   echobeelden.	   Zo	   kunnen	   reverberaties	   de	   resultaten	   van	   de	   2DSTE	  
bepalingen	   beïnvloeden.	   Om	   de	   invloed	   van	   ruis	   op	   de	   2DSTE	   bepalingen	   te	  
reduceren	  wordt	  gebruik	  gemaakt	  van	  filter	  algoritmes.	  Echter,	  het	   filteren	  van	  de	  
echodata	  vormt	  een	  compromis	  tussen	  resolutie	  en	  standaard	  deviatie.	  	  
Daarnaast	   is	   de	   grootte	   van	  de	  hartkamer	   van	  belang.	   In	   het	   geval	   van	   een	   grote	  
ventrikel	  kan	  het	  lastig	  blijken	  te	  zijn	  om	  de	  gehele	  hartkamer	  in	  beeld	  te	  krijgen.	  Dit	  
geldt	   met	   name	   voor	   de	   apicaal	   gelegen	   segmenten.	   Echter	   als	   de	   apicale	  
segmenten	  niet	  meegenomen	  worden	  in	  de	  2DSTE	  analyse	  kan	  dit	  van	  significante	  
invloed	   zijn	   op	   de	   verkregen	   resultaten.	   Het	   is	   dus	   van	   belang	   om	   (te	   pogen)	   de	  
gehele	  hartkamer	  in	  beeld	  te	  krijgen.	  	  
	  
ONBEKENDE	  SOFTWARE	  ALGORITMES	  	  
Bij	   speckle	   tracking	  en	  het	  uiteindelijk	   verkrijgen	  van	   strainwaardes	  wordt	  gebruik	  
gemaakt	  van	  zoek-­‐	  en	  filter	  algoritmes.	  Het	  exacte	  effect	  van	  deze	  algoritmes	  op	  de	  
verkregen	  resultaten	  vertegenwoordigt	  een	  spreekwoordelijke	  ‘zwarte	  doos’	  en	  kan	  
variëren	   tussen	   de	   software	   van	   diverse	   fabrikanten.	  Dit	   geldt	  met	   name	   voor	   de	  
bepaling	   van	   radiale	   strain	   (-­‐rate).	   De	   verschillen	   tussen	   de	   diverse	   fabrikanten	   is	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gebaseerd	  op	  het	  feit	  dat	  2DSTE	  analyses	  verricht	  worden	  met	  behulp	  van	  data	  die	  
opgeslagen	  zijn	  in	  een	  format	  dat	  eigendom	  is	  van	  desbetreffende	  firma	  en	  dat	  niet	  
geanalyseerd	  kan	  worden	  door	  de	  software	  van	  een	  andere	  firma.	  Momenteel	  is	  het	  
onduidelijk	   hoe	   de	   2DSTE	   bepalingen	   van	   de	   diverse	   echoapparaten	   en	   software	  
fabrikanten	  zich	  onderling	  verhouden.	  Dit	  aspect	  dient	  nader	  onderzocht	  te	  worden	  
voordat	   2DSTE	   een	   vast	   onderdeel	   van	  de	  dagelijkse	   praktijk	   gaat	   vormen.	  Op	  dit	  
moment	   is	   er	   sprake	   van	   een	   gezamenlijke	   inzet	   van	   de	   “American	   Society	   of	  
Echocardiography	  (ASE)”,	  “European	  Association	  of	  Echocardiography	  (EAE)”	  en	  de	  
industrie	  om	  deze	  vraagstukken	  aan	  te	  pakken.	  	  
10.2.2 STANDAARDISATIE 
	  
Om	   vergelijking	   mogelijk	   te	   maken	   tussen	   de	   studieresultaten	   uit	   diverse	  
onderzoeken	  en	  om	  de	  klinische	  toepasbaarheid	  te	  vergoten	  is	  standaardisatie	  van	  
essentieel	  belang.	  	  
Eenduidigheid	  moet	  ontstaan	  over:	  	  
-­‐ Wat	  gemeten	  dient	  te	  worden:	   	  
o Hoeveel	   segmenten	   en	   welke	   segmenten	   moeten	   gemeten	  
worden?	  
De	  diverse	  fabrikanten	  maken	  gebruik	  van	  een	  verschillend	  aantal	  
te	   analyseren	   segmenten	   en	   verschillende	   nomenclatuur.	   Deze	  
verschillen	   dragen	   bij	   aan	   de	   moeilijkheden	   die	   bestaan	   bij	   de	  
onderlinge	  vergelijking	  van	  de	  verkregen	  onderzoeksresultaten.	  	  
o Het	   moment	   waarop	   de	   maximale	   vervorming	   van	   de	   hartspier	  
bepaald	  wordt	   is	  niet	  uniform.	  Onder	  maximale	  vervorming	  (piek	  
strain)	   kan	   verstaan	   worden:	   maximale	   vervorming	   tijdens	   de	  
systole,	   de	   vervorming	   aan	   het	   einde	   van	   de	   systole	   (op	   het	  
moment	   waarop	   de	   aortaklep	   sluit)	   of	   maximale	   vervorming	  
ongeacht	  het	  tijdstip	  tijdens	  de	  hartcyclus	  (systole	  of	  diastole).	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-­‐ Ook	  dienen	  de	  resultaten	  op	  een	  gestandaardiseerde	  wijze	  gerapporteerd	  
te	  worden,	  waardoor	  het	  inzichtelijker	  wordt.	  	  
-­‐ Aangezien	   een	   echocardiografisch	   onderzoek	   waar	   2DSTE	   onderdeel	   van	  
uitmaakt	  een	  veelheid	  aan	  aanvullende	  informatie	  biedt	  is	  het	  noodzakelijk	  
dat	   deze	   uitkomstdata	   dusdanig	   vorm	   krijgen	   zodat	   ze	   passen	   in	   drukke	  
dagelijkse	  klinische	  praktijk.	  De	  data	  dienen	  een	  coherent	  beeld	  te	  vormen	  
dat	   gemakkelijk	   te	   begrijpen	   is	   voor	   een	   clinicus	   die	   wellicht	   nog	   weinig	  
ervaring	  heeft	  met	  deze	  techniek.	  	  
10.2.3 PROGNOSTISCHE BETEKENIS 
	  
Het	  is	  nu	  van	  belang	  om	  de	  bruikbaarheid	  van	  2DSTE	  voor	  het	  maken	  van	  klinische	  
beslissingen	   alsmede	   de	   prognostische	   waarde	   van	   2DSTE	   bevindingen	   vast	   te	  
stellen.	   Toekomstig	   onderzoek	   is	   wenselijk	   om	   de	   sensitiviteit	   en	   specificiteit	   van	  
2DSTE	  bepalingen	  te	  onderzoeken	  in	  diverse	  aandoeningen	  en	  de	  sterke	  en	  minder	  
sterke	   eigenschappen	   van	   deze	   techniek	   te	   bepalen.	   De	   correlatie	   tussen	  
(herhaaldelijke)	  2DSTE	  metingen	  en	  klinische	  uitkomstmaten	  op	  de	  langere	  termijn	  
zal	   moeten	   onderzocht	   door	   middel	   van	   longitudinale	   interventie	   studies.	   Doel	  
hierbij	   zal	   hierbij	   zijn	   om	   afkapwaardes	   voor	   strainparameters	   te	   formuleren	   en	  
deze	  te	  correleren	  aan	  medisch	  inhoudelijke	  beslissingen	  en	  harde	  uitkomstmaten.	  
Hiervoor	  zijn	  prospectief	  opgezette	  studies	  nodig,	  alsmede	  het	  standaardiseren	  van	  
2DSTE	   onderzoeksmethodes,	   moeten	   de	   bovengenoemde	   problemen	   aangepakt	  
worden	   en	   dient	   2DSTE	   uiteindelijk	   een	   plek	   te	   krijgen	   in	   de	   realiteit	   van	   de	  
dagelijkse	  klinische	  praktijk.	  	  
10.3 CONCLUSIE 
	  
Het	  is	  duidelijk	  dat	  toekomstig	  onderzoek	  en	  verdere	  technische	  ontwikkelingen	  van	  
belang	   zijn	  om	  deze	   techniek	  een	  plek	   te	  geven	   in	  de	  dagelijkse	  klinische	  praktijk.	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Wij	  zijn	  echter	  van	  mening	  dat	  de	  perspectieven	  voor	  2DSTE	  gunstig	  zijn	  en	  dat	  het	  
een	  waardevolle	  aanvulling	  is	  op	  het	  echografisch	  onderzoek	  van	  het	  hart.	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“Silent	  gratitude	  isn't	  much	  use	  to	  anyone.”	  (G.B.	  Stern)	  
	  
Nu	  het	  einde	  van	  dit	  wetenschappelijke	  avontuur	  nadert	  wil	   ik	  van	  de	  gelegenheid	  
gebruik	  maken	  om	  eenieder	  te	  bedanken	  die	  mij	  opgeleid,	  gestimuleerd	  en	  bovenal	  
gesteund	  heeft	  tijdens	  deze	  boeiende	  maar	  zeker	  ook	  uitdagende	  periode.	  	  
	  
Hoewel	  het	  gebruikelijk	  is	  om	  te	  beginnen	  met	  de	  promotores,	  neem	  ik	  de	  vrijheid	  
van	   het	   gebaande	   pad	   af	   te	   wijken	   en	   allereerst	   mijn	   beide	   copromotoren	   te	  
bedanken	  voor	  hun	  uitzonderlijke	  steun.	  	  
Dr.	  L.	  Kapusta,	  lieve	  Livia,	  jij	  bent	  de	  spil	  geweest	  van	  dit	  onderzoek.	  Jouw	  tomeloze	  
inzet	   en	   aanstekelijke	   enthousiasme	   waren	   essentieel.	   Aan	   nieuwe,	   boeiende	  
ideeën	  en	  vraagstellingen	  geen	  gebrek.	  De	  terugkeer	  van	  jou	  en	  je	  gezin	  naar	  jullie	  
‘roots’	   in	   Israël	   maakte	   dat	   we	   iets	   creatiever	   moesten	   zijn	   in	   onze	  
overlegmomenten	   dan	   gebruikelijk.	   Gelukkig	   heeft	   de	   technologie	   zich	   niet	   alleen	  
op	  echocardiografisch	  gebied	   sterk	  ontwikkeld.	  Met	  behulp	  van	  Skype	  hebben	  we	  
heel	  wat	  gedachten	  uitgewisseld	  en	  kon	  je	  tevens	  getuige	  zijn	  van	  de	  belevenissen	  
van	  onze	  zoons.	  Buiten	  het	   feit	  dat	   je	  de	  wetenschap	  evident	  hoog	   in	  het	  vaandel	  
hebt	  staan,	  ben	  je	  een	  familiemens	  pur	  sang.	  Je	  hebt	  oog	  en	  oor	  voor	  ieders	  verhaal.	  
Je	  hartelijke	  houding	  en	   interesse	  hebben	  ertoe	  geleid	  dat	   ik	   je	   inmiddels	  echt	  als	  
familie	  ben	  gaan	  beschouwen.	  Zeer	  bedankt	  voor	  alles	  wat	  je	  voor	  me	  hebt	  gedaan!	  
Ik	  weet	  zeker	  dat	  we	  elkaar	  niet	  uit	  het	  oog	  zullen	  verliezen.	  
	  
Veel	  dank	  ben	  ik	  verschuldigd	  aan	  dr.	  ir.	  C.	  L.	  de	  Korte.	  Beste	  Chris,	  jouw	  kennis	  op	  
technisch	   vlak	   is	   voor	   een	   medicus	   als	   ik	   van	   onschatbare	   waarde	   geweest.	   De	  
inbreng	   die	   je	   leverde	   was	   steevast	   snel	   en	   ‘to	   the	   point’.	   Ik	   hoop	   dat	   we	   in	   de	  
toekomst	  nog	  vaker	  samen	  zullen	  werken.	  	  
	  
Uiteraard	  ben	  ik	  mijn	  promotores,	  prof.	  dr.	  ir.	  J.	  M.	  Thijssen	  en	  prof.	  dr.	  R.	  de	  Groot	  
veel	  dank	  verschuldigd.	  Beste	  Han,	  je	  kritische	  noot	  heeft	  me	  scherp	  gehouden.	  Op	  
uiterst	  vriendelijke	  wijze	  wist	  je	  de	  vinger	  op	  de	  zere	  plek	  te	  leggen	  en	  kwam	  je	  met	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suggesties	  voor	  verbetering.	  Ik	  heb	  hier	  ontzettend	  veel	  van	  geleerd.	  Veel	  dank	  voor	  
de	  plezierige	  samenwerking.	  Beste	  Ronald,	  dank	  voor	  je	  inzet,	  steun	  en	  ook	  voor	  de	  
wijze	  woorden	  met	  betrekking	  tot	  je	  visie	  op	  mijn	  eventuele	  toekomstplannen.	  	  
	  
Zonder	   mijn	   opleider,	   dr.	   J.	   M.T.	   Draaisma,	   had	   ik	   dit	   proefschrift	   nooit	   zo	  
voorspoedig	  kunnen	  volbrengen.	  Beste	  Jos,	  je	  bent	  een	  opleider	  in	  hart	  en	  nieren	  en	  
bovenal	  een	  boeiend	  mens.	  Jij	  hebt	  dit	  onderzoek	  en	  mij	  gesteund	  in	  een	  tijd	  waarin	  
de	  druk	  het	  hoogst	  was.	  Ik	  ben	  je	  hiervoor	  zeer	  dankbaar.	  Daarnaast	  ben	  jij	  degene	  
die	  ertoe	  heeft	  bijgedragen	  dat	  ik	  besloten	  heb	  me	  verder	  te	  ontwikkelen	  binnen	  de	  
kindercardiologie.	  
	  
Mijn	   dank	   ook	   aan	   de	   leden	   van	   de	   corona,	   in	   het	   bijzonder	   de	  
manuscriptcommissie	   bestaande	   uit:	   prof.dr.	  W.M.	   Prokop,	   prof.dr.	  M.J.	   de	   Boer,	  
prof.	  dr.	  L.	  Mertens.	  Zeer	  bedankt	  voor	  de	  beoordeling	  van	  mijn	  manuscript.	  	  
	  
Zonder	  de	  inzet	  en	  hulp	  van	  Gert	  Weijers	  was	  het	  onderzoek	  ongetwijfeld	  gestrand.	  
Gert,	   de	  momenten	  waarop	   je	  mij	   hebt	   bijgestaan	  met	   technische	   ondersteuning	  
zijn	   ontelbaar.	   Dank	   dat	   je	   een	   digibeet	   als	   mij	   zo	   geduldig	   wegwijs	   hebt	   willen	  
maken	  in	  de	  wereld	  van	  nullen	  en	  enen.	  
	  
Annelies	  M.	  Mavinkurve-­‐Groothuis	  en	  Marlieke	  E.	  Barends,	  ik	  dank	  jullie	  voor	  jullie	  
hulp	  en	  ondersteuning.	  Ook	  alle	  andere	  coauteurs	  dank	  ik	  hartelijk	  voor	  de	  prettige	  
samenwerking.	  Dit	  geldt	  ook	  voor	  de	  echolaboranten	  Imke	  Tomasouw-­‐Janssen,	  Bob	  
Rijk,	  Romana	  D’Ancona,	  Nelly	  Jacobs	  en	  Marian	  Zwartjes-­‐van	  Helfteren.	  
	  
Aparte	   vermelding	   verdient	   ook	   Ton	   Feuth.	   Ton,	   je	   bent	   van	   onmisbare	   waarde	  
geweest	  bij	  de	   statistische	  onderbouwing	  van	  mijn	  manuscripten.	  Bedankt	  voor	   je	  
zorgvuldige	  ondersteuning	  en	  gedegen	  expertise.	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Ook	  Ronald	  Tanke,	  Annette	  Reimer	  en	  Michiel	  Schokking	  wil	   ik	  hartelijk	  bedanken	  
voor	   de	   manier	   waarop	   zij	   mij	   wegwijs	   hebben	   gemaakt	   in	   de	   echocardiografie.	  
Dankzij	   hun	   geduld	   en	   sturing	   heb	   ik	   mijn	   eerste	   stappen	   kunnen	   zetten	   bij	   het	  
zelfstandig	  verrichten	  van	  echocardiogrammen.	  	  
	  
Jaap,	  behalve	  voor	  het	   feit	  dat	   je	  mijn	  paranimf	  wilt	   zijn,	  dank	   ik	   je	  ook	  zeer	  voor	  
onze	  hechte	  vriendschap.	  De	  afgelopen	  10	   jaar	  hebben	  we	  lief	  en	   leed	  gedeeld	  en	  
ben	  ik	  vereerd	  dat	  ik	  je	  mijn	  beste	  vriend	  mag	  noemen.	  En	  inmiddels	  ben	  je	  ook	  de	  
favoriete	  speelkameraad	  van	  onze	  zoons!	  
	  
Last,	  but	  certainly	  not	  least,	  wil	  ik	  mijn	  gezin	  en	  familie	  bedanken.	  	  
	  
Allereerst	  mijn	   vriend,	   en	   liefde	   van	  mijn	   leven,	  Vincent.	  Wat	  ben	   ik	   gelukkig	  met	  
jou!	  Je	  bent	  mijn	  steun	  en	  toeverlaat.	  Er	  gaat	  geen	  dag	  voorbij	  waarop	  we	  niet	  tot	  
tranen	  toe	  aan	  het	   lachen	  zijn,	  veelal	  om	  de	  meest	  banale	  dingen.	   Jij	  die	  probeert	  
mij	   te	   laten	   schrikken	   door	   in	   de	   trapkast	   te	   gaan	   zitten.	   Ik	   die	   vervolgens	   ‘per	  
ongeluk’	   de	   kast	   op	   slot	   doe.	   Als	  we	  uit	   eten	   gaan	   in	   een	   sterrenrestaurant	   en	   jij	  
heerlijk	  genietend	  zegt	  dat	  je	  nog	  nooit	  zulke	  heerlijke	  en	  rode	  zalm	  hebt	  gegeten.	  
Waarop	  ik	  je	  erop	  wijs	  dat	  je	  tomaat	  aan	  het	  eten	  bent.	  Of	  als	  ik	  weer	  eens	  laat	  zien	  
dat	   ik	   geen	   enkel	   besef	   van	   topografie	   heb	   en	   tijdens	   het	   kaartlezen	   zeg	   dat	   de	  
snelweg	  stante	  pede	  ophoudt.	  Of	  dat	  we	  op	  weg	  van	  Nijmegen	  naar	  Berlijn	  na	  3	  uur	  
flink	  doorrijden	  een	  bord	  boven	  de	  weg	  zien:	  “Nijmegen	  50	  km”.	  	  
Op	   momenten	   waarop	   ik	   terneergeslagen	   ben	   weet	   jij	   me	   met	   jouw	   immer	  
positieve	  instelling	  op	  te	  beuren.	  Als	   ik	  een	  ‘computer-­‐crisis’	  heb	  weet	  jij	  met	  vaak	  
één	   druk	   op	   de	   knop	   de	   schade	   te	   herstellen.	   Hetgeen	   behoudens	   zeer	  
geruststellend,	   ook	   enigszins	   frustrerend	   is.	   Je	   bent	   naast	   een	   droompartner	   ook	  
een	  fantastische	  vader	  voor	  onze	  zoons.	  Ik	  geniet	  elke	  dag	  van	  de	  momenten	  samen	  
en	  ik	  hoop	  vanuit	  de	  grond	  van	  mijn	  hart	  dat	  we	  dit	  tot	  hoogbejaarde	  leeftijd	  zullen	  
blijven	  doen.	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Onze	   zoons.	   Thomas:	   Wat	   ben	   je	   een	   heerlijk	   mannetje.	   Zo	   vrolijk	   en	   open.	  
Onbevreesd	  en	  schaterlachend	  storm	  jij	  de	  wereld	  in.	  Geen	  enkel	  besef	  van	  gevaar.	  
Geen	   gêne,	   altijd	   op	   ontdekkingstocht.	   Wat	   hoop	   ik	   dat	   jij	   dit	   vast	   kunt	   blijven	  
houden.	   Ik	   zal	   als	   jouw	   moeder	   mijn	   uiterste	   best	   blijven	   doen	   om	   hiervoor	   te	  
zorgen.	  Puur	  door	  er	  te	  zijn	  heb	   jij	  voor	  perspectief	  gezorgd.	  Een	  betere	  motivatie	  
en	  bron	   van	   geluk	   dan	   jij	   is	   er	   niet.	  Mijn	  werk	   als	   kinderarts	   heeft	   door	   jou	   extra	  
diepgang	  gekregen.	  Ik	  begrijp	  nu	  pas	  werkelijk	  wat	  ouders	  meemaken	  als	  ze	  de	  zorg	  
voor	  hun	  kind	  uit	  handen	  moeten	  geven.	  Max:	  je	  bent	  pas	  net	  in	  ons	  leven,	  maar	  we	  
genieten	   iedere	   seconde	   van	   je!	   Ik	   herken	   veel	   van	   mezelf	   in	   jouw	   uiterlijk	   en	  
gedrag.	  Waar	   Thomas	   bruist	   van	   de	   energie,	   ben	   jij	   rustig,	   beheerst,	   geduldig	   en	  
observerend.	  Bovenal	  ben	  je	  een	  ontzettend	  vrolijk	  en	  tevreden	  mannetje.	  Wat	  zijn	  
we	  trots	  op	  jullie	  allebei!!	  
	  
Mijn	  moeder.	  Mam,	   zolang	   ik	  me	   kan	   herinneren	   ben	   jij	  mijn	   grote	   voorbeeld.	   Je	  
zorgzaamheid,	  je	  liefde	  en	  steun	  zijn	  inspirerend.	  Ondanks	  de	  grote	  tegenslagen	  op	  
jouw	   weg	   ben	   je	   krachtiger	   dan	   ooit.	   Ik	   bewonder	   je	   reflectievermogen,	   je	  
zelfbewustzijn	   en	   je	   doorzettingsvermogen.	   Sinds	   jaar	   en	   dag	   ben	   je	   daarom	   een	  
voorbeeld.	  Ook	  bij	  dit	  onderzoek	  heb	  ik	  daarvan	  profijt	  gehad.	  Je	  bent	  een	  prachtig	  
mens,	  en	  ik	  ben	  bijzonder	  gelukkig	  dat	  je	  in	  Cees	  de	  liefde	  gevonden	  hebt	  waarnaar	  
je	  zo	  lang	  zocht.	  	  Cees,	  ik	  bedank	  ook	  jou	  voor	  je	  steun	  aan	  ons	  gezin	  en	  de	  liefde	  die	  
je	  ons	  en	  mijn	  moeder	  geeft.	  	  
	  
Mijn	   vader.	   Pap,	   mijn	   onderzoekende	   aard	   heb	   ik	   van	   jou.	   Je	   bent	   een	   echte	  
autodidact.	   Of	   het	   nu	   een	   nieuwe	   taal	   is	   of	   de	   nieuwste	   inzichten	   op	   gebied	   van	  
kwantummechanica:	  Jij	  draait	  je	  hand	  er	  niet	  voor	  om.	  Ook	  al	  zien	  we	  elkaar	  gezien	  
de	  geografische	  afstand	  niet	  vaak,	  in	  gedachten	  ben	  je	  altijd	  bij	  me.	  	  
	  
Tot	  slot:	  lieve	  opa	  en	  oma:	  jullie	  zijn	  het	  allerliefst!	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